<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Follow‐up strategies following completion of primary cancer treatment in adult cancer survivors - Høeg, BL - 2019 | Cochrane Library</title> <meta content="Follow‐up strategies following completion of primary cancer treatment in adult cancer survivors - Høeg, BL - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012425.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Follow‐up strategies following completion of primary cancer treatment in adult cancer survivors - Høeg, BL - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012425.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012425.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Follow‐up strategies following completion of primary cancer treatment in adult cancer survivors" name="citation_title"/> <meta content="Beverley L Høeg" name="citation_author"/> <meta content="Danish Cancer Society Research Center" name="citation_author_institution"/> <meta content="Pernille E Bidstrup" name="citation_author"/> <meta content="Danish Cancer Society Research Center" name="citation_author_institution"/> <meta content="pernille@cancer.dk" name="citation_author_email"/> <meta content="Randi V Karlsen" name="citation_author"/> <meta content="Danish Cancer Society Research Center" name="citation_author_institution"/> <meta content="Anne Sofie Friberg" name="citation_author"/> <meta content="Vanna Albieri" name="citation_author"/> <meta content="Danish Cancer Society Research Center" name="citation_author_institution"/> <meta content="Susanne O Dalton" name="citation_author"/> <meta content="Lena Saltbæk" name="citation_author"/> <meta content="Klaus Kaae Andersen" name="citation_author"/> <meta content="Danish Cancer Society Research Center" name="citation_author_institution"/> <meta content="Trine Allerslev Horsboel" name="citation_author"/> <meta content="Danish Cancer Society Research Center" name="citation_author_institution"/> <meta content="Christoffer Johansen" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD012425.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/11/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012425.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012425.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012425.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Cancer Survivors [psychology]; *Patient Satisfaction; Anxiety [rehabilitation]; Continuity of Patient Care; Depression [rehabilitation]; Fatigue [rehabilitation]; Follow‐Up Studies; Neoplasm Recurrence, Local [*diagnosis]; Quality of Life; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012425.pub2&amp;doi=10.1002/14651858.CD012425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="dLyXbLct";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012425\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012425\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012425\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012425\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","ja","fa","ko","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012425.pub2",title:"Follow\\u2010up strategies following completion of primary cancer treatment in adult cancer survivors",firstPublishedDate:"Nov 21, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Effective Practice and Organisation of Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=dLyXbLct&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012425.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012425.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012425.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012425.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012425.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012425.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012425.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012425.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012425.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012425.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5681 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012425.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/full#CD012425-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/full#CD012425-sec-0131"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/full#CD012425-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/full#CD012425-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/full#CD012425-sec-0036"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/full#CD012425-sec-0037"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/full#CD012425-sec-0064"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/full#CD012425-sec-0118"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/appendices#CD012425-sec-0136"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/table_n/CD012425StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/table_n/CD012425StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Follow‐up strategies following completion of primary cancer treatment in adult cancer survivors </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/information#CD012425-cr-0002">Beverley L Høeg</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/information#CD012425-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Pernille E Bidstrup</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/information#CD012425-cr-0004">Randi V Karlsen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/information#CD012425-cr-0005">Anne Sofie Friberg</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/information#CD012425-cr-0006">Vanna Albieri</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/information#CD012425-cr-0007">Susanne O Dalton</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/information#CD012425-cr-0008">Lena Saltbæk</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/information#CD012425-cr-0009">Klaus Kaae Andersen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/information#CD012425-cr-0010">Trine Allerslev Horsboel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012425.pub2/information#CD012425-cr-0011">Christoffer Johansen</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/information/en#CD012425-sec-0151">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 November 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012425.pub2">https://doi.org/10.1002/14651858.CD012425.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012425-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012425-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012425-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012425-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012425-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012425-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012425-abs-0001" lang="en"> <section id="CD012425-sec-0001"> <h3 class="title" id="CD012425-sec-0001">Background</h3> <p>Most cancer survivors receive follow‐up care after completion of treatment with the primary aim of detecting recurrence. Traditional follow‐up consisting of fixed visits to a cancer specialist for examinations and tests are expensive and may be burdensome for the patient. Follow‐up strategies involving non‐specialist care providers, different intensity of procedures, or addition of survivorship care packages have been developed and tested, however their effectiveness remains unclear. </p> </section> <section id="CD012425-sec-0002"> <h3 class="title" id="CD012425-sec-0002">Objectives</h3> <p>The objective of this review is to compare the effect of different follow‐up strategies in adult cancer survivors, following completion of primary cancer treatment, on the primary outcomes of overall survival and time to detection of recurrence. Secondary outcomes are health‐related quality of life, anxiety (including fear of recurrence), depression and cost. </p> </section> <section id="CD012425-sec-0003"> <h3 class="title" id="CD012425-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, four other databases and two trials registries on 11 December 2018 together with reference checking, citation searching and contact with study authors to identify additional studies. </p> </section> <section id="CD012425-sec-0004"> <h3 class="title" id="CD012425-sec-0004">Selection criteria</h3> <p>We included all randomised trials comparing different follow‐up strategies for adult cancer survivors following completion of curatively‐intended primary cancer treatment, which included at least one of the outcomes listed above. We compared the effectiveness of: 1) non‐specialist‐led follow‐up (i.e. general practitioner (GP)‐led, nurse‐led, patient‐initiated or shared care) versus specialist‐led follow‐up; 2) less intensive versus more intensive follow‐up (based on clinical visits, examinations and diagnostic procedures) and 3) follow‐up integrating additional care components relevant for detection of recurrence (e.g. patient symptom education or monitoring, or survivorship care plans) versus usual care. </p> </section> <section id="CD012425-sec-0005"> <h3 class="title" id="CD012425-sec-0005">Data collection and analysis</h3> <p>We used the standard methodological guidelines by Cochrane and Cochrane Effective Practice and Organisation of Care (EPOC). We assessed the certainty of the evidence using the GRADE approach. For each comparison, we present synthesised findings for overall survival and time to detection of recurrence as hazard ratios (HR) and for health‐related quality of life, anxiety and depression as mean differences (MD), with 95% confidence intervals (CI). When meta‐analysis was not possible, we reported the results from individual studies. For survival and recurrence, we used meta‐regression analysis where possible to investigate whether the effects varied with regards to cancer site, publication year and study quality. </p> </section> <section id="CD012425-sec-0006"> <h3 class="title" id="CD012425-sec-0006">Main results</h3> <p>We included 53 trials involving 20,832 participants across 12 cancer sites and 15 countries, mainly in Europe, North America and Australia. All the studies were carried out in either a hospital or general practice setting. Seventeen studies compared non‐specialist‐led follow‐up with specialist‐led follow‐up, 24 studies compared intensity of follow‐up and 12 studies compared patient symptom education or monitoring, or survivorship care plans with usual care. Risk of bias was generally low or unclear in most of the studies, with a higher risk of bias in the smaller trials. </p> <p><b>Non‐specialist‐led follow‐up compared with specialist‐led follow‐up</b> </p> <p>It is uncertain how this strategy affects overall survival (HR 1.21, 95% CI 0.68 to 2.15; 2 studies; 603 participants), time to detection of recurrence (4 studies, 1691 participants) or cost (8 studies, 1756 participants) because the certainty of the evidence is very low. </p> <p>Non‐specialist‐ versus specialist‐led follow up may make little or no difference to health‐related quality of life at 12 months (MD 1.06, 95% CI −1.83 to 3.95; 4 studies; 605 participants; low‐certainty evidence); and probably makes little or no difference to anxiety at 12 months (MD −0.03, 95% CI −0.73 to 0.67; 5 studies; 1266 participants; moderate‐certainty evidence). We are more certain that it has little or no effect on depression at 12 months (MD 0.03, 95% CI −0.35 to 0.42; 5 studies; 1266 participants; high‐certainty evidence). </p> <p><b>Less intensive follow‐up compared with more intensive follow‐up</b> </p> <p>Less intensive versus more intensive follow‐up may make little or no difference to overall survival (HR 1.05, 95% CI 0.96 to 1.14; 13 studies; 10,726 participants; low‐certainty evidence) and probably increases time to detection of recurrence (HR 0.85, 95% CI 0.79 to 0.92; 12 studies; 11,276 participants; moderate‐certainty evidence). Meta‐regression analysis showed little or no difference in the intervention effects by cancer site, publication year or study quality. </p> <p>It is uncertain whether this strategy has an effect on health‐related quality of life (3 studies, 2742 participants), anxiety (1 study, 180 participants) or cost (6 studies, 1412 participants) because the certainty of evidence is very low. None of the studies reported on depression. </p> <p><b>Follow‐up strategies integrating additional patient symptom education or monitoring, or survivorship care plans compared with usual care:</b> </p> <p>None of the studies reported on overall survival or time to detection of recurrence.</p> <p>It is uncertain whether this strategy makes a difference to health‐related quality of life (12 studies, 2846 participants), anxiety (1 study, 470 participants), depression (8 studies, 2351 participants) or cost (1 studies, 408 participants), as the certainty of evidence is very low. </p> </section> <section id="CD012425-sec-0007"> <h3 class="title" id="CD012425-sec-0007">Authors' conclusions</h3> <p>Evidence regarding the effectiveness of the different follow‐up strategies varies substantially. Less intensive follow‐up may make little or no difference to overall survival but probably delays detection of recurrence. However, as we did not analyse the two outcomes together, we cannot make direct conclusions about the effect of interventions on survival after detection of recurrence. The effects of non‐specialist‐led follow‐up on survival and detection of recurrence, and how intensity of follow‐up affects health‐related quality of life, anxiety and depression, are uncertain. There was little evidence for the effects of follow‐up integrating additional patient symptom education/monitoring and survivorship care plans. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012425-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012425-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012425-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012425-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012425-abs-0006">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012425-abs-0010">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012425-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012425-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012425-abs-0004" lang="en"> <h3>Follow‐up strategies after completion of primary cancer treatment</h3> <p><b>What is the aim of this review?</b> </p> <p>In this Cochrane Review, we aimed to find out if cancer survivors who received three different types of follow‐up care, after they were treated for their cancer, have better medical and personal outcomes. We collected and assessed all relevant studies and found 53 studies. </p> <p><b>Key messages</b> </p> <p>Non‐specialist‐led follow‐up, such as follow‐up provided by a general practitioner (GP) or nurse, makes little or no difference to health‐related quality of life, anxiety or depression, when compared to specialist‐led follow‐up. We cannot be sure about its effects on overall survival and detection of a cancer returning after treatment (recurrence). </p> <p>Less intensive follow‐up, such as follow‐up with fewer examinations or tests, may make little or no difference to overall survival but probably delays detection of recurrence when compared to more intensive follow‐up. However, other types of studies are needed before we can be certain about the effects of early detection of recurrence on survival. We also cannot be sure about its effect on health‐related quality of life, anxiety and depression. </p> <p>There was little evidence for the final type of follow‐up, which integrated additional components relevant for detection of recurrence, such as patient symptom education or monitoring, or survivorship care plans. </p> <p><b>What was studied in the review?</b> </p> <p>After being treated for cancer, most patients receive follow‐up care to look for signs of recurrence. If the cancer returns, it is thought to be better to detect it earlier, as it allows earlier treatment, which is expected to improve survival for the patient. Traditional follow‐up involving fixed visits to a cancer specialist in a hospital setting for examinations and tests can be expensive and burdensome for the patient. Newer follow‐up strategies involving non‐specialist care providers, different intensity of examinations, or the addition of survivorship care plans have been developed and tested but their effectiveness remains unclear. </p> <p>The aim of our review was to find out if three types of aftercare increased survival, decreased the time until recurrence is detected, and improved patient outcomes such as health‐related quality of life, anxiety and depression, as well as cost. The types of aftercare were: 1) non‐specialist‐led (e.g. GP‐led, nurse‐led, patient‐initiated or shared care) versus specialist‐led follow‐up; 2) less intensive versus more intensive follow‐up (based on frequency or intensity of clinical visits, examinations or diagnostic procedures); and 3) follow‐up integrating additional care components relevant for detection of recurrence (e.g. patient symptom education or monitoring, or survivorship care plans) versus usual care. </p> <p><b>What are the main results of the review?</b> </p> <p>We analysed 53 studies, involving 20,832 participants with 12 types of cancer in 15 different countries, mainly in Europe, North America and Australia. All the studies were carried out in either a hospital or general practice setting. </p> <p><i><b>When cancer survivors receive aftercare led by non‐specialists, such as GPs and nurses:</b> </i> </p> <p>‐ We are not sure if overall survival is affected or if cancer recurrence is detected earlier; </p> <p>‐ It probably makes little or no difference to health‐related quality of life and anxiety and it makes no difference for depression at 12 months of follow‐up; </p> <p>‐ We are not sure there is a difference in costs between these two types of follow‐up strategies. </p> <p><i><b>When cancer survivors receive less intensive aftercare, such as fewer examinations and tests:</b> </i> </p> <p>‐ It may make little or no difference to overall survival but it probably delays detection of recurrence; </p> <p>‐ We are not sure if makes a difference to health‐related quality of life, anxiety and costs. We did not find any studies assessing depression. </p> <p><i><b>When cancer survivors receive aftercare with additional education about their symptoms or survivorship care plans:</b> </i> </p> <p>‐ We are not sure about how this type of aftercare improves health‐related quality of life, anxiety or depression, or if increases the costs of care. We did not find any studies that assessed overall survival or if cancer recurrence is detected earlier. </p> <p><b>How up to date is this review?</b> </p> <p>We reviewed studies that had been published up to 11 December 2018.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012425-sec-0131" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012425-sec-0131">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012425-sec-0208">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012425-sec-0131"></div> <h3 class="title" id="CD012425-sec-0132">Implications for practice</h3> <section id="CD012425-sec-0132"> <p>In many high‐income countries, conventional follow‐up strategies, such as routine examination by a specialist, are being substituted with less intensive and allegedly more strategic approaches. In this context, it is important to evaluate whether these changes may lead to poorer prognosis and patient‐reported outcomes. Our finding that less intensive strategies do not negatively affect overall survival may be considered reassuring, in light of this current trend. </p> <p>Our finding that more intensive strategies detect recurrences earlier have less clear implications. As the two outcomes (recurrence and survival) were not analysed together, we cannot make direct conclusions about the effect of interventions on survival after detection of recurrence. In fact, the content and organisation of conventional follow‐up strategies has long focused on the early detection of recurrences, based on the assumption that early detection of recurrence translates into longer survival through early treatment. As our review is the first to find an effect of less intensive strategies on recurrence, further knowledge is needed. We need more high‐quality studies that use the appropriate approach to evaluate the effect of follow‐up strategies on survival according to detection of recurrence status. Several mechanisms may be at play influencing survival after recurrence compared to overall survival. It is possible that the biology of recurrences is different across cancer sites and that early detection and treatment of oligometastatic recurrence may lead to a survival benefit in some cancer sites but not in others. </p> <p>Despite the lower certainty of the evidence, our results on quality‐of‐life and psychological distress indicate that we do not yet have sufficient knowledge on how to improve these aspects of cancer survivorship to an extent that shows a measurable effect. As we included only studies that focused on cancer follow‐up and excluded studies that only focused on improving quality of life, it is possible that the components in the studies we included were too weak to make a difference. It is also possible that current measurement tools for quality of life, anxiety and depression are inadequate or not optimal for capturing the psychological changes that patients may experience. </p> <p>In many countries, there is currently a discussion about whether the core focus of follow‐up should be broadened from detection of recurrence to further include somatic and psychological late effects. It is thus important to know if it is possible to provide interventions that are able to significantly improve these patient‐reported experiences. Concurrent with this discussion, it has also been suggested that patients should be more directly involved in their cancer follow‐up, for example, through self‐monitoring of symptoms and shared treatment decisions. This is a relatively new way of thinking about cancer follow‐up care. A few of the studies included in this review tested some of these principles, for example, through patient education of symptom monitoring and patient‐initiated contact with health professionals, but further theoretical and clinical development is needed to test ways of organising patient‐centred cancer follow‐up. </p> </section> <h3 class="title" id="CD012425-sec-0133">Implications for research</h3> <section id="CD012425-sec-0133"> <p>Our evaluation of the evidence quality in this review indicates that there is still room for improvement in the quality of randomised trials in cancer follow‐up. Although the blinding of participants often is not possible or ethical, other efforts could be made to minimise bias due to differential treatment or differential assessment of outcomes. Our review also highlights the need to use more optimal methods and statistical analyses where possible, as this has an important impact on the level of certainty of the evidence. Analysing time‐to‐event outcomes as continuous outcomes or dichotomous outcomes increases the risk of biased estimates, makes meta‐analysis difficult and limits the conclusions that are able to be drawn, as a large amount of information from each study becomes lost. For example, reporting time to detection of recurrence as mean times to event may give inaccurate treatment effect estimates, as such analysis only takes into account the subset of participants who have had a recurrence and excludes those who remain cancer‐free. Finally, reporting participant‐years of follow‐up when conducting survival analysis will help enhance the transparency of findings in clinical trials. </p> <p>A possible direction for future research may be investigating the effect of early detection of recurrence on patient outcomes such as survival, when comparing more intensive and less intensive strategies. This may provide the knowledge needed for discussing how much clinical focus should be placed on detecting recurrence as early as possible. Several studies in this review have investigated detection of recurrence and overall survival, but not together. Robust evidence will need to come from analyses using multi‐state models that take into account both the time to detection of recurrence and death for all participants. Although such studies will require a large amount of resources and long follow‐up periods, they would provide the evidence needed to make the decisions that affect the lives of millions of cancer survivors. Such studies may also investigate any potential adverse effects of different follow‐up strategies, an aspect that was outside the scope of this review. </p> <p>Despite the relatively low level of evidence, our review indicates that we need more knowledge on how to improve and provide the necessary medical and psychosocial support that cancer survivors may need. Outcome measurement tools may also need to be developed specifically for the somatic and psychological symptoms in cancer survivors, as most of the outcome measures in the included studies were developed to capture symptoms during cancer treatment. Parallel to the discussion regarding higher levels of patient involvement in treatment, it has been suggested that involving patients in research may also be beneficial, especially when developing patient‐centred interventions. This is a relatively new paradigm in research that is still being investigated. </p> <p>In this review, we have identified many studies that contribute knowledge on a range of important outcomes in a large population of cancer survivors. We have also systematically identified knowledge gaps that remain to be filled. Future research may build and expand on the findings of this review, as well as improve on the limitations of our methods. This knowledge is needed to justify the enormous resources that are increasingly required to provide safe and effective follow‐up for adult cancer survivors around the world. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012425-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012425-sec-0029"></div> <div class="table" id="CD012425-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Non‐specialist‐led versus specialist‐led follow‐up after primary cancer treatment</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Non‐specialist‐led versus specialist‐led follow‐up after primary cancer treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult cancer survivors from the following cancer sites: breast, colon, colorectal, endometrial, ovarian, cervical, melanoma and oesophageal<br/> <b>Setting</b> : outpatient treatment in hospitals or general practice in Australia, Canada, Denmark, Netherlands, Norway, Sweden and UK<br/> <b>Intervention</b> : non‐specialist‐led (i.e. GP‐led, nurse‐led, patient‐initiated or shared care) follow‐up<br/> <b>Comparison</b>: specialist‐led follow‐up </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effects (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<sup>a</sup> <br/> (Number of studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Risk with specialist‐led follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Risk with non‐specialist‐led follow‐up</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>Follow‐up range: 12 months to 60 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 100<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 100</p> <p>(79 to 93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.21<br/> (0.68 to 2.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>603 participants</p> <p>(2 randomised trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 studies reported on overall survival. It is uncertain how non‐specialist‐led follow‐up affects overall survival as the certainty of the evidence is very low. </p> <p>We could not incorporate data from 2 other studies (N =1077) in the meta‐analysis, both reported little or no difference in overall survival. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Difference:</b> 2 fewer survivors in the intervention group per 100 participants (between 10 fewer to 4 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to detection of recurrence</b> </p> <p>Follow‐up range: 3 months to 60 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1691 participants (4 randomised trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies reported on time to detection of recurrence. It is uncertain how non‐specialist‐led follow‐up affects time to detection of recurrence as the certainty of the evidence is very low and we could not pool the reported data. </p> <p>3 studies reported little or no difference in time to detection of recurrence and 1 study reported median time to recurrence but did not carry out any statistical analysis. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life, (at 12 months' follow‐up)</b> </p> <p>EORTC‐C30 global health status scale (higher scores indicate better HRQoL)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.06 higher<br/> (1.83 lower to 3.95 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>605 participants</p> <p>(4 randomised trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thirteen studies reported on HRQoL using EORTC‐C30, SF‐36, SF‐12, EuroQoL‐5D and FACT at different time points. Meta‐analysis of 4 studies showed that non‐specialist‐led follow‐up may make little or no difference in HRQoL at 12 months as measured by the EORTC‐C30 global health status scale. The mean difference did not reach the minimal clinically important difference of 10 points identified for this scale. </p> <p>Studies that we could not incorporate in the meta‐analysis (N = 2385) generally reported that non‐specialist‐led follow‐up made little or no difference to HRQoL. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anxiety (at 12 months' follow‐up)</b> </p> <p>HADS‐Anxiety subscale (higher scores indicate worse anxiety)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.03 lower<br/> (0.73 lower to 0.67 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1266 participants</p> <p>(5 randomised trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 studies reported on anxiety and 2 on fear of recurrence using STAI, HADS and FCRI at different time points. Meta‐analysis of 5 studies showed that non‐specialist‐led follow‐up probably makes little or no difference to anxiety at 12 months as measured by HADS‐Anxiety subscale. The mean difference did not reach the minimal clinically important difference of 1.5 points identified for this scale. </p> <p>Data from the studies that we could not incorporate in the meta‐analysis (N = 1755) generally reported that non‐specialist‐led follow‐up made little or no difference to anxiety and fear of recurrence, except 1 study reporting higher levels of fear of recurrence in the patient‐initiated follow‐up group. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Depression (at 12 months)</b> </p> <p>HADS‐Depression subscale (higher scores indicate worse depression)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.03 higher<br/> (0.35 lower to 0.42 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1266 participants</p> <p>(5 randomised trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eleven studies reported on depression using GHQ‐12 and HADS at different time points. Meta‐analysis of 5 studies showed that non‐specialist‐led follow‐up makes little or no difference to depression at 12 months as measured by HADS‐Depression subscale. The mean difference did not reach the minimal clinically important difference of 1.5 points identified for this scale. </p> <p>The studies that we could not incorporate in the meta‐analysis (N = 1378) generally reported that non‐specialist‐led follow‐up may make little or no difference to depression. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cost</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1756 participants (8 randomised trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eight studies reported cost outcomes but due to the substantial heterogeneity in how they measured and reported them, we could not pool the results in a meta‐analysis. It is uncertain whether non‐specialist‐led follow‐up has an effect on cost when compared with specialist‐led follow‐up, as the certainty of the evidence is very low. </p> <p>6 studies reported lower cost per participant in the non‐specialist‐led group, while 2 studies reported higher cost per participant in the non‐specialist‐led group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>*</b> The basis for the assumed risk in the comparison group (<b>assumed comparator risk, ACR</b> ) is provided in the footnotes. The <b>corresponding risk in the intervention group</b> (and its 95%confidence interval) is based on the ACR and the <b>relative effect</b> of the intervention (and its 95%CI). </p> <p><b>CI</b> : confidence interval; <b>EORTC‐C30:</b> European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; <b>FACT:</b> Functional Assessment of Cancer Therapy scale; <b>FCRI:</b> Fear of Cancer Recurrence Inventory; <b>GHQ‐12:</b> General Health Questionnaire‐12 items; <b>GP:</b> general practitioner; <b>HADS:</b> Hospital Anxiety and Depression Scale; <b>HR:</b> Hazard ratio; <b>HRQoL:</b> health‐related quality of life; <b>MD</b> : mean difference; <b>SF‐36:</b> Short Form Health Survey‐36 items; <b>SF‐12</b> : Short Form Health Survey‐12 items; <b>STAI:</b> State Trait Anxiety Inventory </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>From meta‐analysis if we pooled study results; for all studies if we did not pool study results.<br/> <sup>b</sup>The ACR is the assumed proportion of participants who are alive in the comparison group. <br/> <sup>c</sup>We judged the certainty of evidence to be very low and downgraded by three levels for very serious concerns regarding indirectness and imprecision, as representativeness is limited with only two studies, the HRs were not reported but indirectly estimated and the confidence interval was very wide.<br/> <sup>d</sup>We judged the certainty of evidence to be very low and downgraded by three levels for serious concerns regarding inconsistency, indirectness and imprecision due to few studies, reporting of results by different estimates that could not be pooled and high variance of the result estimates.<br/> <sup>e</sup>We judged the certainty of evidence to be low and downgraded by two levels for serious concerns regarding inconsistency and imprecision due to differing estimates of effect and wide confidence intervals.<br/> <sup>f</sup>We judged the certainty of evidence to be moderate as we downgraded by one level for concerns regarding inconsistency of results and indirectness due to few studies.<br/> <sup>g</sup>We judged the certainty of evidence to be high although we had some concerns regarding indirectness due to few studies.<br/> <sup>h</sup>We judged the certainty of evidence to be very low as the high heterogeneity led to serious concerns regarding inconsistency, indirectness and imprecision in the way cost outcomes were measured and reported across studies. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012425-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Less intensive versus more intensive follow‐up after primary cancer treatment</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Less compared with more intensive components in follow‐up after primary cancer treatment</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adult cancer survivors from the following cancer sites: breast, colorectal, head‐and‐neck, Hodgkin lymphoma, melanoma, non‐small cell lung cancer and testicular cancer<br/> <b>Setting</b> : outpatient treatment in hospitals in Australia, Denmark, China, Finland, France, India, Italy, Netherlands, Spain, Sweden, Switzerland and UK<br/> <b>Intervention</b> : less intensive follow‐up (based on fewer clinical visits, examinations or less intensive diagnostic procedures)<br/> <b>Comparison</b>: more intensive follow‐up </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effects<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<sup>a</sup><br/> (Number of studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Risk with more intensive follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Risk with less intensive follow‐up</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>Follow‐up range: 24 months to 120 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 per 100<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 100</p> <p>(72 to 76)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.05<br/> (0.96 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10,726 participants</p> <p>(13 randomised trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>18 studies reported on overall survival. Meta‐analysis of 13 studies showed that less intensive follow‐up may make little or no difference to overall survival. Meta‐regression analysis showed little or no difference in the intervention effects by cancer site, publication year or study quality. </p> <p>We could not incorporate data from 5 other studies. 3 of these studies reported little or no difference in overall survival (N = 1752), while 2 studies reported improved survival with more intensive follow‐up (N = 544). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Difference:</b> 1 fewer survivor in the intervention group per 100 participants (between 3 fewer to 1 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Time to detection of recurrence</b> </p> <p>Follow‐up range: 12 months to 120 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 100<sup>d</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 100</p> <p>(22 to 25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.85 (0.79 to 0.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>11,276 participants</p> <p>(12 randomised trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>22 studies reported on time to detection of recurrence. Meta‐analysis of 12 studies showed that less intensive follow‐up probably increases time to detection of recurrence. Meta‐regression analysis showed little or no difference in the intervention effects by cancer site, publication year or study quality. </p> <p>We could not incorporate data from 10 other studies. 4 of these studies reported shorter time to detection of recurrence for more intensive follow‐up (N = 854), while 4 other studies reported little or no difference in detection of recurrence (N = 734). 1 study reported results that we could not use for this comparison (N = 337) and 1 study reported results based on only unresectable recurrence (N = 239). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Difference: 3 fewer detected recurrence in the intervention group per 100 participants (between 5 to 2 fewer)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2742 participants (3 randomised trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies reported on HRQoL using SF‐36 and SF‐12 at varying time points. We could not pool the reported data. It is uncertain whether less intensive follow‐up has an effect on HRQoL when compared with more intensive follow‐up, as the certainty of the evidence is very low. </p> <p>All 3 studies reported that less intensive follow‐up may make little or no difference in HRQoL when compared to more intensive follow‐up at time points ranging from 12 months to 5 years. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Anxiety</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 participants (1 randomised trial)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One study reported that less intensive follow‐up may make little or no difference to anxiety at 12 months follow‐up using STAI. </p> <p>It is uncertain whether less intensive follow‐up has an effect on anxiety when compared with more intensive follow‐up, as the certainty of the evidence is very low. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Depression</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of the studies reported depression.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cost</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1412 participants (6 randomised trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 studies reported cost outcomes but due to the substantial heterogeneity in how they measured and reported this outcome, we could not pool the results in a meta‐analysis. It is uncertain whether less intensive follow‐up has an effect on cost when compared with more intensive follow‐up, as the certainty of the evidence is very low. </p> <p>All studies report lower costs for the less intensive arm from the perspective of the participant or healthcare system but the difference in cost varied considerably depending on the components/procedures used in the different interventions. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>*</b> The basis for the assumed risk in the comparison group (<b>assumed comparator risk, ACR</b> ) is provided in the footnotes. The <b>corresponding risk in the intervention group</b> (and its 95%confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95%CI). </p> <p><b>CI</b> : confidence interval; <b>HR:</b> hazard ratio; <b>HRQoL:</b> health‐related quality of life; <b>SF‐36:</b> Short Form Health Survey‐36 items; <b>SF‐12</b> : Short Form Health Survey‐12 items; <b>STAI:</b> State Trait Anxiety Inventory </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>From meta‐analysis if we pooled study results; for all studies if we did not pool study results.<br/> <sup>b</sup>The ACR is the assumed proportion of participants who are alive in the comparison group. <br/> <sup>c</sup>We judged the certainty of evidence to be low as we downgraded by two levels for some concerns regarding study limitations (lack of allocation concealment in one study) and indirectness as the studies were primarily investigating follow‐up after colorectal and breast cancer, and serious concerns regarding imprecision as the confidence interval includes effects that are not trivial (potentially up to 3 fewer survivors per 100 participants).<br/> <sup>d</sup>The ACR is the assumed proportion of participants with a detected recurrence in the comparison group.<br/> <sup>e</sup>We judged the certainty of evidence to be moderate as we downgraded by one level for serious concerns regarding indirectness as seven of the studies did not report hazard ratios, so we indirectly estimated them from published data.<br/> <sup>f</sup>We judged the certainty of evidence to be very low and downgraded by three levels for serious concerns regarding inconsistency, indirectness and imprecision due to the few studies, heterogeneous measures and reporting of results by different estimates that we could not pool.<br/> <sup>g</sup>We judged the certainty of evidence to be very low and downgraded by three levels for serious concerns regarding inconsistency, indirectness and imprecision since there was only one study.<br/> <sup>h</sup>We judged the certainty of evidence to be very low and downgraded by three levels as the substantial heterogeneity led to serious concerns regarding inconsistency, indirectness and imprecision in the way cost was measured and reported across studies. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012425-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Follow‐up integrating additional patient symptom education or monitoring, or survivorship care plans versus usual care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Follow‐up integrating additional</b> patient symptom education or monitoring, or survivorship care plan<b>s versus usual care</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adult cancer survivors from the following cancer sites: breast, colorectal, endometrial, ovarian and prostate cancer<br/> <b>Setting</b> : outpatient treatment in hospitals or general practice in Australia, Canada, Netherlands, Sweden and USA<br/> <b>Intervention:</b> follow‐up integrating additional components relevant for detection of recurrence (e.g. patient symptom education or monitoring, or survivorship care plans (SCP))<br/> <b>Comparison</b>: usual care </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effects<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of studies</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Risk with usual care</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Risk with follow‐up integrating additional patient symptom education/monitoring or SCP</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the studies reported overall survival.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time‐to‐ detection of recurrence</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the studies reported detection of recurrence.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life, (HRQoL)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2846 participants (12 randomised trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 studies reported on HRQoL using EORTC‐C30, SF‐36, SF‐12, FACT and City of Hope QoL scale at varying time points. We could not pool the reported data. It is uncertain whether follow‐up integrating additional patient symptom education/monitoring or SCP has an effect on HRQoL when compared with usual care, as the certainty of the evidence is very low. </p> <p>11 studies reported that follow‐up integrating additional patient education/SCP may make little or no difference to HRQoL when compared to usual care at follow‐up ranging from 6 months to 12 months. 1 study reported that SCP and patient coaching improved HRQoL at 3 months' follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anxiety</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>470 participants (1 randomised trial)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One study reported that SCP may make little or no difference to anxiety at 12 months' follow‐up using HADS. </p> <p>It is uncertain whether follow‐up integrating additional patient symptom education/monitoring or SCP has an effect on anxiety when compared with usual care, as the certainty of the evidence is very low. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Depression</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2351 participants (8 randomised trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Very low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 studies reported on depression using HADS, POMS, PHQ‐9, BSI‐18, CES‐D and the distress thermometer at varying time points. We could not pool the reported data. It is uncertain whether follow‐up integrating additional patient symptom education/monitoring or SCP has an effect on depression when compared with usual care, as the certainty of the evidence is very low. </p> <p>7 studies reported that follow‐up integrating additional patient education/SCP may make little or no difference to depression when compared to usual care at follow‐up ranging from 3 months to 12 months. 1 study reported that the intervention improved symptoms of depression at 12 months' follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cost</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>408 participants (1 randomised trial)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One study reported that the use of SCP make little or no difference to cost at 2 years' follow‐up. </p> <p>It is uncertain whether follow‐up integrating additional patient symptom education/monitoring or SCP has an effect on cost when compared with usual care, as the certainty of the evidence is very low. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>*</b>The corresponding risk in the intervention group (and its 95%confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%CI). </p> <p><b>BSI‐18:</b> Brief Symptom Inventory‐18 items, <b>CES‐D:</b> Center for Epidemiological Studies‐Depression scale; <b>CI</b> : confidence interval; <b>EORTC‐C30:</b> European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; <b>FACT:</b> Functional Assessment of Cancer Therapy scale; <b>HADS:</b> Hospital Anxiety and Depression Scale; <b>HRQoL:</b> health‐related quality of life; <b>PHQ‐9:</b> Patient Health Questionaire‐9 items; <b>POMS:</b> Profile of Mood States; <b>QoL:</b> quality of life; <b>SCP:</b> survivorship care plans; <b>SF‐36:</b> Short Form Health Survey‐36 items; <b>SF‐12</b>: Short Form Health Survey‐12 items </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We judged the overall certainty of evidence to be very low and downgraded by three levels for serious concerns regarding study limitations, indirectness and imprecision due to studies being at high risk of bias, the heterogeneous measures and reporting of results by different estimates that could not be pooled.<br/> <sup>b</sup>We judged the certainty of evidence to be very low and downgraded by three levels for serious concerns regarding inconsistency, indirectness and imprecision since there was only one study.<br/> <sup>c</sup>We judged the overall certainty of evidence to be very low and downgraded by three levels for serious concerns regarding study limitations, indirectness and imprecision due to one study at high risk of bias, the heterogeneous measures and reporting of results by different estimates that could not be pooled.<br/> <sup>d</sup>We judged the certainty of evidence to be very low and downgraded by three levels for serious concerns regarding inconsistency, indirectness and imprecision since there was only one study. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012425-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012425-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012425-sec-0161">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD012425-sec-0030"></div> <section id="CD012425-sec-0031"> <h3 class="title" id="CD012425-sec-0031">Description of the condition</h3> <p>Cancer has become a leading cause of death worldwide. Over 14 million new cases of cancer currently occur each year, and the World Health Organization expects this figure to rise by 70% over the next two decades (<a href="./references#CD012425-bbs2-0193" title="StewartBW , WildCP , (editors) . World Cancer Report 2014. International Agency for Research on Cancer, WHO Press, 2014. ">World Cancer Report 2014</a>). Coupled with ever‐improving screening programmes and cancer treatment procedures, these numbers are resulting in a burgeoning population of cancer survivors, who are channeled into many years of routine follow‐up care after they have completed their primary cancer treatment (<a href="./references#CD012425-bbs2-0141" title="DaviesNJ , BatehupL . Towards a personalised approach to aftercare: a review of cancer follow‐up in the UK. Journal of Cancer Survivorship2011;5(2):142‐51. ">Davies 2011</a>). In many countries, cancer is increasingly being managed as a chronic disease (<a href="./references#CD012425-bbs2-0176" title="RosePW , WatsonE . What is the value of routine follow‐up after diagnosis and treatment of cancer?. British Journal of General Practice2009;59(564):482‐3. ">Rose 2009</a>). </p> <p>Cancer is heterogeneous, with a range of cancer types, treatments, and outcomes. We will limit this review to the adult population, as childhood cancers differ biologically and aetiologically from adult cancers, resulting in different treatments and follow‐up issues (<a href="./references#CD012425-bbs2-0135" title="BleyerWA . The impact of childhood cancer on the United States and the world. CA: a Cancer Journal for Clinicians1990;40(6):355‐67. [DOI: 10.3322/canjclin.40.6.355] ">Bleyer 1990</a>). The post‐treatment physical and psychosocial sequelae experienced by adult cancer survivors vary greatly (<a href="./references#CD012425-bbs2-0157" title="HowellD , HackTF , OliverTK , ChulakT , MayoS , AubinM , et al. Models of care for post‐treatment follow‐up of adult cancer survivors: a systematic review and quality appraisal of the evidence. Journal of Cancer Survivorship2012;6(4):359‐71. [PUBMED: 22777364] ">Howell 2012</a>). However, regardless of cancer site, key areas of concern for survivors include the development of recurrent or new cancers, late and long‐term effects of cancer and its treatment, and psychosocial and functional issues, such as depression, fear of recurrence, and difficulties navigating aftercare services (<a href="./references#CD012425-bbs2-0159" title="JorgensenML , YoungJM , SolomonMJ . Optimal delivery of colorectal cancer follow‐up care: improving patient outcomes. Patient Related Outcome Measures2015;6:127‐38. [DOI: 10.2147/PROM.S49589] ">Jorgensen 2015</a>; <a href="./references#CD012425-bbs2-0162" title="LandierW . Survivorship care: essential components and models of delivery. Oncology2009;23(4 Suppl Nurse Ed):46‐53. [PUBMED: 19856598] ">Landier 2009</a>). Cancer follow‐up care has been developed to address these concerns and unsurprisingly, is becoming a complex intervention with increased utilisation of new strategies that attempt to meet patient needs, and be clinically effective and cost‐effective at the same time (<a href="./references#CD012425-bbs2-0141" title="DaviesNJ , BatehupL . Towards a personalised approach to aftercare: a review of cancer follow‐up in the UK. Journal of Cancer Survivorship2011;5(2):142‐51. ">Davies 2011</a>; <a href="./references#CD012425-bbs2-0176" title="RosePW , WatsonE . What is the value of routine follow‐up after diagnosis and treatment of cancer?. British Journal of General Practice2009;59(564):482‐3. ">Rose 2009</a>). </p> </section> <section id="CD012425-sec-0032"> <h3 class="title" id="CD012425-sec-0032">Description of the intervention</h3> <p>Cancer follow‐up refers to the process of care delivered after the completion of primary cancer treatment, with the main objective being surveillance and prompt detection of recurrence or new cancers, in order to optimise further treatment outcomes (<a href="./references#CD012425-bbs2-0138" title="CollinsRF , BekkerHL , DodwellDJ . Follow‐up care of patients treated for breast cancer: a structured review. Cancer Treatment Reviews2004;30(1):19‐35. [PUBMED: 14766124] ">Collins 2004</a>). Secondary objectives of follow‐up programmes include identifying and managing side and late effects of cancer and its treatment, providing informational and psychological support, and relevant referrals to rehabilitation and other healthcare services (<a href="./references#CD012425-bbs2-0176" title="RosePW , WatsonE . What is the value of routine follow‐up after diagnosis and treatment of cancer?. British Journal of General Practice2009;59(564):482‐3. ">Rose 2009</a>). There is currently no formal definition of what a follow‐up strategy is, even as follow‐up interventions are becoming increasingly complex and comprise many elements that have been developed over the past few decades in order to meet the objectives stated above (<a href="./references#CD012425-bbs2-0157" title="HowellD , HackTF , OliverTK , ChulakT , MayoS , AubinM , et al. Models of care for post‐treatment follow‐up of adult cancer survivors: a systematic review and quality appraisal of the evidence. Journal of Cancer Survivorship2012;6(4):359‐71. [PUBMED: 22777364] ">Howell 2012</a>). Thus, we define follow‐up strategies as the co‐ordination and organisation of these elements, and in Box 1, we systematically distinguish between the various elements, based on the 'Five Ws and one H' framework, and give existing examples of each: <b>w</b> hy follow‐up intervention, <b>w</b> ho leads the intervention, <b>w</b> here does it take place, <b>w</b> hen are visits scheduled, <b>w</b>hat is delivered in each session<i>,</i> and <b>h</b>ow is care delivered (<a href="./references#CD012425-bbs2-0183" title="Spencer‐ThomasO . Press release: getting the facts straight. www.owenspencer‐thomas.com (accessed 21 October 2016). ">Spencer‐Thomas 2016</a>). While the framework is typically associated with the discipline of journalism, we have found it may be applied to understand systematically the complexity of cancer follow‐up strategies. </p> <section id="CD012425-sec-0033"> <h4 class="title">Box 1. Elements that make up cancer follow‐up strategies</h4> <p> <div class="table" id="CD012425-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Follow‐up question</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Examples</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Why follow‐up intervention?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012425-list-0001"> <li> <p>Early detection of recurrence</p> </li> <li> <p>Identification and management of physical and psychological symptoms</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Who leads?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012425-list-0002"> <li> <p>Specialist‐led (e.g. oncologist or surgeon)</p> </li> <li> <p>Nurse‐led</p> </li> <li> <p>General practitioner (GP)‐led</p> </li> <li> <p>Shared care</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Where do visits take place?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012425-list-0003"> <li> <p>Primary care</p> </li> <li> <p>Secondary care</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>When are visits scheduled?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012425-list-0004"> <li> <p>Calendar‐based: fixed frequency, timing, and length of follow‐up</p> </li> <li> <p>Patient‐initiated, based on symptoms</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>What is delivered?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012425-list-0005"> <li> <p>Surveillance components: physical examination, biochemical tests, imaging procedures, etc. </p> </li> <li> <p>Aftercare components: patient information, symptom education, survivorship care plans, referrals to other services, etc. </p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>How is care delivered?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD012425-list-0006"> <li> <p>Face‐to‐face</p> </li> <li> <p>Technology‐mediated: telephone, email, etc.</p> </li> </ul> </p> </td> </tr> </tbody> </table> </div> </p> <p>Routine follow‐up programmes traditionally consist of fixed, specialist‐led, face‐to‐face outpatient visits in a hospital setting, which are scheduled frequently during the first few years (usually every two to four months), when the risk of recurrence is the highest, followed by longer intervals between visits in subsequent years, for up to 10 years or more (<a href="./references#CD012425-bbs2-0142" title="DeFeliceF , MusioD , TomboliniV . Follow‐up in head and neck cancer: a management dilemma. Advances in Otolaryngology2015;2015:1‐4. [DOI: 10.1155/2015/703450] ">De Felice 2015</a>). Appointments almost always consist of surveillance components aimed at detection of recurrence, such as clinical examinations, blood tests or imaging procedures, and also increasingly include aftercare components, such as patient education sessions, survivorship care plans and support in managing quality of life and psychosocial issues (<a href="./references#CD012425-bbs2-0141" title="DaviesNJ , BatehupL . Towards a personalised approach to aftercare: a review of cancer follow‐up in the UK. Journal of Cancer Survivorship2011;5(2):142‐51. ">Davies 2011</a>). More intensive follow‐up interventions have been defined by having more surveillance components in each appointment (<a href="./references#CD012425-bbs2-0138" title="CollinsRF , BekkerHL , DodwellDJ . Follow‐up care of patients treated for breast cancer: a structured review. Cancer Treatment Reviews2004;30(1):19‐35. [PUBMED: 14766124] ">Collins 2004</a>). Certain aftercare components, such as symptom education and integration of a survivorship care plan in clinical care may also be expected to have an impact on detection of recurrence, as patients may be more likely to recognise and self‐report signs of recurrence or adhere to follow‐up visits. </p> <p>Not surprisingly, cancer follow‐up constitutes a heavy burden on national healthcare systems, and conventional specialist‐led follow‐up is increasingly unsustainable (<a href="./references#CD012425-bbs2-0141" title="DaviesNJ , BatehupL . Towards a personalised approach to aftercare: a review of cancer follow‐up in the UK. Journal of Cancer Survivorship2011;5(2):142‐51. ">Davies 2011</a>). Therefore, other strategies, which are less comprehensive and may be more cost‐effective, have been suggested, including: nurse‐led follow‐up, GP‐led follow‐up in primary care, patient‐initiated follow‐up, fewer appointments, and the use of less intensive tests and diagnostic procedures (<a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a>; <a href="./references#CD012425-bbs2-0144" title="DickinsonR , HallS , SinclairJE , BondC , MurchieP . Using technology to deliver cancer follow‐up: a systematic review. BMC Cancer2014;14(311):1‐16. [DOI: 10.1186/1471‐2407‐14‐311] ">Dickinson 2014</a>; <a href="./references#CD012425-bbs2-0153" title="HallS , SamuelL , MurchieP . Toward shared follow‐up for cancer: developing the model with patients and GPs. Family Practice2011;28(5):554‐64. [DOI: 10.1093/fampra/cmr012] ">Hall 2011</a>; <a href="./references#CD012425-bbs2-0168" title="OeffingerKC , McCabeMS . Models for delivering survivorship care. Journal of Clinical Oncology2006;24(32):5117‐24. [PUBMED: 17093273] ">Oeffinger 2006</a>; <a href="./references#CD012425-bbs2-0176" title="RosePW , WatsonE . What is the value of routine follow‐up after diagnosis and treatment of cancer?. British Journal of General Practice2009;59(564):482‐3. ">Rose 2009</a>). Another area of research in cancer follow‐up is the addition of survivorship packages that include patient education or information, such as a survivorship care plan (<a href="./references#CD012425-bbs2-0017" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14:260. [DOI: 10.1186/1745‐6215‐14‐260] JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a nurse‐led supportive care package (survivor care) for survivors of colorectal cancer. Cancer Nursing2015;38(4 Suppl 1):S16‐7. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (Survivor‐Care, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2015;33(15 Suppl 1):9566. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , SchofieldP , ArandaS , YoungJ , ButowP . Randomised controlled trial (RCT) of a comprehensive post‐treatment support package (survivor‐care) for bowel cancer survivors. Psycho‐oncology2010;19:S193. ">Jefford 2016</a>). Regardless of follow‐up strategy, the main aims continue to be surveillance aimed at early detection of recurrence, aftercare for late and long‐term effects, and support for psychosocial and functional needs (<a href="./references#CD012425-bbs2-0162" title="LandierW . Survivorship care: essential components and models of delivery. Oncology2009;23(4 Suppl Nurse Ed):46‐53. [PUBMED: 19856598] ">Landier 2009</a>). Expected outcomes for effective follow‐up strategies are improved survival rates, prompt detection of recurrence, and better management of physical and psychological problems, leading to better quality of life for cancer survivors (<a href="./references#CD012425-bbs2-0163" title="LewisR , NealR , WilliamsN , FranceB , HendryM , RussellD , et al. Follow up of cancer in primary care versus secondary care: a systematic review. British Journal of General Practice2009;59:234‐47. [DOI: 10.3399/bjgp09X453567] ">Lewis 2009a</a>). The current shift towards fewer visits with healthcare professionals and focus on patient empowerment, is also aimed at increasing survivors' capability to self‐manage their condition and self‐initiate contact with healthcare systems. However, this may increase anxiety and distress among survivors who lack the ability to self‐monitor and self‐manage (<a href="./references#CD012425-bbs2-0163" title="LewisR , NealR , WilliamsN , FranceB , HendryM , RussellD , et al. Follow up of cancer in primary care versus secondary care: a systematic review. British Journal of General Practice2009;59:234‐47. [DOI: 10.3399/bjgp09X453567] ">Lewis 2009a</a>). </p> </section> </section> <section id="CD012425-sec-0034"> <h3 class="title" id="CD012425-sec-0034">How the intervention might work</h3> <p>Different mechanisms have been suggested to link the various components of follow‐up interventions with their outcomes. Surveillance is based on the rationale that the earlier a cancer recurrence is detected, the more amenable it will be to treatment, and therefore, the higher the survival rate (<a href="./references#CD012425-bbs2-0137" title="ClarkeT , GalaalK , BryantA , NaikR . Evaluation of follow‐up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD006119.pub3] ">Clarke 2014</a>). However, few trials have studied these two outcomes together and currently, there is no strong evidence that routine surveillance improves time to detection of recurrence or overall survival (<a href="./references#CD012425-bbs2-0137" title="ClarkeT , GalaalK , BryantA , NaikR . Evaluation of follow‐up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD006119.pub3] ">Clarke 2014</a>; <a href="./references#CD012425-bbs2-0158" title="JefferyM , HickeyBE , HiderPN , SeeAM . Follow‐up strategies for patients treated for non‐metastatic colorectal cancer. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD002200.pub3] ">Jeffery 2016</a>; <a href="./references#CD012425-bbs2-0167" title="MoschettiI , CinquiniM , LambertiniM , LevaggiA , LiberatiA . Follow‐up strategies for women treated for early breast cancer. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD001768.pub3] ">Moschetti 2016</a>). Furthermore, symptoms of recurrences are frequently detected by patients themselves, between scheduled visits, and traditional hospital‐based appointments often fail to meet patients' supportive care needs (<a href="./references#CD012425-bbs2-0142" title="DeFeliceF , MusioD , TomboliniV . Follow‐up in head and neck cancer: a management dilemma. Advances in Otolaryngology2015;2015:1‐4. [DOI: 10.1155/2015/703450] ">De Felice 2015</a>). This has led to an increased focus on strategies where patients are trained to recognise, report, and self‐manage symptoms of recurrence, late and long‐term side‐effects, emotional distress, and functional needs (<a href="./references#CD012425-bbs2-0141" title="DaviesNJ , BatehupL . Towards a personalised approach to aftercare: a review of cancer follow‐up in the UK. Journal of Cancer Survivorship2011;5(2):142‐51. ">Davies 2011</a>). This may be achieved through patient information and symptom education programmes, psychosocial support provided by trained nurses, and quick referral to specialised care, rehabilitation, and other healthcare services when needed (<a href="./references#CD012425-bbs2-0141" title="DaviesNJ , BatehupL . Towards a personalised approach to aftercare: a review of cancer follow‐up in the UK. Journal of Cancer Survivorship2011;5(2):142‐51. ">Davies 2011</a>). There is evidence that such strategies are positively accepted by patients, and may improve patient‐reported outcomes, such as health‐related quality of life (<a href="./references#CD012425-bbs2-0136" title="BrennanME , ButowP , MarvenM , SpillaneAJ , BoyleFM . Survivorship care after breast cancer treatment‐ experiences and preferences of Australian women. Breast2011;20(3):271‐7. [DOI: 10.1016/j.breast.2010.12.006] ">Brennan 2011</a>; <a href="./references#CD012425-bbs2-0141" title="DaviesNJ , BatehupL . Towards a personalised approach to aftercare: a review of cancer follow‐up in the UK. Journal of Cancer Survivorship2011;5(2):142‐51. ">Davies 2011</a>). In <a href="#CD012425-fig-0001">Figure 1</a>, we constructed a model that summarises the potential links between follow‐up strategies, possible mechanisms, and expected outcomes. As illustrated, cancer‐related factors (e.g. cancer type and treatment) and patient‐related factors (e.g. age and sex) determine the symptoms relevant to a particular patient group, which in turn, inform the organisation of the different elements within specific follow‐up strategies. Therefore, follow‐up strategies might work through different mechanisms for different patient groups, to achieve the expected outcomes of survival and symptom management. </p> <div class="figure" id="CD012425-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Proposed model of cancer follow‐up, mechanisms and possible outcomes" data-id="CD012425-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Proposed model of cancer follow‐up, mechanisms and possible outcomes</p> </div> </div> </div> </section> <section id="CD012425-sec-0035"> <h3 class="title" id="CD012425-sec-0035">Why it is important to do this review</h3> <p>Due to the rapidly rising numbers of cancer survivors, healthcare systems are under increasing pressure to optimise follow‐up interventions to meet patients' physical, psychological, and functional needs, while remaining economically viable (<a href="./references#CD012425-bbs2-0163" title="LewisR , NealR , WilliamsN , FranceB , HendryM , RussellD , et al. Follow up of cancer in primary care versus secondary care: a systematic review. British Journal of General Practice2009;59:234‐47. [DOI: 10.3399/bjgp09X453567] ">Lewis 2009a</a>). New models of follow‐up care continue to be developed and implemented, affecting the lives of millions of survivors, but guidance for the development of effective follow‐up strategies has been limited so far by the small number of randomised trials available for each cancer site and the heterogeneity of these studies. The optimal content and organisation of follow‐up procedures are still under debate (<a href="./references#CD012425-bbs2-0184" title="SperdutiI , ViciP , TinariN , GamucciT , DeTursiM , CorteseG , et al. Breast cancer follow‐up strategies in randomized phase III adjuvant clinical trials: a systematic review. Journal of Experimental &amp; Clinical Cancer Research2013;32(1):89. ">Sperduti 2013</a>). Currently, four Cochrane Reviews on follow‐up strategies have been published for specific cancer sites (breast cancer (<a href="./references#CD012425-bbs2-0167" title="MoschettiI , CinquiniM , LambertiniM , LevaggiA , LiberatiA . Follow‐up strategies for women treated for early breast cancer. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD001768.pub3] ">Moschetti 2016</a>), non‐metastatic colorectal cancer (<a href="./references#CD012425-bbs2-0158" title="JefferyM , HickeyBE , HiderPN , SeeAM . Follow‐up strategies for patients treated for non‐metastatic colorectal cancer. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD002200.pub3] ">Jeffery 2016</a>), cervical cancer (<a href="./references#CD012425-bbs2-0161" title="LanceleyA , FianderA , McCormackM , BryantA . Follow‐up protocols for women with cervical cancer after primary treatment. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD008767.pub2] ">Lanceley 2013</a>), and epithelial ovarian cancer (<a href="./references#CD012425-bbs2-0137" title="ClarkeT , GalaalK , BryantA , NaikR . Evaluation of follow‐up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD006119.pub3] ">Clarke 2014</a>)) but with the exception of the review on colorectal cancer follow‐up, they have lacked the power to draw conclusions on the effects of different follow‐up strategies due to the lack of studies. One Cochrane Review evaluated follow‐up interventions regardless of type of cancer, but the focus was on interventions that improved continuity of care across the entire period of cancer treatment, and the outcomes of survival and recurrence were not included (<a href="./references#CD012425-bbs2-0133" title="AubinM , GiguereA , MartinM , VerreaultR , FitchMI , KazanjianA , et al. Interventions to improve continuity of care in the follow‐up of patients with cancer. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD007672.pub2] ">Aubin 2012</a>). This review sets out to fill this gap by including randomised trials of cancer follow‐up strategies across all cancer sites. By doing so, we seek to overcome the limitation of low numbers of trials in certain sites and provide a systematic overview of the latest available evidence for follow‐up strategies in multiple cancer types, including those that have not been previously represented (e.g. lung cancer, head and neck cancer, etc.). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012425-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012425-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012425-sec-0167">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012425-sec-0036"></div> <p>The objective of this review is to compare the effect of different follow‐up strategies in adult cancer survivors, following completion of primary cancer treatment, on the primary outcomes of overall survival and time to detection of recurrence. Secondary outcomes are health‐related quality of life, anxiety (including fear of recurrence), depression and cost. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012425-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012425-sec-0037">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012425-sec-0168">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012425-sec-0037"></div> <section id="CD012425-sec-0038"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012425-sec-0039"> <h4 class="title">Types of studies</h4> <p>We included all randomised trials that compared different follow‐up strategies in adult cancer survivors who had completed curatively intended primary cancer treatment, with respect to the outcomes of overall survival, time to detection of recurrence, health‐related quality of life, depression, anxiety and cost. We did not put any restrictions on the language of the publication. Studies published in other languages were translated into English if necessary. </p> </section> <section id="CD012425-sec-0040"> <h4 class="title">Types of participants</h4> <p>We included trials that involved adults (18 years of age or older) who had completed curatively‐intended primary cancer treatment. Participants must have been histologically and clinically diagnosed with cancer, regardless of cancer type and stage. </p> </section> <section id="CD012425-sec-0041"> <h4 class="title">Types of interventions</h4> <p>We included trials that compared any of the following interventions that might be expected to have an impact of detection of recurrence. </p> <p> <ul id="CD012425-list-0007"> <li> <p>Non‐specialist‐led follow‐up (i.e. GP‐led, nurse‐led, patient‐initiated or shared care) versus specialist‐led follow‐up </p> </li> <li> <p>Less intensive versus more intensive follow‐up (based on clinical visits, examinations and diagnostic procedures) </p> </li> <li> <p>Follow‐up integrating additional patient symptom education or monitoring, or survivorship care plans versus usual care </p> </li> </ul> </p> <p>We excluded studies testing only psychosocial or rehabilitation components or studies investigating diagnostic components that were not integrated as part of clinical cancer follow‐up. </p> </section> <section id="CD012425-sec-0042"> <h4 class="title">Types of outcome measures</h4> <section id="CD012425-sec-0043"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012425-list-0008"> <li> <p>Overall survival: calculated from time of randomisation or recruitment to study until time of death </p> </li> <li> <p>Time to detection of recurrence: calculated from time of randomisation or recruitment to study until detection of recurrence. In some studies, this outcome was called disease‐free survival. </p> </li> </ul> </p> </section> <section id="CD012425-sec-0044"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012425-list-0009"> <li> <p>Health‐related quality of life</p> </li> <li> <p>Anxiety (including fear of recurrence)</p> </li> <li> <p>Depression</p> </li> <li> <p>Cost</p> </li> </ul> </p> <p>We included all studies that planned to report or reported on at least one of our outcome measures. We only considered health‐related quality of life, anxiety and depression if studies measured them using validated scales, such as the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for cancer patients (EORTC QLQ‐C30; <a href="./references#CD012425-bbs2-0131" title="AaronsonNK , AhmedzaiS , BergmanB , BullingerM , CullA , DuezNJ , et al. The European Organization for Research and Treatment of Cancer QLQ‐C30: a quality‐of‐life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute1993;85(5):365‐76. [PUBMED: 8433390] ">Aaronson 1993</a>), the 36‐item Short Form Health Survey (SF‐36; <a href="./references#CD012425-bbs2-0190" title="WareJE , KosinskiMA , KellerSD . SF‐36 physical and mental health summary scales: a user’s manual. Boston, Mass: The Health Institute, New England Medical Center, 1994. ">Ware 1994</a>), the Hospital Anxiety and Depression Scale (HADS; <a href="./references#CD012425-bbs2-0182" title="SnaithRP . The Hospital Anxiety And Depression Scale. Health and Quality of Life Outcomes2003;1:29. [PUBMED: 12914662] ">Snaith 2003</a>), etc. For all included studies, we also extracted cost outcome data if they were reported. </p> </section> </section> </section> <section id="CD012425-sec-0045"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012425-sec-0046"> <h4 class="title">Electronic searches</h4> <p>The review authors developed the search strategies in consultation with the Effective Practice and Organisation of Care (EPOC) Information Specialist (IS), who also ensured that the search strategy was peer‐reviewed by a second IS. We searched the Cochrane Database of Systematic Reviews (CDSR) and the Database of Abstracts of Reviews of Effects (DARE) for related systematic reviews and the databases below for primary studies on 11 December 2018: </p> <p> <ul id="CD012425-list-0010"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 12) in the Cochrane Library </p> </li> <li> <p>MEDLINE Ovid, including Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations and Versions (1946 to 11 December 2018) </p> </li> <li> <p>Embase Ovid (1974 to 11 December 2018)</p> </li> <li> <p>PsycINFO Ovid (1967 to 11 December 2018)</p> </li> <li> <p>CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature; 1982 to 11 December 2018) </p> </li> </ul> </p> <p>Search strategies are comprised of keywords and controlled vocabulary terms. We applied no language or time limits. All strategies used are provided in <a href="./appendices#CD012425-sec-0137">Appendix 1</a>. </p> </section> <section id="CD012425-sec-0047"> <h4 class="title">Searching other resources</h4> <p>We also searched the following registers for ongoing trials on 11 December 2018:</p> <p> <ul id="CD012425-list-0011"> <li> <p>International Clinical Trials Registry Platform (ICTRP), Word Health Organization (WHO), <a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a> </p> </li> <li> <p>ClinicalTrials.gov, US National Institutes of Health (NIH), <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>. </p> </li> </ul> </p> <p>Additionally, we reviewed reference lists of all included studies and relevant systematic reviews, as well as contacted authors of relevant studies and reviews to clarify reported published information and to seek unpublished results and data. </p> </section> </section> <section id="CD012425-sec-0048"> <h3 class="title" id="CD012425-sec-0048">Data collection and analysis</h3> <section id="CD012425-sec-0049"> <h4 class="title">Selection of studies</h4> <p>We uploaded all titles and abstracts retrieved by electronic searching and through other sources into Covidence, which is an online platform that facilitates the management of the systematic review process (<a href="./references#CD012425-bbs2-0140" title="Veritas Health Innovation. Covidence. Version accessed 19 December 2016. Melbourne, Australia: Veritas Health Innovation. ">Covidence</a>). We used Covidence to carry out both the title/abstract screening stage and the full‐text screening stage. Five review authors (BLH, RVK, LS, ASF and TAH) independently screened all titles and abstracts for inclusion and we obtained the full text of study reports and publications coded as "Yes" or "Maybe". Thereafter, the authors independently screened the full texts to identify studies for inclusion. We tagged excluded studies with the reason for exclusion, following a similar hierarchy as the screening algorithm: wrong intervention, wrong patient population (e.g. patients were not cancer‐free or were treated for recurrence) or wrong outcome. These reasons are predefined in Covidence. We resolved any disagreements during both screening stages through regularly held discussion meetings with the rest of the author team. We also identified ongoing studies and recorded any information available. We extracted Information from Covidence regarding the selection process to complete a PRISMA flow diagram (<a href="./references#CD012425-bbs2-0165" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6:e1000100. ">Liberati 2009</a>; <a href="#CD012425-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD012425-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD012425-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD012425-sec-0050"> <h4 class="title">Data extraction and management</h4> <p>We used a modified Cochrane data collection form from our editorial group, Cochrane Effective Practice and Organisation of Care (EPOC), to capture study characteristics and outcome data (<a href="./references#CD012425-bbs2-0145" title="Cochrane EffectivePractice , Organisation of Care(EPOC) . Data collection form. EPOC resources for review authors. Available from epoc.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 21 October 2016). ">EPOC 2013</a>). We used the first five studies to pilot and refine the template. Five review authors (BLH, RVK, LS, ASF and TAH) extracted the following study characteristics from included studies. </p> <p> <ul id="CD012425-list-0012"> <li> <p>Methods: study design, number of study centres and location, study setting, withdrawals, date of study, follow‐up </p> </li> <li> <p>Participants: cancer site, number, mean age, age range, gender, cancer stage, diagnostic criteria, inclusion criteria, exclusion criteria, other relevant characteristics </p> </li> <li> <p>Interventions: intervention type, intervention components, comparison, fidelity assessment</p> </li> <li> <p>Outcomes: main and other outcomes specified and collected, time points reported</p> </li> <li> <p>Notes: funding for trial, notable conflicts of interest of trial authors, and ethical approval </p> </li> </ul> </p> <p>For each study, one review author extracted all the pre‐defined relevant data and another review author independently read all the publications from the same study and double‐checked the form to ensure accuracy and that there were no missing data. We only extracted outcome data for outcomes relevant for this review. For studies with multiple reports, we extracted data from all the reports, if relevant. We resolved any disagreements during discussion meetings with the rest of the review author team. To minimise error, the review authors used the guidance provided in Chapter 7 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012425-bbs2-0155" title="HigginsJP , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>), and took the online Cochrane Interactive Learning course on selecting studies and collecting data (<a href="./references#CD012425-bbs2-0177" title="SambunjakD , CumpstonM , WattsC . Module 4: Selecting studies and collecting data. In: Cochrane Interactive Learning: Conducting an intervention review, Cochrane, 2017. Available from training.cochrane.org/interactivelearning. ">Sambunjak 2017</a>). We used information from the data collection forms to create the '<a href="./references#CD012425-sec-0158" title="">Characteristics of included studies</a>' table. We noted if the study did not contribute data that could be pooled in a meta‐analysis. </p> </section> <section id="CD012425-sec-0051"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Five review authors (BLH, RVK, LS, ASF and TAH) independently assessed risk of bias for each study, using the criteria outlined in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012425-bbs2-0156" title="HigginsJP , AltmanDG , Sterne JA(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>) and guidance from EPOC (<a href="./references#CD012425-bbs2-0146" title="Cochrane EffectivePractice , Organisation of Care(EPOC) . Suggested risk of bias criteria for EPOC reviews. EPOC Resources for review authors. Available from epoc.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 21 October 2016). ">EPOC 2015</a>). To further minimise error, the authors also took the Cochrane Interactive Learning course on introduction to study quality and risk of bias (<a href="./references#CD012425-bbs2-0170" title="PageMJ , HigginsJ , SambunjakD , CumpstonM , WattsC . Module 5: Introduction to study quality and risk of bias. In: Cochrane Interactive Learning: Conducting an intervention review, Cochrane, 2017. Available from training.cochrane.org/interactivelearning. ">Page 2017</a>). We resolved disagreements by discussion with the rest of the author team or with the editors of this review. We assessed the risk of bias according to the following domains. </p> <p> <ul id="CD012425-list-0013"> <li> <p>Random sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding of participants and personnel</p> </li> <li> <p>Blinding of outcome assessment</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other bias, including baseline imbalances and risk of contamination</p> </li> </ul> </p> <p>As the risk of detection bias differs for objective outcomes (survival and recurrence) and patient‐reported outcomes (quality of life, anxiety and depression), we assessed the risk of bias by type of outcome for the following domains: blinding of participants and personnel, blinding of outcome assessment and incomplete outcome data (<a href="./references#CD012425-bbs2-0156" title="HigginsJP , AltmanDG , Sterne JA(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). For blinding of outcome assessment, we further assessed the risk of bias separately for survival and time to detection of recurrence because while there can be no doubt as to death, time to detection of recurrence may be influenced by judgement regarding clinical tests and assessments, which may be affected by lack of blinding. </p> <p>We classified each potential source of bias as high, low, or unclear, and provide a quote from the study report and justification for our judgement in the 'Risk of bias' table. When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. </p> </section> <section id="CD012425-sec-0052"> <h4 class="title">Measures of treatment effect</h4> <section id="CD012425-sec-0053"> <h5 class="title">Time‐to‐event outcomes</h5> <p>We have presented time‐to‐event outcomes, overall survival and time to detection of recurrence, as hazard ratios (HRs) (<a href="./references#CD012425-bbs2-0143" title="DeeksJJ , HigginsJP , Altman DG(editors) , on behalf of the Cochrane Statistical Methods Group. Deeks JJ, Higgins JPT, Altman DG Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). We estimated log HRs and the associated standard error (SE) required for a meta‐analysis using the calculator in Review Manager 5 (<a href="./references#CD012425-bbs2-0175" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>) and a spreadsheet developed by <a href="./references#CD012425-bbs2-0188" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. [DOI: 0.1186/1745‐6215‐8‐16] ">Tierney 2007</a> that provides 11 methods for calculating HRs and the associated variance depending on the information available in each study. We used Method 3 for studies that provided a HR and its associated confidence interval (CI), Method 9 for studies that provided a P‐value from a log‐rank test, the number of events and the numbers randomised to each arm and Method 11 when a study only provided Kaplan‐Meier curves and numbers at risk. For multi‐armed studies, we also used the approach proposed by <a href="./references#CD012425-bbs2-0171" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. [PUBMED: 9921604] ">Parmar 1998</a> to estimate the overall log HR and its variance for the combined intervention arms.We also contacted the authors of relevant studies for additional information where possible and noted this, along with any response, in the <a href="./references#CD012425-sec-0158" title="">Characteristics of included studies</a>. </p> <p>We did not specify the minimal clinically important difference (MCID) (<a href="./references#CD012425-bbs2-0172" title="PatrickDL , GuyattGH , AcquadroC . Chapter 17: Patient‐reported outcomes. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Patrick 2011</a>) for survival and time to detection of recurrence for this review. Instead, we assessed the importance of effects and the precision of the estimates based on how likely it seemed to us that some people would make different decisions if the true effect was near one end or the other of the CI, for example, when the CI includes effects that are not trivial (<a href="./references#CD012425-bbs2-0148" title="Cochrane EffectivePractice , Organisation of Care(EPOC) . Reporting the effects of an intervention in EPOC reviews. EPOC Resources for review authors. Available at: epoc.cochrane.org/resources/epoc‐resourcesreview‐authors (accessed 21 October 2016). ">EPOC 2018</a>). </p> </section> <section id="CD012425-sec-0054"> <h5 class="title">Continuous outcomes</h5> <p>For health‐related quality of life, anxiety and depression, we calculated the mean difference (MD) for each measurement tool together with the 95% CI by using the mean final value scores and the associated standard deviations (SD) in each study (<a href="./references#CD012425-bbs2-0143" title="DeeksJJ , HigginsJP , Altman DG(editors) , on behalf of the Cochrane Statistical Methods Group. Deeks JJ, Higgins JPT, Altman DG Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). We used final value scores at 12 months as this was the time point reported by the majority of the included studies and because we considered one year a sufficient period of time to assess a meaningful effect of the intervention on patient‐reported outcomes. We also used mean final value scores and the associated SDs instead of other estimates of treatment effects because this was the measurement most consistently reported across the included studies. We did not use the standardised mean difference (SMD) because the different scales/subscales often measure different dimensions of an outcome and combining the results would not be meaningful. </p> <p>In the few studies where means and SDs were not reported, we attempted to contact the study author of for the required information. Where possible, we estimated the mean and SD using the methods described in Chapter 7 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012425-bbs2-0155" title="HigginsJP , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>), and in <a href="./references#CD012425-bbs2-0189" title="WanX , WangW , LiuJ , TongT . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology2014;14(1):135. [DOI: 10.1186/1471‐2288‐14‐135.] ">Wan 2014</a>. For each measurement tool, we state the range of scores possible, whether an increase in score is desirable and the MCID, if available from the literature. Information regarding whether a study author was contacted, what information was requested, and whether we received a reply was noted in the <a href="./references#CD012425-sec-0158" title="">Characteristics of included studies</a> table. </p> </section> </section> <section id="CD012425-sec-0055"> <h4 class="title">Unit of analysis issues</h4> <p>We included cluster‐randomised trials in the meta‐analysis only if we were able to extract an estimate of the treatment effect from an analysis that properly accounted for the cluster design. For trials with multiple intervention groups, we only included the group with the intervention that met the inclusion criteria for this review (<a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a>), or we combined the intervention groups (<a href="./references#CD012425-bbs2-0036" title="MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017;21(32):1‐86. MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00560365 (first received 20 December 2016). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology2011;29(15 Suppl 1):3521. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. [DOI: 10.1001/jama.2013.285718] PughSA , FullerA , PereraR , GeorgeS , MantD , PrimroseJ . The follow‐up after colorectal cancer surgery trial: randomised trial of follow‐up after colorectal cancer surgery and outcome following recurrence. Journal of the American College of Surgeons2014;219(4 Suppl 1):e46‐7. PughSA , MantD , ShinkinsB , MellorJ , PereraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology2016;27(Suppl 6):no pagination. ShinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PloS One2017;12(3):e0171810. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;105(6):658‐62. ">Primrose 2014</a>), and created a single pair‐wise comparison with the control group for the meta‐analysis. We did not include cross‐over trials in this review. </p> </section> <section id="CD012425-sec-0056"> <h4 class="title">Dealing with missing data</h4> <p>We report missing data and attrition rates for the included studies as part of the 'Risk of bias' assessment under the domain 'Incomplete outcome data'. Where possible, we contacted study authors in order to verify key study characteristics and obtain unreported outcome data. Almost all the included studies reported intention‐to‐treat (ITT) analyses or methods to impute missing data, thus indicating an ITT approach. If a study reported both ITT and per‐protocol analyses, we extracted only ITT outcome data. We did not impute missing data and we did not request individual patient data. </p> </section> <section id="CD012425-sec-0057"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the Chi<sup>2</sup> test and the I² statistic (<a href="./references#CD012425-bbs2-0154" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>), to measure statistical heterogeneity among the trials in the analysis for each outcome (<a href="./references#CD012425-bbs2-0143" title="DeeksJJ , HigginsJP , Altman DG(editors) , on behalf of the Cochrane Statistical Methods Group. Deeks JJ, Higgins JPT, Altman DG Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>; <a href="./references#CD012425-bbs2-0187" title="ThompsonSG , HigginsJP . How should meta‐regression analyses be undertaken and interpreted?. Statistics in Medicine2002;21(11):1559‐73. [PUBMED: 12111920] ">Thompson 2002</a>). We expected clinical heterogeneity, as there was substantial variation across studies on study and patient characteristics. Therefore, regardless of the statistical heterogeneity level, we planned and performed a random‐effects meta‐regression analysis, as reported below, to investigate prespecified study differences. </p> </section> <section id="CD012425-sec-0058"> <h4 class="title">Assessment of reporting biases</h4> <p>For outcomes where we were able to pool more than 10 studies, we created and examined a funnel plot to explore possible publication biases and interpreted the results with caution (<a href="./references#CD012425-bbs2-0186" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials. BMJ2011;343:d4002. [DOI: 10.1136/bmj.d4002] ">Sterne 2011</a>). For studies where a protocol had been published or the study had been prospectively registered, we compared the predefined outcome measures with those that the study reported as part of the risk of bias assessment under the domain 'Selective reporting'. </p> </section> <section id="CD012425-sec-0059"> <h4 class="title">Data synthesis</h4> <p>For time‐to‐event outcomes, we carried out a meta‐analysis for all the trials where it was possible to estimate a log HR and associated sampling variance. We present relative effects (HR) and estimated anticipated absolute effects in terms of the absolute risk of event‐free survival (i.e. the event being death) for overall survival, and as the absolute risk of an event for recurrence, based on formulae found in <a href="./references#CD012425-bbs2-0180" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , GuyattGH . Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA editor(s). Draft version (29 January 2019) for inclusion in: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). London: Cochrane, 2019. Available from www.training.cochrane.org/handbook. ">Schünemann 2019</a>. </p> <p>For continuous outcomes, we carried out a meta‐analysis for each scale or subscale if at least three studies reported a measurement scale or subscale at 12 months' follow‐up, in order to have reasonable representativeness and probability of detecting the effect of interest. </p> <p>We synthesised data based on three intervention comparisons:</p> <p> <ol id="CD012425-list-0014"> <li> <p>Non‐specialist‐led follow‐up (i.e. GP‐led, nurse‐led, patient‐initiated or shared care) versus specialist‐led follow‐up </p> </li> <li> <p>Less intensive versus more intensive follow‐up (based on clinical visits, examinations and procedures). In trials where the intervention group received the more intensive treatment, the reported estimates for intervention and comparison arms were reversed. </p> </li> <li> <p>Follow‐up integrating additional patient symptom education or monitoring, or survivorship care plans versus usual care </p> </li> </ol> </p> <p>In each comparison group, we followed the same procedures with regards to undertaking a possible meta‐analysis and meta‐regression analysis (see <a href="#CD012425-sec-0061">Subgroup analysis and investigation of heterogeneity</a>). We carried out all meta‐analyses in Review Manager 5 using the inverse variance random‐effects method (<a href="./references#CD012425-bbs2-0175" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We carried out meta‐regression in the statistical software R (version 3.5.1, package 'meta'; <a href="./references#CD012425-bbs2-0174" title="R Core Team. R: a language and environment for statistical computing. Version accessed 1 February 2018. Vienna, Austria: R Foundation for Statistical Computing. ">R 2017</a>), and the codes are available in <a href="./appendices#CD012425-sec-0145">Appendix 2</a> . For the studies that reported data that we could not pool in the meta‐analyses, we have presented the findings in a narrative manner (<a href="./references#CD012425-bbs2-0143" title="DeeksJJ , HigginsJP , Altman DG(editors) , on behalf of the Cochrane Statistical Methods Group. Deeks JJ, Higgins JPT, Altman DG Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). </p> <section id="CD012425-sec-0060"> <h5 class="title">'Summary of findings' tables</h5> <p>For each intervention comparison, we used the GRADEpro software (<a href="./references#CD012425-bbs2-0151" title="GRADE Working Group, McMaster University (developed by Evidence Prime, Inc.). GRADEpro GDT. Version accessed 21 October 2016. Hamilton (ON): GRADE Working Group, McMaster University (developed by Evidence Prime, Inc.). ">GRADEpro GDT 2015</a>), to create a 'Summary of findings' table for overall survival, time to detection of recurrence, health‐related quality of life, anxiety, depression and cost. We assessed the overall certainty of evidence for each outcome using the five GRADE considerations: study limitations (risk of bias), consistency (of effect and measurement across studies), imprecision (wide confidence intervals in study estimates), indirectness (representativeness and whether we had to indirectly calculate effect estimates), and publication bias (through funnel plots if we pooled 10 or more studies; <a href="./references#CD012425-bbs2-0178" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s) . Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html. ">Schünemann 2013</a>). We also used the methods and recommendations described in Section 8.5 (<a href="./references#CD012425-bbs2-0156" title="HigginsJP , AltmanDG , Sterne JA(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>), and Chapter 12 (<a href="./references#CD012425-bbs2-0179" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al. on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Schünemann 2017</a>), of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> and the EPOC worksheets (<a href="./references#CD012425-bbs2-0147" title="Cochrane EffectivePractice , Organisation of Care(EPOC) . EPOC worksheets for preparing a Summary of Findings (SoF) table using GRADE. EPOC Resources for review authors. Available at: epoc.cochrane.org/resources/epoc‐resources‐review‐authors (accessed 21 October 2016). ">EPOC 2017</a>), and attach the GRADE evidence profiles for each outcome in <a href="./appendices#CD012425-sec-0148">Appendix 3</a>. </p> <p>As we only included randomised trials, the evidence certainty started at 'high', If we identified any serious concerns in any of the five GRADE domains, we downgraded the certainty of the evidence accordingly by either one level to 'moderate.' two levels to 'low' or three levels to 'very low' (<a href="./references#CD012425-bbs2-0152" title="GuyattGH , OxmanAD , VistG , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE Working Group. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336:924‐6. ">Guyatt 2008</a>). Three review authors (BLH, RVK and ASF) carried out the GRADE assessments of each outcome and we resolved any disagreements with the rest of the review author group. For the outcomes of health‐related quality of life, anxiety and depression, we presented the findings from the EORTC‐C30 Global health status subscale, the HADS‐Anxiety subscale and the HADS‐Depression subscale, as we judged the results from these subscales to be most representative of the outcome. Additional outcome information that we were not able to incorporate into the evidence from the meta‐analyses are noted in the comments section. </p> </section> </section> <section id="CD012425-sec-0061"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>An important aim of this review is to investigate how characteristics of all the different strategies may relate to outcome effects. Therefore, we investigated this heterogeneity by performing meta‐regression analysis, that is, including various predefined study characteristics as explanatory variables and testing for significance. By doing so, we aimed to compare the effect of various follow‐up strategies without splitting participant data into subgroups, where conclusions may be misleading if there are a limited number of studies available. To avoid false positive conclusions that can occur through post‐hoc analyses, we identified the co‐variates we wished to investigate a priori (<a href="./references#CD012425-bbs2-0187" title="ThompsonSG , HigginsJP . How should meta‐regression analyses be undertaken and interpreted?. Statistics in Medicine2002;21(11):1559‐73. [PUBMED: 12111920] ">Thompson 2002</a>), and carried out a meta‐regression analysis to investigate how the following variables relate to the primary outcomes of overall survival and time to detection of recurrence: </p> <p> <ul id="CD012425-list-0015"> <li> <p>cancer site;</p> </li> <li> <p>sex of participant;</p> </li> <li> <p>age of participant;</p> </li> <li> <p>study quality (i.e. high (4‐5 low 'Risk of bias' judgements); moderate (2‐3 low 'Risk of bias' judgements); low (0‐1 low 'Risk of bias' judgements)); </p> </li> <li> <p>year of publication (i.e. before 2000; after 2000).</p> </li> </ul> </p> <p>We note that associations derived from meta‐regressions are observational, and that the risk of bias must be taken into account in the interpretation of results. Due to insufficient studies, we were not able to carry out meta‐regression analyses for the continuous outcomes and we present our findings in a narrative manner (<a href="./references#CD012425-bbs2-0143" title="DeeksJJ , HigginsJP , Altman DG(editors) , on behalf of the Cochrane Statistical Methods Group. Deeks JJ, Higgins JPT, Altman DG Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). We did not carry out subgroup analysis. </p> </section> <section id="CD012425-sec-0062"> <h4 class="title">Sensitivity analysis</h4> <p>For each meta‐analysis, we carried out a sensitivity analysis whereby we restricted the analysis to studies with published HRs, means and SD, and we noted their impact on effect sizes. We did not restrict the analysis to studies with low risk of bias, as we had already investigated the effect of study quality through meta‐regression. </p> <section id="CD012425-sec-0063"> <h5 class="title">Assesment of bias in conducting the systematic review</h5> <p>We conducted this review according to the published protocol and report all deviations in the '<a href="#CD012425-sec-0155">Differences between protocol and review</a>' section below. We used PRISMA statement (<a href="./references#CD012425-bbs2-0165" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6:e1000100. ">Liberati 2009</a>), to guide the reporting of this review. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012425-sec-0064" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012425-sec-0064"></div> <section id="CD012425-sec-0065"> <h3 class="title">Description of studies</h3> <section id="CD012425-sec-0066"> <h4 class="title">Results of the search</h4> <p>After the removal of duplicates, the electronic search yielded 9110 references and we identified a further 17 references from other sources. Following title and abstract screening, we identified and retrieved the full text of 297 references and collated the references into 131 studies. Following full‐text screening, we identified 81 studies for inclusion, of which 28 studies were ongoing (see <a href="./references#CD012425-sec-0158" title="">Characteristics of included studies</a> and <a href="./references#CD012425-sec-0160" title="">Characteristics of ongoing studies</a> tables). We excluded 50 studies with reasons (see <a href="./references#CD012425-sec-0159" title="">Characteristics of excluded studies</a>). The screening flow diagram and the proportions of included studies that contributed to each comparison and outcome can be seen in <a href="#CD012425-fig-0002">Figure 2</a> (<a href="./references#CD012425-bbs2-0166" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: the PRISMA Statement. PLoS Medicine2009;6(7):e1000097. ">Moher 2009</a>). </p> </section> <section id="CD012425-sec-0067"> <h4 class="title">Included studies</h4> <p>Below, we provide a brief summary of the 53 included studies. Two of the included studies were cluster‐randomised trials (<a href="./references#CD012425-bbs2-0031" title="MurchieP , NicolsonMC , HannafordPC , RajaEA , LeeAJ , CampbellNC . Patient satisfaction with GP‐led melanoma follow‐up: a randomised controlled trial. British Journal of Cancer2010;102(10):1447‐55. ">Murchie 2010</a>; <a href="./references#CD012425-bbs2-0038" title="DeRooijBH , EzendamNP , NicolaijeKA , LodderP , VosMC , PijnenborgJM , et al. Survivorship care plans have a negative impact on long‐term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. Quality of Life Research2018;27(6):1533‐44. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2‐year follow‐up ‐ The ROGY care trial. Gynecologic Oncology2017;145(2):319‐28. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Long‐term impact of survivorship care plans on ovarian cancer patient reported outcomes‐new results of the ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):64‐5. DeRooijBH , EzendamNP , NicolaijeKA , VosMC , PijnenborgJM , BollD , et al. The indirect effects of survivorship care plans on quality of life, anxiety and depression‐the ROGY care trial. Supportive Care in Cancer2017;25(2 Suppl 1):S53‐4. DeRooijBH , EzendamNP , VosMC , PijnenborgJM , BollD , KruitwagenRF , et al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. Cancer Epub 2018 Nov 30;125(5):788‐97. [DOI: 10.1002/cncr.31844] EzendamN , DeRooijB , NicolaijeK , VosC , PijnenborgJ , BollD , et al. Long‐term impact of cancer survivorship care plans on patient outcomes‐the randomized controlled ROGY care trial. International Journal of Gynecological Cancer2016;26:91. EzendamNP , VanBroekhovenM , Van DePoll‐FranseLV , DeRooijBH . The role of illness perceptions in smoking, alcohol consumption and weight changes among gynaecological cancer survivors. Quality of Life Research2016;25(1 Suppl 1):114. JeppesenMM , EzendamNP , PijnenborgJM , VosMC , BollD , KruitwagenRF , et al. The impact of the survivorship care plan on health care use: 2‐year follow‐up results of the ROGY care trial. Journal of Cancer Survivorship2018;12(1):18‐27. NicolaijeKA , EzendamNP , VosMC , PijnenborgJM , BollD , BossEA , et al. Impact of an automatically generated cancer survivorship care plan on patient‐reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial. Journal of Clinical Oncology2015;33(31):3550‐9. Van dePoll‐FranseL , NicolaijeK , EzendamN , VosC , BollD , PijnenborgJ , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY CARE): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Psycho‐oncology2013;22:341‐2. Van dePoll‐FranseLV , JeppesenMM , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. The survivorship care plan increases the use of primary care in anxious and irradiated endometrial cancer patients. Two year outcomes of the pragmatic cluster randomized ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):164. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosCM , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY Care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosMC , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. European Journal of Cancer2013;49:S720. Van dePoll‐FranseLV , NicolaijeKA , VosMC , PijnenborgJM , BollD , HussonO , et al. The impact of a cancer survivorship care plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials2011;12:256. ">ROGY 2015</a>), and three studies were multi‐armed (<a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a>; <a href="./references#CD012425-bbs2-0036" title="MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017;21(32):1‐86. MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00560365 (first received 20 December 2016). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology2011;29(15 Suppl 1):3521. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. [DOI: 10.1001/jama.2013.285718] PughSA , FullerA , PereraR , GeorgeS , MantD , PrimroseJ . The follow‐up after colorectal cancer surgery trial: randomised trial of follow‐up after colorectal cancer surgery and outcome following recurrence. Journal of the American College of Surgeons2014;219(4 Suppl 1):e46‐7. PughSA , MantD , ShinkinsB , MellorJ , PereraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology2016;27(Suppl 6):no pagination. ShinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PloS One2017;12(3):e0171810. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;105(6):658‐62. ">Primrose 2014</a>; <a href="./references#CD012425-bbs2-0043" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk‐adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>). </p> <section id="CD012425-sec-0068"> <h5 class="title">Participants, cancer site and setting</h5> <p>The included studies randomised 20,832 participants and spanned 12 cancer sites: 18 studies with participants who had breast cancer (<a href="./references#CD012425-bbs2-0002" title="BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Economic evaluation of a randomized clinical trial of hospital versus telephone follow‐up after treatment for breast cancer. British Journal of Surgery2009;96(12):1406‐15. [DOI: 10.1002/bjs.6753] BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Is telephone follow‐up by specialist nurses a cost effective approach?. European Journal of Cancer Supplements2009;7(2‐3):230‐1. BeaverK , Tysver‐RobinsonD , CampbellM , TwomeyM , WilliamsonS , HindleyA , et al. Comparing hospital and telephone follow‐up after treatment for breast cancer: randomised equivalence trial. BMJ2009;338:a3147. [DOI: 10.1136/bmj.a3147] ">Beaver 2009</a>; <a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a>; <a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a>; <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a>; <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>; <a href="./references#CD012425-bbs2-0015" title="BoekhoutAH , MaunsellE , PondGR , JulianJA , CoyleD , LevineMN , et al. A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial. Journal of Cancer Survivorship2015;9(4):683‐91. CoyleD , GrunfeldE , CoyleK , JulianJA , PondGR , FolkesA , et al. Cost‐effectiveness of a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):6082. CoyleD , GrunfeldE , CoyleK , PondG , JulianJA , LevineMN . Cost effectiveness of a survivorship care plan for breast cancer survivors. Journal of Oncology Practice2014;10(2):e86‐92. GrunfeldE , JulianJA , PondG , MaunsellE , CoyleD , FolkesA , et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. Journal of Clinical Oncology2011;29(36):4755‐62. GrunfeldE , LevineMN , JulianJA , PondGR , MaunsellE , FolkesA , et al. Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):9005. GrunfeldE , PondG , MaunsellE , LevineMN , JulianJA , CoyleD . Impact of survivorship care plans (SCP) on adherence to guidelines, health service measures, and patient‐reported outcomes (PRO): extended results of a multicenter randomized clinical trial (RCT) with breast cancer survivors. European Journal of Cancer2012;48:S147. ">Grunfeld 2011</a>; <a href="./references#CD012425-bbs2-0016" title="HershmanDL , GreenleeH , AwadD , KalinskyK , MaurerM , KranwinkelG , et al. Randomized controlled trial of a clinic‐based survivorship intervention following adjuvant therapy in breast cancer survivors. Breast Cancer Research and Treatment2013;138(3):795‐806. ">Hershman 2013</a>; <a href="./references#CD012425-bbs2-0019" title="JuarezG , HurriaA , FerrellB . Effectiveness of an education intervention on quality of life in Latina breast cancer survivors. Psycho‐oncology2012;21:110. JuarezG , HurriaA , UmanG , FerrellB . Impact of a bilingual education intervention on the quality of life of Latina breast cancer survivors. Oncology Nursing Forum2013;40(1):E50‐60. [DOI: 10.1188/13.ONF.E50‐E60] ">Juarez 2013</a>; <a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a>; <a href="./references#CD012425-bbs2-0021" title="DentJ , ToppingA , FergusonC , StephensonJ , McCoyM , AllinsonV , et al. To follow up or not? A new model of supportive care for early breast cancer. Journal of Clinical Oncology2011;29(15 Suppl 1):no pagination. KirshbaumMN , DentJ , StephensonJ , ToppingAE , AllinsonV , McCoyM , et al. Open access follow‐up care for early breast cancer: a randomised controlled quality of life analysis. European Journal of Cancer Care2017;26(4):e12577. [DOI: 10.1111/ecc.12577] ">Kirshbaum 2017</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0024" title="KokkoR , HakamaM , HolliK . Follow‐up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Research and Treatment2005;93(3):255‐60. KokkoR , HakamaM , HolliK . Role of chest X‐ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Research and Treatment2003;81(1):33‐9. ">Kokko 2003</a>; <a href="./references#CD012425-bbs2-0025" title="KvaleEA , Demark‐WahnefriedW , MenesesK , BaeS , HuangCH , AzueroCB , et al. Patient centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer Research2015;75(9 Suppl 1):no pagination. KvaleEA , HuangCS , MenesesKM , Demark‐WahnefriedW , BaeS , AzueroCB , et al. Patient‐centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer2016;122(20):3232‐42. ">Kvale 2016</a>; <a href="./references#CD012425-bbs2-0028" title="MalyRC , GriggsJJ , LiuY , LiangLJ , GanzPA . A randomized controlled trial of survivorship care plans among low‐income breast cancer survivors. Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. MalyRC , LiangLJ , LiuY , GriggsJJ , GanzPA . Randomized controlled trial of survivorship care plans among low‐income, predominant Latina breast cancer survivors. Journal of Clinical Oncology2017;35(16):1814‐21. NCT01627366 . Study of survivorship care plans and outcomes in underserved breast cancer survivors. clinicaltrials.gov/ct2/show/NCT01627366 (first received 17 December 2018). ">Maly 2017</a>; <a href="./references#CD012425-bbs2-0033" title="OltraA , SantaballaA , MontalarJ , MunárrizB , PastorM , MeseguerA , et al. Cost‐benefit evaluation of a follow‐up program in patients with advanced breast cancer. Randomized study. Revista de Oncología1999;1(Suppl 1):165. OltraA , SantaballaA , MunárrizB , PastorM , MontalarJ . Cost‐benefit analysis of a follow‐up program in patients with breast cancer: a randomized prospective study. Breast Journal2007;13(6):571‐4. ">Oltra 2007</a>; <a href="./references#CD012425-bbs2-0039" title="PalliD , RussoA , SaievaC , CiattoS , Rosselli Del TurcoM , DistanteV , et al. Intensive vs clinical follow‐up after treatment of primary breast cancer: 10‐year update of a randomized trial. National Research Council Project on Breast Cancer Follow‐up. JAMA1999;281(17):1586. Roselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . The efficacy of intensive follow‐up testing in breast cancer cases. Annals of Oncology1995;6(Suppl 2):37‐9. Rosselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . Intensive diagnostic follow‐up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow‐up. JAMA1994;271(20):1593‐7. ">Rosselli Del Turco 1994</a>; <a href="./references#CD012425-bbs2-0040" title="RuddyKJ , BakerEL , GuoH , GoldsteinMJ , WinerEP , ShulmanLN , et al. Randomized trial evaluating a coordinated survivorship care program for early stage breast cancer. Cancer Research2013;73(24 Suppl 1):OT2‐5‐02. RuddyKJ , GuoH , BakerE , GoldsteinM , MullaneyEE , ShulmanLN , et al. Coordinated follow‐up breast cancer survivorship care program study. Journal of Clinical Oncology2015;33(15 Suppl 1):e17727. RuddyKJ , GuoH , BakerEL , GoldsteinMJ , MullaneyEE , ShulmanLN , et al. Randomized phase 2 trial of a coordinated breast cancer follow‐up care program. Cancer2016;122:3546‐54. ">Ruddy 2016</a>; <a href="./references#CD012425-bbs2-0044" title="SheppardC , HigginsB , WiseM , YiangouC , DuboisD , KilburnS . Breast cancer follow up: a randomised controlled trial comparing point of need access versus routine 6‐monthly clinical review. European Journal of Oncology Nursing2009;13(1):2‐8. [DOI: 10.1016/j.ejon.2008.11.005] ">Sheppard 2009</a>), 16 studies in colorectal cancer (<a href="./references#CD012425-bbs2-0003" title="BeaverK , CampbellM , WilliamsonS , ProcterD , SheridanJ , HeathJ , et al. An exploratory randomized controlled trial comparing telephone and hospital follow‐up after treatment for colorectal cancer. Colorectal Disease2012;14(10):1201‐9. [DOI: 10.1111/j.1463‐1318.2012.02936.x] ">Beaver 2012</a>; <a href="./references#CD012425-bbs2-0011" title="GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata). A randomized trial of intensive versus minimalist follow‐up of patients with resected Dukes B‐C colorectal cancer: the pilot phase. Tumori1998;84(Suppl):89. GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. NCT02409472 . Intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. clinicaltrials.gov/ct2/show/NCT02409472 (first received 20 December 2016). RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] ">GILDA 2016</a>; <a href="./references#CD012425-bbs2-0017" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14:260. [DOI: 10.1186/1745‐6215‐14‐260] JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a nurse‐led supportive care package (survivor care) for survivors of colorectal cancer. Cancer Nursing2015;38(4 Suppl 1):S16‐7. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (Survivor‐Care, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2015;33(15 Suppl 1):9566. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , SchofieldP , ArandaS , YoungJ , ButowP . Randomised controlled trial (RCT) of a comprehensive post‐treatment support package (survivor‐care) for bowel cancer survivors. Psycho‐oncology2010;19:S193. ">Jefford 2016</a>; <a href="./references#CD012425-bbs2-0022" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomized study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Gastroenterology1999;34(5):509‐15. KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;149:159‐62. ">Kjeldsen 1997</a>; <a href="./references#CD012425-bbs2-0026" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1992</a>; <a href="./references#CD012425-bbs2-0032" title="OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD012425-bbs2-0035" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA , et al. Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD012425-bbs2-0036" title="MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017;21(32):1‐86. MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00560365 (first received 20 December 2016). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology2011;29(15 Suppl 1):3521. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. [DOI: 10.1001/jama.2013.285718] PughSA , FullerA , PereraR , GeorgeS , MantD , PrimroseJ . The follow‐up after colorectal cancer surgery trial: randomised trial of follow‐up after colorectal cancer surgery and outcome following recurrence. Journal of the American College of Surgeons2014;219(4 Suppl 1):e46‐7. PughSA , MantD , ShinkinsB , MellorJ , PereraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology2016;27(Suppl 6):no pagination. ShinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PloS One2017;12(3):e0171810. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;105(6):658‐62. ">Primrose 2014</a>; <a href="./references#CD012425-bbs2-0037" title="BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial [Efectividad del seguimiento postoperatorio en los pacientes con cáncer colorrectal para la detección de recidivas curables. Análisis preliminar de un estudio multicéntrico, controlado y aleatorizado]. Gastroenterologia y Hepatologia2001;24(2):92, abstract no: 13. BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Preliminary analysis of a multicenter controlled trial to evaluate the effectiveness of postoperative follow‐up to detect curable recurrences in patients with colorectal cancer [Análisis preliminar de un estudio multicéntrico controlado y aleatorizado destinado a evaluar la efectividad del seguimiento postoperatorio en la detección de recidivas curables en los pacientes con cáncer colorrectal]. Gastroenterologia y Hepatologia2001;24(3):150. Rodriguez‐MorantaF , CastellsA , SaloJ , ArcusaA , BoadasJ , BessaV , et al. Efficacy of postoperative surveillance after radical surgery for colorectal cancer (CRC). Analysis of a prospective, multicenter, randomized controlled trial. Journal of Gastroenterology2005;128(4 Suppl 2):Abstract W967. Rodríguez‐MorantaF , SalóJ , AcrusaA , BoadasJ , BessaX , PiñolV , et al. Efficacy of postoperative surveillance in patients with colorectal cancer after radical surgery. A prospective, multicenter, randomized study. Gastroenterologia y Hepatologia2005;28(3):197‐8, abstract no: 126. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , Bessa , X , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD012425-bbs2-0042" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gastroenterology1998;114(1):7‐14. SchoemakerD , BlackR , GilesL , ToouliJ , AlcornJ . Addition of intensive follow‐up procedures to standard follow‐up did not improve survival in patients with colorectal cancer. Evidence‐Based Medicine1998;3(5):140. ">Schoemaker 1998</a>; <a href="./references#CD012425-bbs2-0043" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk‐adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD012425-bbs2-0045" title="SobhaniI , TiretE , LebtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>; <a href="./references#CD012425-bbs2-0046" title="NCT00624260 . Impact of PET Scan on the curative strategy of colo‐rectal cancers : a randomized study. clinicaltrials.gov/ct2/show/NCT00624260 (first received 20 December 2016). SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an openlabel multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology2017;35(15 Suppl 1):no pagination. SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal2017;5(5 Suppl 1):A13. SobhaniI , IttiE , LucianiA , BaumgaertnerI , LayeseR , AndreT , et al. Colorectal cancer (CRC) monitoring by 6‐monthly 18FDG‐PET/CT: an open‐label multicentre randomised trial. Annals of Oncology2018;29(4):931‐7. ">Sobhani 2018</a>; <a href="./references#CD012425-bbs2-0049" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>; <a href="./references#CD012425-bbs2-0052" title="NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00225641 (first received 20 December 2016). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PahlmanL , et al. Intensity of follow up after surgery for colorectal cancer. Colorectal Disease2014;16:93. Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA2018;319(20):2095‐103. ">Wille‐Jorgensen 2018</a>; <a href="./references#CD012425-bbs2-0053" title='ACTRN12608000252314 . Cancer care after surgery – the CONNECT study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82819 (first received 20 December 2016). HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Connect: a pilot RCT to improve outcomes for people with colorectal cancer. Asia‐Pacific Journal of Clinical Oncology2009;5:A159. HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Randomized pilot evaluation of the supportive care intervention "CONNECT" for people following surgery for colorectal cancer. Diseases of the Colon and Rectum2011;54(5):622‐31. YoungJM , ButowPN , WalshJ , DurcinoskaI , DobbinsTA , RodwellL , et al. Multicenter randomized trial of centralized nurse‐led telephone‐based care coordination to improve outcomes after surgical resection for colorectal cancer: the CONNECT intervention. Journal of Clinical Oncology2013;31(28):3585‐91. [DOI: 10.1200/JCO.2012.48.1036] '>Young 2013</a>), three studies in non‐small cell lung cancer (NSCLC) (<a href="./references#CD012425-bbs2-0010" title="GambazziF , FreyLD , BruehlmeierM , JanthurWD , GraberSM , HeubergerJ , et al. Comparing two imaging methods for follow‐up of lung cancer treatment: a randomized pilot study. Annals of Thoracic Surgery2018;107(2):430‐5. [DOI: 10.1016/j.athoracsur.2018.08.015] ">Gambazzi 2018</a>; <a href="./references#CD012425-bbs2-0029" title="MonteilJ , VergnenègreA , BertinF , DalmayF , GaillardS , BonnaudF , et al. Randomized follow‐up study of resected NSCLC patients: conventional versus 18F‐DG coincidence imaging. Anticancer Research2010;30(9):3811‐6. NCT00199615 . Follow‐up of patients with curative‐intent surgical resection for NSCLC. clinicaltrials.gov/ct2/show/NCT00199615 (first received 20 December 2016). ">Monteil 2010</a>; <a href="./references#CD012425-bbs2-0051" title="NCT00198341 . Post‐surgical non‐small cell lung cancer (NSCLC) follow‐up. clinicaltrials.gov/ct2/show/NCT00198341 (first received 20 December 2016). WesteelV . Follow‐up of the patient after curative treatment. Lung Cancer2011;71:S10‐1. WesteelV . Surveillance and second primary malignancies in lung cancer survivors. Journal of Thoracic Oncology2018;13(10 Suppl):S277‐8. WesteelV , BarlesiF , DomasJ , GirardP , FoucherP , LafitteJJ , et al. Postoperative follow‐up of lung cancer: randomized trial comparing two follow‐up programs in completely resected non‐small cell lung cancer (IFCT‐0302). Journal of Clinical Oncology2012;30(15 Suppl 1):no pagination. WesteelV , BarlesiF , FoucherP , LafitteJ , DomasJ , GirardP , et al. Recurrences and 2nd primary cancers in the IFCT‐0302 trial assessing a CT‐scan‐based follow‐up after lung cancer surgery. Journal of Thoracic Oncology2017;12(11 Suppl 2):S1788‐9. WesteelV , BarlesiF , FoucherP , LafitteJ‐J , DomasJ , GirardP , et al. Results of the phase III IFCT‐0302 trial assessing minimal versus CT‐scan‐based follow‐up for completely resected non‐small cell lung cancer (NSCLC). Annals of Oncology2017;28(Suppl 5):v452. WesteelV , BarlesiF , FoucherP , LafitteJJ , DomasJ , GirardP , et al. Compliance with follow‐up programs after surgery for non‐small cell lung cancer in the phase III IFCT‐0302 trial. Journal of Thoracic Oncology2015;10(9 Suppl 2):S239. WesteelV , LebitasyMP , MercierM , LafitteJJ , DomasJ , GirardPl . IFCT‐0302 trial: randomised study comparing two follow‐up schedules in completely resected non‐small cell lung cancer [Protocole IFCT‐0302 : essai randomisé de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués]. Revue des Maladies Respiratoires2007;2(5):645‐52. ">Westeel 2012</a>), two studies in colon cancer (<a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad 2013</a>; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>), two studies in endometrial cancer (<a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a>; <a href="./references#CD012425-bbs2-0018" title="JeppesenMM , JensenPT , GilsaD , DePont ChristensenR , JensenMM , MogensenO . The effect of patient‐initiated follow‐up on fear of recurrence and health care use: a randomized trial in early‐stage endometrial cancer. International Journal of Gynecological Cancer2017;27(Supplement 4):1107. JeppesenMM , JensenPT , HansenDG , ChristensenRD , MogensenO . Authors' reply re: Patient‐initiated follow‐up affects fear of recurrence and health care use: a randomised trial in early‐stage endometrial cancer. BJOG2018;125(13):1778‐9. JeppesenMM , JensenPT , HansenDG , ChristensenRD , MogensenO . Patient‐initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early‐stage endometrial cancer. BJOG2018;125(13):1705‐14. TegnerowiczJ . Re: Patient‐initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early‐stage endometrial cancer. BJOG2018;1125(13):1778. ">Jeppesen 2018</a>), two studies in gynaecological cancer (<a href="./references#CD012425-bbs2-0038" title="DeRooijBH , EzendamNP , NicolaijeKA , LodderP , VosMC , PijnenborgJM , et al. Survivorship care plans have a negative impact on long‐term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. Quality of Life Research2018;27(6):1533‐44. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2‐year follow‐up ‐ The ROGY care trial. Gynecologic Oncology2017;145(2):319‐28. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Long‐term impact of survivorship care plans on ovarian cancer patient reported outcomes‐new results of the ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):64‐5. DeRooijBH , EzendamNP , NicolaijeKA , VosMC , PijnenborgJM , BollD , et al. The indirect effects of survivorship care plans on quality of life, anxiety and depression‐the ROGY care trial. Supportive Care in Cancer2017;25(2 Suppl 1):S53‐4. DeRooijBH , EzendamNP , VosMC , PijnenborgJM , BollD , KruitwagenRF , et al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. Cancer Epub 2018 Nov 30;125(5):788‐97. [DOI: 10.1002/cncr.31844] EzendamN , DeRooijB , NicolaijeK , VosC , PijnenborgJ , BollD , et al. Long‐term impact of cancer survivorship care plans on patient outcomes‐the randomized controlled ROGY care trial. International Journal of Gynecological Cancer2016;26:91. EzendamNP , VanBroekhovenM , Van DePoll‐FranseLV , DeRooijBH . The role of illness perceptions in smoking, alcohol consumption and weight changes among gynaecological cancer survivors. Quality of Life Research2016;25(1 Suppl 1):114. JeppesenMM , EzendamNP , PijnenborgJM , VosMC , BollD , KruitwagenRF , et al. The impact of the survivorship care plan on health care use: 2‐year follow‐up results of the ROGY care trial. Journal of Cancer Survivorship2018;12(1):18‐27. NicolaijeKA , EzendamNP , VosMC , PijnenborgJM , BollD , BossEA , et al. Impact of an automatically generated cancer survivorship care plan on patient‐reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial. Journal of Clinical Oncology2015;33(31):3550‐9. Van dePoll‐FranseL , NicolaijeK , EzendamN , VosC , BollD , PijnenborgJ , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY CARE): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Psycho‐oncology2013;22:341‐2. Van dePoll‐FranseLV , JeppesenMM , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. The survivorship care plan increases the use of primary care in anxious and irradiated endometrial cancer patients. Two year outcomes of the pragmatic cluster randomized ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):164. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosCM , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY Care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosMC , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. European Journal of Cancer2013;49:S720. Van dePoll‐FranseLV , NicolaijeKA , VosMC , PijnenborgJM , BollD , HussonO , et al. The impact of a cancer survivorship care plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials2011;12:256. ">ROGY 2015</a>; <a href="./references#CD012425-bbs2-0030" title="MorrisonV , SpencerLH , LeesonS . Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a randomised feasibility trial. Psycho‐oncology2017;26(Suppl 2):3‐4. MorrisonV , SpencerLH , TottonN , PyeK , YeoST , ButterworthC , et al. Trial of optimal personalised care after treatment‐gynaecological cancer (TOPCAT‐G): a randomized feasibility trial. International Journal of Gynecological Cancer2018;28(2):401‐11. PyeK , TottonN , StuartN , WhitakerR , MorrisonV , EdwardsRT , et al. Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a study protocol for a randomised feasibility trial. Pilot and Feasibility Studies2016;2:67. [DOI 10.1186/s40814‐016‐0108‐5] ">Morrison 2018</a>), two studies in melanoma (<a href="./references#CD012425-bbs2-0007" title="DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . Prospective randomized clinical trial for the evaluation of a stage adjusted reduced follow‐up schedule in cutaneous melanoma patients: results after one year. Annals of Surgical Oncology2016;23(1 Suppl 1):S30. DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . The MELFO‐study: prospective randomized clinical trial for the evaluation of a stage‐adjusted reduced follow‐up schedule in cutaneous melanoma patients ‐ results after 1 year. Annals of Surgical Oncology2016;23(9):2762‐71. [DOI: 10.1245/s10434‐016‐5263‐7] DeckersE , Hoekstra‐WeebersJ , DamudeS , FranckenA , Ter MeulenS , BastiaannetE , et al. The MELFO‐study: a multi‐center prospective randomized clinical trial on the effects of a reduced stage‐adjusted follow‐up schedule on cutaneous melanoma IB‐IIC patients: results after 3‐years. Annals of Surgical Oncology2018;25(1 Suppl 1):S40. NCT01018004 . Comparing follow‐up schedules in patients with newly diagnosed stage IB or stage II melanoma. clinicaltrials.gov/ct2/show/NCT01018004 (first received 20 December 2016). ">Damude 2016</a>; <a href="./references#CD012425-bbs2-0031" title="MurchieP , NicolsonMC , HannafordPC , RajaEA , LeeAJ , CampbellNC . Patient satisfaction with GP‐led melanoma follow‐up: a randomised controlled trial. British Journal of Cancer2010;102(10):1447‐55. ">Murchie 2010</a>), two studies with prostate cancer (<a href="./references#CD012425-bbs2-0008" title="DavisKM , DawsonD , KellyS , RedS , PenekS , LynchJ , et al. Monitoring of health‐related quality of life and symptoms in prostate cancer survivors: a randomized trial. Journal of Supportive Oncology2013;11(4):174‐82. ">Davis 2013</a>; <a href="./references#CD012425-bbs2-0009" title="ACTRN12610000938000 . The ProCare Trial: a randomised controlled trial of follow up of men with prostate cancer in primary care. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336116 (first received 20 December 2016). EmeryJ , DooreyJ , JeffordM , KingM , PirottaM , HayneD , et al. Protocol for the ProCare Trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. BMJ Open2014;4(3):e004972. [DOI: 10.1136/bmjopen‐2014‐004972] EmeryJ , SchofieldP , JeffordM , KingM , PirottaM , HayneD , et al. The ProCare trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. Asia‐Pacific Journal of Clinical Oncology2014;10:157. EmeryJD , JeffordM , KingM , HayneD , MartinA , DooreyJ , et al. ProCare Trial: a phase II randomized controlled trial of shared care for follow‐up of men with prostate cancer. BJU International2016;119(3):381‐89. [DOI: 10.1111/bju.13593] KingM . Procare/PC4 study update. Asia‐Pacific Journal of Clinical Oncology2012;8:23. ">Emery 2016</a>), two studies with oesophageal cancer (<a href="./references#CD012425-bbs2-0027" title="MalmströmM , IvarssonB , KlefsgårdR , PerssonK , JakobssonU , JohanssonJ . The effect of a nurse led telephone supportive care programme on patients' quality of life, received information and health care contacts after oesophageal cancer surgery‐a six month RCT‐follow‐up study. International Journal of Nursing Studies2016;64:86‐95. [DOI: 10.1016/j.ijnurstu.2016.09.009] ">Malmstrom 2016</a>; <a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a>), and one study each in Hodgkin lymphoma (<a href="./references#CD012425-bbs2-0034" title="PicardiM , PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , et al. Advanced‐stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission‐‐a randomized trial of routine surveillance imaging procedures. Radiology2014;272(1):262‐74. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: Ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2015;100:7‐8. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2014;99:398‐9. ">Picardi 2014</a>), testicular cancer (<a href="./references#CD012425-bbs2-0041" title="GoodmanA . How often to follow up? Study shows two CT scans as good as five for low‐risk testicular cancer. Oncology Times2007;29(12):54‐5. NCT00003420 . CT scans in treating patients with stage I testicular cancer after undergoing orchiectomy. clinicaltrials.gov/ct2/show/NCT00003420 (first received 20 December 2016). RustinGJ , MeadGM , StenningSP , VaseyPA , AassN , HuddartRA , et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197‐‐the National Cancer Research Institute Testis Cancer Clinical Studies Group. Journal of Clinical Oncology2007;25(11):1310‐5. ">Rustin 2007</a>), head‐and‐neck cancer (<a href="./references#CD012425-bbs2-0047" title="Van DerMeulenI , MayA , RosW , OosteromM , HordijkGJ , KooleR , et al. Effects of a nurse‐led psychosocial intervention on depressive symptoms and health‐related quality of life in patients with head and neck cancer: a randomized controlled trial. Psycho‐oncology2013;22(Suppl 3):17. Van derMeulenIC , MayAM , RosWJ , OosteromM , HordijkGJ , KooleR , et al. One‐year effect of a nurse‐led psychosocial intervention on depressive symptoms in patients with head and neck cancer: a randomized controlled trial. Oncologist2013;18(3):336‐44. [DOI: 10.1634/theoncologist.2012‐0299] ">Van der Meulen 2013</a>) and oral cancer (<a href="./references#CD012425-bbs2-0006" title="D'CruzA , VaishR , GuptaS , AryaS , HawaldarRW , ShahS . Does addition of neck ultrasonography to physical examination, in follow‐up of patients with early stage, clinically node negative oral cancers, influence outcome? A randomized control trial (RCT). Journal of Clinical Oncology2016;34(15 Suppl 6):no pagination. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node‐negative oral cancer. New England Journal of Medicine2015;373(6):521‐9. NCT00193765 . Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. clinicaltrials.gov/ct2/show/NCT00193765 (first received 20 December 2016). ">D'Cruz 2016</a>). The majority of the studies included participants with cancer stages I, II and III, while six studies also included participants with stage IV cancer at diagnosis, who had completed curatively‐intended treatment (<a href="./references#CD012425-bbs2-0010" title="GambazziF , FreyLD , BruehlmeierM , JanthurWD , GraberSM , HeubergerJ , et al. Comparing two imaging methods for follow‐up of lung cancer treatment: a randomized pilot study. Annals of Thoracic Surgery2018;107(2):430‐5. [DOI: 10.1016/j.athoracsur.2018.08.015] ">Gambazzi 2018</a>; <a href="./references#CD012425-bbs2-0034" title="PicardiM , PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , et al. Advanced‐stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission‐‐a randomized trial of routine surveillance imaging procedures. Radiology2014;272(1):262‐74. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: Ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2015;100:7‐8. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2014;99:398‐9. ">Picardi 2014</a>; <a href="./references#CD012425-bbs2-0038" title="DeRooijBH , EzendamNP , NicolaijeKA , LodderP , VosMC , PijnenborgJM , et al. Survivorship care plans have a negative impact on long‐term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. Quality of Life Research2018;27(6):1533‐44. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2‐year follow‐up ‐ The ROGY care trial. Gynecologic Oncology2017;145(2):319‐28. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Long‐term impact of survivorship care plans on ovarian cancer patient reported outcomes‐new results of the ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):64‐5. DeRooijBH , EzendamNP , NicolaijeKA , VosMC , PijnenborgJM , BollD , et al. The indirect effects of survivorship care plans on quality of life, anxiety and depression‐the ROGY care trial. Supportive Care in Cancer2017;25(2 Suppl 1):S53‐4. DeRooijBH , EzendamNP , VosMC , PijnenborgJM , BollD , KruitwagenRF , et al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. Cancer Epub 2018 Nov 30;125(5):788‐97. [DOI: 10.1002/cncr.31844] EzendamN , DeRooijB , NicolaijeK , VosC , PijnenborgJ , BollD , et al. Long‐term impact of cancer survivorship care plans on patient outcomes‐the randomized controlled ROGY care trial. International Journal of Gynecological Cancer2016;26:91. EzendamNP , VanBroekhovenM , Van DePoll‐FranseLV , DeRooijBH . The role of illness perceptions in smoking, alcohol consumption and weight changes among gynaecological cancer survivors. Quality of Life Research2016;25(1 Suppl 1):114. JeppesenMM , EzendamNP , PijnenborgJM , VosMC , BollD , KruitwagenRF , et al. The impact of the survivorship care plan on health care use: 2‐year follow‐up results of the ROGY care trial. Journal of Cancer Survivorship2018;12(1):18‐27. NicolaijeKA , EzendamNP , VosMC , PijnenborgJM , BollD , BossEA , et al. Impact of an automatically generated cancer survivorship care plan on patient‐reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial. Journal of Clinical Oncology2015;33(31):3550‐9. Van dePoll‐FranseL , NicolaijeK , EzendamN , VosC , BollD , PijnenborgJ , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY CARE): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Psycho‐oncology2013;22:341‐2. Van dePoll‐FranseLV , JeppesenMM , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. The survivorship care plan increases the use of primary care in anxious and irradiated endometrial cancer patients. Two year outcomes of the pragmatic cluster randomized ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):164. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosCM , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY Care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosMC , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. European Journal of Cancer2013;49:S720. Van dePoll‐FranseLV , NicolaijeKA , VosMC , PijnenborgJM , BollD , HussonO , et al. The impact of a cancer survivorship care plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials2011;12:256. ">ROGY 2015</a>; <a href="./references#CD012425-bbs2-0045" title="SobhaniI , TiretE , LebtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>; <a href="./references#CD012425-bbs2-0046" title="NCT00624260 . Impact of PET Scan on the curative strategy of colo‐rectal cancers : a randomized study. clinicaltrials.gov/ct2/show/NCT00624260 (first received 20 December 2016). SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an openlabel multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology2017;35(15 Suppl 1):no pagination. SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal2017;5(5 Suppl 1):A13. SobhaniI , IttiE , LucianiA , BaumgaertnerI , LayeseR , AndreT , et al. Colorectal cancer (CRC) monitoring by 6‐monthly 18FDG‐PET/CT: an open‐label multicentre randomised trial. Annals of Oncology2018;29(4):931‐7. ">Sobhani 2018</a>; <a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a>). The studies had follow‐up periods ranging from six months to five years. </p> <p>All the studies were carried out in either a hospital or general practice setting and 15 countries were represented: the UK (<a href="./references#CD012425-bbs2-0002" title="BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Economic evaluation of a randomized clinical trial of hospital versus telephone follow‐up after treatment for breast cancer. British Journal of Surgery2009;96(12):1406‐15. [DOI: 10.1002/bjs.6753] BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Is telephone follow‐up by specialist nurses a cost effective approach?. European Journal of Cancer Supplements2009;7(2‐3):230‐1. BeaverK , Tysver‐RobinsonD , CampbellM , TwomeyM , WilliamsonS , HindleyA , et al. Comparing hospital and telephone follow‐up after treatment for breast cancer: randomised equivalence trial. BMJ2009;338:a3147. [DOI: 10.1136/bmj.a3147] ">Beaver 2009</a>; <a href="./references#CD012425-bbs2-0003" title="BeaverK , CampbellM , WilliamsonS , ProcterD , SheridanJ , HeathJ , et al. An exploratory randomized controlled trial comparing telephone and hospital follow‐up after treatment for colorectal cancer. Colorectal Disease2012;14(10):1201‐9. [DOI: 10.1111/j.1463‐1318.2012.02936.x] ">Beaver 2012</a>; <a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a>; <a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a>; <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a>; <a href="./references#CD012425-bbs2-0021" title="DentJ , ToppingA , FergusonC , StephensonJ , McCoyM , AllinsonV , et al. To follow up or not? A new model of supportive care for early breast cancer. Journal of Clinical Oncology2011;29(15 Suppl 1):no pagination. KirshbaumMN , DentJ , StephensonJ , ToppingAE , AllinsonV , McCoyM , et al. Open access follow‐up care for early breast cancer: a randomised controlled quality of life analysis. European Journal of Cancer Care2017;26(4):e12577. [DOI: 10.1111/ecc.12577] ">Kirshbaum 2017</a>; <a href="./references#CD012425-bbs2-0030" title="MorrisonV , SpencerLH , LeesonS . Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a randomised feasibility trial. Psycho‐oncology2017;26(Suppl 2):3‐4. MorrisonV , SpencerLH , TottonN , PyeK , YeoST , ButterworthC , et al. Trial of optimal personalised care after treatment‐gynaecological cancer (TOPCAT‐G): a randomized feasibility trial. International Journal of Gynecological Cancer2018;28(2):401‐11. PyeK , TottonN , StuartN , WhitakerR , MorrisonV , EdwardsRT , et al. Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a study protocol for a randomised feasibility trial. Pilot and Feasibility Studies2016;2:67. [DOI 10.1186/s40814‐016‐0108‐5] ">Morrison 2018</a>; <a href="./references#CD012425-bbs2-0031" title="MurchieP , NicolsonMC , HannafordPC , RajaEA , LeeAJ , CampbellNC . Patient satisfaction with GP‐led melanoma follow‐up: a randomised controlled trial. British Journal of Cancer2010;102(10):1447‐55. ">Murchie 2010</a>; <a href="./references#CD012425-bbs2-0036" title="MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017;21(32):1‐86. MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00560365 (first received 20 December 2016). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology2011;29(15 Suppl 1):3521. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. [DOI: 10.1001/jama.2013.285718] PughSA , FullerA , PereraR , GeorgeS , MantD , PrimroseJ . The follow‐up after colorectal cancer surgery trial: randomised trial of follow‐up after colorectal cancer surgery and outcome following recurrence. Journal of the American College of Surgeons2014;219(4 Suppl 1):e46‐7. PughSA , MantD , ShinkinsB , MellorJ , PereraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology2016;27(Suppl 6):no pagination. ShinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PloS One2017;12(3):e0171810. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;105(6):658‐62. ">Primrose 2014</a>; <a href="./references#CD012425-bbs2-0041" title="GoodmanA . How often to follow up? Study shows two CT scans as good as five for low‐risk testicular cancer. Oncology Times2007;29(12):54‐5. NCT00003420 . CT scans in treating patients with stage I testicular cancer after undergoing orchiectomy. clinicaltrials.gov/ct2/show/NCT00003420 (first received 20 December 2016). RustinGJ , MeadGM , StenningSP , VaseyPA , AassN , HuddartRA , et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197‐‐the National Cancer Research Institute Testis Cancer Clinical Studies Group. Journal of Clinical Oncology2007;25(11):1310‐5. ">Rustin 2007</a>; <a href="./references#CD012425-bbs2-0044" title="SheppardC , HigginsB , WiseM , YiangouC , DuboisD , KilburnS . Breast cancer follow up: a randomised controlled trial comparing point of need access versus routine 6‐monthly clinical review. European Journal of Oncology Nursing2009;13(1):2‐8. [DOI: 10.1016/j.ejon.2008.11.005] ">Sheppard 2009</a>), Italy (<a href="./references#CD012425-bbs2-0011" title="GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata). A randomized trial of intensive versus minimalist follow‐up of patients with resected Dukes B‐C colorectal cancer: the pilot phase. Tumori1998;84(Suppl):89. GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. NCT02409472 . Intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. clinicaltrials.gov/ct2/show/NCT02409472 (first received 20 December 2016). RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] ">GILDA 2016</a>; <a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a>; <a href="./references#CD012425-bbs2-0034" title="PicardiM , PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , et al. Advanced‐stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission‐‐a randomized trial of routine surveillance imaging procedures. Radiology2014;272(1):262‐74. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: Ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2015;100:7‐8. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2014;99:398‐9. ">Picardi 2014</a>; <a href="./references#CD012425-bbs2-0035" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA , et al. Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD012425-bbs2-0039" title="PalliD , RussoA , SaievaC , CiattoS , Rosselli Del TurcoM , DistanteV , et al. Intensive vs clinical follow‐up after treatment of primary breast cancer: 10‐year update of a randomized trial. National Research Council Project on Breast Cancer Follow‐up. JAMA1999;281(17):1586. Roselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . The efficacy of intensive follow‐up testing in breast cancer cases. Annals of Oncology1995;6(Suppl 2):37‐9. Rosselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . Intensive diagnostic follow‐up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow‐up. JAMA1994;271(20):1593‐7. ">Rosselli Del Turco 1994</a>; <a href="./references#CD012425-bbs2-0043" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk‐adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>), Australia (<a href="./references#CD012425-bbs2-0009" title="ACTRN12610000938000 . The ProCare Trial: a randomised controlled trial of follow up of men with prostate cancer in primary care. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336116 (first received 20 December 2016). EmeryJ , DooreyJ , JeffordM , KingM , PirottaM , HayneD , et al. Protocol for the ProCare Trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. BMJ Open2014;4(3):e004972. [DOI: 10.1136/bmjopen‐2014‐004972] EmeryJ , SchofieldP , JeffordM , KingM , PirottaM , HayneD , et al. The ProCare trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. Asia‐Pacific Journal of Clinical Oncology2014;10:157. EmeryJD , JeffordM , KingM , HayneD , MartinA , DooreyJ , et al. ProCare Trial: a phase II randomized controlled trial of shared care for follow‐up of men with prostate cancer. BJU International2016;119(3):381‐89. [DOI: 10.1111/bju.13593] KingM . Procare/PC4 study update. Asia‐Pacific Journal of Clinical Oncology2012;8:23. ">Emery 2016</a>; <a href="./references#CD012425-bbs2-0017" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14:260. [DOI: 10.1186/1745‐6215‐14‐260] JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a nurse‐led supportive care package (survivor care) for survivors of colorectal cancer. Cancer Nursing2015;38(4 Suppl 1):S16‐7. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (Survivor‐Care, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2015;33(15 Suppl 1):9566. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , SchofieldP , ArandaS , YoungJ , ButowP . Randomised controlled trial (RCT) of a comprehensive post‐treatment support package (survivor‐care) for bowel cancer survivors. Psycho‐oncology2010;19:S193. ">Jefford 2016</a>; <a href="./references#CD012425-bbs2-0042" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gastroenterology1998;114(1):7‐14. SchoemakerD , BlackR , GilesL , ToouliJ , AlcornJ . Addition of intensive follow‐up procedures to standard follow‐up did not improve survival in patients with colorectal cancer. Evidence‐Based Medicine1998;3(5):140. ">Schoemaker 1998</a>; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>; <a href="./references#CD012425-bbs2-0053" title='ACTRN12608000252314 . Cancer care after surgery – the CONNECT study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82819 (first received 20 December 2016). HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Connect: a pilot RCT to improve outcomes for people with colorectal cancer. Asia‐Pacific Journal of Clinical Oncology2009;5:A159. HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Randomized pilot evaluation of the supportive care intervention "CONNECT" for people following surgery for colorectal cancer. Diseases of the Colon and Rectum2011;54(5):622‐31. YoungJM , ButowPN , WalshJ , DurcinoskaI , DobbinsTA , RodwellL , et al. Multicenter randomized trial of centralized nurse‐led telephone‐based care coordination to improve outcomes after surgical resection for colorectal cancer: the CONNECT intervention. Journal of Clinical Oncology2013;31(28):3585‐91. [DOI: 10.1200/JCO.2012.48.1036] '>Young 2013</a>), the USA (<a href="./references#CD012425-bbs2-0008" title="DavisKM , DawsonD , KellyS , RedS , PenekS , LynchJ , et al. Monitoring of health‐related quality of life and symptoms in prostate cancer survivors: a randomized trial. Journal of Supportive Oncology2013;11(4):174‐82. ">Davis 2013</a>; <a href="./references#CD012425-bbs2-0016" title="HershmanDL , GreenleeH , AwadD , KalinskyK , MaurerM , KranwinkelG , et al. Randomized controlled trial of a clinic‐based survivorship intervention following adjuvant therapy in breast cancer survivors. Breast Cancer Research and Treatment2013;138(3):795‐806. ">Hershman 2013</a>; <a href="./references#CD012425-bbs2-0019" title="JuarezG , HurriaA , FerrellB . Effectiveness of an education intervention on quality of life in Latina breast cancer survivors. Psycho‐oncology2012;21:110. JuarezG , HurriaA , UmanG , FerrellB . Impact of a bilingual education intervention on the quality of life of Latina breast cancer survivors. Oncology Nursing Forum2013;40(1):E50‐60. [DOI: 10.1188/13.ONF.E50‐E60] ">Juarez 2013</a>; <a href="./references#CD012425-bbs2-0025" title="KvaleEA , Demark‐WahnefriedW , MenesesK , BaeS , HuangCH , AzueroCB , et al. Patient centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer Research2015;75(9 Suppl 1):no pagination. KvaleEA , HuangCS , MenesesKM , Demark‐WahnefriedW , BaeS , AzueroCB , et al. Patient‐centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer2016;122(20):3232‐42. ">Kvale 2016</a>; <a href="./references#CD012425-bbs2-0028" title="MalyRC , GriggsJJ , LiuY , LiangLJ , GanzPA . A randomized controlled trial of survivorship care plans among low‐income breast cancer survivors. Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. MalyRC , LiangLJ , LiuY , GriggsJJ , GanzPA . Randomized controlled trial of survivorship care plans among low‐income, predominant Latina breast cancer survivors. Journal of Clinical Oncology2017;35(16):1814‐21. NCT01627366 . Study of survivorship care plans and outcomes in underserved breast cancer survivors. clinicaltrials.gov/ct2/show/NCT01627366 (first received 17 December 2018). ">Maly 2017</a>; <a href="./references#CD012425-bbs2-0040" title="RuddyKJ , BakerEL , GuoH , GoldsteinMJ , WinerEP , ShulmanLN , et al. Randomized trial evaluating a coordinated survivorship care program for early stage breast cancer. Cancer Research2013;73(24 Suppl 1):OT2‐5‐02. RuddyKJ , GuoH , BakerE , GoldsteinM , MullaneyEE , ShulmanLN , et al. Coordinated follow‐up breast cancer survivorship care program study. Journal of Clinical Oncology2015;33(15 Suppl 1):e17727. RuddyKJ , GuoH , BakerEL , GoldsteinMJ , MullaneyEE , ShulmanLN , et al. Randomized phase 2 trial of a coordinated breast cancer follow‐up care program. Cancer2016;122:3546‐54. ">Ruddy 2016</a>), the Netherlands (<a href="./references#CD012425-bbs2-0007" title="DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . Prospective randomized clinical trial for the evaluation of a stage adjusted reduced follow‐up schedule in cutaneous melanoma patients: results after one year. Annals of Surgical Oncology2016;23(1 Suppl 1):S30. DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . The MELFO‐study: prospective randomized clinical trial for the evaluation of a stage‐adjusted reduced follow‐up schedule in cutaneous melanoma patients ‐ results after 1 year. Annals of Surgical Oncology2016;23(9):2762‐71. [DOI: 10.1245/s10434‐016‐5263‐7] DeckersE , Hoekstra‐WeebersJ , DamudeS , FranckenA , Ter MeulenS , BastiaannetE , et al. The MELFO‐study: a multi‐center prospective randomized clinical trial on the effects of a reduced stage‐adjusted follow‐up schedule on cutaneous melanoma IB‐IIC patients: results after 3‐years. Annals of Surgical Oncology2018;25(1 Suppl 1):S40. NCT01018004 . Comparing follow‐up schedules in patients with newly diagnosed stage IB or stage II melanoma. clinicaltrials.gov/ct2/show/NCT01018004 (first received 20 December 2016). ">Damude 2016</a>; <a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a>; <a href="./references#CD012425-bbs2-0038" title="DeRooijBH , EzendamNP , NicolaijeKA , LodderP , VosMC , PijnenborgJM , et al. Survivorship care plans have a negative impact on long‐term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. Quality of Life Research2018;27(6):1533‐44. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2‐year follow‐up ‐ The ROGY care trial. Gynecologic Oncology2017;145(2):319‐28. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Long‐term impact of survivorship care plans on ovarian cancer patient reported outcomes‐new results of the ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):64‐5. DeRooijBH , EzendamNP , NicolaijeKA , VosMC , PijnenborgJM , BollD , et al. The indirect effects of survivorship care plans on quality of life, anxiety and depression‐the ROGY care trial. Supportive Care in Cancer2017;25(2 Suppl 1):S53‐4. DeRooijBH , EzendamNP , VosMC , PijnenborgJM , BollD , KruitwagenRF , et al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. Cancer Epub 2018 Nov 30;125(5):788‐97. [DOI: 10.1002/cncr.31844] EzendamN , DeRooijB , NicolaijeK , VosC , PijnenborgJ , BollD , et al. Long‐term impact of cancer survivorship care plans on patient outcomes‐the randomized controlled ROGY care trial. International Journal of Gynecological Cancer2016;26:91. EzendamNP , VanBroekhovenM , Van DePoll‐FranseLV , DeRooijBH . The role of illness perceptions in smoking, alcohol consumption and weight changes among gynaecological cancer survivors. Quality of Life Research2016;25(1 Suppl 1):114. JeppesenMM , EzendamNP , PijnenborgJM , VosMC , BollD , KruitwagenRF , et al. The impact of the survivorship care plan on health care use: 2‐year follow‐up results of the ROGY care trial. Journal of Cancer Survivorship2018;12(1):18‐27. NicolaijeKA , EzendamNP , VosMC , PijnenborgJM , BollD , BossEA , et al. Impact of an automatically generated cancer survivorship care plan on patient‐reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial. Journal of Clinical Oncology2015;33(31):3550‐9. Van dePoll‐FranseL , NicolaijeK , EzendamN , VosC , BollD , PijnenborgJ , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY CARE): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Psycho‐oncology2013;22:341‐2. Van dePoll‐FranseLV , JeppesenMM , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. The survivorship care plan increases the use of primary care in anxious and irradiated endometrial cancer patients. Two year outcomes of the pragmatic cluster randomized ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):164. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosCM , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY Care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosMC , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. European Journal of Cancer2013;49:S720. Van dePoll‐FranseLV , NicolaijeKA , VosMC , PijnenborgJM , BollD , HussonO , et al. The impact of a cancer survivorship care plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials2011;12:256. ">ROGY 2015</a>; <a href="./references#CD012425-bbs2-0047" title="Van DerMeulenI , MayA , RosW , OosteromM , HordijkGJ , KooleR , et al. Effects of a nurse‐led psychosocial intervention on depressive symptoms and health‐related quality of life in patients with head and neck cancer: a randomized controlled trial. Psycho‐oncology2013;22(Suppl 3):17. Van derMeulenIC , MayAM , RosWJ , OosteromM , HordijkGJ , KooleR , et al. One‐year effect of a nurse‐led psychosocial intervention on depressive symptoms in patients with head and neck cancer: a randomized controlled trial. Oncologist2013;18(3):336‐44. [DOI: 10.1634/theoncologist.2012‐0299] ">Van der Meulen 2013</a>; <a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a>), France (<a href="./references#CD012425-bbs2-0029" title="MonteilJ , VergnenègreA , BertinF , DalmayF , GaillardS , BonnaudF , et al. Randomized follow‐up study of resected NSCLC patients: conventional versus 18F‐DG coincidence imaging. Anticancer Research2010;30(9):3811‐6. NCT00199615 . Follow‐up of patients with curative‐intent surgical resection for NSCLC. clinicaltrials.gov/ct2/show/NCT00199615 (first received 20 December 2016). ">Monteil 2010</a>; <a href="./references#CD012425-bbs2-0045" title="SobhaniI , TiretE , LebtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>; <a href="./references#CD012425-bbs2-0046" title="NCT00624260 . Impact of PET Scan on the curative strategy of colo‐rectal cancers : a randomized study. clinicaltrials.gov/ct2/show/NCT00624260 (first received 20 December 2016). SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an openlabel multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology2017;35(15 Suppl 1):no pagination. SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal2017;5(5 Suppl 1):A13. SobhaniI , IttiE , LucianiA , BaumgaertnerI , LayeseR , AndreT , et al. Colorectal cancer (CRC) monitoring by 6‐monthly 18FDG‐PET/CT: an open‐label multicentre randomised trial. Annals of Oncology2018;29(4):931‐7. ">Sobhani 2018</a>; <a href="./references#CD012425-bbs2-0051" title="NCT00198341 . Post‐surgical non‐small cell lung cancer (NSCLC) follow‐up. clinicaltrials.gov/ct2/show/NCT00198341 (first received 20 December 2016). WesteelV . Follow‐up of the patient after curative treatment. Lung Cancer2011;71:S10‐1. WesteelV . Surveillance and second primary malignancies in lung cancer survivors. Journal of Thoracic Oncology2018;13(10 Suppl):S277‐8. WesteelV , BarlesiF , DomasJ , GirardP , FoucherP , LafitteJJ , et al. Postoperative follow‐up of lung cancer: randomized trial comparing two follow‐up programs in completely resected non‐small cell lung cancer (IFCT‐0302). Journal of Clinical Oncology2012;30(15 Suppl 1):no pagination. WesteelV , BarlesiF , FoucherP , LafitteJ , DomasJ , GirardP , et al. Recurrences and 2nd primary cancers in the IFCT‐0302 trial assessing a CT‐scan‐based follow‐up after lung cancer surgery. Journal of Thoracic Oncology2017;12(11 Suppl 2):S1788‐9. WesteelV , BarlesiF , FoucherP , LafitteJ‐J , DomasJ , GirardP , et al. Results of the phase III IFCT‐0302 trial assessing minimal versus CT‐scan‐based follow‐up for completely resected non‐small cell lung cancer (NSCLC). Annals of Oncology2017;28(Suppl 5):v452. WesteelV , BarlesiF , FoucherP , LafitteJJ , DomasJ , GirardP , et al. Compliance with follow‐up programs after surgery for non‐small cell lung cancer in the phase III IFCT‐0302 trial. Journal of Thoracic Oncology2015;10(9 Suppl 2):S239. WesteelV , LebitasyMP , MercierM , LafitteJJ , DomasJ , GirardPl . IFCT‐0302 trial: randomised study comparing two follow‐up schedules in completely resected non‐small cell lung cancer [Protocole IFCT‐0302 : essai randomisé de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués]. Revue des Maladies Respiratoires2007;2(5):645‐52. ">Westeel 2012</a>), Canada (<a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>; <a href="./references#CD012425-bbs2-0015" title="BoekhoutAH , MaunsellE , PondGR , JulianJA , CoyleD , LevineMN , et al. A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial. Journal of Cancer Survivorship2015;9(4):683‐91. CoyleD , GrunfeldE , CoyleK , JulianJA , PondGR , FolkesA , et al. Cost‐effectiveness of a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):6082. CoyleD , GrunfeldE , CoyleK , PondG , JulianJA , LevineMN . Cost effectiveness of a survivorship care plan for breast cancer survivors. Journal of Oncology Practice2014;10(2):e86‐92. GrunfeldE , JulianJA , PondG , MaunsellE , CoyleD , FolkesA , et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. Journal of Clinical Oncology2011;29(36):4755‐62. GrunfeldE , LevineMN , JulianJA , PondGR , MaunsellE , FolkesA , et al. Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):9005. GrunfeldE , PondG , MaunsellE , LevineMN , JulianJA , CoyleD . Impact of survivorship care plans (SCP) on adherence to guidelines, health service measures, and patient‐reported outcomes (PRO): extended results of a multicenter randomized clinical trial (RCT) with breast cancer survivors. European Journal of Cancer2012;48:S147. ">Grunfeld 2011</a>), Denmark (<a href="./references#CD012425-bbs2-0018" title="JeppesenMM , JensenPT , GilsaD , DePont ChristensenR , JensenMM , MogensenO . The effect of patient‐initiated follow‐up on fear of recurrence and health care use: a randomized trial in early‐stage endometrial cancer. International Journal of Gynecological Cancer2017;27(Supplement 4):1107. JeppesenMM , JensenPT , HansenDG , ChristensenRD , MogensenO . Authors' reply re: Patient‐initiated follow‐up affects fear of recurrence and health care use: a randomised trial in early‐stage endometrial cancer. BJOG2018;125(13):1778‐9. JeppesenMM , JensenPT , HansenDG , ChristensenRD , MogensenO . Patient‐initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early‐stage endometrial cancer. BJOG2018;125(13):1705‐14. TegnerowiczJ . Re: Patient‐initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early‐stage endometrial cancer. BJOG2018;1125(13):1778. ">Jeppesen 2018</a>; <a href="./references#CD012425-bbs2-0022" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomized study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Gastroenterology1999;34(5):509‐15. KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;149:159‐62. ">Kjeldsen 1997</a>; <a href="./references#CD012425-bbs2-0052" title="NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00225641 (first received 20 December 2016). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PahlmanL , et al. Intensity of follow up after surgery for colorectal cancer. Colorectal Disease2014;16:93. Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA2018;319(20):2095‐103. ">Wille‐Jorgensen 2018</a>), Sweden (<a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0027" title="MalmströmM , IvarssonB , KlefsgårdR , PerssonK , JakobssonU , JohanssonJ . The effect of a nurse led telephone supportive care programme on patients' quality of life, received information and health care contacts after oesophageal cancer surgery‐a six month RCT‐follow‐up study. International Journal of Nursing Studies2016;64:86‐95. [DOI: 10.1016/j.ijnurstu.2016.09.009] ">Malmstrom 2016</a>; <a href="./references#CD012425-bbs2-0032" title="OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>), Finland (<a href="./references#CD012425-bbs2-0024" title="KokkoR , HakamaM , HolliK . Follow‐up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Research and Treatment2005;93(3):255‐60. KokkoR , HakamaM , HolliK . Role of chest X‐ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Research and Treatment2003;81(1):33‐9. ">Kokko 2003</a>; <a href="./references#CD012425-bbs2-0026" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1992</a>), Spain (<a href="./references#CD012425-bbs2-0033" title="OltraA , SantaballaA , MontalarJ , MunárrizB , PastorM , MeseguerA , et al. Cost‐benefit evaluation of a follow‐up program in patients with advanced breast cancer. Randomized study. Revista de Oncología1999;1(Suppl 1):165. OltraA , SantaballaA , MunárrizB , PastorM , MontalarJ . Cost‐benefit analysis of a follow‐up program in patients with breast cancer: a randomized prospective study. Breast Journal2007;13(6):571‐4. ">Oltra 2007</a>; <a href="./references#CD012425-bbs2-0037" title="BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial [Efectividad del seguimiento postoperatorio en los pacientes con cáncer colorrectal para la detección de recidivas curables. Análisis preliminar de un estudio multicéntrico, controlado y aleatorizado]. Gastroenterologia y Hepatologia2001;24(2):92, abstract no: 13. BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Preliminary analysis of a multicenter controlled trial to evaluate the effectiveness of postoperative follow‐up to detect curable recurrences in patients with colorectal cancer [Análisis preliminar de un estudio multicéntrico controlado y aleatorizado destinado a evaluar la efectividad del seguimiento postoperatorio en la detección de recidivas curables en los pacientes con cáncer colorrectal]. Gastroenterologia y Hepatologia2001;24(3):150. Rodriguez‐MorantaF , CastellsA , SaloJ , ArcusaA , BoadasJ , BessaV , et al. Efficacy of postoperative surveillance after radical surgery for colorectal cancer (CRC). Analysis of a prospective, multicenter, randomized controlled trial. Journal of Gastroenterology2005;128(4 Suppl 2):Abstract W967. Rodríguez‐MorantaF , SalóJ , AcrusaA , BoadasJ , BessaX , PiñolV , et al. Efficacy of postoperative surveillance in patients with colorectal cancer after radical surgery. A prospective, multicenter, randomized study. Gastroenterologia y Hepatologia2005;28(3):197‐8, abstract no: 126. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , Bessa , X , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>), China (<a href="./references#CD012425-bbs2-0049" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>), India (<a href="./references#CD012425-bbs2-0006" title="D'CruzA , VaishR , GuptaS , AryaS , HawaldarRW , ShahS . Does addition of neck ultrasonography to physical examination, in follow‐up of patients with early stage, clinically node negative oral cancers, influence outcome? A randomized control trial (RCT). Journal of Clinical Oncology2016;34(15 Suppl 6):no pagination. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node‐negative oral cancer. New England Journal of Medicine2015;373(6):521‐9. NCT00193765 . Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. clinicaltrials.gov/ct2/show/NCT00193765 (first received 20 December 2016). ">D'Cruz 2016</a>), Norway (<a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad 2013</a>), and Switzerland (<a href="./references#CD012425-bbs2-0010" title="GambazziF , FreyLD , BruehlmeierM , JanthurWD , GraberSM , HeubergerJ , et al. Comparing two imaging methods for follow‐up of lung cancer treatment: a randomized pilot study. Annals of Thoracic Surgery2018;107(2):430‐5. [DOI: 10.1016/j.athoracsur.2018.08.015] ">Gambazzi 2018</a>). </p> <p>Nine studies did not report funding source (<a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a>; <a href="./references#CD012425-bbs2-0007" title="DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . Prospective randomized clinical trial for the evaluation of a stage adjusted reduced follow‐up schedule in cutaneous melanoma patients: results after one year. Annals of Surgical Oncology2016;23(1 Suppl 1):S30. DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . The MELFO‐study: prospective randomized clinical trial for the evaluation of a stage‐adjusted reduced follow‐up schedule in cutaneous melanoma patients ‐ results after 1 year. Annals of Surgical Oncology2016;23(9):2762‐71. [DOI: 10.1245/s10434‐016‐5263‐7] DeckersE , Hoekstra‐WeebersJ , DamudeS , FranckenA , Ter MeulenS , BastiaannetE , et al. The MELFO‐study: a multi‐center prospective randomized clinical trial on the effects of a reduced stage‐adjusted follow‐up schedule on cutaneous melanoma IB‐IIC patients: results after 3‐years. Annals of Surgical Oncology2018;25(1 Suppl 1):S40. NCT01018004 . Comparing follow‐up schedules in patients with newly diagnosed stage IB or stage II melanoma. clinicaltrials.gov/ct2/show/NCT01018004 (first received 20 December 2016). ">Damude 2016</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0026" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1992</a>; <a href="./references#CD012425-bbs2-0033" title="OltraA , SantaballaA , MontalarJ , MunárrizB , PastorM , MeseguerA , et al. Cost‐benefit evaluation of a follow‐up program in patients with advanced breast cancer. Randomized study. Revista de Oncología1999;1(Suppl 1):165. OltraA , SantaballaA , MunárrizB , PastorM , MontalarJ . Cost‐benefit analysis of a follow‐up program in patients with breast cancer: a randomized prospective study. Breast Journal2007;13(6):571‐4. ">Oltra 2007</a>; <a href="./references#CD012425-bbs2-0035" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA , et al. Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD012425-bbs2-0041" title="GoodmanA . How often to follow up? Study shows two CT scans as good as five for low‐risk testicular cancer. Oncology Times2007;29(12):54‐5. NCT00003420 . CT scans in treating patients with stage I testicular cancer after undergoing orchiectomy. clinicaltrials.gov/ct2/show/NCT00003420 (first received 20 December 2016). RustinGJ , MeadGM , StenningSP , VaseyPA , AassN , HuddartRA , et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197‐‐the National Cancer Research Institute Testis Cancer Clinical Studies Group. Journal of Clinical Oncology2007;25(11):1310‐5. ">Rustin 2007</a>; <a href="./references#CD012425-bbs2-0043" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk‐adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD012425-bbs2-0049" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>). The remaining studies were funded by either academic, public or non‐profit sources, although two studies also reported contributions from industry (<a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a>; <a href="./references#CD012425-bbs2-0051" title="NCT00198341 . Post‐surgical non‐small cell lung cancer (NSCLC) follow‐up. clinicaltrials.gov/ct2/show/NCT00198341 (first received 20 December 2016). WesteelV . Follow‐up of the patient after curative treatment. Lung Cancer2011;71:S10‐1. WesteelV . Surveillance and second primary malignancies in lung cancer survivors. Journal of Thoracic Oncology2018;13(10 Suppl):S277‐8. WesteelV , BarlesiF , DomasJ , GirardP , FoucherP , LafitteJJ , et al. Postoperative follow‐up of lung cancer: randomized trial comparing two follow‐up programs in completely resected non‐small cell lung cancer (IFCT‐0302). Journal of Clinical Oncology2012;30(15 Suppl 1):no pagination. WesteelV , BarlesiF , FoucherP , LafitteJ , DomasJ , GirardP , et al. Recurrences and 2nd primary cancers in the IFCT‐0302 trial assessing a CT‐scan‐based follow‐up after lung cancer surgery. Journal of Thoracic Oncology2017;12(11 Suppl 2):S1788‐9. WesteelV , BarlesiF , FoucherP , LafitteJ‐J , DomasJ , GirardP , et al. Results of the phase III IFCT‐0302 trial assessing minimal versus CT‐scan‐based follow‐up for completely resected non‐small cell lung cancer (NSCLC). Annals of Oncology2017;28(Suppl 5):v452. WesteelV , BarlesiF , FoucherP , LafitteJJ , DomasJ , GirardP , et al. Compliance with follow‐up programs after surgery for non‐small cell lung cancer in the phase III IFCT‐0302 trial. Journal of Thoracic Oncology2015;10(9 Suppl 2):S239. WesteelV , LebitasyMP , MercierM , LafitteJJ , DomasJ , GirardPl . IFCT‐0302 trial: randomised study comparing two follow‐up schedules in completely resected non‐small cell lung cancer [Protocole IFCT‐0302 : essai randomisé de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués]. Revue des Maladies Respiratoires2007;2(5):645‐52. ">Westeel 2012</a>). Authors from six studies reported disclosures on potential conflicts of interests (<a href="./references#CD012425-bbs2-0017" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14:260. [DOI: 10.1186/1745‐6215‐14‐260] JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a nurse‐led supportive care package (survivor care) for survivors of colorectal cancer. Cancer Nursing2015;38(4 Suppl 1):S16‐7. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (Survivor‐Care, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2015;33(15 Suppl 1):9566. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , SchofieldP , ArandaS , YoungJ , ButowP . Randomised controlled trial (RCT) of a comprehensive post‐treatment support package (survivor‐care) for bowel cancer survivors. Psycho‐oncology2010;19:S193. ">Jefford 2016</a>; <a href="./references#CD012425-bbs2-0028" title="MalyRC , GriggsJJ , LiuY , LiangLJ , GanzPA . A randomized controlled trial of survivorship care plans among low‐income breast cancer survivors. Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. MalyRC , LiangLJ , LiuY , GriggsJJ , GanzPA . Randomized controlled trial of survivorship care plans among low‐income, predominant Latina breast cancer survivors. Journal of Clinical Oncology2017;35(16):1814‐21. NCT01627366 . Study of survivorship care plans and outcomes in underserved breast cancer survivors. clinicaltrials.gov/ct2/show/NCT01627366 (first received 17 December 2018). ">Maly 2017</a>; <a href="./references#CD012425-bbs2-0036" title="MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017;21(32):1‐86. MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00560365 (first received 20 December 2016). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology2011;29(15 Suppl 1):3521. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. [DOI: 10.1001/jama.2013.285718] PughSA , FullerA , PereraR , GeorgeS , MantD , PrimroseJ . The follow‐up after colorectal cancer surgery trial: randomised trial of follow‐up after colorectal cancer surgery and outcome following recurrence. Journal of the American College of Surgeons2014;219(4 Suppl 1):e46‐7. PughSA , MantD , ShinkinsB , MellorJ , PereraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology2016;27(Suppl 6):no pagination. ShinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PloS One2017;12(3):e0171810. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;105(6):658‐62. ">Primrose 2014</a>; <a href="./references#CD012425-bbs2-0038" title="DeRooijBH , EzendamNP , NicolaijeKA , LodderP , VosMC , PijnenborgJM , et al. Survivorship care plans have a negative impact on long‐term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. Quality of Life Research2018;27(6):1533‐44. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2‐year follow‐up ‐ The ROGY care trial. Gynecologic Oncology2017;145(2):319‐28. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Long‐term impact of survivorship care plans on ovarian cancer patient reported outcomes‐new results of the ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):64‐5. DeRooijBH , EzendamNP , NicolaijeKA , VosMC , PijnenborgJM , BollD , et al. The indirect effects of survivorship care plans on quality of life, anxiety and depression‐the ROGY care trial. Supportive Care in Cancer2017;25(2 Suppl 1):S53‐4. DeRooijBH , EzendamNP , VosMC , PijnenborgJM , BollD , KruitwagenRF , et al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. Cancer Epub 2018 Nov 30;125(5):788‐97. [DOI: 10.1002/cncr.31844] EzendamN , DeRooijB , NicolaijeK , VosC , PijnenborgJ , BollD , et al. Long‐term impact of cancer survivorship care plans on patient outcomes‐the randomized controlled ROGY care trial. International Journal of Gynecological Cancer2016;26:91. EzendamNP , VanBroekhovenM , Van DePoll‐FranseLV , DeRooijBH . The role of illness perceptions in smoking, alcohol consumption and weight changes among gynaecological cancer survivors. Quality of Life Research2016;25(1 Suppl 1):114. JeppesenMM , EzendamNP , PijnenborgJM , VosMC , BollD , KruitwagenRF , et al. The impact of the survivorship care plan on health care use: 2‐year follow‐up results of the ROGY care trial. Journal of Cancer Survivorship2018;12(1):18‐27. NicolaijeKA , EzendamNP , VosMC , PijnenborgJM , BollD , BossEA , et al. Impact of an automatically generated cancer survivorship care plan on patient‐reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial. Journal of Clinical Oncology2015;33(31):3550‐9. Van dePoll‐FranseL , NicolaijeK , EzendamN , VosC , BollD , PijnenborgJ , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY CARE): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Psycho‐oncology2013;22:341‐2. Van dePoll‐FranseLV , JeppesenMM , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. The survivorship care plan increases the use of primary care in anxious and irradiated endometrial cancer patients. Two year outcomes of the pragmatic cluster randomized ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):164. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosCM , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY Care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosMC , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. European Journal of Cancer2013;49:S720. Van dePoll‐FranseLV , NicolaijeKA , VosMC , PijnenborgJM , BollD , HussonO , et al. The impact of a cancer survivorship care plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials2011;12:256. ">ROGY 2015</a>; <a href="./references#CD012425-bbs2-0040" title="RuddyKJ , BakerEL , GuoH , GoldsteinMJ , WinerEP , ShulmanLN , et al. Randomized trial evaluating a coordinated survivorship care program for early stage breast cancer. Cancer Research2013;73(24 Suppl 1):OT2‐5‐02. RuddyKJ , GuoH , BakerE , GoldsteinM , MullaneyEE , ShulmanLN , et al. Coordinated follow‐up breast cancer survivorship care program study. Journal of Clinical Oncology2015;33(15 Suppl 1):e17727. RuddyKJ , GuoH , BakerEL , GoldsteinMJ , MullaneyEE , ShulmanLN , et al. Randomized phase 2 trial of a coordinated breast cancer follow‐up care program. Cancer2016;122:3546‐54. ">Ruddy 2016</a>; <a href="./references#CD012425-bbs2-0052" title="NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00225641 (first received 20 December 2016). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PahlmanL , et al. Intensity of follow up after surgery for colorectal cancer. Colorectal Disease2014;16:93. Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA2018;319(20):2095‐103. ">Wille‐Jorgensen 2018</a>). </p> </section> <section id="CD012425-sec-0069"> <h5 class="title">Types of interventions</h5> <p>The included studies investigated a wide range of interventions, and details of the types of interventions, comparisons and follow‐up periods are given in the <a href="./references#CD012425-sec-0158" title="">Characteristics of included studies</a> tables. </p> <p>Six studies compared nurse‐led follow‐up with conventional specialist‐led follow‐up (<a href="./references#CD012425-bbs2-0002" title="BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Economic evaluation of a randomized clinical trial of hospital versus telephone follow‐up after treatment for breast cancer. British Journal of Surgery2009;96(12):1406‐15. [DOI: 10.1002/bjs.6753] BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Is telephone follow‐up by specialist nurses a cost effective approach?. European Journal of Cancer Supplements2009;7(2‐3):230‐1. BeaverK , Tysver‐RobinsonD , CampbellM , TwomeyM , WilliamsonS , HindleyA , et al. Comparing hospital and telephone follow‐up after treatment for breast cancer: randomised equivalence trial. BMJ2009;338:a3147. [DOI: 10.1136/bmj.a3147] ">Beaver 2009</a>; <a href="./references#CD012425-bbs2-0003" title="BeaverK , CampbellM , WilliamsonS , ProcterD , SheridanJ , HeathJ , et al. An exploratory randomized controlled trial comparing telephone and hospital follow‐up after treatment for colorectal cancer. Colorectal Disease2012;14(10):1201‐9. [DOI: 10.1111/j.1463‐1318.2012.02936.x] ">Beaver 2012</a>; <a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a>; <a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a>; <a href="./references#CD012425-bbs2-0030" title="MorrisonV , SpencerLH , LeesonS . Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a randomised feasibility trial. Psycho‐oncology2017;26(Suppl 2):3‐4. MorrisonV , SpencerLH , TottonN , PyeK , YeoST , ButterworthC , et al. Trial of optimal personalised care after treatment‐gynaecological cancer (TOPCAT‐G): a randomized feasibility trial. International Journal of Gynecological Cancer2018;28(2):401‐11. PyeK , TottonN , StuartN , WhitakerR , MorrisonV , EdwardsRT , et al. Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a study protocol for a randomised feasibility trial. Pilot and Feasibility Studies2016;2:67. [DOI 10.1186/s40814‐016‐0108‐5] ">Morrison 2018</a>; <a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a>). </p> <p>Five studies compared GP‐led follow‐up with conventional specialist‐led follow‐up (<a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad 2013</a>; <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a>; <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>; <a href="./references#CD012425-bbs2-0031" title="MurchieP , NicolsonMC , HannafordPC , RajaEA , LeeAJ , CampbellNC . Patient satisfaction with GP‐led melanoma follow‐up: a randomised controlled trial. British Journal of Cancer2010;102(10):1447‐55. ">Murchie 2010</a>; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>). </p> <p>Five studies compared patient‐initiated follow‐up with conventional specialist‐led follow‐up (<a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a>; <a href="./references#CD012425-bbs2-0018" title="JeppesenMM , JensenPT , GilsaD , DePont ChristensenR , JensenMM , MogensenO . The effect of patient‐initiated follow‐up on fear of recurrence and health care use: a randomized trial in early‐stage endometrial cancer. International Journal of Gynecological Cancer2017;27(Supplement 4):1107. JeppesenMM , JensenPT , HansenDG , ChristensenRD , MogensenO . Authors' reply re: Patient‐initiated follow‐up affects fear of recurrence and health care use: a randomised trial in early‐stage endometrial cancer. BJOG2018;125(13):1778‐9. JeppesenMM , JensenPT , HansenDG , ChristensenRD , MogensenO . Patient‐initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early‐stage endometrial cancer. BJOG2018;125(13):1705‐14. TegnerowiczJ . Re: Patient‐initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early‐stage endometrial cancer. BJOG2018;1125(13):1778. ">Jeppesen 2018</a>; <a href="./references#CD012425-bbs2-0021" title="DentJ , ToppingA , FergusonC , StephensonJ , McCoyM , AllinsonV , et al. To follow up or not? A new model of supportive care for early breast cancer. Journal of Clinical Oncology2011;29(15 Suppl 1):no pagination. KirshbaumMN , DentJ , StephensonJ , ToppingAE , AllinsonV , McCoyM , et al. Open access follow‐up care for early breast cancer: a randomised controlled quality of life analysis. European Journal of Cancer Care2017;26(4):e12577. [DOI: 10.1111/ecc.12577] ">Kirshbaum 2017</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0044" title="SheppardC , HigginsB , WiseM , YiangouC , DuboisD , KilburnS . Breast cancer follow up: a randomised controlled trial comparing point of need access versus routine 6‐monthly clinical review. European Journal of Oncology Nursing2009;13(1):2‐8. [DOI: 10.1016/j.ejon.2008.11.005] ">Sheppard 2009</a>). This type of follow‐up was also referred to as 'open‐access' or 'on‐demand' follow‐up in some of the publications. </p> <p>One study compared shared care (where a number of hospital visits are replaced by GP‐appointments) with conventional specialist‐led follow‐up (<a href="./references#CD012425-bbs2-0009" title="ACTRN12610000938000 . The ProCare Trial: a randomised controlled trial of follow up of men with prostate cancer in primary care. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336116 (first received 20 December 2016). EmeryJ , DooreyJ , JeffordM , KingM , PirottaM , HayneD , et al. Protocol for the ProCare Trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. BMJ Open2014;4(3):e004972. [DOI: 10.1136/bmjopen‐2014‐004972] EmeryJ , SchofieldP , JeffordM , KingM , PirottaM , HayneD , et al. The ProCare trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. Asia‐Pacific Journal of Clinical Oncology2014;10:157. EmeryJD , JeffordM , KingM , HayneD , MartinA , DooreyJ , et al. ProCare Trial: a phase II randomized controlled trial of shared care for follow‐up of men with prostate cancer. BJU International2016;119(3):381‐89. [DOI: 10.1111/bju.13593] KingM . Procare/PC4 study update. Asia‐Pacific Journal of Clinical Oncology2012;8:23. ">Emery 2016</a>). </p> <p>Four studies compared frequency of follow‐up visits: one study compared fewer visits with more frequent visits (<a href="./references#CD012425-bbs2-0007" title="DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . Prospective randomized clinical trial for the evaluation of a stage adjusted reduced follow‐up schedule in cutaneous melanoma patients: results after one year. Annals of Surgical Oncology2016;23(1 Suppl 1):S30. DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . The MELFO‐study: prospective randomized clinical trial for the evaluation of a stage‐adjusted reduced follow‐up schedule in cutaneous melanoma patients ‐ results after 1 year. Annals of Surgical Oncology2016;23(9):2762‐71. [DOI: 10.1245/s10434‐016‐5263‐7] DeckersE , Hoekstra‐WeebersJ , DamudeS , FranckenA , Ter MeulenS , BastiaannetE , et al. The MELFO‐study: a multi‐center prospective randomized clinical trial on the effects of a reduced stage‐adjusted follow‐up schedule on cutaneous melanoma IB‐IIC patients: results after 3‐years. Annals of Surgical Oncology2018;25(1 Suppl 1):S40. NCT01018004 . Comparing follow‐up schedules in patients with newly diagnosed stage IB or stage II melanoma. clinicaltrials.gov/ct2/show/NCT01018004 (first received 20 December 2016). ">Damude 2016</a>), while three compared more frequent visits with fewer visits (<a href="./references#CD012425-bbs2-0022" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomized study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Gastroenterology1999;34(5):509‐15. KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;149:159‐62. ">Kjeldsen 1997</a>; <a href="./references#CD012425-bbs2-0035" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA , et al. Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD012425-bbs2-0052" title="NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00225641 (first received 20 December 2016). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PahlmanL , et al. Intensity of follow up after surgery for colorectal cancer. Colorectal Disease2014;16:93. Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA2018;319(20):2095‐103. ">Wille‐Jorgensen 2018</a>). When the latter three studies contributed data to the meta‐analysis comparing less intensive to more intensive follow‐up, we reversed the reported estimates for intervention and comparison arms. </p> <p>Two studies compared a less intensive follow‐up intervention to more intensive follow‐up: <a href="./references#CD012425-bbs2-0034" title="PicardiM , PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , et al. Advanced‐stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission‐‐a randomized trial of routine surveillance imaging procedures. Radiology2014;272(1):262‐74. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: Ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2015;100:7‐8. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2014;99:398‐9. ">Picardi 2014</a> compared follow‐up based on the use of chest X‐rays with follow‐up using PET/CT scans in Hodgkin lymphoma survivors, while <a href="./references#CD012425-bbs2-0041" title="GoodmanA . How often to follow up? Study shows two CT scans as good as five for low‐risk testicular cancer. Oncology Times2007;29(12):54‐5. NCT00003420 . CT scans in treating patients with stage I testicular cancer after undergoing orchiectomy. clinicaltrials.gov/ct2/show/NCT00003420 (first received 20 December 2016). RustinGJ , MeadGM , StenningSP , VaseyPA , AassN , HuddartRA , et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197‐‐the National Cancer Research Institute Testis Cancer Clinical Studies Group. Journal of Clinical Oncology2007;25(11):1310‐5. ">Rustin 2007</a> compared follow‐up based on two CT scans with follow‐up based on five CT scans in testicular cancer survivors. </p> <p>Eighteen studies compared a more intensive follow‐up intervention to less intensive follow‐up based on the use of additional or more intensive surveillance components, for example, additional examinations, imaging procedures or blood tests for biomarkers (<a href="./references#CD012425-bbs2-0006" title="D'CruzA , VaishR , GuptaS , AryaS , HawaldarRW , ShahS . Does addition of neck ultrasonography to physical examination, in follow‐up of patients with early stage, clinically node negative oral cancers, influence outcome? A randomized control trial (RCT). Journal of Clinical Oncology2016;34(15 Suppl 6):no pagination. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node‐negative oral cancer. New England Journal of Medicine2015;373(6):521‐9. NCT00193765 . Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. clinicaltrials.gov/ct2/show/NCT00193765 (first received 20 December 2016). ">D'Cruz 2016</a>; <a href="./references#CD012425-bbs2-0010" title="GambazziF , FreyLD , BruehlmeierM , JanthurWD , GraberSM , HeubergerJ , et al. Comparing two imaging methods for follow‐up of lung cancer treatment: a randomized pilot study. Annals of Thoracic Surgery2018;107(2):430‐5. [DOI: 10.1016/j.athoracsur.2018.08.015] ">Gambazzi 2018</a>; <a href="./references#CD012425-bbs2-0011" title="GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata). A randomized trial of intensive versus minimalist follow‐up of patients with resected Dukes B‐C colorectal cancer: the pilot phase. Tumori1998;84(Suppl):89. GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. NCT02409472 . Intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. clinicaltrials.gov/ct2/show/NCT02409472 (first received 20 December 2016). RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] ">GILDA 2016</a>; <a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a>; <a href="./references#CD012425-bbs2-0024" title="KokkoR , HakamaM , HolliK . Follow‐up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Research and Treatment2005;93(3):255‐60. KokkoR , HakamaM , HolliK . Role of chest X‐ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Research and Treatment2003;81(1):33‐9. ">Kokko 2003</a>; <a href="./references#CD012425-bbs2-0026" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1992</a>; <a href="./references#CD012425-bbs2-0029" title="MonteilJ , VergnenègreA , BertinF , DalmayF , GaillardS , BonnaudF , et al. Randomized follow‐up study of resected NSCLC patients: conventional versus 18F‐DG coincidence imaging. Anticancer Research2010;30(9):3811‐6. NCT00199615 . Follow‐up of patients with curative‐intent surgical resection for NSCLC. clinicaltrials.gov/ct2/show/NCT00199615 (first received 20 December 2016). ">Monteil 2010</a>; <a href="./references#CD012425-bbs2-0032" title="OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD012425-bbs2-0033" title="OltraA , SantaballaA , MontalarJ , MunárrizB , PastorM , MeseguerA , et al. Cost‐benefit evaluation of a follow‐up program in patients with advanced breast cancer. Randomized study. Revista de Oncología1999;1(Suppl 1):165. OltraA , SantaballaA , MunárrizB , PastorM , MontalarJ . Cost‐benefit analysis of a follow‐up program in patients with breast cancer: a randomized prospective study. Breast Journal2007;13(6):571‐4. ">Oltra 2007</a>; <a href="./references#CD012425-bbs2-0036" title="MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017;21(32):1‐86. MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00560365 (first received 20 December 2016). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology2011;29(15 Suppl 1):3521. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. [DOI: 10.1001/jama.2013.285718] PughSA , FullerA , PereraR , GeorgeS , MantD , PrimroseJ . The follow‐up after colorectal cancer surgery trial: randomised trial of follow‐up after colorectal cancer surgery and outcome following recurrence. Journal of the American College of Surgeons2014;219(4 Suppl 1):e46‐7. PughSA , MantD , ShinkinsB , MellorJ , PereraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology2016;27(Suppl 6):no pagination. ShinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PloS One2017;12(3):e0171810. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;105(6):658‐62. ">Primrose 2014</a>; <a href="./references#CD012425-bbs2-0037" title="BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial [Efectividad del seguimiento postoperatorio en los pacientes con cáncer colorrectal para la detección de recidivas curables. Análisis preliminar de un estudio multicéntrico, controlado y aleatorizado]. Gastroenterologia y Hepatologia2001;24(2):92, abstract no: 13. BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Preliminary analysis of a multicenter controlled trial to evaluate the effectiveness of postoperative follow‐up to detect curable recurrences in patients with colorectal cancer [Análisis preliminar de un estudio multicéntrico controlado y aleatorizado destinado a evaluar la efectividad del seguimiento postoperatorio en la detección de recidivas curables en los pacientes con cáncer colorrectal]. Gastroenterologia y Hepatologia2001;24(3):150. Rodriguez‐MorantaF , CastellsA , SaloJ , ArcusaA , BoadasJ , BessaV , et al. Efficacy of postoperative surveillance after radical surgery for colorectal cancer (CRC). Analysis of a prospective, multicenter, randomized controlled trial. Journal of Gastroenterology2005;128(4 Suppl 2):Abstract W967. Rodríguez‐MorantaF , SalóJ , AcrusaA , BoadasJ , BessaX , PiñolV , et al. Efficacy of postoperative surveillance in patients with colorectal cancer after radical surgery. A prospective, multicenter, randomized study. Gastroenterologia y Hepatologia2005;28(3):197‐8, abstract no: 126. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , Bessa , X , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD012425-bbs2-0039" title="PalliD , RussoA , SaievaC , CiattoS , Rosselli Del TurcoM , DistanteV , et al. Intensive vs clinical follow‐up after treatment of primary breast cancer: 10‐year update of a randomized trial. National Research Council Project on Breast Cancer Follow‐up. JAMA1999;281(17):1586. Roselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . The efficacy of intensive follow‐up testing in breast cancer cases. Annals of Oncology1995;6(Suppl 2):37‐9. Rosselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . Intensive diagnostic follow‐up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow‐up. JAMA1994;271(20):1593‐7. ">Rosselli Del Turco 1994</a>; <a href="./references#CD012425-bbs2-0042" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gastroenterology1998;114(1):7‐14. SchoemakerD , BlackR , GilesL , ToouliJ , AlcornJ . Addition of intensive follow‐up procedures to standard follow‐up did not improve survival in patients with colorectal cancer. Evidence‐Based Medicine1998;3(5):140. ">Schoemaker 1998</a>; <a href="./references#CD012425-bbs2-0043" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk‐adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD012425-bbs2-0045" title="SobhaniI , TiretE , LebtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>; <a href="./references#CD012425-bbs2-0046" title="NCT00624260 . Impact of PET Scan on the curative strategy of colo‐rectal cancers : a randomized study. clinicaltrials.gov/ct2/show/NCT00624260 (first received 20 December 2016). SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an openlabel multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology2017;35(15 Suppl 1):no pagination. SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal2017;5(5 Suppl 1):A13. SobhaniI , IttiE , LucianiA , BaumgaertnerI , LayeseR , AndreT , et al. Colorectal cancer (CRC) monitoring by 6‐monthly 18FDG‐PET/CT: an open‐label multicentre randomised trial. Annals of Oncology2018;29(4):931‐7. ">Sobhani 2018</a>; <a href="./references#CD012425-bbs2-0049" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>; <a href="./references#CD012425-bbs2-0051" title="NCT00198341 . Post‐surgical non‐small cell lung cancer (NSCLC) follow‐up. clinicaltrials.gov/ct2/show/NCT00198341 (first received 20 December 2016). WesteelV . Follow‐up of the patient after curative treatment. Lung Cancer2011;71:S10‐1. WesteelV . Surveillance and second primary malignancies in lung cancer survivors. Journal of Thoracic Oncology2018;13(10 Suppl):S277‐8. WesteelV , BarlesiF , DomasJ , GirardP , FoucherP , LafitteJJ , et al. Postoperative follow‐up of lung cancer: randomized trial comparing two follow‐up programs in completely resected non‐small cell lung cancer (IFCT‐0302). Journal of Clinical Oncology2012;30(15 Suppl 1):no pagination. WesteelV , BarlesiF , FoucherP , LafitteJ , DomasJ , GirardP , et al. Recurrences and 2nd primary cancers in the IFCT‐0302 trial assessing a CT‐scan‐based follow‐up after lung cancer surgery. Journal of Thoracic Oncology2017;12(11 Suppl 2):S1788‐9. WesteelV , BarlesiF , FoucherP , LafitteJ‐J , DomasJ , GirardP , et al. Results of the phase III IFCT‐0302 trial assessing minimal versus CT‐scan‐based follow‐up for completely resected non‐small cell lung cancer (NSCLC). Annals of Oncology2017;28(Suppl 5):v452. WesteelV , BarlesiF , FoucherP , LafitteJJ , DomasJ , GirardP , et al. Compliance with follow‐up programs after surgery for non‐small cell lung cancer in the phase III IFCT‐0302 trial. Journal of Thoracic Oncology2015;10(9 Suppl 2):S239. WesteelV , LebitasyMP , MercierM , LafitteJJ , DomasJ , GirardPl . IFCT‐0302 trial: randomised study comparing two follow‐up schedules in completely resected non‐small cell lung cancer [Protocole IFCT‐0302 : essai randomisé de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués]. Revue des Maladies Respiratoires2007;2(5):645‐52. ">Westeel 2012</a>). When these studies contributed data to the meta‐analysis, we reversed the reported estimates for intervention and comparison arms. </p> <p>Twelve studies investigated the addition of care or information components to usual care that might be expected to affect surveillance of recurrences, such as symptom monitoring and feedback (<a href="./references#CD012425-bbs2-0008" title="DavisKM , DawsonD , KellyS , RedS , PenekS , LynchJ , et al. Monitoring of health‐related quality of life and symptoms in prostate cancer survivors: a randomized trial. Journal of Supportive Oncology2013;11(4):174‐82. ">Davis 2013</a>), implementation of survivorship care plans/packages in clinical care (<a href="./references#CD012425-bbs2-0015" title="BoekhoutAH , MaunsellE , PondGR , JulianJA , CoyleD , LevineMN , et al. A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial. Journal of Cancer Survivorship2015;9(4):683‐91. CoyleD , GrunfeldE , CoyleK , JulianJA , PondGR , FolkesA , et al. Cost‐effectiveness of a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):6082. CoyleD , GrunfeldE , CoyleK , PondG , JulianJA , LevineMN . Cost effectiveness of a survivorship care plan for breast cancer survivors. Journal of Oncology Practice2014;10(2):e86‐92. GrunfeldE , JulianJA , PondG , MaunsellE , CoyleD , FolkesA , et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. Journal of Clinical Oncology2011;29(36):4755‐62. GrunfeldE , LevineMN , JulianJA , PondGR , MaunsellE , FolkesA , et al. Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):9005. GrunfeldE , PondG , MaunsellE , LevineMN , JulianJA , CoyleD . Impact of survivorship care plans (SCP) on adherence to guidelines, health service measures, and patient‐reported outcomes (PRO): extended results of a multicenter randomized clinical trial (RCT) with breast cancer survivors. European Journal of Cancer2012;48:S147. ">Grunfeld 2011</a>; <a href="./references#CD012425-bbs2-0016" title="HershmanDL , GreenleeH , AwadD , KalinskyK , MaurerM , KranwinkelG , et al. Randomized controlled trial of a clinic‐based survivorship intervention following adjuvant therapy in breast cancer survivors. Breast Cancer Research and Treatment2013;138(3):795‐806. ">Hershman 2013</a>; <a href="./references#CD012425-bbs2-0017" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14:260. [DOI: 10.1186/1745‐6215‐14‐260] JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a nurse‐led supportive care package (survivor care) for survivors of colorectal cancer. Cancer Nursing2015;38(4 Suppl 1):S16‐7. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (Survivor‐Care, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2015;33(15 Suppl 1):9566. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , SchofieldP , ArandaS , YoungJ , ButowP . Randomised controlled trial (RCT) of a comprehensive post‐treatment support package (survivor‐care) for bowel cancer survivors. Psycho‐oncology2010;19:S193. ">Jefford 2016</a>; <a href="./references#CD012425-bbs2-0025" title="KvaleEA , Demark‐WahnefriedW , MenesesK , BaeS , HuangCH , AzueroCB , et al. Patient centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer Research2015;75(9 Suppl 1):no pagination. KvaleEA , HuangCS , MenesesKM , Demark‐WahnefriedW , BaeS , AzueroCB , et al. Patient‐centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer2016;122(20):3232‐42. ">Kvale 2016</a>; <a href="./references#CD012425-bbs2-0028" title="MalyRC , GriggsJJ , LiuY , LiangLJ , GanzPA . A randomized controlled trial of survivorship care plans among low‐income breast cancer survivors. Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. MalyRC , LiangLJ , LiuY , GriggsJJ , GanzPA . Randomized controlled trial of survivorship care plans among low‐income, predominant Latina breast cancer survivors. Journal of Clinical Oncology2017;35(16):1814‐21. NCT01627366 . Study of survivorship care plans and outcomes in underserved breast cancer survivors. clinicaltrials.gov/ct2/show/NCT01627366 (first received 17 December 2018). ">Maly 2017</a>; <a href="./references#CD012425-bbs2-0038" title="DeRooijBH , EzendamNP , NicolaijeKA , LodderP , VosMC , PijnenborgJM , et al. Survivorship care plans have a negative impact on long‐term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. Quality of Life Research2018;27(6):1533‐44. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2‐year follow‐up ‐ The ROGY care trial. Gynecologic Oncology2017;145(2):319‐28. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Long‐term impact of survivorship care plans on ovarian cancer patient reported outcomes‐new results of the ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):64‐5. DeRooijBH , EzendamNP , NicolaijeKA , VosMC , PijnenborgJM , BollD , et al. The indirect effects of survivorship care plans on quality of life, anxiety and depression‐the ROGY care trial. Supportive Care in Cancer2017;25(2 Suppl 1):S53‐4. DeRooijBH , EzendamNP , VosMC , PijnenborgJM , BollD , KruitwagenRF , et al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. Cancer Epub 2018 Nov 30;125(5):788‐97. [DOI: 10.1002/cncr.31844] EzendamN , DeRooijB , NicolaijeK , VosC , PijnenborgJ , BollD , et al. Long‐term impact of cancer survivorship care plans on patient outcomes‐the randomized controlled ROGY care trial. International Journal of Gynecological Cancer2016;26:91. EzendamNP , VanBroekhovenM , Van DePoll‐FranseLV , DeRooijBH . The role of illness perceptions in smoking, alcohol consumption and weight changes among gynaecological cancer survivors. Quality of Life Research2016;25(1 Suppl 1):114. JeppesenMM , EzendamNP , PijnenborgJM , VosMC , BollD , KruitwagenRF , et al. The impact of the survivorship care plan on health care use: 2‐year follow‐up results of the ROGY care trial. Journal of Cancer Survivorship2018;12(1):18‐27. NicolaijeKA , EzendamNP , VosMC , PijnenborgJM , BollD , BossEA , et al. Impact of an automatically generated cancer survivorship care plan on patient‐reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial. Journal of Clinical Oncology2015;33(31):3550‐9. Van dePoll‐FranseL , NicolaijeK , EzendamN , VosC , BollD , PijnenborgJ , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY CARE): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Psycho‐oncology2013;22:341‐2. Van dePoll‐FranseLV , JeppesenMM , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. The survivorship care plan increases the use of primary care in anxious and irradiated endometrial cancer patients. Two year outcomes of the pragmatic cluster randomized ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):164. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosCM , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY Care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosMC , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. European Journal of Cancer2013;49:S720. Van dePoll‐FranseLV , NicolaijeKA , VosMC , PijnenborgJM , BollD , HussonO , et al. The impact of a cancer survivorship care plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials2011;12:256. ">ROGY 2015</a>; <a href="./references#CD012425-bbs2-0040" title="RuddyKJ , BakerEL , GuoH , GoldsteinMJ , WinerEP , ShulmanLN , et al. Randomized trial evaluating a coordinated survivorship care program for early stage breast cancer. Cancer Research2013;73(24 Suppl 1):OT2‐5‐02. RuddyKJ , GuoH , BakerE , GoldsteinM , MullaneyEE , ShulmanLN , et al. Coordinated follow‐up breast cancer survivorship care program study. Journal of Clinical Oncology2015;33(15 Suppl 1):e17727. RuddyKJ , GuoH , BakerEL , GoldsteinMJ , MullaneyEE , ShulmanLN , et al. Randomized phase 2 trial of a coordinated breast cancer follow‐up care program. Cancer2016;122:3546‐54. ">Ruddy 2016</a>), or implementation of supportive care packages that included patient education on symptoms of recurrence (<a href="./references#CD012425-bbs2-0019" title="JuarezG , HurriaA , FerrellB . Effectiveness of an education intervention on quality of life in Latina breast cancer survivors. Psycho‐oncology2012;21:110. JuarezG , HurriaA , UmanG , FerrellB . Impact of a bilingual education intervention on the quality of life of Latina breast cancer survivors. Oncology Nursing Forum2013;40(1):E50‐60. [DOI: 10.1188/13.ONF.E50‐E60] ">Juarez 2013</a>; <a href="./references#CD012425-bbs2-0027" title="MalmströmM , IvarssonB , KlefsgårdR , PerssonK , JakobssonU , JohanssonJ . The effect of a nurse led telephone supportive care programme on patients' quality of life, received information and health care contacts after oesophageal cancer surgery‐a six month RCT‐follow‐up study. International Journal of Nursing Studies2016;64:86‐95. [DOI: 10.1016/j.ijnurstu.2016.09.009] ">Malmstrom 2016</a>; <a href="./references#CD012425-bbs2-0047" title="Van DerMeulenI , MayA , RosW , OosteromM , HordijkGJ , KooleR , et al. Effects of a nurse‐led psychosocial intervention on depressive symptoms and health‐related quality of life in patients with head and neck cancer: a randomized controlled trial. Psycho‐oncology2013;22(Suppl 3):17. Van derMeulenIC , MayAM , RosWJ , OosteromM , HordijkGJ , KooleR , et al. One‐year effect of a nurse‐led psychosocial intervention on depressive symptoms in patients with head and neck cancer: a randomized controlled trial. Oncologist2013;18(3):336‐44. [DOI: 10.1634/theoncologist.2012‐0299] ">Van der Meulen 2013</a>; <a href="./references#CD012425-bbs2-0053" title='ACTRN12608000252314 . Cancer care after surgery – the CONNECT study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82819 (first received 20 December 2016). HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Connect: a pilot RCT to improve outcomes for people with colorectal cancer. Asia‐Pacific Journal of Clinical Oncology2009;5:A159. HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Randomized pilot evaluation of the supportive care intervention "CONNECT" for people following surgery for colorectal cancer. Diseases of the Colon and Rectum2011;54(5):622‐31. YoungJM , ButowPN , WalshJ , DurcinoskaI , DobbinsTA , RodwellL , et al. Multicenter randomized trial of centralized nurse‐led telephone‐based care coordination to improve outcomes after surgical resection for colorectal cancer: the CONNECT intervention. Journal of Clinical Oncology2013;31(28):3585‐91. [DOI: 10.1200/JCO.2012.48.1036] '>Young 2013</a>). </p> </section> <section id="CD012425-sec-0070"> <h5 class="title">Outcomes</h5> <section id="CD012425-sec-0071"> <h6 class="title">Overall survival</h6> <p>Twenty‐two studies reported on the outcome of overall survival (<a href="./references#CD012425-bbs2-0006" title="D'CruzA , VaishR , GuptaS , AryaS , HawaldarRW , ShahS . Does addition of neck ultrasonography to physical examination, in follow‐up of patients with early stage, clinically node negative oral cancers, influence outcome? A randomized control trial (RCT). Journal of Clinical Oncology2016;34(15 Suppl 6):no pagination. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node‐negative oral cancer. New England Journal of Medicine2015;373(6):521‐9. NCT00193765 . Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. clinicaltrials.gov/ct2/show/NCT00193765 (first received 20 December 2016). ">D'Cruz 2016</a>; <a href="./references#CD012425-bbs2-0011" title="GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata). A randomized trial of intensive versus minimalist follow‐up of patients with resected Dukes B‐C colorectal cancer: the pilot phase. Tumori1998;84(Suppl):89. GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. NCT02409472 . Intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. clinicaltrials.gov/ct2/show/NCT02409472 (first received 20 December 2016). RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] ">GILDA 2016</a>; <a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a>; <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>; <a href="./references#CD012425-bbs2-0022" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomized study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Gastroenterology1999;34(5):509‐15. KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;149:159‐62. ">Kjeldsen 1997</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0024" title="KokkoR , HakamaM , HolliK . Follow‐up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Research and Treatment2005;93(3):255‐60. KokkoR , HakamaM , HolliK . Role of chest X‐ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Research and Treatment2003;81(1):33‐9. ">Kokko 2003</a>; <a href="./references#CD012425-bbs2-0026" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1992</a>; <a href="./references#CD012425-bbs2-0029" title="MonteilJ , VergnenègreA , BertinF , DalmayF , GaillardS , BonnaudF , et al. Randomized follow‐up study of resected NSCLC patients: conventional versus 18F‐DG coincidence imaging. Anticancer Research2010;30(9):3811‐6. NCT00199615 . Follow‐up of patients with curative‐intent surgical resection for NSCLC. clinicaltrials.gov/ct2/show/NCT00199615 (first received 20 December 2016). ">Monteil 2010</a>; <a href="./references#CD012425-bbs2-0032" title="OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD012425-bbs2-0035" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA , et al. Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD012425-bbs2-0036" title="MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017;21(32):1‐86. MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00560365 (first received 20 December 2016). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology2011;29(15 Suppl 1):3521. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. [DOI: 10.1001/jama.2013.285718] PughSA , FullerA , PereraR , GeorgeS , MantD , PrimroseJ . The follow‐up after colorectal cancer surgery trial: randomised trial of follow‐up after colorectal cancer surgery and outcome following recurrence. Journal of the American College of Surgeons2014;219(4 Suppl 1):e46‐7. PughSA , MantD , ShinkinsB , MellorJ , PereraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology2016;27(Suppl 6):no pagination. ShinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PloS One2017;12(3):e0171810. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;105(6):658‐62. ">Primrose 2014</a>; <a href="./references#CD012425-bbs2-0037" title="BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial [Efectividad del seguimiento postoperatorio en los pacientes con cáncer colorrectal para la detección de recidivas curables. Análisis preliminar de un estudio multicéntrico, controlado y aleatorizado]. Gastroenterologia y Hepatologia2001;24(2):92, abstract no: 13. BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Preliminary analysis of a multicenter controlled trial to evaluate the effectiveness of postoperative follow‐up to detect curable recurrences in patients with colorectal cancer [Análisis preliminar de un estudio multicéntrico controlado y aleatorizado destinado a evaluar la efectividad del seguimiento postoperatorio en la detección de recidivas curables en los pacientes con cáncer colorrectal]. Gastroenterologia y Hepatologia2001;24(3):150. Rodriguez‐MorantaF , CastellsA , SaloJ , ArcusaA , BoadasJ , BessaV , et al. Efficacy of postoperative surveillance after radical surgery for colorectal cancer (CRC). Analysis of a prospective, multicenter, randomized controlled trial. Journal of Gastroenterology2005;128(4 Suppl 2):Abstract W967. Rodríguez‐MorantaF , SalóJ , AcrusaA , BoadasJ , BessaX , PiñolV , et al. Efficacy of postoperative surveillance in patients with colorectal cancer after radical surgery. A prospective, multicenter, randomized study. Gastroenterologia y Hepatologia2005;28(3):197‐8, abstract no: 126. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , Bessa , X , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD012425-bbs2-0039" title="PalliD , RussoA , SaievaC , CiattoS , Rosselli Del TurcoM , DistanteV , et al. Intensive vs clinical follow‐up after treatment of primary breast cancer: 10‐year update of a randomized trial. National Research Council Project on Breast Cancer Follow‐up. JAMA1999;281(17):1586. Roselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . The efficacy of intensive follow‐up testing in breast cancer cases. Annals of Oncology1995;6(Suppl 2):37‐9. Rosselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . Intensive diagnostic follow‐up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow‐up. JAMA1994;271(20):1593‐7. ">Rosselli Del Turco 1994</a>; <a href="./references#CD012425-bbs2-0042" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gastroenterology1998;114(1):7‐14. SchoemakerD , BlackR , GilesL , ToouliJ , AlcornJ . Addition of intensive follow‐up procedures to standard follow‐up did not improve survival in patients with colorectal cancer. Evidence‐Based Medicine1998;3(5):140. ">Schoemaker 1998</a>; <a href="./references#CD012425-bbs2-0043" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk‐adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD012425-bbs2-0046" title="NCT00624260 . Impact of PET Scan on the curative strategy of colo‐rectal cancers : a randomized study. clinicaltrials.gov/ct2/show/NCT00624260 (first received 20 December 2016). SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an openlabel multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology2017;35(15 Suppl 1):no pagination. SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal2017;5(5 Suppl 1):A13. SobhaniI , IttiE , LucianiA , BaumgaertnerI , LayeseR , AndreT , et al. Colorectal cancer (CRC) monitoring by 6‐monthly 18FDG‐PET/CT: an open‐label multicentre randomised trial. Annals of Oncology2018;29(4):931‐7. ">Sobhani 2018</a>; <a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a>; <a href="./references#CD012425-bbs2-0049" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>; <a href="./references#CD012425-bbs2-0051" title="NCT00198341 . Post‐surgical non‐small cell lung cancer (NSCLC) follow‐up. clinicaltrials.gov/ct2/show/NCT00198341 (first received 20 December 2016). WesteelV . Follow‐up of the patient after curative treatment. Lung Cancer2011;71:S10‐1. WesteelV . Surveillance and second primary malignancies in lung cancer survivors. Journal of Thoracic Oncology2018;13(10 Suppl):S277‐8. WesteelV , BarlesiF , DomasJ , GirardP , FoucherP , LafitteJJ , et al. Postoperative follow‐up of lung cancer: randomized trial comparing two follow‐up programs in completely resected non‐small cell lung cancer (IFCT‐0302). Journal of Clinical Oncology2012;30(15 Suppl 1):no pagination. WesteelV , BarlesiF , FoucherP , LafitteJ , DomasJ , GirardP , et al. Recurrences and 2nd primary cancers in the IFCT‐0302 trial assessing a CT‐scan‐based follow‐up after lung cancer surgery. Journal of Thoracic Oncology2017;12(11 Suppl 2):S1788‐9. WesteelV , BarlesiF , FoucherP , LafitteJ‐J , DomasJ , GirardP , et al. Results of the phase III IFCT‐0302 trial assessing minimal versus CT‐scan‐based follow‐up for completely resected non‐small cell lung cancer (NSCLC). Annals of Oncology2017;28(Suppl 5):v452. WesteelV , BarlesiF , FoucherP , LafitteJJ , DomasJ , GirardP , et al. Compliance with follow‐up programs after surgery for non‐small cell lung cancer in the phase III IFCT‐0302 trial. Journal of Thoracic Oncology2015;10(9 Suppl 2):S239. WesteelV , LebitasyMP , MercierM , LafitteJJ , DomasJ , GirardPl . IFCT‐0302 trial: randomised study comparing two follow‐up schedules in completely resected non‐small cell lung cancer [Protocole IFCT‐0302 : essai randomisé de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués]. Revue des Maladies Respiratoires2007;2(5):645‐52. ">Westeel 2012</a>; <a href="./references#CD012425-bbs2-0052" title="NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00225641 (first received 20 December 2016). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PahlmanL , et al. Intensity of follow up after surgery for colorectal cancer. Colorectal Disease2014;16:93. Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA2018;319(20):2095‐103. ">Wille‐Jorgensen 2018</a>). Eight studies reported HRs (<a href="./references#CD012425-bbs2-0006" title="D'CruzA , VaishR , GuptaS , AryaS , HawaldarRW , ShahS . Does addition of neck ultrasonography to physical examination, in follow‐up of patients with early stage, clinically node negative oral cancers, influence outcome? A randomized control trial (RCT). Journal of Clinical Oncology2016;34(15 Suppl 6):no pagination. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node‐negative oral cancer. New England Journal of Medicine2015;373(6):521‐9. NCT00193765 . Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. clinicaltrials.gov/ct2/show/NCT00193765 (first received 20 December 2016). ">D'Cruz 2016</a>; <a href="./references#CD012425-bbs2-0011" title="GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata). A randomized trial of intensive versus minimalist follow‐up of patients with resected Dukes B‐C colorectal cancer: the pilot phase. Tumori1998;84(Suppl):89. GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. NCT02409472 . Intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. clinicaltrials.gov/ct2/show/NCT02409472 (first received 20 December 2016). RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] ">GILDA 2016</a>; <a href="./references#CD012425-bbs2-0037" title="BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial [Efectividad del seguimiento postoperatorio en los pacientes con cáncer colorrectal para la detección de recidivas curables. Análisis preliminar de un estudio multicéntrico, controlado y aleatorizado]. Gastroenterologia y Hepatologia2001;24(2):92, abstract no: 13. BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Preliminary analysis of a multicenter controlled trial to evaluate the effectiveness of postoperative follow‐up to detect curable recurrences in patients with colorectal cancer [Análisis preliminar de un estudio multicéntrico controlado y aleatorizado destinado a evaluar la efectividad del seguimiento postoperatorio en la detección de recidivas curables en los pacientes con cáncer colorrectal]. Gastroenterologia y Hepatologia2001;24(3):150. Rodriguez‐MorantaF , CastellsA , SaloJ , ArcusaA , BoadasJ , BessaV , et al. Efficacy of postoperative surveillance after radical surgery for colorectal cancer (CRC). Analysis of a prospective, multicenter, randomized controlled trial. Journal of Gastroenterology2005;128(4 Suppl 2):Abstract W967. Rodríguez‐MorantaF , SalóJ , AcrusaA , BoadasJ , BessaX , PiñolV , et al. Efficacy of postoperative surveillance in patients with colorectal cancer after radical surgery. A prospective, multicenter, randomized study. Gastroenterologia y Hepatologia2005;28(3):197‐8, abstract no: 126. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , Bessa , X , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD012425-bbs2-0039" title="PalliD , RussoA , SaievaC , CiattoS , Rosselli Del TurcoM , DistanteV , et al. Intensive vs clinical follow‐up after treatment of primary breast cancer: 10‐year update of a randomized trial. National Research Council Project on Breast Cancer Follow‐up. JAMA1999;281(17):1586. Roselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . The efficacy of intensive follow‐up testing in breast cancer cases. Annals of Oncology1995;6(Suppl 2):37‐9. Rosselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . Intensive diagnostic follow‐up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow‐up. JAMA1994;271(20):1593‐7. ">Rosselli Del Turco 1994</a>; <a href="./references#CD012425-bbs2-0042" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gastroenterology1998;114(1):7‐14. SchoemakerD , BlackR , GilesL , ToouliJ , AlcornJ . Addition of intensive follow‐up procedures to standard follow‐up did not improve survival in patients with colorectal cancer. Evidence‐Based Medicine1998;3(5):140. ">Schoemaker 1998</a>; <a href="./references#CD012425-bbs2-0049" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>; <a href="./references#CD012425-bbs2-0051" title="NCT00198341 . Post‐surgical non‐small cell lung cancer (NSCLC) follow‐up. clinicaltrials.gov/ct2/show/NCT00198341 (first received 20 December 2016). WesteelV . Follow‐up of the patient after curative treatment. Lung Cancer2011;71:S10‐1. WesteelV . Surveillance and second primary malignancies in lung cancer survivors. Journal of Thoracic Oncology2018;13(10 Suppl):S277‐8. WesteelV , BarlesiF , DomasJ , GirardP , FoucherP , LafitteJJ , et al. Postoperative follow‐up of lung cancer: randomized trial comparing two follow‐up programs in completely resected non‐small cell lung cancer (IFCT‐0302). Journal of Clinical Oncology2012;30(15 Suppl 1):no pagination. WesteelV , BarlesiF , FoucherP , LafitteJ , DomasJ , GirardP , et al. Recurrences and 2nd primary cancers in the IFCT‐0302 trial assessing a CT‐scan‐based follow‐up after lung cancer surgery. Journal of Thoracic Oncology2017;12(11 Suppl 2):S1788‐9. WesteelV , BarlesiF , FoucherP , LafitteJ‐J , DomasJ , GirardP , et al. Results of the phase III IFCT‐0302 trial assessing minimal versus CT‐scan‐based follow‐up for completely resected non‐small cell lung cancer (NSCLC). Annals of Oncology2017;28(Suppl 5):v452. WesteelV , BarlesiF , FoucherP , LafitteJJ , DomasJ , GirardP , et al. Compliance with follow‐up programs after surgery for non‐small cell lung cancer in the phase III IFCT‐0302 trial. Journal of Thoracic Oncology2015;10(9 Suppl 2):S239. WesteelV , LebitasyMP , MercierM , LafitteJJ , DomasJ , GirardPl . IFCT‐0302 trial: randomised study comparing two follow‐up schedules in completely resected non‐small cell lung cancer [Protocole IFCT‐0302 : essai randomisé de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués]. Revue des Maladies Respiratoires2007;2(5):645‐52. ">Westeel 2012</a>; <a href="./references#CD012425-bbs2-0052" title="NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00225641 (first received 20 December 2016). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PahlmanL , et al. Intensity of follow up after surgery for colorectal cancer. Colorectal Disease2014;16:93. Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA2018;319(20):2095‐103. ">Wille‐Jorgensen 2018</a>), and we were able to calculate HRs for seven studies based on the information reported or obtained from the study authors (<a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a>; <a href="./references#CD012425-bbs2-0022" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomized study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Gastroenterology1999;34(5):509‐15. KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;149:159‐62. ">Kjeldsen 1997</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0026" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1992</a>; <a href="./references#CD012425-bbs2-0032" title="OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD012425-bbs2-0046" title="NCT00624260 . Impact of PET Scan on the curative strategy of colo‐rectal cancers : a randomized study. clinicaltrials.gov/ct2/show/NCT00624260 (first received 20 December 2016). SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an openlabel multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology2017;35(15 Suppl 1):no pagination. SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal2017;5(5 Suppl 1):A13. SobhaniI , IttiE , LucianiA , BaumgaertnerI , LayeseR , AndreT , et al. Colorectal cancer (CRC) monitoring by 6‐monthly 18FDG‐PET/CT: an open‐label multicentre randomised trial. Annals of Oncology2018;29(4):931‐7. ">Sobhani 2018</a>; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>), thus yielding 15 studies that contributed data for meta‐analysis. The remaining seven studies either did not carry out survival analysis or reported insufficient information to estimate a HR. </p> </section> <section id="CD012425-sec-0072"> <h6 class="title">Time to detection of recurrence</h6> <p>Thirty studies reported on the outcome of time to detection of recurrence/disease‐free survival (<a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad 2013</a>; <a href="./references#CD012425-bbs2-0002" title="BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Economic evaluation of a randomized clinical trial of hospital versus telephone follow‐up after treatment for breast cancer. British Journal of Surgery2009;96(12):1406‐15. [DOI: 10.1002/bjs.6753] BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Is telephone follow‐up by specialist nurses a cost effective approach?. European Journal of Cancer Supplements2009;7(2‐3):230‐1. BeaverK , Tysver‐RobinsonD , CampbellM , TwomeyM , WilliamsonS , HindleyA , et al. Comparing hospital and telephone follow‐up after treatment for breast cancer: randomised equivalence trial. BMJ2009;338:a3147. [DOI: 10.1136/bmj.a3147] ">Beaver 2009</a>; <a href="./references#CD012425-bbs2-0003" title="BeaverK , CampbellM , WilliamsonS , ProcterD , SheridanJ , HeathJ , et al. An exploratory randomized controlled trial comparing telephone and hospital follow‐up after treatment for colorectal cancer. Colorectal Disease2012;14(10):1201‐9. [DOI: 10.1111/j.1463‐1318.2012.02936.x] ">Beaver 2012</a>; <a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a>; <a href="./references#CD012425-bbs2-0007" title="DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . Prospective randomized clinical trial for the evaluation of a stage adjusted reduced follow‐up schedule in cutaneous melanoma patients: results after one year. Annals of Surgical Oncology2016;23(1 Suppl 1):S30. DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . The MELFO‐study: prospective randomized clinical trial for the evaluation of a stage‐adjusted reduced follow‐up schedule in cutaneous melanoma patients ‐ results after 1 year. Annals of Surgical Oncology2016;23(9):2762‐71. [DOI: 10.1245/s10434‐016‐5263‐7] DeckersE , Hoekstra‐WeebersJ , DamudeS , FranckenA , Ter MeulenS , BastiaannetE , et al. The MELFO‐study: a multi‐center prospective randomized clinical trial on the effects of a reduced stage‐adjusted follow‐up schedule on cutaneous melanoma IB‐IIC patients: results after 3‐years. Annals of Surgical Oncology2018;25(1 Suppl 1):S40. NCT01018004 . Comparing follow‐up schedules in patients with newly diagnosed stage IB or stage II melanoma. clinicaltrials.gov/ct2/show/NCT01018004 (first received 20 December 2016). ">Damude 2016</a>; <a href="./references#CD012425-bbs2-0010" title="GambazziF , FreyLD , BruehlmeierM , JanthurWD , GraberSM , HeubergerJ , et al. Comparing two imaging methods for follow‐up of lung cancer treatment: a randomized pilot study. Annals of Thoracic Surgery2018;107(2):430‐5. [DOI: 10.1016/j.athoracsur.2018.08.015] ">Gambazzi 2018</a>; <a href="./references#CD012425-bbs2-0011" title="GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata). A randomized trial of intensive versus minimalist follow‐up of patients with resected Dukes B‐C colorectal cancer: the pilot phase. Tumori1998;84(Suppl):89. GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. NCT02409472 . Intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. clinicaltrials.gov/ct2/show/NCT02409472 (first received 20 December 2016). RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] ">GILDA 2016</a>; <a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a>; <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a>; <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>; <a href="./references#CD012425-bbs2-0022" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomized study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Gastroenterology1999;34(5):509‐15. KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;149:159‐62. ">Kjeldsen 1997</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0024" title="KokkoR , HakamaM , HolliK . Follow‐up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Research and Treatment2005;93(3):255‐60. KokkoR , HakamaM , HolliK . Role of chest X‐ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Research and Treatment2003;81(1):33‐9. ">Kokko 2003</a>; <a href="./references#CD012425-bbs2-0026" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1992</a>; <a href="./references#CD012425-bbs2-0029" title="MonteilJ , VergnenègreA , BertinF , DalmayF , GaillardS , BonnaudF , et al. Randomized follow‐up study of resected NSCLC patients: conventional versus 18F‐DG coincidence imaging. Anticancer Research2010;30(9):3811‐6. NCT00199615 . Follow‐up of patients with curative‐intent surgical resection for NSCLC. clinicaltrials.gov/ct2/show/NCT00199615 (first received 20 December 2016). ">Monteil 2010</a>; <a href="./references#CD012425-bbs2-0032" title="OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD012425-bbs2-0033" title="OltraA , SantaballaA , MontalarJ , MunárrizB , PastorM , MeseguerA , et al. Cost‐benefit evaluation of a follow‐up program in patients with advanced breast cancer. Randomized study. Revista de Oncología1999;1(Suppl 1):165. OltraA , SantaballaA , MunárrizB , PastorM , MontalarJ . Cost‐benefit analysis of a follow‐up program in patients with breast cancer: a randomized prospective study. Breast Journal2007;13(6):571‐4. ">Oltra 2007</a>; <a href="./references#CD012425-bbs2-0034" title="PicardiM , PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , et al. Advanced‐stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission‐‐a randomized trial of routine surveillance imaging procedures. Radiology2014;272(1):262‐74. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: Ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2015;100:7‐8. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2014;99:398‐9. ">Picardi 2014</a>; <a href="./references#CD012425-bbs2-0035" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA , et al. Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD012425-bbs2-0036" title="MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017;21(32):1‐86. MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00560365 (first received 20 December 2016). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology2011;29(15 Suppl 1):3521. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. [DOI: 10.1001/jama.2013.285718] PughSA , FullerA , PereraR , GeorgeS , MantD , PrimroseJ . The follow‐up after colorectal cancer surgery trial: randomised trial of follow‐up after colorectal cancer surgery and outcome following recurrence. Journal of the American College of Surgeons2014;219(4 Suppl 1):e46‐7. PughSA , MantD , ShinkinsB , MellorJ , PereraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology2016;27(Suppl 6):no pagination. ShinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PloS One2017;12(3):e0171810. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;105(6):658‐62. ">Primrose 2014</a>; <a href="./references#CD012425-bbs2-0037" title="BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial [Efectividad del seguimiento postoperatorio en los pacientes con cáncer colorrectal para la detección de recidivas curables. Análisis preliminar de un estudio multicéntrico, controlado y aleatorizado]. Gastroenterologia y Hepatologia2001;24(2):92, abstract no: 13. BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Preliminary analysis of a multicenter controlled trial to evaluate the effectiveness of postoperative follow‐up to detect curable recurrences in patients with colorectal cancer [Análisis preliminar de un estudio multicéntrico controlado y aleatorizado destinado a evaluar la efectividad del seguimiento postoperatorio en la detección de recidivas curables en los pacientes con cáncer colorrectal]. Gastroenterologia y Hepatologia2001;24(3):150. Rodriguez‐MorantaF , CastellsA , SaloJ , ArcusaA , BoadasJ , BessaV , et al. Efficacy of postoperative surveillance after radical surgery for colorectal cancer (CRC). Analysis of a prospective, multicenter, randomized controlled trial. Journal of Gastroenterology2005;128(4 Suppl 2):Abstract W967. Rodríguez‐MorantaF , SalóJ , AcrusaA , BoadasJ , BessaX , PiñolV , et al. Efficacy of postoperative surveillance in patients with colorectal cancer after radical surgery. A prospective, multicenter, randomized study. Gastroenterologia y Hepatologia2005;28(3):197‐8, abstract no: 126. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , Bessa , X , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD012425-bbs2-0039" title="PalliD , RussoA , SaievaC , CiattoS , Rosselli Del TurcoM , DistanteV , et al. Intensive vs clinical follow‐up after treatment of primary breast cancer: 10‐year update of a randomized trial. National Research Council Project on Breast Cancer Follow‐up. JAMA1999;281(17):1586. Roselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . The efficacy of intensive follow‐up testing in breast cancer cases. Annals of Oncology1995;6(Suppl 2):37‐9. Rosselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . Intensive diagnostic follow‐up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow‐up. JAMA1994;271(20):1593‐7. ">Rosselli Del Turco 1994</a>; <a href="./references#CD012425-bbs2-0041" title="GoodmanA . How often to follow up? Study shows two CT scans as good as five for low‐risk testicular cancer. Oncology Times2007;29(12):54‐5. NCT00003420 . CT scans in treating patients with stage I testicular cancer after undergoing orchiectomy. clinicaltrials.gov/ct2/show/NCT00003420 (first received 20 December 2016). RustinGJ , MeadGM , StenningSP , VaseyPA , AassN , HuddartRA , et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197‐‐the National Cancer Research Institute Testis Cancer Clinical Studies Group. Journal of Clinical Oncology2007;25(11):1310‐5. ">Rustin 2007</a>; <a href="./references#CD012425-bbs2-0043" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk‐adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD012425-bbs2-0045" title="SobhaniI , TiretE , LebtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>; <a href="./references#CD012425-bbs2-0046" title="NCT00624260 . Impact of PET Scan on the curative strategy of colo‐rectal cancers : a randomized study. clinicaltrials.gov/ct2/show/NCT00624260 (first received 20 December 2016). SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an openlabel multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology2017;35(15 Suppl 1):no pagination. SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal2017;5(5 Suppl 1):A13. SobhaniI , IttiE , LucianiA , BaumgaertnerI , LayeseR , AndreT , et al. Colorectal cancer (CRC) monitoring by 6‐monthly 18FDG‐PET/CT: an open‐label multicentre randomised trial. Annals of Oncology2018;29(4):931‐7. ">Sobhani 2018</a>; <a href="./references#CD012425-bbs2-0049" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>; <a href="./references#CD012425-bbs2-0051" title="NCT00198341 . Post‐surgical non‐small cell lung cancer (NSCLC) follow‐up. clinicaltrials.gov/ct2/show/NCT00198341 (first received 20 December 2016). WesteelV . Follow‐up of the patient after curative treatment. Lung Cancer2011;71:S10‐1. WesteelV . Surveillance and second primary malignancies in lung cancer survivors. Journal of Thoracic Oncology2018;13(10 Suppl):S277‐8. WesteelV , BarlesiF , DomasJ , GirardP , FoucherP , LafitteJJ , et al. Postoperative follow‐up of lung cancer: randomized trial comparing two follow‐up programs in completely resected non‐small cell lung cancer (IFCT‐0302). Journal of Clinical Oncology2012;30(15 Suppl 1):no pagination. WesteelV , BarlesiF , FoucherP , LafitteJ , DomasJ , GirardP , et al. Recurrences and 2nd primary cancers in the IFCT‐0302 trial assessing a CT‐scan‐based follow‐up after lung cancer surgery. Journal of Thoracic Oncology2017;12(11 Suppl 2):S1788‐9. WesteelV , BarlesiF , FoucherP , LafitteJ‐J , DomasJ , GirardP , et al. Results of the phase III IFCT‐0302 trial assessing minimal versus CT‐scan‐based follow‐up for completely resected non‐small cell lung cancer (NSCLC). Annals of Oncology2017;28(Suppl 5):v452. WesteelV , BarlesiF , FoucherP , LafitteJJ , DomasJ , GirardP , et al. Compliance with follow‐up programs after surgery for non‐small cell lung cancer in the phase III IFCT‐0302 trial. Journal of Thoracic Oncology2015;10(9 Suppl 2):S239. WesteelV , LebitasyMP , MercierM , LafitteJJ , DomasJ , GirardPl . IFCT‐0302 trial: randomised study comparing two follow‐up schedules in completely resected non‐small cell lung cancer [Protocole IFCT‐0302 : essai randomisé de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués]. Revue des Maladies Respiratoires2007;2(5):645‐52. ">Westeel 2012</a>; <a href="./references#CD012425-bbs2-0052" title="NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00225641 (first received 20 December 2016). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PahlmanL , et al. Intensity of follow up after surgery for colorectal cancer. Colorectal Disease2014;16:93. Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA2018;319(20):2095‐103. ">Wille‐Jorgensen 2018</a>). Four studies calculated time to detection of recurrence from the time of presentation of symptoms/suspicion of recurrence instead of from randomisation, as defined in our protocol, and we did not include the results from these studies in our analysis (<a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad 2013</a>; <a href="./references#CD012425-bbs2-0002" title="BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Economic evaluation of a randomized clinical trial of hospital versus telephone follow‐up after treatment for breast cancer. British Journal of Surgery2009;96(12):1406‐15. [DOI: 10.1002/bjs.6753] BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Is telephone follow‐up by specialist nurses a cost effective approach?. European Journal of Cancer Supplements2009;7(2‐3):230‐1. BeaverK , Tysver‐RobinsonD , CampbellM , TwomeyM , WilliamsonS , HindleyA , et al. Comparing hospital and telephone follow‐up after treatment for breast cancer: randomised equivalence trial. BMJ2009;338:a3147. [DOI: 10.1136/bmj.a3147] ">Beaver 2009</a>; <a href="./references#CD012425-bbs2-0003" title="BeaverK , CampbellM , WilliamsonS , ProcterD , SheridanJ , HeathJ , et al. An exploratory randomized controlled trial comparing telephone and hospital follow‐up after treatment for colorectal cancer. Colorectal Disease2012;14(10):1201‐9. [DOI: 10.1111/j.1463‐1318.2012.02936.x] ">Beaver 2012</a>; <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a>). Three study reported HRs (<a href="./references#CD012425-bbs2-0011" title="GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata). A randomized trial of intensive versus minimalist follow‐up of patients with resected Dukes B‐C colorectal cancer: the pilot phase. Tumori1998;84(Suppl):89. GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. NCT02409472 . Intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. clinicaltrials.gov/ct2/show/NCT02409472 (first received 20 December 2016). RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] ">GILDA 2016</a>; <a href="./references#CD012425-bbs2-0051" title="NCT00198341 . Post‐surgical non‐small cell lung cancer (NSCLC) follow‐up. clinicaltrials.gov/ct2/show/NCT00198341 (first received 20 December 2016). WesteelV . Follow‐up of the patient after curative treatment. Lung Cancer2011;71:S10‐1. WesteelV . Surveillance and second primary malignancies in lung cancer survivors. Journal of Thoracic Oncology2018;13(10 Suppl):S277‐8. WesteelV , BarlesiF , DomasJ , GirardP , FoucherP , LafitteJJ , et al. Postoperative follow‐up of lung cancer: randomized trial comparing two follow‐up programs in completely resected non‐small cell lung cancer (IFCT‐0302). Journal of Clinical Oncology2012;30(15 Suppl 1):no pagination. WesteelV , BarlesiF , FoucherP , LafitteJ , DomasJ , GirardP , et al. Recurrences and 2nd primary cancers in the IFCT‐0302 trial assessing a CT‐scan‐based follow‐up after lung cancer surgery. Journal of Thoracic Oncology2017;12(11 Suppl 2):S1788‐9. WesteelV , BarlesiF , FoucherP , LafitteJ‐J , DomasJ , GirardP , et al. Results of the phase III IFCT‐0302 trial assessing minimal versus CT‐scan‐based follow‐up for completely resected non‐small cell lung cancer (NSCLC). Annals of Oncology2017;28(Suppl 5):v452. WesteelV , BarlesiF , FoucherP , LafitteJJ , DomasJ , GirardP , et al. Compliance with follow‐up programs after surgery for non‐small cell lung cancer in the phase III IFCT‐0302 trial. Journal of Thoracic Oncology2015;10(9 Suppl 2):S239. WesteelV , LebitasyMP , MercierM , LafitteJJ , DomasJ , GirardPl . IFCT‐0302 trial: randomised study comparing two follow‐up schedules in completely resected non‐small cell lung cancer [Protocole IFCT‐0302 : essai randomisé de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués]. Revue des Maladies Respiratoires2007;2(5):645‐52. ">Westeel 2012</a>; <a href="./references#CD012425-bbs2-0052" title="NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00225641 (first received 20 December 2016). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PahlmanL , et al. Intensity of follow up after surgery for colorectal cancer. Colorectal Disease2014;16:93. Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA2018;319(20):2095‐103. ">Wille‐Jorgensen 2018</a>), and we were able to calculate HRs for nine studies based on the information reported or obtained from the authors (<a href="./references#CD012425-bbs2-0010" title="GambazziF , FreyLD , BruehlmeierM , JanthurWD , GraberSM , HeubergerJ , et al. Comparing two imaging methods for follow‐up of lung cancer treatment: a randomized pilot study. Annals of Thoracic Surgery2018;107(2):430‐5. [DOI: 10.1016/j.athoracsur.2018.08.015] ">Gambazzi 2018</a>; <a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a>; <a href="./references#CD012425-bbs2-0022" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomized study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Gastroenterology1999;34(5):509‐15. KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;149:159‐62. ">Kjeldsen 1997</a>; <a href="./references#CD012425-bbs2-0034" title="PicardiM , PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , et al. Advanced‐stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission‐‐a randomized trial of routine surveillance imaging procedures. Radiology2014;272(1):262‐74. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: Ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2015;100:7‐8. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2014;99:398‐9. ">Picardi 2014</a>; <a href="./references#CD012425-bbs2-0036" title="MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017;21(32):1‐86. MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00560365 (first received 20 December 2016). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology2011;29(15 Suppl 1):3521. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. [DOI: 10.1001/jama.2013.285718] PughSA , FullerA , PereraR , GeorgeS , MantD , PrimroseJ . The follow‐up after colorectal cancer surgery trial: randomised trial of follow‐up after colorectal cancer surgery and outcome following recurrence. Journal of the American College of Surgeons2014;219(4 Suppl 1):e46‐7. PughSA , MantD , ShinkinsB , MellorJ , PereraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology2016;27(Suppl 6):no pagination. ShinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PloS One2017;12(3):e0171810. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;105(6):658‐62. ">Primrose 2014</a>; <a href="./references#CD012425-bbs2-0037" title="BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial [Efectividad del seguimiento postoperatorio en los pacientes con cáncer colorrectal para la detección de recidivas curables. Análisis preliminar de un estudio multicéntrico, controlado y aleatorizado]. Gastroenterologia y Hepatologia2001;24(2):92, abstract no: 13. BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Preliminary analysis of a multicenter controlled trial to evaluate the effectiveness of postoperative follow‐up to detect curable recurrences in patients with colorectal cancer [Análisis preliminar de un estudio multicéntrico controlado y aleatorizado destinado a evaluar la efectividad del seguimiento postoperatorio en la detección de recidivas curables en los pacientes con cáncer colorrectal]. Gastroenterologia y Hepatologia2001;24(3):150. Rodriguez‐MorantaF , CastellsA , SaloJ , ArcusaA , BoadasJ , BessaV , et al. Efficacy of postoperative surveillance after radical surgery for colorectal cancer (CRC). Analysis of a prospective, multicenter, randomized controlled trial. Journal of Gastroenterology2005;128(4 Suppl 2):Abstract W967. Rodríguez‐MorantaF , SalóJ , AcrusaA , BoadasJ , BessaX , PiñolV , et al. Efficacy of postoperative surveillance in patients with colorectal cancer after radical surgery. A prospective, multicenter, randomized study. Gastroenterologia y Hepatologia2005;28(3):197‐8, abstract no: 126. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , Bessa , X , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD012425-bbs2-0039" title="PalliD , RussoA , SaievaC , CiattoS , Rosselli Del TurcoM , DistanteV , et al. Intensive vs clinical follow‐up after treatment of primary breast cancer: 10‐year update of a randomized trial. National Research Council Project on Breast Cancer Follow‐up. JAMA1999;281(17):1586. Roselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . The efficacy of intensive follow‐up testing in breast cancer cases. Annals of Oncology1995;6(Suppl 2):37‐9. Rosselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . Intensive diagnostic follow‐up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow‐up. JAMA1994;271(20):1593‐7. ">Rosselli Del Turco 1994</a>; <a href="./references#CD012425-bbs2-0041" title="GoodmanA . How often to follow up? Study shows two CT scans as good as five for low‐risk testicular cancer. Oncology Times2007;29(12):54‐5. NCT00003420 . CT scans in treating patients with stage I testicular cancer after undergoing orchiectomy. clinicaltrials.gov/ct2/show/NCT00003420 (first received 20 December 2016). RustinGJ , MeadGM , StenningSP , VaseyPA , AassN , HuddartRA , et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197‐‐the National Cancer Research Institute Testis Cancer Clinical Studies Group. Journal of Clinical Oncology2007;25(11):1310‐5. ">Rustin 2007</a>; <a href="./references#CD012425-bbs2-0045" title="SobhaniI , TiretE , LebtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>), thus yielding twelve studies that contributed data for the meta‐analysis. The remaining studies either did not carry out survival analysis or reported insufficient information to estimate a HR. </p> </section> <section id="CD012425-sec-0073"> <h6 class="title">Health‐related quality of life</h6> <p>Twenty‐eight studies reported on the outcome of health‐related quality of life using a variety of validated measurement scales, such as the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30; <a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad 2013</a>; <a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a>; <a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a>; <a href="./references#CD012425-bbs2-0017" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14:260. [DOI: 10.1186/1745‐6215‐14‐260] JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a nurse‐led supportive care package (survivor care) for survivors of colorectal cancer. Cancer Nursing2015;38(4 Suppl 1):S16‐7. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (Survivor‐Care, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2015;33(15 Suppl 1):9566. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , SchofieldP , ArandaS , YoungJ , ButowP . Randomised controlled trial (RCT) of a comprehensive post‐treatment support package (survivor‐care) for bowel cancer survivors. Psycho‐oncology2010;19:S193. ">Jefford 2016</a>; <a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a>; <a href="./references#CD012425-bbs2-0021" title="DentJ , ToppingA , FergusonC , StephensonJ , McCoyM , AllinsonV , et al. To follow up or not? A new model of supportive care for early breast cancer. Journal of Clinical Oncology2011;29(15 Suppl 1):no pagination. KirshbaumMN , DentJ , StephensonJ , ToppingAE , AllinsonV , McCoyM , et al. Open access follow‐up care for early breast cancer: a randomised controlled quality of life analysis. European Journal of Cancer Care2017;26(4):e12577. [DOI: 10.1111/ecc.12577] ">Kirshbaum 2017</a>; <a href="./references#CD012425-bbs2-0027" title="MalmströmM , IvarssonB , KlefsgårdR , PerssonK , JakobssonU , JohanssonJ . The effect of a nurse led telephone supportive care programme on patients' quality of life, received information and health care contacts after oesophageal cancer surgery‐a six month RCT‐follow‐up study. International Journal of Nursing Studies2016;64:86‐95. [DOI: 10.1016/j.ijnurstu.2016.09.009] ">Malmstrom 2016</a>; <a href="./references#CD012425-bbs2-0030" title="MorrisonV , SpencerLH , LeesonS . Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a randomised feasibility trial. Psycho‐oncology2017;26(Suppl 2):3‐4. MorrisonV , SpencerLH , TottonN , PyeK , YeoST , ButterworthC , et al. Trial of optimal personalised care after treatment‐gynaecological cancer (TOPCAT‐G): a randomized feasibility trial. International Journal of Gynecological Cancer2018;28(2):401‐11. PyeK , TottonN , StuartN , WhitakerR , MorrisonV , EdwardsRT , et al. Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a study protocol for a randomised feasibility trial. Pilot and Feasibility Studies2016;2:67. [DOI 10.1186/s40814‐016‐0108‐5] ">Morrison 2018</a>; <a href="./references#CD012425-bbs2-0038" title="DeRooijBH , EzendamNP , NicolaijeKA , LodderP , VosMC , PijnenborgJM , et al. Survivorship care plans have a negative impact on long‐term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. Quality of Life Research2018;27(6):1533‐44. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2‐year follow‐up ‐ The ROGY care trial. Gynecologic Oncology2017;145(2):319‐28. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Long‐term impact of survivorship care plans on ovarian cancer patient reported outcomes‐new results of the ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):64‐5. DeRooijBH , EzendamNP , NicolaijeKA , VosMC , PijnenborgJM , BollD , et al. The indirect effects of survivorship care plans on quality of life, anxiety and depression‐the ROGY care trial. Supportive Care in Cancer2017;25(2 Suppl 1):S53‐4. DeRooijBH , EzendamNP , VosMC , PijnenborgJM , BollD , KruitwagenRF , et al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. Cancer Epub 2018 Nov 30;125(5):788‐97. [DOI: 10.1002/cncr.31844] EzendamN , DeRooijB , NicolaijeK , VosC , PijnenborgJ , BollD , et al. Long‐term impact of cancer survivorship care plans on patient outcomes‐the randomized controlled ROGY care trial. International Journal of Gynecological Cancer2016;26:91. EzendamNP , VanBroekhovenM , Van DePoll‐FranseLV , DeRooijBH . The role of illness perceptions in smoking, alcohol consumption and weight changes among gynaecological cancer survivors. Quality of Life Research2016;25(1 Suppl 1):114. JeppesenMM , EzendamNP , PijnenborgJM , VosMC , BollD , KruitwagenRF , et al. The impact of the survivorship care plan on health care use: 2‐year follow‐up results of the ROGY care trial. Journal of Cancer Survivorship2018;12(1):18‐27. NicolaijeKA , EzendamNP , VosMC , PijnenborgJM , BollD , BossEA , et al. Impact of an automatically generated cancer survivorship care plan on patient‐reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial. Journal of Clinical Oncology2015;33(31):3550‐9. Van dePoll‐FranseL , NicolaijeK , EzendamN , VosC , BollD , PijnenborgJ , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY CARE): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Psycho‐oncology2013;22:341‐2. Van dePoll‐FranseLV , JeppesenMM , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. The survivorship care plan increases the use of primary care in anxious and irradiated endometrial cancer patients. Two year outcomes of the pragmatic cluster randomized ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):164. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosCM , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY Care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosMC , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. European Journal of Cancer2013;49:S720. Van dePoll‐FranseLV , NicolaijeKA , VosMC , PijnenborgJM , BollD , HussonO , et al. The impact of a cancer survivorship care plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials2011;12:256. ">ROGY 2015</a>; <a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a>), the 36‐item Short Form Health Survey (SF‐36; <a href="./references#CD012425-bbs2-0007" title="DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . Prospective randomized clinical trial for the evaluation of a stage adjusted reduced follow‐up schedule in cutaneous melanoma patients: results after one year. Annals of Surgical Oncology2016;23(1 Suppl 1):S30. DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . The MELFO‐study: prospective randomized clinical trial for the evaluation of a stage‐adjusted reduced follow‐up schedule in cutaneous melanoma patients ‐ results after 1 year. Annals of Surgical Oncology2016;23(9):2762‐71. [DOI: 10.1245/s10434‐016‐5263‐7] DeckersE , Hoekstra‐WeebersJ , DamudeS , FranckenA , Ter MeulenS , BastiaannetE , et al. The MELFO‐study: a multi‐center prospective randomized clinical trial on the effects of a reduced stage‐adjusted follow‐up schedule on cutaneous melanoma IB‐IIC patients: results after 3‐years. Annals of Surgical Oncology2018;25(1 Suppl 1):S40. NCT01018004 . Comparing follow‐up schedules in patients with newly diagnosed stage IB or stage II melanoma. clinicaltrials.gov/ct2/show/NCT01018004 (first received 20 December 2016). ">Damude 2016</a>; <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a>; <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>; <a href="./references#CD012425-bbs2-0015" title="BoekhoutAH , MaunsellE , PondGR , JulianJA , CoyleD , LevineMN , et al. A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial. Journal of Cancer Survivorship2015;9(4):683‐91. CoyleD , GrunfeldE , CoyleK , JulianJA , PondGR , FolkesA , et al. Cost‐effectiveness of a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):6082. CoyleD , GrunfeldE , CoyleK , PondG , JulianJA , LevineMN . Cost effectiveness of a survivorship care plan for breast cancer survivors. Journal of Oncology Practice2014;10(2):e86‐92. GrunfeldE , JulianJA , PondG , MaunsellE , CoyleD , FolkesA , et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. Journal of Clinical Oncology2011;29(36):4755‐62. GrunfeldE , LevineMN , JulianJA , PondGR , MaunsellE , FolkesA , et al. Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):9005. GrunfeldE , PondG , MaunsellE , LevineMN , JulianJA , CoyleD . Impact of survivorship care plans (SCP) on adherence to guidelines, health service measures, and patient‐reported outcomes (PRO): extended results of a multicenter randomized clinical trial (RCT) with breast cancer survivors. European Journal of Cancer2012;48:S147. ">Grunfeld 2011</a>; <a href="./references#CD012425-bbs2-0025" title="KvaleEA , Demark‐WahnefriedW , MenesesK , BaeS , HuangCH , AzueroCB , et al. Patient centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer Research2015;75(9 Suppl 1):no pagination. KvaleEA , HuangCS , MenesesKM , Demark‐WahnefriedW , BaeS , AzueroCB , et al. Patient‐centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer2016;122(20):3232‐42. ">Kvale 2016</a>; <a href="./references#CD012425-bbs2-0031" title="MurchieP , NicolsonMC , HannafordPC , RajaEA , LeeAJ , CampbellNC . Patient satisfaction with GP‐led melanoma follow‐up: a randomised controlled trial. British Journal of Cancer2010;102(10):1447‐55. ">Murchie 2010</a>), the 12‐item Short Form Health Survey (SF‐12; <a href="./references#CD012425-bbs2-0008" title="DavisKM , DawsonD , KellyS , RedS , PenekS , LynchJ , et al. Monitoring of health‐related quality of life and symptoms in prostate cancer survivors: a randomized trial. Journal of Supportive Oncology2013;11(4):174‐82. ">Davis 2013</a>; <a href="./references#CD012425-bbs2-0011" title="GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata). A randomized trial of intensive versus minimalist follow‐up of patients with resected Dukes B‐C colorectal cancer: the pilot phase. Tumori1998;84(Suppl):89. GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. NCT02409472 . Intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. clinicaltrials.gov/ct2/show/NCT02409472 (first received 20 December 2016). RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] ">GILDA 2016</a>; <a href="./references#CD012425-bbs2-0028" title="MalyRC , GriggsJJ , LiuY , LiangLJ , GanzPA . A randomized controlled trial of survivorship care plans among low‐income breast cancer survivors. Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. MalyRC , LiangLJ , LiuY , GriggsJJ , GanzPA . Randomized controlled trial of survivorship care plans among low‐income, predominant Latina breast cancer survivors. Journal of Clinical Oncology2017;35(16):1814‐21. NCT01627366 . Study of survivorship care plans and outcomes in underserved breast cancer survivors. clinicaltrials.gov/ct2/show/NCT01627366 (first received 17 December 2018). ">Maly 2017</a>; <a href="./references#CD012425-bbs2-0040" title="RuddyKJ , BakerEL , GuoH , GoldsteinMJ , WinerEP , ShulmanLN , et al. Randomized trial evaluating a coordinated survivorship care program for early stage breast cancer. Cancer Research2013;73(24 Suppl 1):OT2‐5‐02. RuddyKJ , GuoH , BakerE , GoldsteinM , MullaneyEE , ShulmanLN , et al. Coordinated follow‐up breast cancer survivorship care program study. Journal of Clinical Oncology2015;33(15 Suppl 1):e17727. RuddyKJ , GuoH , BakerEL , GoldsteinMJ , MullaneyEE , ShulmanLN , et al. Randomized phase 2 trial of a coordinated breast cancer follow‐up care program. Cancer2016;122:3546‐54. ">Ruddy 2016</a>; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>), the Functional Assessment of Cancer Therapy ‐ General (FACT‐G; <a href="./references#CD012425-bbs2-0008" title="DavisKM , DawsonD , KellyS , RedS , PenekS , LynchJ , et al. Monitoring of health‐related quality of life and symptoms in prostate cancer survivors: a randomized trial. Journal of Supportive Oncology2013;11(4):174‐82. ">Davis 2013</a>), Breast (FACT‐B; <a href="./references#CD012425-bbs2-0016" title="HershmanDL , GreenleeH , AwadD , KalinskyK , MaurerM , KranwinkelG , et al. Randomized controlled trial of a clinic‐based survivorship intervention following adjuvant therapy in breast cancer survivors. Breast Cancer Research and Treatment2013;138(3):795‐806. ">Hershman 2013</a>; <a href="./references#CD012425-bbs2-0044" title="SheppardC , HigginsB , WiseM , YiangouC , DuboisD , KilburnS . Breast cancer follow up: a randomised controlled trial comparing point of need access versus routine 6‐monthly clinical review. European Journal of Oncology Nursing2009;13(1):2‐8. [DOI: 10.1016/j.ejon.2008.11.005] ">Sheppard 2009</a>), Colorectal (FACT‐C); <a href="./references#CD012425-bbs2-0053" title='ACTRN12608000252314 . Cancer care after surgery – the CONNECT study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82819 (first received 20 December 2016). HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Connect: a pilot RCT to improve outcomes for people with colorectal cancer. Asia‐Pacific Journal of Clinical Oncology2009;5:A159. HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Randomized pilot evaluation of the supportive care intervention "CONNECT" for people following surgery for colorectal cancer. Diseases of the Colon and Rectum2011;54(5):622‐31. YoungJM , ButowPN , WalshJ , DurcinoskaI , DobbinsTA , RodwellL , et al. Multicenter randomized trial of centralized nurse‐led telephone‐based care coordination to improve outcomes after surgical resection for colorectal cancer: the CONNECT intervention. Journal of Clinical Oncology2013;31(28):3585‐91. [DOI: 10.1200/JCO.2012.48.1036] '>Young 2013</a>), the EuroQol‐5D (<a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad 2013</a>; <a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a>), and the City of Hope Quality of Life Questionnaire (<a href="./references#CD012425-bbs2-0019" title="JuarezG , HurriaA , FerrellB . Effectiveness of an education intervention on quality of life in Latina breast cancer survivors. Psycho‐oncology2012;21:110. JuarezG , HurriaA , UmanG , FerrellB . Impact of a bilingual education intervention on the quality of life of Latina breast cancer survivors. Oncology Nursing Forum2013;40(1):E50‐60. [DOI: 10.1188/13.ONF.E50‐E60] ">Juarez 2013</a>). An older study (<a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a>), measured quality of life using a compilation of items selected from several quality‐of‐life instruments available in 1985. The results of the EORTC‐C30, SF‐36 and SF‐12 are not reported as overall scores but by subscales measuring specific domains of health‐related quality of life. We carried out a meta‐analysis for results at 12 months for scales or subscales that were reported by at least three studies as specified in our Methods section under <a href="#CD012425-sec-0059">Data synthesis</a>. We have reported the studies that contributed data to meta‐analysis for each specific scale or subscale in the results section below. </p> </section> <section id="CD012425-sec-0074"> <h6 class="title">Anxiety</h6> <p>Fourteen studies reported on the outcome of anxiety: five studies used the State Trait Anxiety Inventory (STAI; <a href="./references#CD012425-bbs2-0002" title="BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Economic evaluation of a randomized clinical trial of hospital versus telephone follow‐up after treatment for breast cancer. British Journal of Surgery2009;96(12):1406‐15. [DOI: 10.1002/bjs.6753] BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Is telephone follow‐up by specialist nurses a cost effective approach?. European Journal of Cancer Supplements2009;7(2‐3):230‐1. BeaverK , Tysver‐RobinsonD , CampbellM , TwomeyM , WilliamsonS , HindleyA , et al. Comparing hospital and telephone follow‐up after treatment for breast cancer: randomised equivalence trial. BMJ2009;338:a3147. [DOI: 10.1136/bmj.a3147] ">Beaver 2009</a>; <a href="./references#CD012425-bbs2-0003" title="BeaverK , CampbellM , WilliamsonS , ProcterD , SheridanJ , HeathJ , et al. An exploratory randomized controlled trial comparing telephone and hospital follow‐up after treatment for colorectal cancer. Colorectal Disease2012;14(10):1201‐9. [DOI: 10.1111/j.1463‐1318.2012.02936.x] ">Beaver 2012</a>; <a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a>; <a href="./references#CD012425-bbs2-0007" title="DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . Prospective randomized clinical trial for the evaluation of a stage adjusted reduced follow‐up schedule in cutaneous melanoma patients: results after one year. Annals of Surgical Oncology2016;23(1 Suppl 1):S30. DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . The MELFO‐study: prospective randomized clinical trial for the evaluation of a stage‐adjusted reduced follow‐up schedule in cutaneous melanoma patients ‐ results after 1 year. Annals of Surgical Oncology2016;23(9):2762‐71. [DOI: 10.1245/s10434‐016‐5263‐7] DeckersE , Hoekstra‐WeebersJ , DamudeS , FranckenA , Ter MeulenS , BastiaannetE , et al. The MELFO‐study: a multi‐center prospective randomized clinical trial on the effects of a reduced stage‐adjusted follow‐up schedule on cutaneous melanoma IB‐IIC patients: results after 3‐years. Annals of Surgical Oncology2018;25(1 Suppl 1):S40. NCT01018004 . Comparing follow‐up schedules in patients with newly diagnosed stage IB or stage II melanoma. clinicaltrials.gov/ct2/show/NCT01018004 (first received 20 December 2016). ">Damude 2016</a>; <a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a>), and nine studies used the Hospital Anxiety and Depression Scale ‐ Anxiety subscale (HADS‐Anxiety; <a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a>; <a href="./references#CD012425-bbs2-0009" title="ACTRN12610000938000 . The ProCare Trial: a randomised controlled trial of follow up of men with prostate cancer in primary care. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336116 (first received 20 December 2016). EmeryJ , DooreyJ , JeffordM , KingM , PirottaM , HayneD , et al. Protocol for the ProCare Trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. BMJ Open2014;4(3):e004972. [DOI: 10.1136/bmjopen‐2014‐004972] EmeryJ , SchofieldP , JeffordM , KingM , PirottaM , HayneD , et al. The ProCare trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. Asia‐Pacific Journal of Clinical Oncology2014;10:157. EmeryJD , JeffordM , KingM , HayneD , MartinA , DooreyJ , et al. ProCare Trial: a phase II randomized controlled trial of shared care for follow‐up of men with prostate cancer. BJU International2016;119(3):381‐89. [DOI: 10.1111/bju.13593] KingM . Procare/PC4 study update. Asia‐Pacific Journal of Clinical Oncology2012;8:23. ">Emery 2016</a>; <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a>; <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>; <a href="./references#CD012425-bbs2-0021" title="DentJ , ToppingA , FergusonC , StephensonJ , McCoyM , AllinsonV , et al. To follow up or not? A new model of supportive care for early breast cancer. Journal of Clinical Oncology2011;29(15 Suppl 1):no pagination. KirshbaumMN , DentJ , StephensonJ , ToppingAE , AllinsonV , McCoyM , et al. Open access follow‐up care for early breast cancer: a randomised controlled quality of life analysis. European Journal of Cancer Care2017;26(4):e12577. [DOI: 10.1111/ecc.12577] ">Kirshbaum 2017</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0031" title="MurchieP , NicolsonMC , HannafordPC , RajaEA , LeeAJ , CampbellNC . Patient satisfaction with GP‐led melanoma follow‐up: a randomised controlled trial. British Journal of Cancer2010;102(10):1447‐55. ">Murchie 2010</a>; <a href="./references#CD012425-bbs2-0038" title="DeRooijBH , EzendamNP , NicolaijeKA , LodderP , VosMC , PijnenborgJM , et al. Survivorship care plans have a negative impact on long‐term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. Quality of Life Research2018;27(6):1533‐44. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2‐year follow‐up ‐ The ROGY care trial. Gynecologic Oncology2017;145(2):319‐28. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Long‐term impact of survivorship care plans on ovarian cancer patient reported outcomes‐new results of the ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):64‐5. DeRooijBH , EzendamNP , NicolaijeKA , VosMC , PijnenborgJM , BollD , et al. The indirect effects of survivorship care plans on quality of life, anxiety and depression‐the ROGY care trial. Supportive Care in Cancer2017;25(2 Suppl 1):S53‐4. DeRooijBH , EzendamNP , VosMC , PijnenborgJM , BollD , KruitwagenRF , et al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. Cancer Epub 2018 Nov 30;125(5):788‐97. [DOI: 10.1002/cncr.31844] EzendamN , DeRooijB , NicolaijeK , VosC , PijnenborgJ , BollD , et al. Long‐term impact of cancer survivorship care plans on patient outcomes‐the randomized controlled ROGY care trial. International Journal of Gynecological Cancer2016;26:91. EzendamNP , VanBroekhovenM , Van DePoll‐FranseLV , DeRooijBH . The role of illness perceptions in smoking, alcohol consumption and weight changes among gynaecological cancer survivors. Quality of Life Research2016;25(1 Suppl 1):114. JeppesenMM , EzendamNP , PijnenborgJM , VosMC , BollD , KruitwagenRF , et al. The impact of the survivorship care plan on health care use: 2‐year follow‐up results of the ROGY care trial. Journal of Cancer Survivorship2018;12(1):18‐27. NicolaijeKA , EzendamNP , VosMC , PijnenborgJM , BollD , BossEA , et al. Impact of an automatically generated cancer survivorship care plan on patient‐reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial. Journal of Clinical Oncology2015;33(31):3550‐9. Van dePoll‐FranseL , NicolaijeK , EzendamN , VosC , BollD , PijnenborgJ , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY CARE): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Psycho‐oncology2013;22:341‐2. Van dePoll‐FranseLV , JeppesenMM , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. The survivorship care plan increases the use of primary care in anxious and irradiated endometrial cancer patients. Two year outcomes of the pragmatic cluster randomized ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):164. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosCM , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY Care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosMC , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. European Journal of Cancer2013;49:S720. Van dePoll‐FranseLV , NicolaijeKA , VosMC , PijnenborgJM , BollD , HussonO , et al. The impact of a cancer survivorship care plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials2011;12:256. ">ROGY 2015</a>; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>). Two studies reported on fear of recurrence: one using a three‐item questionnaire that was still being tested (<a href="./references#CD012425-bbs2-0044" title="SheppardC , HigginsB , WiseM , YiangouC , DuboisD , KilburnS . Breast cancer follow up: a randomised controlled trial comparing point of need access versus routine 6‐monthly clinical review. European Journal of Oncology Nursing2009;13(1):2‐8. [DOI: 10.1016/j.ejon.2008.11.005] ">Sheppard 2009</a>), and one using the Fear of Cancer Recurrence Inventory (<a href="./references#CD012425-bbs2-0018" title="JeppesenMM , JensenPT , GilsaD , DePont ChristensenR , JensenMM , MogensenO . The effect of patient‐initiated follow‐up on fear of recurrence and health care use: a randomized trial in early‐stage endometrial cancer. International Journal of Gynecological Cancer2017;27(Supplement 4):1107. JeppesenMM , JensenPT , HansenDG , ChristensenRD , MogensenO . Authors' reply re: Patient‐initiated follow‐up affects fear of recurrence and health care use: a randomised trial in early‐stage endometrial cancer. BJOG2018;125(13):1778‐9. JeppesenMM , JensenPT , HansenDG , ChristensenRD , MogensenO . Patient‐initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early‐stage endometrial cancer. BJOG2018;125(13):1705‐14. TegnerowiczJ . Re: Patient‐initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early‐stage endometrial cancer. BJOG2018;1125(13):1778. ">Jeppesen 2018</a>). We carried out a meta‐analysis for results at 12 months for scales or subscales that were reported by at least three studies as specified in our Methods section under <a href="#CD012425-sec-0059">Data synthesis</a>. We have reported the studies that contributed data to meta‐analysis for each specific scale or subscale in the results section below. </p> </section> <section id="CD012425-sec-0075"> <h6 class="title">Depression</h6> <p>Nineteen studies reported on the outcome of depression or psychological distress: nine studies used the Hospital Anxiety and Depression Scale ‐ Depression subscale (HADS‐Depression; <a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a>; <a href="./references#CD012425-bbs2-0009" title="ACTRN12610000938000 . The ProCare Trial: a randomised controlled trial of follow up of men with prostate cancer in primary care. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336116 (first received 20 December 2016). EmeryJ , DooreyJ , JeffordM , KingM , PirottaM , HayneD , et al. Protocol for the ProCare Trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. BMJ Open2014;4(3):e004972. [DOI: 10.1136/bmjopen‐2014‐004972] EmeryJ , SchofieldP , JeffordM , KingM , PirottaM , HayneD , et al. The ProCare trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. Asia‐Pacific Journal of Clinical Oncology2014;10:157. EmeryJD , JeffordM , KingM , HayneD , MartinA , DooreyJ , et al. ProCare Trial: a phase II randomized controlled trial of shared care for follow‐up of men with prostate cancer. BJU International2016;119(3):381‐89. [DOI: 10.1111/bju.13593] KingM . Procare/PC4 study update. Asia‐Pacific Journal of Clinical Oncology2012;8:23. ">Emery 2016</a>; <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a>; <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>; <a href="./references#CD012425-bbs2-0021" title="DentJ , ToppingA , FergusonC , StephensonJ , McCoyM , AllinsonV , et al. To follow up or not? A new model of supportive care for early breast cancer. Journal of Clinical Oncology2011;29(15 Suppl 1):no pagination. KirshbaumMN , DentJ , StephensonJ , ToppingAE , AllinsonV , McCoyM , et al. Open access follow‐up care for early breast cancer: a randomised controlled quality of life analysis. European Journal of Cancer Care2017;26(4):e12577. [DOI: 10.1111/ecc.12577] ">Kirshbaum 2017</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0031" title="MurchieP , NicolsonMC , HannafordPC , RajaEA , LeeAJ , CampbellNC . Patient satisfaction with GP‐led melanoma follow‐up: a randomised controlled trial. British Journal of Cancer2010;102(10):1447‐55. ">Murchie 2010</a>; <a href="./references#CD012425-bbs2-0038" title="DeRooijBH , EzendamNP , NicolaijeKA , LodderP , VosMC , PijnenborgJM , et al. Survivorship care plans have a negative impact on long‐term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. Quality of Life Research2018;27(6):1533‐44. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2‐year follow‐up ‐ The ROGY care trial. Gynecologic Oncology2017;145(2):319‐28. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Long‐term impact of survivorship care plans on ovarian cancer patient reported outcomes‐new results of the ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):64‐5. DeRooijBH , EzendamNP , NicolaijeKA , VosMC , PijnenborgJM , BollD , et al. The indirect effects of survivorship care plans on quality of life, anxiety and depression‐the ROGY care trial. Supportive Care in Cancer2017;25(2 Suppl 1):S53‐4. DeRooijBH , EzendamNP , VosMC , PijnenborgJM , BollD , KruitwagenRF , et al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. Cancer Epub 2018 Nov 30;125(5):788‐97. [DOI: 10.1002/cncr.31844] EzendamN , DeRooijB , NicolaijeK , VosC , PijnenborgJ , BollD , et al. Long‐term impact of cancer survivorship care plans on patient outcomes‐the randomized controlled ROGY care trial. International Journal of Gynecological Cancer2016;26:91. EzendamNP , VanBroekhovenM , Van DePoll‐FranseLV , DeRooijBH . The role of illness perceptions in smoking, alcohol consumption and weight changes among gynaecological cancer survivors. Quality of Life Research2016;25(1 Suppl 1):114. JeppesenMM , EzendamNP , PijnenborgJM , VosMC , BollD , KruitwagenRF , et al. The impact of the survivorship care plan on health care use: 2‐year follow‐up results of the ROGY care trial. Journal of Cancer Survivorship2018;12(1):18‐27. NicolaijeKA , EzendamNP , VosMC , PijnenborgJM , BollD , BossEA , et al. Impact of an automatically generated cancer survivorship care plan on patient‐reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial. Journal of Clinical Oncology2015;33(31):3550‐9. Van dePoll‐FranseL , NicolaijeK , EzendamN , VosC , BollD , PijnenborgJ , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY CARE): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Psycho‐oncology2013;22:341‐2. Van dePoll‐FranseLV , JeppesenMM , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. The survivorship care plan increases the use of primary care in anxious and irradiated endometrial cancer patients. Two year outcomes of the pragmatic cluster randomized ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):164. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosCM , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY Care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosMC , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. European Journal of Cancer2013;49:S720. Van dePoll‐FranseLV , NicolaijeKA , VosMC , PijnenborgJM , BollD , HussonO , et al. The impact of a cancer survivorship care plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials2011;12:256. ">ROGY 2015</a>; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>), three used the General Heath Questionnaire (GHQ‐12; <a href="./references#CD012425-bbs2-0002" title="BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Economic evaluation of a randomized clinical trial of hospital versus telephone follow‐up after treatment for breast cancer. British Journal of Surgery2009;96(12):1406‐15. [DOI: 10.1002/bjs.6753] BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Is telephone follow‐up by specialist nurses a cost effective approach?. European Journal of Cancer Supplements2009;7(2‐3):230‐1. BeaverK , Tysver‐RobinsonD , CampbellM , TwomeyM , WilliamsonS , HindleyA , et al. Comparing hospital and telephone follow‐up after treatment for breast cancer: randomised equivalence trial. BMJ2009;338:a3147. [DOI: 10.1136/bmj.a3147] ">Beaver 2009</a>; <a href="./references#CD012425-bbs2-0003" title="BeaverK , CampbellM , WilliamsonS , ProcterD , SheridanJ , HeathJ , et al. An exploratory randomized controlled trial comparing telephone and hospital follow‐up after treatment for colorectal cancer. Colorectal Disease2012;14(10):1201‐9. [DOI: 10.1111/j.1463‐1318.2012.02936.x] ">Beaver 2012</a>; <a href="./references#CD012425-bbs2-0044" title="SheppardC , HigginsB , WiseM , YiangouC , DuboisD , KilburnS . Breast cancer follow up: a randomised controlled trial comparing point of need access versus routine 6‐monthly clinical review. European Journal of Oncology Nursing2009;13(1):2‐8. [DOI: 10.1016/j.ejon.2008.11.005] ">Sheppard 2009</a>), two studies each used the Center for Epidemiological Studies‐Depression scale (CES‐D; <a href="./references#CD012425-bbs2-0016" title="HershmanDL , GreenleeH , AwadD , KalinskyK , MaurerM , KranwinkelG , et al. Randomized controlled trial of a clinic‐based survivorship intervention following adjuvant therapy in breast cancer survivors. Breast Cancer Research and Treatment2013;138(3):795‐806. ">Hershman 2013</a>; <a href="./references#CD012425-bbs2-0047" title="Van DerMeulenI , MayA , RosW , OosteromM , HordijkGJ , KooleR , et al. Effects of a nurse‐led psychosocial intervention on depressive symptoms and health‐related quality of life in patients with head and neck cancer: a randomized controlled trial. Psycho‐oncology2013;22(Suppl 3):17. Van derMeulenIC , MayAM , RosWJ , OosteromM , HordijkGJ , KooleR , et al. One‐year effect of a nurse‐led psychosocial intervention on depressive symptoms in patients with head and neck cancer: a randomized controlled trial. Oncologist2013;18(3):336‐44. [DOI: 10.1634/theoncologist.2012‐0299] ">Van der Meulen 2013</a>), and the Distress thermometer (<a href="./references#CD012425-bbs2-0019" title="JuarezG , HurriaA , FerrellB . Effectiveness of an education intervention on quality of life in Latina breast cancer survivors. Psycho‐oncology2012;21:110. JuarezG , HurriaA , UmanG , FerrellB . Impact of a bilingual education intervention on the quality of life of Latina breast cancer survivors. Oncology Nursing Forum2013;40(1):E50‐60. [DOI: 10.1188/13.ONF.E50‐E60] ">Juarez 2013</a>, <a href="./references#CD012425-bbs2-0053" title='ACTRN12608000252314 . Cancer care after surgery – the CONNECT study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82819 (first received 20 December 2016). HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Connect: a pilot RCT to improve outcomes for people with colorectal cancer. Asia‐Pacific Journal of Clinical Oncology2009;5:A159. HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Randomized pilot evaluation of the supportive care intervention "CONNECT" for people following surgery for colorectal cancer. Diseases of the Colon and Rectum2011;54(5):622‐31. YoungJM , ButowPN , WalshJ , DurcinoskaI , DobbinsTA , RodwellL , et al. Multicenter randomized trial of centralized nurse‐led telephone‐based care coordination to improve outcomes after surgical resection for colorectal cancer: the CONNECT intervention. Journal of Clinical Oncology2013;31(28):3585‐91. [DOI: 10.1200/JCO.2012.48.1036] '>Young 2013</a>), one study each used the Patient Health Questionnaire (PHQ‐9; <a href="./references#CD012425-bbs2-0025" title="KvaleEA , Demark‐WahnefriedW , MenesesK , BaeS , HuangCH , AzueroCB , et al. Patient centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer Research2015;75(9 Suppl 1):no pagination. KvaleEA , HuangCS , MenesesKM , Demark‐WahnefriedW , BaeS , AzueroCB , et al. Patient‐centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer2016;122(20):3232‐42. ">Kvale 2016</a>), the Profile of Mood States (POMS; <a href="./references#CD012425-bbs2-0015" title="BoekhoutAH , MaunsellE , PondGR , JulianJA , CoyleD , LevineMN , et al. A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial. Journal of Cancer Survivorship2015;9(4):683‐91. CoyleD , GrunfeldE , CoyleK , JulianJA , PondGR , FolkesA , et al. Cost‐effectiveness of a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):6082. CoyleD , GrunfeldE , CoyleK , PondG , JulianJA , LevineMN . Cost effectiveness of a survivorship care plan for breast cancer survivors. Journal of Oncology Practice2014;10(2):e86‐92. GrunfeldE , JulianJA , PondG , MaunsellE , CoyleD , FolkesA , et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. Journal of Clinical Oncology2011;29(36):4755‐62. GrunfeldE , LevineMN , JulianJA , PondGR , MaunsellE , FolkesA , et al. Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):9005. GrunfeldE , PondG , MaunsellE , LevineMN , JulianJA , CoyleD . Impact of survivorship care plans (SCP) on adherence to guidelines, health service measures, and patient‐reported outcomes (PRO): extended results of a multicenter randomized clinical trial (RCT) with breast cancer survivors. European Journal of Cancer2012;48:S147. ">Grunfeld 2011</a>), and the Brief Symptom Inventory (BSI‐18; <a href="./references#CD012425-bbs2-0017" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14:260. [DOI: 10.1186/1745‐6215‐14‐260] JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a nurse‐led supportive care package (survivor care) for survivors of colorectal cancer. Cancer Nursing2015;38(4 Suppl 1):S16‐7. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (Survivor‐Care, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2015;33(15 Suppl 1):9566. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , SchofieldP , ArandaS , YoungJ , ButowP . Randomised controlled trial (RCT) of a comprehensive post‐treatment support package (survivor‐care) for bowel cancer survivors. Psycho‐oncology2010;19:S193. ">Jefford 2016</a>). We carried out a meta‐analysis for results at 12 months only for scales or subscales that were reported by at least three studies as specified in our Methods section under <a href="#CD012425-sec-0059">Data synthesis</a>. We have reported the studies that contributed data to meta‐analysis for each specific scale or subscale in the results section below. </p> </section> <section id="CD012425-sec-0076"> <h6 class="title">Cost</h6> <p>Sixteen studies reported cost outcomes (<a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad 2013</a>; <a href="./references#CD012425-bbs2-0002" title="BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Economic evaluation of a randomized clinical trial of hospital versus telephone follow‐up after treatment for breast cancer. British Journal of Surgery2009;96(12):1406‐15. [DOI: 10.1002/bjs.6753] BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Is telephone follow‐up by specialist nurses a cost effective approach?. European Journal of Cancer Supplements2009;7(2‐3):230‐1. BeaverK , Tysver‐RobinsonD , CampbellM , TwomeyM , WilliamsonS , HindleyA , et al. Comparing hospital and telephone follow‐up after treatment for breast cancer: randomised equivalence trial. BMJ2009;338:a3147. [DOI: 10.1136/bmj.a3147] ">Beaver 2009</a>; <a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a>; <a href="./references#CD012425-bbs2-0007" title="DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . Prospective randomized clinical trial for the evaluation of a stage adjusted reduced follow‐up schedule in cutaneous melanoma patients: results after one year. Annals of Surgical Oncology2016;23(1 Suppl 1):S30. DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . The MELFO‐study: prospective randomized clinical trial for the evaluation of a stage‐adjusted reduced follow‐up schedule in cutaneous melanoma patients ‐ results after 1 year. Annals of Surgical Oncology2016;23(9):2762‐71. [DOI: 10.1245/s10434‐016‐5263‐7] DeckersE , Hoekstra‐WeebersJ , DamudeS , FranckenA , Ter MeulenS , BastiaannetE , et al. The MELFO‐study: a multi‐center prospective randomized clinical trial on the effects of a reduced stage‐adjusted follow‐up schedule on cutaneous melanoma IB‐IIC patients: results after 3‐years. Annals of Surgical Oncology2018;25(1 Suppl 1):S40. NCT01018004 . Comparing follow‐up schedules in patients with newly diagnosed stage IB or stage II melanoma. clinicaltrials.gov/ct2/show/NCT01018004 (first received 20 December 2016). ">Damude 2016</a>; <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a>; <a href="./references#CD012425-bbs2-0015" title="BoekhoutAH , MaunsellE , PondGR , JulianJA , CoyleD , LevineMN , et al. A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial. Journal of Cancer Survivorship2015;9(4):683‐91. CoyleD , GrunfeldE , CoyleK , JulianJA , PondGR , FolkesA , et al. Cost‐effectiveness of a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):6082. CoyleD , GrunfeldE , CoyleK , PondG , JulianJA , LevineMN . Cost effectiveness of a survivorship care plan for breast cancer survivors. Journal of Oncology Practice2014;10(2):e86‐92. GrunfeldE , JulianJA , PondG , MaunsellE , CoyleD , FolkesA , et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. Journal of Clinical Oncology2011;29(36):4755‐62. GrunfeldE , LevineMN , JulianJA , PondGR , MaunsellE , FolkesA , et al. Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):9005. GrunfeldE , PondG , MaunsellE , LevineMN , JulianJA , CoyleD . Impact of survivorship care plans (SCP) on adherence to guidelines, health service measures, and patient‐reported outcomes (PRO): extended results of a multicenter randomized clinical trial (RCT) with breast cancer survivors. European Journal of Cancer2012;48:S147. ">Grunfeld 2011</a>; <a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0024" title="KokkoR , HakamaM , HolliK . Follow‐up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Research and Treatment2005;93(3):255‐60. KokkoR , HakamaM , HolliK . Role of chest X‐ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Research and Treatment2003;81(1):33‐9. ">Kokko 2003</a>; <a href="./references#CD012425-bbs2-0029" title="MonteilJ , VergnenègreA , BertinF , DalmayF , GaillardS , BonnaudF , et al. Randomized follow‐up study of resected NSCLC patients: conventional versus 18F‐DG coincidence imaging. Anticancer Research2010;30(9):3811‐6. NCT00199615 . Follow‐up of patients with curative‐intent surgical resection for NSCLC. clinicaltrials.gov/ct2/show/NCT00199615 (first received 20 December 2016). ">Monteil 2010</a>; <a href="./references#CD012425-bbs2-0030" title="MorrisonV , SpencerLH , LeesonS . Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a randomised feasibility trial. Psycho‐oncology2017;26(Suppl 2):3‐4. MorrisonV , SpencerLH , TottonN , PyeK , YeoST , ButterworthC , et al. Trial of optimal personalised care after treatment‐gynaecological cancer (TOPCAT‐G): a randomized feasibility trial. International Journal of Gynecological Cancer2018;28(2):401‐11. PyeK , TottonN , StuartN , WhitakerR , MorrisonV , EdwardsRT , et al. Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a study protocol for a randomised feasibility trial. Pilot and Feasibility Studies2016;2:67. [DOI 10.1186/s40814‐016‐0108‐5] ">Morrison 2018</a>; <a href="./references#CD012425-bbs2-0033" title="OltraA , SantaballaA , MontalarJ , MunárrizB , PastorM , MeseguerA , et al. Cost‐benefit evaluation of a follow‐up program in patients with advanced breast cancer. Randomized study. Revista de Oncología1999;1(Suppl 1):165. OltraA , SantaballaA , MunárrizB , PastorM , MontalarJ . Cost‐benefit analysis of a follow‐up program in patients with breast cancer: a randomized prospective study. Breast Journal2007;13(6):571‐4. ">Oltra 2007</a>; <a href="./references#CD012425-bbs2-0034" title="PicardiM , PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , et al. Advanced‐stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission‐‐a randomized trial of routine surveillance imaging procedures. Radiology2014;272(1):262‐74. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: Ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2015;100:7‐8. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2014;99:398‐9. ">Picardi 2014</a>; <a href="./references#CD012425-bbs2-0037" title="BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial [Efectividad del seguimiento postoperatorio en los pacientes con cáncer colorrectal para la detección de recidivas curables. Análisis preliminar de un estudio multicéntrico, controlado y aleatorizado]. Gastroenterologia y Hepatologia2001;24(2):92, abstract no: 13. BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Preliminary analysis of a multicenter controlled trial to evaluate the effectiveness of postoperative follow‐up to detect curable recurrences in patients with colorectal cancer [Análisis preliminar de un estudio multicéntrico controlado y aleatorizado destinado a evaluar la efectividad del seguimiento postoperatorio en la detección de recidivas curables en los pacientes con cáncer colorrectal]. Gastroenterologia y Hepatologia2001;24(3):150. Rodriguez‐MorantaF , CastellsA , SaloJ , ArcusaA , BoadasJ , BessaV , et al. Efficacy of postoperative surveillance after radical surgery for colorectal cancer (CRC). Analysis of a prospective, multicenter, randomized controlled trial. Journal of Gastroenterology2005;128(4 Suppl 2):Abstract W967. Rodríguez‐MorantaF , SalóJ , AcrusaA , BoadasJ , BessaX , PiñolV , et al. Efficacy of postoperative surveillance in patients with colorectal cancer after radical surgery. A prospective, multicenter, randomized study. Gastroenterologia y Hepatologia2005;28(3):197‐8, abstract no: 126. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , Bessa , X , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD012425-bbs2-0043" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk‐adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a>). However, there was high heterogeneity in how the studies measured and reported this outcome and we could not pool the results in a meta‐analysis. </p> </section> </section> </section> <section id="CD012425-sec-0077"> <h4 class="title">Excluded studies</h4> <p>We excluded 44 studies with reasons. Following recommendations from the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, we classified studies as excluded with reason only if they were studies one might reasonably expect to be eligible for inclusion (see <a href="./references#CD012425-sec-0159" title="">Characteristics of excluded studies</a> table; <a href="./references#CD012425-bbs2-0155" title="HigginsJP , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). We excluded studies if the intervention was not follow‐up treatment after primary cancer treatment (wrong intervention; <a href="./references#CD012425-bbs2-0055" title="ChangSN , ShunSC , LaiYH , ChenCH , SheuJC . Effects of telephone follow‐up consultations on discharged patients with liver cancer following non‐surgical treatment. Supportive Care in Cancer2013;21:S102. ">Chang 2013</a>; <a href="./references#CD012425-bbs2-0061" title="HelgesenF , AnderssonSO , GustafssonO , VarenhorstE , GobénB , CarnockS , et al. Follow‐up of prostate cancer patients by on‐demand contacts with a specialist nurse: a randomized study. Scandinavian Journal of Urology and Nephrology2000;34(1):55‐61. ">Helgesen 2000</a>; <a href="./references#CD012425-bbs2-0070" title="MajhailNS , MurphyE , LaudP , PreusslerJM , DenzenEM , AbettiB , et al. Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors. Haematologia2019;104(5):1084‐92. MajhailNS , MurphyEA , LaudP , PreusslerJ , DenzenE , AdamsA , et al. Individualized treatment summaries and survivorship care plans (SCPs) for hematopoietic cell transplant (HCT) survivors reduces cancer treatment distress in a randomized, multicenter study. Blood2017;130 Suppl 1:no pagination. ">Majhail 2019</a>; <a href="./references#CD012425-bbs2-0071" title="MathewJ , PrinslooP , AgrawalA , GutteridgeE , MarenahC , RobertsonJF , et al. Pilot randomised study of early intervention based on tumour markers in the follow‐up of patients with primary breast cancer. Breast2014;23(5):567‐72. ">Mathew 2014</a>; <a href="./references#CD012425-bbs2-0082" title="NCT03125070 . Self‐management program and survivorship care plan in improving the health of cancer survivors after stem cell transplant. clinicaltrials.gov/ct2/show/NCT03125070 (first received 17 December 2018). ">NCT03125070</a>; <a href="./references#CD012425-bbs2-0084" title="NCT03360994 . WATChmAN virtual testicular cancer clinic. clinicaltrials.gov/ct2/show/NCT03360994 (first received 17 December 2018). ">NCT03360994</a>; <a href="./references#CD012425-bbs2-0089" title="Ploos van AmstelFK , PrinsJB , Van derGraafWT , PetersME , OttevangerPB . The effectiveness of a nurse‐led intervention with the distress thermometer for patients treated with curative intent for breast cancer: design of a randomized controlled trial. BMC Cancer2016;16:520. ">Ploos van Amstel 2016</a>; <a href="./references#CD012425-bbs2-0092" title="RustinGJ , Van derBurgME , GriffinCL , GuthrieD , LamontA , JaysonGC , et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet2010;376(9747):1155‐63. ">Rustin 2010</a>; <a href="./references#CD012425-bbs2-0096" title="SongL , DunlapKL , TanX , ChenRC , NielsenME , RabenbergRL , et al. Enhancing survivorship care planning for patients with localized prostate cancer using a couple‐focused mHealth symptom self‐management program: protocol for a feasibility study. JMIR Research Protocols2018;7(2):e51. SongL , MayerDK , TanX , NielsenME , ChenRC , NorthouseLL . Feasibility and preliminary effects: using a symptom self management mhealth program to enhance survivorship care plans for men with localized prostate cancer and their partners. Supportive Care in Cancer2018;26((Suppl 3)):S394. ">Song 2018</a>; <a href="./references#CD012425-bbs2-0097" title="StanciuMA , MorrisC , MakinM , WatsonE , BulgerJ , EvansR , et al. A pilot randomised controlled trial of personalised care after treatment for prostate cancer (TOPCAT‐P): nurse‐led holistic‐needs assessment and individualised psychoeducational intervention: study protocol. BMJ Open2015;5(6):e008470. ">Stanciu 2015</a>; <a href="./references#CD012425-bbs2-0101" title="VisserA , GovaertP , SchloozM , DalenT , JansenL , LaarhovenH , et al. Cost‐analyses of group medical consultation (GMCS) in the follow‐up of breast cancer. Psycho‐oncology2014;23:137. VisserA , LaarhovenH , SchloozM , DalenT , PrinsJ . Evaluation of group medical consultations in the follow‐up of breast cancer: a randomized controlled pilot study. Psycho‐oncology2013;22:344. VisserA , LaarhovenHW , GovaertPH , SchloozMS , JansenL , DalenT , et al. Group medical consultations in the follow‐up of breast cancer: a randomized feasibility study. Journal of Cancer Survivorship2015;9(3):450‐61. VisserA , PrinsJ , JansenL , DalenT , LaarhovenH . Group medical consultations (GMCs) in combination with tablet‐based video GMCs as an alternative for individual breast cancer follow‐up visits: results from a randomized controlled trial. Psycho‐oncology2015;24:45. ">Visser 2015</a>; <a href="./references#CD012425-bbs2-0102" title="WatsonE , RoseP , FrithE , HamdyF , NealD , KastnerC , et al. PROSPECTIV—a pilot trial of a nurse‐led psychoeducational intervention delivered in primary care to prostate cancer survivors: study protocol for a randomised controlled trial. BMJ Open2014;4(5):e005186. WatsonEK , ShinkinsB , MathesonL , BurnsRM , FrithE , NealD , et al. Supporting prostate cancer survivors in primary care: findings from a pilot trial of a nurse‐led psycho‐educational intervention (PROSPECTIV). European Journal of Oncology Nursing2018;32:73‐81. ">Watson 2014</a>), if the participants included patients who were not cancer‐free or were being treated for a recurrence (wrong patient population; <a href="./references#CD012425-bbs2-0062" title="HoltedahlK , NorumJ , AnvikT , RichardsenE . Do cancer patients benefit from short‐term contact with a general practitioner following cancer treatment? A randomised, controlled study. Supportive Care in Cancer2005;13(11):949‐56. ">Holtedahl 2005</a>; <a href="./references#CD012425-bbs2-0067" title="LanceleyA , BerzuiniC , BurnellM , GesslerS , MorrisS , RyanA , et al. Ovarian cancer follow‐up: a preliminary comparison of 2 approaches. International Journal of Gynecological Cancer2017;27(1):59‐68. ">Lanceley 2017</a>; <a href="./references#CD012425-bbs2-0072" title="MooreS , CornerJ , HavilandJ , WellsM , SalmonE , NormandC , et al. Erratum: Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial (British Medical Journal (1145‐1147)). BMJ2002;325(7377):1386. MooreS , CornerJ , HavilandJ , WellsM , SalmonE , NormandC , et al. Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial. BMJ2002;325(7373):1145‐52. ">Moore 2002</a>; <a href="./references#CD012425-bbs2-0075" title="NCT01973946 . Cancer symptom monitoring telephone system with nurse practitioner (NP) follow up. clinicaltrials.gov/ct2/show/NCT01973946 (first received 20 December 2016). ">NCT01973946</a>; <a href="./references#CD012425-bbs2-0077" title="NCT02200133 . Randomized study of individualized care plans for hematopoietic cell transplant survivors. clinicaltrials.gov/ct2/show/NCT02200133 (first received 20 December 2016). ">NCT02200133</a>; <a href="./references#CD012425-bbs2-0079" title="NCT02361099 . SENTINEL: impact of the use of a web‐application for the detection of lung cancer relapse. clinicaltrials.gov/ct2/show/NCT02361099 (first received 20 December 2016). ">NCT02361099</a>; <a href="./references#CD012425-bbs2-0081" title="NCT03056469 . Patient‐reported outcomes integrated in the follow‐up of patients with hematological cancer. clinicaltrials.gov/ct2/show/NCT03056469 (first received 17 December 2018). ">NCT03056469</a>; <a href="./references#CD012425-bbs2-0085" title="NCT03424837 . A survivorship care plan and embedded navigation tool. clinicaltrials.gov/ct2/show/NCT03424837 (first received 17 December 2018). ">NCT03424837</a>; <a href="./references#CD012425-bbs2-0086" title="NCT03608410 . Intensified follow‐up of lung cancer using weekly questionnaires via the internet. clinicaltrials.gov/ct2/show/NCT03608410 (first received 17 December 2018). ">NCT03608410</a>; <a href="./references#CD012425-bbs2-0090" title="PuriA , GuliaA . Trial for optimal surveillance in sarcoma. Pediatric Blood and Cancer2011;57 (5):717. PuriA , GuliaA , HawaldarR , RanganathanP , BadweR . Does intensity of surveillance affect survival after surgery for sarcomas? Results of a randomized noninferiority trial. Pediatric Blood and Cancer2014;61:S117. PuriA , RanganathanP , GuliaA , CrastoS , HawaldarR , BadweRA . Does a less intensive surveillance protocol affect the survival of patients after treatment of a sarcoma of the limb? Updated results of the randomized TOSS study. Bone Joint Journal2018;100‐B(2):262‐8. ">Puri 2018</a>; <a href="./references#CD012425-bbs2-0094" title="SkolarusTA , MetregerT , HwangS , KimHM , GrubbRL3rd , GingrichJR , et al. Optimizing veteran‐centered prostate cancer survivorship care: study protocol for a randomized controlled trial. Trials2017;18(1):181. ">Skolarus 2017</a>; <a href="./references#CD012425-bbs2-0099" title="VanRhijnBW . Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU International2011;108(7):1123‐4. Van derAaMN , SteyerbergEW , BangmaCH , VanRhijnBW , ZwarthoffEC , Van derKwastTH . Cystoscopy revisited as the gold standard for detection of bladder cancer recurrence: Diagnostic review bias in a randomised prospective trial. Journal of Urology2009;181(4 Suppl 1):690. ">Van Rhijn 2011</a>), if our primary or secondary outcomes of interest were not an outcome included by the study (wrong outcomes; <a href="./references#CD012425-bbs2-0058" title="FaithfullS , CornerJ , MeyerL , HuddartR , DearnaleyD . Evaluation of nurse‐led follow up for patients undergoing pelvic radiotherapy. British Journal of Cancer2001;85(12):1853‐64. ">Faithfull 2001</a>; <a href="./references#CD012425-bbs2-0059" title="GullifordT , OpomuM , WilsonE , HanhamI , EpsteinR . Popularity of less frequent follow up for breast cancer in randomised study: initial findings from the hotline study. BMJ (Clinical Research Ed.)1997;314(7075):174‐7. ">Gulliford 1997</a>; <a href="./references#CD012425-bbs2-0060" title="HaqR , Brezden‐MasleyC , LeeR , RichterS , GeorgeRL , SimpsonJ , et al. Results of a randomized controlled study of personalized care plans in breast cancer survivors from a single institution. Journal of Clinical Oncology2015;33(28 Suppl 1):109. ">Haq 2015</a>; <a href="./references#CD012425-bbs2-0064" title="JeffordM , Lotfi‐JamK , BaravelliC , GroganS , RogersM , KrishnasamyM , et al. Development and pilot testing of a nurse‐led posttreatment support package for bowel cancer survivors. Asia‐Pacific Journal of Clinical Oncology2011;34(3):E1‐10. ">Jefford 2011</a>; <a href="./references#CD012425-bbs2-0069" title="LyuKX , ZhaoJ , WangB , XiongGX , YangWQ , LiuQH , et al. Smartphone application weChat for clinical follow‐up of discharged patients with head and neck tumors: a randomized controlled trial. Chinese Medical Journal2016;129(23):2816‐23. ">Lyu 2016</a>; <a href="./references#CD012425-bbs2-0073" title="NCT00049465 . Standard follow‐up compared with extended follow‐up in treating patients who have undergone stem cell transplantation for cancer. clinicaltrials.gov/ct2/show/NCT00049465 (first received 20 December 2016). ">NCT00049465</a>; <a href="./references#CD012425-bbs2-0074" title="NCT01824745 . Survivorship care planning in improving the quality of life in breast cancer survivors. clinicaltrials.gov/ct2/show/NCT01824745 (first received 20 December 2016). ">NCT01824745</a>; <a href="./references#CD012425-bbs2-0078" title="NCT02209415 . EUS‐based follow‐up on R0‐resected patients for esophageal, gastric and pancreatic cancer (EUFURO). clinicaltrials.gov/ct2/show/NCT02209415 (first received 20 December 2016). ">NCT02209415</a>; <a href="./references#CD012425-bbs2-0083" title="NCT03271099 . Patient navigation in cancer survivorship at a safety net institution. clinicaltrials.gov/ct2/show/NCT03271099 (first received 17 December 2018). ">NCT03271099</a>; <a href="./references#CD012425-bbs2-0087" title="NCT03618017 . The ConnectedCancerCare pilot study (CCC). clinicaltrials.gov/ct2/show/NCT03618017 (first received 17 December 2018). ">NCT03618017</a>; <a href="./references#CD012425-bbs2-0088" title="ParkerPA , BanerjeeSC , MatasarMJ , BylundCL , RogersM , FrancoK , et al. Efficacy of a survivorship‐focused consultation versus a time‐controlled rehabilitation consultation in patients with lymphoma: a cluster randomized controlled trial. Cancer2018;124(23):4567‐76. ">Parker 2018</a>; <a href="./references#CD012425-bbs2-0095" title="SmithKC , TolbertE , HannumSM , RadhakrishnanA , ZornK , BlackfordA , et al. Comparing web‐based provider‐initiated and patient‐initiated survivorship care planning for cancer patients: a randomized controlled trial. JMIR Cancer2016;2(2):e12. ">Smith 2016</a>; <a href="./references#CD012425-bbs2-0098" title="StrandE , NygrenI , BergkvistL , SmedhK . Nurse or surgeon follow‐up after rectal cancer: a randomized trial. Colorectal Disease2011;13(9):999‐1003. ">Strand 2011</a>; <a href="./references#CD012425-bbs2-0103" title="MeliskoME , MihalisE , ErnestM , RugoHS , ParkJW , MoasserMM , et al. A pilot study comparing a patient‐centered symptom‐reporting follow‐up program to standard care in patients who have completed the acute phase of treatment for early breast cancer. Journal of Clinical Oncology2010;28(15 Suppl 1):TPS272. NCT01308775 . Comparing (SIS.NET) to standard care in patients who have completed the acute phase of treatment for early breast cancer. clinicaltrials.gov/ct2/show/NCT01308775 (first received 20 December 2016). WheelockA , BockM , MihalisE , HwangJ , ShepardNL , RugoH , et al. Incorporation of web‐based symptom reporting and management in follow‐up (FU) care for early‐stage breast cancer. Supportive Care in Cancer2012;20:S269‐70. WheelockA , BockM , MihalisE , ShepardN , MooreDH , ErnestML , et al. A randomized trial evaluating the integration of online questionnaires into follow‐up (FU) care for early‐stage breast cancer (ESBC). Journal of Clinical Oncology2012;30(15 Suppl 1):no pagination. WheelockAE , BockMA , MartinEL , HwangJ , ErnestML , RugoHS , et al. SIS.NET: a randomized controlled trial evaluating a web‐based system for symptom management after treatment of breast cancer. Cancer2015;121(6):893‐9. ">Wheelock 2015</a>), or if it was not a standard randomised trial (wrong design; <a href="./references#CD012425-bbs2-0091" title="RogersSN , LoweD , LowiesC , YeoST , AllmarkC , McAveryD , et al. Improving quality of life through the routine use of the patient concerns inventory for head and neck cancer patients: a cluster preference randomized controlled trial. BMC Cancer2018;18(1):444. ">Rogers 2018</a>; <a href="./references#CD012425-bbs2-0093" title="SamawiH , YinY , LimHJ , RenoufDJ , CheungWY . Primary care vs. oncology‐driven surveillance following adjuvant chemotherapy in resected pancreas cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):no pagination. ">Samawi 2017</a>; <a href="./references#CD012425-bbs2-0100" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer2013;49:S480. VerberneC , Van denHeuvelE , DeBockGH , GrossmannI , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcinoembryonic (CEA) measurements and CEA‐triggered Imaging. Annals of Surgical Oncology2014;21(1 Suppl 1):S6. VerberneC , WiggersT , DeBockGH , GrossmannI . Sensitivity and specificity of CEA in colorectal cancer follow‐up. European Journal of Surgical Oncology2014;40(11):S104. VerberneC , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up ‐ Survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology2016;42(9):S106. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐6. VerberneCJ , ZhanZ , HeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. ZhanZ , VerberneCJ , Van denHeuvelER , GrossmannI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PloS One2017;12(9):e0184740. '>Verberne 2015</a>). Two potential studies registered on the ClinicalTrials.gov trials registry were reported as being withdrawn (<a href="./references#CD012425-bbs2-0076" title="NCT01993901 . The influence of CSRT‐led telephone follow‐up on ESAS scores in patients who have been treated with lung SBRT. clinicaltrials.gov/ct2/show/NCT01993901 (first received 20 December 2016). ">NCT01993901</a>; <a href="./references#CD012425-bbs2-0080" title="NCT02655068 . Phase III trial of PET/CT vs. CT surveillance for head and neck cancer. clinicaltrials.gov/ct2/show/NCT02655068 (first received 20 December 2016). ">NCT02655068</a>), and one study was never started due to lack of funding (<a href="./references#CD012425-bbs2-0065" title="KesslerL , LoggersE , GatsonisC , PatrickD , SullivanS , HanashS , et al. Surveillance trial to improve longevity in lung cancer patients (STILL). American Journal of Respiratory and Critical Care Medicine2013;187:ASS39. ">Kessler 2013</a>). </p> </section> </section> <section id="CD012425-sec-0078"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD012425-fig-0003">Figure 3</a> shows the summary of the 'Risk of bias' assessments for all the included studies. Reasons for the authors' judgements are given for each study in the 'Risk of bias' tables under the <a href="./references#CD012425-sec-0158" title="">Characteristics of included studies</a>. </p> <div class="figure" id="CD012425-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. Blank items indicate that this type of outcome was not reported by the study" data-id="CD012425-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. Blank items indicate that this type of outcome was not reported by the study </p> </div> </div> </div> <section id="CD012425-sec-0079"> <h4 class="title">Allocation</h4> <section id="CD012425-sec-0080"> <h5 class="title">Random sequence generation</h5> <p>Forty studies clearly stated the methods used for random sequence generation and we judged the risk of selection bias in these studies to be low (<a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad 2013</a>; <a href="./references#CD012425-bbs2-0002" title="BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Economic evaluation of a randomized clinical trial of hospital versus telephone follow‐up after treatment for breast cancer. British Journal of Surgery2009;96(12):1406‐15. [DOI: 10.1002/bjs.6753] BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Is telephone follow‐up by specialist nurses a cost effective approach?. European Journal of Cancer Supplements2009;7(2‐3):230‐1. BeaverK , Tysver‐RobinsonD , CampbellM , TwomeyM , WilliamsonS , HindleyA , et al. Comparing hospital and telephone follow‐up after treatment for breast cancer: randomised equivalence trial. BMJ2009;338:a3147. [DOI: 10.1136/bmj.a3147] ">Beaver 2009</a>; <a href="./references#CD012425-bbs2-0003" title="BeaverK , CampbellM , WilliamsonS , ProcterD , SheridanJ , HeathJ , et al. An exploratory randomized controlled trial comparing telephone and hospital follow‐up after treatment for colorectal cancer. Colorectal Disease2012;14(10):1201‐9. [DOI: 10.1111/j.1463‐1318.2012.02936.x] ">Beaver 2012</a>; <a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a>; <a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a>; <a href="./references#CD012425-bbs2-0006" title="D'CruzA , VaishR , GuptaS , AryaS , HawaldarRW , ShahS . Does addition of neck ultrasonography to physical examination, in follow‐up of patients with early stage, clinically node negative oral cancers, influence outcome? A randomized control trial (RCT). Journal of Clinical Oncology2016;34(15 Suppl 6):no pagination. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node‐negative oral cancer. New England Journal of Medicine2015;373(6):521‐9. NCT00193765 . Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. clinicaltrials.gov/ct2/show/NCT00193765 (first received 20 December 2016). ">D'Cruz 2016</a>; <a href="./references#CD012425-bbs2-0007" title="DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . Prospective randomized clinical trial for the evaluation of a stage adjusted reduced follow‐up schedule in cutaneous melanoma patients: results after one year. Annals of Surgical Oncology2016;23(1 Suppl 1):S30. DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . The MELFO‐study: prospective randomized clinical trial for the evaluation of a stage‐adjusted reduced follow‐up schedule in cutaneous melanoma patients ‐ results after 1 year. Annals of Surgical Oncology2016;23(9):2762‐71. [DOI: 10.1245/s10434‐016‐5263‐7] DeckersE , Hoekstra‐WeebersJ , DamudeS , FranckenA , Ter MeulenS , BastiaannetE , et al. The MELFO‐study: a multi‐center prospective randomized clinical trial on the effects of a reduced stage‐adjusted follow‐up schedule on cutaneous melanoma IB‐IIC patients: results after 3‐years. Annals of Surgical Oncology2018;25(1 Suppl 1):S40. NCT01018004 . Comparing follow‐up schedules in patients with newly diagnosed stage IB or stage II melanoma. clinicaltrials.gov/ct2/show/NCT01018004 (first received 20 December 2016). ">Damude 2016</a>; <a href="./references#CD012425-bbs2-0008" title="DavisKM , DawsonD , KellyS , RedS , PenekS , LynchJ , et al. Monitoring of health‐related quality of life and symptoms in prostate cancer survivors: a randomized trial. Journal of Supportive Oncology2013;11(4):174‐82. ">Davis 2013</a>; <a href="./references#CD012425-bbs2-0009" title="ACTRN12610000938000 . The ProCare Trial: a randomised controlled trial of follow up of men with prostate cancer in primary care. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336116 (first received 20 December 2016). EmeryJ , DooreyJ , JeffordM , KingM , PirottaM , HayneD , et al. Protocol for the ProCare Trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. BMJ Open2014;4(3):e004972. [DOI: 10.1136/bmjopen‐2014‐004972] EmeryJ , SchofieldP , JeffordM , KingM , PirottaM , HayneD , et al. The ProCare trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. Asia‐Pacific Journal of Clinical Oncology2014;10:157. EmeryJD , JeffordM , KingM , HayneD , MartinA , DooreyJ , et al. ProCare Trial: a phase II randomized controlled trial of shared care for follow‐up of men with prostate cancer. BJU International2016;119(3):381‐89. [DOI: 10.1111/bju.13593] KingM . Procare/PC4 study update. Asia‐Pacific Journal of Clinical Oncology2012;8:23. ">Emery 2016</a>; <a href="./references#CD012425-bbs2-0010" title="GambazziF , FreyLD , BruehlmeierM , JanthurWD , GraberSM , HeubergerJ , et al. Comparing two imaging methods for follow‐up of lung cancer treatment: a randomized pilot study. Annals of Thoracic Surgery2018;107(2):430‐5. [DOI: 10.1016/j.athoracsur.2018.08.015] ">Gambazzi 2018</a>; <a href="./references#CD012425-bbs2-0011" title="GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata). A randomized trial of intensive versus minimalist follow‐up of patients with resected Dukes B‐C colorectal cancer: the pilot phase. Tumori1998;84(Suppl):89. GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. NCT02409472 . Intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. clinicaltrials.gov/ct2/show/NCT02409472 (first received 20 December 2016). RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] ">GILDA 2016</a>; <a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a>; <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a>; <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>; <a href="./references#CD012425-bbs2-0015" title="BoekhoutAH , MaunsellE , PondGR , JulianJA , CoyleD , LevineMN , et al. A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial. Journal of Cancer Survivorship2015;9(4):683‐91. CoyleD , GrunfeldE , CoyleK , JulianJA , PondGR , FolkesA , et al. Cost‐effectiveness of a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):6082. CoyleD , GrunfeldE , CoyleK , PondG , JulianJA , LevineMN . Cost effectiveness of a survivorship care plan for breast cancer survivors. Journal of Oncology Practice2014;10(2):e86‐92. GrunfeldE , JulianJA , PondG , MaunsellE , CoyleD , FolkesA , et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. Journal of Clinical Oncology2011;29(36):4755‐62. GrunfeldE , LevineMN , JulianJA , PondGR , MaunsellE , FolkesA , et al. Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):9005. GrunfeldE , PondG , MaunsellE , LevineMN , JulianJA , CoyleD . Impact of survivorship care plans (SCP) on adherence to guidelines, health service measures, and patient‐reported outcomes (PRO): extended results of a multicenter randomized clinical trial (RCT) with breast cancer survivors. European Journal of Cancer2012;48:S147. ">Grunfeld 2011</a>; <a href="./references#CD012425-bbs2-0016" title="HershmanDL , GreenleeH , AwadD , KalinskyK , MaurerM , KranwinkelG , et al. Randomized controlled trial of a clinic‐based survivorship intervention following adjuvant therapy in breast cancer survivors. Breast Cancer Research and Treatment2013;138(3):795‐806. ">Hershman 2013</a>; <a href="./references#CD012425-bbs2-0017" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14:260. [DOI: 10.1186/1745‐6215‐14‐260] JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a nurse‐led supportive care package (survivor care) for survivors of colorectal cancer. Cancer Nursing2015;38(4 Suppl 1):S16‐7. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (Survivor‐Care, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2015;33(15 Suppl 1):9566. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , SchofieldP , ArandaS , YoungJ , ButowP . Randomised controlled trial (RCT) of a comprehensive post‐treatment support package (survivor‐care) for bowel cancer survivors. Psycho‐oncology2010;19:S193. ">Jefford 2016</a>; <a href="./references#CD012425-bbs2-0018" title="JeppesenMM , JensenPT , GilsaD , DePont ChristensenR , JensenMM , MogensenO . The effect of patient‐initiated follow‐up on fear of recurrence and health care use: a randomized trial in early‐stage endometrial cancer. International Journal of Gynecological Cancer2017;27(Supplement 4):1107. JeppesenMM , JensenPT , HansenDG , ChristensenRD , MogensenO . Authors' reply re: Patient‐initiated follow‐up affects fear of recurrence and health care use: a randomised trial in early‐stage endometrial cancer. BJOG2018;125(13):1778‐9. JeppesenMM , JensenPT , HansenDG , ChristensenRD , MogensenO . Patient‐initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early‐stage endometrial cancer. BJOG2018;125(13):1705‐14. TegnerowiczJ . Re: Patient‐initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early‐stage endometrial cancer. BJOG2018;1125(13):1778. ">Jeppesen 2018</a>; <a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0025" title="KvaleEA , Demark‐WahnefriedW , MenesesK , BaeS , HuangCH , AzueroCB , et al. Patient centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer Research2015;75(9 Suppl 1):no pagination. KvaleEA , HuangCS , MenesesKM , Demark‐WahnefriedW , BaeS , AzueroCB , et al. Patient‐centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer2016;122(20):3232‐42. ">Kvale 2016</a>; <a href="./references#CD012425-bbs2-0027" title="MalmströmM , IvarssonB , KlefsgårdR , PerssonK , JakobssonU , JohanssonJ . The effect of a nurse led telephone supportive care programme on patients' quality of life, received information and health care contacts after oesophageal cancer surgery‐a six month RCT‐follow‐up study. International Journal of Nursing Studies2016;64:86‐95. [DOI: 10.1016/j.ijnurstu.2016.09.009] ">Malmstrom 2016</a>; <a href="./references#CD012425-bbs2-0028" title="MalyRC , GriggsJJ , LiuY , LiangLJ , GanzPA . A randomized controlled trial of survivorship care plans among low‐income breast cancer survivors. Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. MalyRC , LiangLJ , LiuY , GriggsJJ , GanzPA . Randomized controlled trial of survivorship care plans among low‐income, predominant Latina breast cancer survivors. Journal of Clinical Oncology2017;35(16):1814‐21. NCT01627366 . Study of survivorship care plans and outcomes in underserved breast cancer survivors. clinicaltrials.gov/ct2/show/NCT01627366 (first received 17 December 2018). ">Maly 2017</a>; <a href="./references#CD012425-bbs2-0030" title="MorrisonV , SpencerLH , LeesonS . Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a randomised feasibility trial. Psycho‐oncology2017;26(Suppl 2):3‐4. MorrisonV , SpencerLH , TottonN , PyeK , YeoST , ButterworthC , et al. Trial of optimal personalised care after treatment‐gynaecological cancer (TOPCAT‐G): a randomized feasibility trial. International Journal of Gynecological Cancer2018;28(2):401‐11. PyeK , TottonN , StuartN , WhitakerR , MorrisonV , EdwardsRT , et al. Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a study protocol for a randomised feasibility trial. Pilot and Feasibility Studies2016;2:67. [DOI 10.1186/s40814‐016‐0108‐5] ">Morrison 2018</a>; <a href="./references#CD012425-bbs2-0031" title="MurchieP , NicolsonMC , HannafordPC , RajaEA , LeeAJ , CampbellNC . Patient satisfaction with GP‐led melanoma follow‐up: a randomised controlled trial. British Journal of Cancer2010;102(10):1447‐55. ">Murchie 2010</a>; <a href="./references#CD012425-bbs2-0034" title="PicardiM , PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , et al. Advanced‐stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission‐‐a randomized trial of routine surveillance imaging procedures. Radiology2014;272(1):262‐74. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: Ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2015;100:7‐8. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2014;99:398‐9. ">Picardi 2014</a>; <a href="./references#CD012425-bbs2-0036" title="MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017;21(32):1‐86. MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00560365 (first received 20 December 2016). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology2011;29(15 Suppl 1):3521. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. [DOI: 10.1001/jama.2013.285718] PughSA , FullerA , PereraR , GeorgeS , MantD , PrimroseJ . The follow‐up after colorectal cancer surgery trial: randomised trial of follow‐up after colorectal cancer surgery and outcome following recurrence. Journal of the American College of Surgeons2014;219(4 Suppl 1):e46‐7. PughSA , MantD , ShinkinsB , MellorJ , PereraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology2016;27(Suppl 6):no pagination. ShinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PloS One2017;12(3):e0171810. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;105(6):658‐62. ">Primrose 2014</a>; <a href="./references#CD012425-bbs2-0037" title="BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial [Efectividad del seguimiento postoperatorio en los pacientes con cáncer colorrectal para la detección de recidivas curables. Análisis preliminar de un estudio multicéntrico, controlado y aleatorizado]. Gastroenterologia y Hepatologia2001;24(2):92, abstract no: 13. BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Preliminary analysis of a multicenter controlled trial to evaluate the effectiveness of postoperative follow‐up to detect curable recurrences in patients with colorectal cancer [Análisis preliminar de un estudio multicéntrico controlado y aleatorizado destinado a evaluar la efectividad del seguimiento postoperatorio en la detección de recidivas curables en los pacientes con cáncer colorrectal]. Gastroenterologia y Hepatologia2001;24(3):150. Rodriguez‐MorantaF , CastellsA , SaloJ , ArcusaA , BoadasJ , BessaV , et al. Efficacy of postoperative surveillance after radical surgery for colorectal cancer (CRC). Analysis of a prospective, multicenter, randomized controlled trial. Journal of Gastroenterology2005;128(4 Suppl 2):Abstract W967. Rodríguez‐MorantaF , SalóJ , AcrusaA , BoadasJ , BessaX , PiñolV , et al. Efficacy of postoperative surveillance in patients with colorectal cancer after radical surgery. A prospective, multicenter, randomized study. Gastroenterologia y Hepatologia2005;28(3):197‐8, abstract no: 126. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , Bessa , X , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD012425-bbs2-0038" title="DeRooijBH , EzendamNP , NicolaijeKA , LodderP , VosMC , PijnenborgJM , et al. Survivorship care plans have a negative impact on long‐term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. Quality of Life Research2018;27(6):1533‐44. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2‐year follow‐up ‐ The ROGY care trial. Gynecologic Oncology2017;145(2):319‐28. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Long‐term impact of survivorship care plans on ovarian cancer patient reported outcomes‐new results of the ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):64‐5. DeRooijBH , EzendamNP , NicolaijeKA , VosMC , PijnenborgJM , BollD , et al. The indirect effects of survivorship care plans on quality of life, anxiety and depression‐the ROGY care trial. Supportive Care in Cancer2017;25(2 Suppl 1):S53‐4. DeRooijBH , EzendamNP , VosMC , PijnenborgJM , BollD , KruitwagenRF , et al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. Cancer Epub 2018 Nov 30;125(5):788‐97. [DOI: 10.1002/cncr.31844] EzendamN , DeRooijB , NicolaijeK , VosC , PijnenborgJ , BollD , et al. Long‐term impact of cancer survivorship care plans on patient outcomes‐the randomized controlled ROGY care trial. International Journal of Gynecological Cancer2016;26:91. EzendamNP , VanBroekhovenM , Van DePoll‐FranseLV , DeRooijBH . The role of illness perceptions in smoking, alcohol consumption and weight changes among gynaecological cancer survivors. Quality of Life Research2016;25(1 Suppl 1):114. JeppesenMM , EzendamNP , PijnenborgJM , VosMC , BollD , KruitwagenRF , et al. The impact of the survivorship care plan on health care use: 2‐year follow‐up results of the ROGY care trial. Journal of Cancer Survivorship2018;12(1):18‐27. NicolaijeKA , EzendamNP , VosMC , PijnenborgJM , BollD , BossEA , et al. Impact of an automatically generated cancer survivorship care plan on patient‐reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial. Journal of Clinical Oncology2015;33(31):3550‐9. Van dePoll‐FranseL , NicolaijeK , EzendamN , VosC , BollD , PijnenborgJ , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY CARE): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Psycho‐oncology2013;22:341‐2. Van dePoll‐FranseLV , JeppesenMM , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. The survivorship care plan increases the use of primary care in anxious and irradiated endometrial cancer patients. Two year outcomes of the pragmatic cluster randomized ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):164. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosCM , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY Care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosMC , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. European Journal of Cancer2013;49:S720. Van dePoll‐FranseLV , NicolaijeKA , VosMC , PijnenborgJM , BollD , HussonO , et al. The impact of a cancer survivorship care plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials2011;12:256. ">ROGY 2015</a>; <a href="./references#CD012425-bbs2-0039" title="PalliD , RussoA , SaievaC , CiattoS , Rosselli Del TurcoM , DistanteV , et al. Intensive vs clinical follow‐up after treatment of primary breast cancer: 10‐year update of a randomized trial. National Research Council Project on Breast Cancer Follow‐up. JAMA1999;281(17):1586. Roselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . The efficacy of intensive follow‐up testing in breast cancer cases. Annals of Oncology1995;6(Suppl 2):37‐9. Rosselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . Intensive diagnostic follow‐up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow‐up. JAMA1994;271(20):1593‐7. ">Rosselli Del Turco 1994</a>; <a href="./references#CD012425-bbs2-0041" title="GoodmanA . How often to follow up? Study shows two CT scans as good as five for low‐risk testicular cancer. Oncology Times2007;29(12):54‐5. NCT00003420 . CT scans in treating patients with stage I testicular cancer after undergoing orchiectomy. clinicaltrials.gov/ct2/show/NCT00003420 (first received 20 December 2016). RustinGJ , MeadGM , StenningSP , VaseyPA , AassN , HuddartRA , et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197‐‐the National Cancer Research Institute Testis Cancer Clinical Studies Group. Journal of Clinical Oncology2007;25(11):1310‐5. ">Rustin 2007</a>; <a href="./references#CD012425-bbs2-0042" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gastroenterology1998;114(1):7‐14. SchoemakerD , BlackR , GilesL , ToouliJ , AlcornJ . Addition of intensive follow‐up procedures to standard follow‐up did not improve survival in patients with colorectal cancer. Evidence‐Based Medicine1998;3(5):140. ">Schoemaker 1998</a>; <a href="./references#CD012425-bbs2-0044" title="SheppardC , HigginsB , WiseM , YiangouC , DuboisD , KilburnS . Breast cancer follow up: a randomised controlled trial comparing point of need access versus routine 6‐monthly clinical review. European Journal of Oncology Nursing2009;13(1):2‐8. [DOI: 10.1016/j.ejon.2008.11.005] ">Sheppard 2009</a>; <a href="./references#CD012425-bbs2-0046" title="NCT00624260 . Impact of PET Scan on the curative strategy of colo‐rectal cancers : a randomized study. clinicaltrials.gov/ct2/show/NCT00624260 (first received 20 December 2016). SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an openlabel multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology2017;35(15 Suppl 1):no pagination. SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal2017;5(5 Suppl 1):A13. SobhaniI , IttiE , LucianiA , BaumgaertnerI , LayeseR , AndreT , et al. Colorectal cancer (CRC) monitoring by 6‐monthly 18FDG‐PET/CT: an open‐label multicentre randomised trial. Annals of Oncology2018;29(4):931‐7. ">Sobhani 2018</a>; <a href="./references#CD012425-bbs2-0047" title="Van DerMeulenI , MayA , RosW , OosteromM , HordijkGJ , KooleR , et al. Effects of a nurse‐led psychosocial intervention on depressive symptoms and health‐related quality of life in patients with head and neck cancer: a randomized controlled trial. Psycho‐oncology2013;22(Suppl 3):17. Van derMeulenIC , MayAM , RosWJ , OosteromM , HordijkGJ , KooleR , et al. One‐year effect of a nurse‐led psychosocial intervention on depressive symptoms in patients with head and neck cancer: a randomized controlled trial. Oncologist2013;18(3):336‐44. [DOI: 10.1634/theoncologist.2012‐0299] ">Van der Meulen 2013</a>; <a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a>; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>; <a href="./references#CD012425-bbs2-0051" title="NCT00198341 . Post‐surgical non‐small cell lung cancer (NSCLC) follow‐up. clinicaltrials.gov/ct2/show/NCT00198341 (first received 20 December 2016). WesteelV . Follow‐up of the patient after curative treatment. Lung Cancer2011;71:S10‐1. WesteelV . Surveillance and second primary malignancies in lung cancer survivors. Journal of Thoracic Oncology2018;13(10 Suppl):S277‐8. WesteelV , BarlesiF , DomasJ , GirardP , FoucherP , LafitteJJ , et al. Postoperative follow‐up of lung cancer: randomized trial comparing two follow‐up programs in completely resected non‐small cell lung cancer (IFCT‐0302). Journal of Clinical Oncology2012;30(15 Suppl 1):no pagination. WesteelV , BarlesiF , FoucherP , LafitteJ , DomasJ , GirardP , et al. Recurrences and 2nd primary cancers in the IFCT‐0302 trial assessing a CT‐scan‐based follow‐up after lung cancer surgery. Journal of Thoracic Oncology2017;12(11 Suppl 2):S1788‐9. WesteelV , BarlesiF , FoucherP , LafitteJ‐J , DomasJ , GirardP , et al. Results of the phase III IFCT‐0302 trial assessing minimal versus CT‐scan‐based follow‐up for completely resected non‐small cell lung cancer (NSCLC). Annals of Oncology2017;28(Suppl 5):v452. WesteelV , BarlesiF , FoucherP , LafitteJJ , DomasJ , GirardP , et al. Compliance with follow‐up programs after surgery for non‐small cell lung cancer in the phase III IFCT‐0302 trial. Journal of Thoracic Oncology2015;10(9 Suppl 2):S239. WesteelV , LebitasyMP , MercierM , LafitteJJ , DomasJ , GirardPl . IFCT‐0302 trial: randomised study comparing two follow‐up schedules in completely resected non‐small cell lung cancer [Protocole IFCT‐0302 : essai randomisé de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués]. Revue des Maladies Respiratoires2007;2(5):645‐52. ">Westeel 2012</a>; <a href="./references#CD012425-bbs2-0052" title="NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00225641 (first received 20 December 2016). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PahlmanL , et al. Intensity of follow up after surgery for colorectal cancer. Colorectal Disease2014;16:93. Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA2018;319(20):2095‐103. ">Wille‐Jorgensen 2018</a>; <a href="./references#CD012425-bbs2-0053" title='ACTRN12608000252314 . Cancer care after surgery – the CONNECT study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82819 (first received 20 December 2016). HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Connect: a pilot RCT to improve outcomes for people with colorectal cancer. Asia‐Pacific Journal of Clinical Oncology2009;5:A159. HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Randomized pilot evaluation of the supportive care intervention "CONNECT" for people following surgery for colorectal cancer. Diseases of the Colon and Rectum2011;54(5):622‐31. YoungJM , ButowPN , WalshJ , DurcinoskaI , DobbinsTA , RodwellL , et al. Multicenter randomized trial of centralized nurse‐led telephone‐based care coordination to improve outcomes after surgical resection for colorectal cancer: the CONNECT intervention. Journal of Clinical Oncology2013;31(28):3585‐91. [DOI: 10.1200/JCO.2012.48.1036] '>Young 2013</a>). The remaining thirteen studies did not provide sufficient information and we judged the risk of bias to be unclear (<a href="./references#CD012425-bbs2-0019" title="JuarezG , HurriaA , FerrellB . Effectiveness of an education intervention on quality of life in Latina breast cancer survivors. Psycho‐oncology2012;21:110. JuarezG , HurriaA , UmanG , FerrellB . Impact of a bilingual education intervention on the quality of life of Latina breast cancer survivors. Oncology Nursing Forum2013;40(1):E50‐60. [DOI: 10.1188/13.ONF.E50‐E60] ">Juarez 2013</a>; <a href="./references#CD012425-bbs2-0021" title="DentJ , ToppingA , FergusonC , StephensonJ , McCoyM , AllinsonV , et al. To follow up or not? A new model of supportive care for early breast cancer. Journal of Clinical Oncology2011;29(15 Suppl 1):no pagination. KirshbaumMN , DentJ , StephensonJ , ToppingAE , AllinsonV , McCoyM , et al. Open access follow‐up care for early breast cancer: a randomised controlled quality of life analysis. European Journal of Cancer Care2017;26(4):e12577. [DOI: 10.1111/ecc.12577] ">Kirshbaum 2017</a>; <a href="./references#CD012425-bbs2-0022" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomized study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Gastroenterology1999;34(5):509‐15. KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;149:159‐62. ">Kjeldsen 1997</a>; <a href="./references#CD012425-bbs2-0024" title="KokkoR , HakamaM , HolliK . Follow‐up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Research and Treatment2005;93(3):255‐60. KokkoR , HakamaM , HolliK . Role of chest X‐ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Research and Treatment2003;81(1):33‐9. ">Kokko 2003</a>; <a href="./references#CD012425-bbs2-0026" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1992</a>; <a href="./references#CD012425-bbs2-0029" title="MonteilJ , VergnenègreA , BertinF , DalmayF , GaillardS , BonnaudF , et al. Randomized follow‐up study of resected NSCLC patients: conventional versus 18F‐DG coincidence imaging. Anticancer Research2010;30(9):3811‐6. NCT00199615 . Follow‐up of patients with curative‐intent surgical resection for NSCLC. clinicaltrials.gov/ct2/show/NCT00199615 (first received 20 December 2016). ">Monteil 2010</a>; <a href="./references#CD012425-bbs2-0032" title="OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD012425-bbs2-0033" title="OltraA , SantaballaA , MontalarJ , MunárrizB , PastorM , MeseguerA , et al. Cost‐benefit evaluation of a follow‐up program in patients with advanced breast cancer. Randomized study. Revista de Oncología1999;1(Suppl 1):165. OltraA , SantaballaA , MunárrizB , PastorM , MontalarJ . Cost‐benefit analysis of a follow‐up program in patients with breast cancer: a randomized prospective study. Breast Journal2007;13(6):571‐4. ">Oltra 2007</a>; <a href="./references#CD012425-bbs2-0035" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA , et al. Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD012425-bbs2-0040" title="RuddyKJ , BakerEL , GuoH , GoldsteinMJ , WinerEP , ShulmanLN , et al. Randomized trial evaluating a coordinated survivorship care program for early stage breast cancer. Cancer Research2013;73(24 Suppl 1):OT2‐5‐02. RuddyKJ , GuoH , BakerE , GoldsteinM , MullaneyEE , ShulmanLN , et al. Coordinated follow‐up breast cancer survivorship care program study. Journal of Clinical Oncology2015;33(15 Suppl 1):e17727. RuddyKJ , GuoH , BakerEL , GoldsteinMJ , MullaneyEE , ShulmanLN , et al. Randomized phase 2 trial of a coordinated breast cancer follow‐up care program. Cancer2016;122:3546‐54. ">Ruddy 2016</a>; <a href="./references#CD012425-bbs2-0043" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk‐adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD012425-bbs2-0045" title="SobhaniI , TiretE , LebtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>; <a href="./references#CD012425-bbs2-0049" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>. </p> </section> <section id="CD012425-sec-0081"> <h5 class="title">Allocation concealment</h5> <p>We judged 37 studies to be at low risk of bias (<a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad 2013</a>; <a href="./references#CD012425-bbs2-0002" title="BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Economic evaluation of a randomized clinical trial of hospital versus telephone follow‐up after treatment for breast cancer. British Journal of Surgery2009;96(12):1406‐15. [DOI: 10.1002/bjs.6753] BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Is telephone follow‐up by specialist nurses a cost effective approach?. European Journal of Cancer Supplements2009;7(2‐3):230‐1. BeaverK , Tysver‐RobinsonD , CampbellM , TwomeyM , WilliamsonS , HindleyA , et al. Comparing hospital and telephone follow‐up after treatment for breast cancer: randomised equivalence trial. BMJ2009;338:a3147. [DOI: 10.1136/bmj.a3147] ">Beaver 2009</a>; <a href="./references#CD012425-bbs2-0003" title="BeaverK , CampbellM , WilliamsonS , ProcterD , SheridanJ , HeathJ , et al. An exploratory randomized controlled trial comparing telephone and hospital follow‐up after treatment for colorectal cancer. Colorectal Disease2012;14(10):1201‐9. [DOI: 10.1111/j.1463‐1318.2012.02936.x] ">Beaver 2012</a>; <a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a>; <a href="./references#CD012425-bbs2-0006" title="D'CruzA , VaishR , GuptaS , AryaS , HawaldarRW , ShahS . Does addition of neck ultrasonography to physical examination, in follow‐up of patients with early stage, clinically node negative oral cancers, influence outcome? A randomized control trial (RCT). Journal of Clinical Oncology2016;34(15 Suppl 6):no pagination. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node‐negative oral cancer. New England Journal of Medicine2015;373(6):521‐9. NCT00193765 . Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. clinicaltrials.gov/ct2/show/NCT00193765 (first received 20 December 2016). ">D'Cruz 2016</a>; <a href="./references#CD012425-bbs2-0007" title="DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . Prospective randomized clinical trial for the evaluation of a stage adjusted reduced follow‐up schedule in cutaneous melanoma patients: results after one year. Annals of Surgical Oncology2016;23(1 Suppl 1):S30. DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . The MELFO‐study: prospective randomized clinical trial for the evaluation of a stage‐adjusted reduced follow‐up schedule in cutaneous melanoma patients ‐ results after 1 year. Annals of Surgical Oncology2016;23(9):2762‐71. [DOI: 10.1245/s10434‐016‐5263‐7] DeckersE , Hoekstra‐WeebersJ , DamudeS , FranckenA , Ter MeulenS , BastiaannetE , et al. The MELFO‐study: a multi‐center prospective randomized clinical trial on the effects of a reduced stage‐adjusted follow‐up schedule on cutaneous melanoma IB‐IIC patients: results after 3‐years. Annals of Surgical Oncology2018;25(1 Suppl 1):S40. NCT01018004 . Comparing follow‐up schedules in patients with newly diagnosed stage IB or stage II melanoma. clinicaltrials.gov/ct2/show/NCT01018004 (first received 20 December 2016). ">Damude 2016</a>; <a href="./references#CD012425-bbs2-0008" title="DavisKM , DawsonD , KellyS , RedS , PenekS , LynchJ , et al. Monitoring of health‐related quality of life and symptoms in prostate cancer survivors: a randomized trial. Journal of Supportive Oncology2013;11(4):174‐82. ">Davis 2013</a>; <a href="./references#CD012425-bbs2-0009" title="ACTRN12610000938000 . The ProCare Trial: a randomised controlled trial of follow up of men with prostate cancer in primary care. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336116 (first received 20 December 2016). EmeryJ , DooreyJ , JeffordM , KingM , PirottaM , HayneD , et al. Protocol for the ProCare Trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. BMJ Open2014;4(3):e004972. [DOI: 10.1136/bmjopen‐2014‐004972] EmeryJ , SchofieldP , JeffordM , KingM , PirottaM , HayneD , et al. The ProCare trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. Asia‐Pacific Journal of Clinical Oncology2014;10:157. EmeryJD , JeffordM , KingM , HayneD , MartinA , DooreyJ , et al. ProCare Trial: a phase II randomized controlled trial of shared care for follow‐up of men with prostate cancer. BJU International2016;119(3):381‐89. [DOI: 10.1111/bju.13593] KingM . Procare/PC4 study update. Asia‐Pacific Journal of Clinical Oncology2012;8:23. ">Emery 2016</a>; <a href="./references#CD012425-bbs2-0010" title="GambazziF , FreyLD , BruehlmeierM , JanthurWD , GraberSM , HeubergerJ , et al. Comparing two imaging methods for follow‐up of lung cancer treatment: a randomized pilot study. Annals of Thoracic Surgery2018;107(2):430‐5. [DOI: 10.1016/j.athoracsur.2018.08.015] ">Gambazzi 2018</a>; <a href="./references#CD012425-bbs2-0011" title="GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata). A randomized trial of intensive versus minimalist follow‐up of patients with resected Dukes B‐C colorectal cancer: the pilot phase. Tumori1998;84(Suppl):89. GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. NCT02409472 . Intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. clinicaltrials.gov/ct2/show/NCT02409472 (first received 20 December 2016). RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] ">GILDA 2016</a>; <a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a>; <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a>; <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>; <a href="./references#CD012425-bbs2-0015" title="BoekhoutAH , MaunsellE , PondGR , JulianJA , CoyleD , LevineMN , et al. A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial. Journal of Cancer Survivorship2015;9(4):683‐91. CoyleD , GrunfeldE , CoyleK , JulianJA , PondGR , FolkesA , et al. Cost‐effectiveness of a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):6082. CoyleD , GrunfeldE , CoyleK , PondG , JulianJA , LevineMN . Cost effectiveness of a survivorship care plan for breast cancer survivors. Journal of Oncology Practice2014;10(2):e86‐92. GrunfeldE , JulianJA , PondG , MaunsellE , CoyleD , FolkesA , et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. Journal of Clinical Oncology2011;29(36):4755‐62. GrunfeldE , LevineMN , JulianJA , PondGR , MaunsellE , FolkesA , et al. Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):9005. GrunfeldE , PondG , MaunsellE , LevineMN , JulianJA , CoyleD . Impact of survivorship care plans (SCP) on adherence to guidelines, health service measures, and patient‐reported outcomes (PRO): extended results of a multicenter randomized clinical trial (RCT) with breast cancer survivors. European Journal of Cancer2012;48:S147. ">Grunfeld 2011</a>; <a href="./references#CD012425-bbs2-0016" title="HershmanDL , GreenleeH , AwadD , KalinskyK , MaurerM , KranwinkelG , et al. Randomized controlled trial of a clinic‐based survivorship intervention following adjuvant therapy in breast cancer survivors. Breast Cancer Research and Treatment2013;138(3):795‐806. ">Hershman 2013</a>; <a href="./references#CD012425-bbs2-0018" title="JeppesenMM , JensenPT , GilsaD , DePont ChristensenR , JensenMM , MogensenO . The effect of patient‐initiated follow‐up on fear of recurrence and health care use: a randomized trial in early‐stage endometrial cancer. International Journal of Gynecological Cancer2017;27(Supplement 4):1107. JeppesenMM , JensenPT , HansenDG , ChristensenRD , MogensenO . Authors' reply re: Patient‐initiated follow‐up affects fear of recurrence and health care use: a randomised trial in early‐stage endometrial cancer. BJOG2018;125(13):1778‐9. JeppesenMM , JensenPT , HansenDG , ChristensenRD , MogensenO . Patient‐initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early‐stage endometrial cancer. BJOG2018;125(13):1705‐14. TegnerowiczJ . Re: Patient‐initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early‐stage endometrial cancer. BJOG2018;1125(13):1778. ">Jeppesen 2018</a>; <a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0027" title="MalmströmM , IvarssonB , KlefsgårdR , PerssonK , JakobssonU , JohanssonJ . The effect of a nurse led telephone supportive care programme on patients' quality of life, received information and health care contacts after oesophageal cancer surgery‐a six month RCT‐follow‐up study. International Journal of Nursing Studies2016;64:86‐95. [DOI: 10.1016/j.ijnurstu.2016.09.009] ">Malmstrom 2016</a>; <a href="./references#CD012425-bbs2-0028" title="MalyRC , GriggsJJ , LiuY , LiangLJ , GanzPA . A randomized controlled trial of survivorship care plans among low‐income breast cancer survivors. Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. MalyRC , LiangLJ , LiuY , GriggsJJ , GanzPA . Randomized controlled trial of survivorship care plans among low‐income, predominant Latina breast cancer survivors. Journal of Clinical Oncology2017;35(16):1814‐21. NCT01627366 . Study of survivorship care plans and outcomes in underserved breast cancer survivors. clinicaltrials.gov/ct2/show/NCT01627366 (first received 17 December 2018). ">Maly 2017</a>; <a href="./references#CD012425-bbs2-0030" title="MorrisonV , SpencerLH , LeesonS . Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a randomised feasibility trial. Psycho‐oncology2017;26(Suppl 2):3‐4. MorrisonV , SpencerLH , TottonN , PyeK , YeoST , ButterworthC , et al. Trial of optimal personalised care after treatment‐gynaecological cancer (TOPCAT‐G): a randomized feasibility trial. International Journal of Gynecological Cancer2018;28(2):401‐11. PyeK , TottonN , StuartN , WhitakerR , MorrisonV , EdwardsRT , et al. Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a study protocol for a randomised feasibility trial. Pilot and Feasibility Studies2016;2:67. [DOI 10.1186/s40814‐016‐0108‐5] ">Morrison 2018</a>; <a href="./references#CD012425-bbs2-0031" title="MurchieP , NicolsonMC , HannafordPC , RajaEA , LeeAJ , CampbellNC . Patient satisfaction with GP‐led melanoma follow‐up: a randomised controlled trial. British Journal of Cancer2010;102(10):1447‐55. ">Murchie 2010</a>; <a href="./references#CD012425-bbs2-0034" title="PicardiM , PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , et al. Advanced‐stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission‐‐a randomized trial of routine surveillance imaging procedures. Radiology2014;272(1):262‐74. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: Ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2015;100:7‐8. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2014;99:398‐9. ">Picardi 2014</a>; <a href="./references#CD012425-bbs2-0036" title="MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017;21(32):1‐86. MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00560365 (first received 20 December 2016). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology2011;29(15 Suppl 1):3521. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. [DOI: 10.1001/jama.2013.285718] PughSA , FullerA , PereraR , GeorgeS , MantD , PrimroseJ . The follow‐up after colorectal cancer surgery trial: randomised trial of follow‐up after colorectal cancer surgery and outcome following recurrence. Journal of the American College of Surgeons2014;219(4 Suppl 1):e46‐7. PughSA , MantD , ShinkinsB , MellorJ , PereraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology2016;27(Suppl 6):no pagination. ShinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PloS One2017;12(3):e0171810. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;105(6):658‐62. ">Primrose 2014</a>; <a href="./references#CD012425-bbs2-0037" title="BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial [Efectividad del seguimiento postoperatorio en los pacientes con cáncer colorrectal para la detección de recidivas curables. Análisis preliminar de un estudio multicéntrico, controlado y aleatorizado]. Gastroenterologia y Hepatologia2001;24(2):92, abstract no: 13. BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Preliminary analysis of a multicenter controlled trial to evaluate the effectiveness of postoperative follow‐up to detect curable recurrences in patients with colorectal cancer [Análisis preliminar de un estudio multicéntrico controlado y aleatorizado destinado a evaluar la efectividad del seguimiento postoperatorio en la detección de recidivas curables en los pacientes con cáncer colorrectal]. Gastroenterologia y Hepatologia2001;24(3):150. Rodriguez‐MorantaF , CastellsA , SaloJ , ArcusaA , BoadasJ , BessaV , et al. Efficacy of postoperative surveillance after radical surgery for colorectal cancer (CRC). Analysis of a prospective, multicenter, randomized controlled trial. Journal of Gastroenterology2005;128(4 Suppl 2):Abstract W967. Rodríguez‐MorantaF , SalóJ , AcrusaA , BoadasJ , BessaX , PiñolV , et al. Efficacy of postoperative surveillance in patients with colorectal cancer after radical surgery. A prospective, multicenter, randomized study. Gastroenterologia y Hepatologia2005;28(3):197‐8, abstract no: 126. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , Bessa , X , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD012425-bbs2-0038" title="DeRooijBH , EzendamNP , NicolaijeKA , LodderP , VosMC , PijnenborgJM , et al. Survivorship care plans have a negative impact on long‐term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. Quality of Life Research2018;27(6):1533‐44. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2‐year follow‐up ‐ The ROGY care trial. Gynecologic Oncology2017;145(2):319‐28. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Long‐term impact of survivorship care plans on ovarian cancer patient reported outcomes‐new results of the ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):64‐5. DeRooijBH , EzendamNP , NicolaijeKA , VosMC , PijnenborgJM , BollD , et al. The indirect effects of survivorship care plans on quality of life, anxiety and depression‐the ROGY care trial. Supportive Care in Cancer2017;25(2 Suppl 1):S53‐4. DeRooijBH , EzendamNP , VosMC , PijnenborgJM , BollD , KruitwagenRF , et al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. Cancer Epub 2018 Nov 30;125(5):788‐97. [DOI: 10.1002/cncr.31844] EzendamN , DeRooijB , NicolaijeK , VosC , PijnenborgJ , BollD , et al. Long‐term impact of cancer survivorship care plans on patient outcomes‐the randomized controlled ROGY care trial. International Journal of Gynecological Cancer2016;26:91. EzendamNP , VanBroekhovenM , Van DePoll‐FranseLV , DeRooijBH . The role of illness perceptions in smoking, alcohol consumption and weight changes among gynaecological cancer survivors. Quality of Life Research2016;25(1 Suppl 1):114. JeppesenMM , EzendamNP , PijnenborgJM , VosMC , BollD , KruitwagenRF , et al. The impact of the survivorship care plan on health care use: 2‐year follow‐up results of the ROGY care trial. Journal of Cancer Survivorship2018;12(1):18‐27. NicolaijeKA , EzendamNP , VosMC , PijnenborgJM , BollD , BossEA , et al. Impact of an automatically generated cancer survivorship care plan on patient‐reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial. Journal of Clinical Oncology2015;33(31):3550‐9. Van dePoll‐FranseL , NicolaijeK , EzendamN , VosC , BollD , PijnenborgJ , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY CARE): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Psycho‐oncology2013;22:341‐2. Van dePoll‐FranseLV , JeppesenMM , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. The survivorship care plan increases the use of primary care in anxious and irradiated endometrial cancer patients. Two year outcomes of the pragmatic cluster randomized ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):164. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosCM , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY Care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosMC , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. European Journal of Cancer2013;49:S720. Van dePoll‐FranseLV , NicolaijeKA , VosMC , PijnenborgJM , BollD , HussonO , et al. The impact of a cancer survivorship care plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials2011;12:256. ">ROGY 2015</a>; <a href="./references#CD012425-bbs2-0039" title="PalliD , RussoA , SaievaC , CiattoS , Rosselli Del TurcoM , DistanteV , et al. Intensive vs clinical follow‐up after treatment of primary breast cancer: 10‐year update of a randomized trial. National Research Council Project on Breast Cancer Follow‐up. JAMA1999;281(17):1586. Roselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . The efficacy of intensive follow‐up testing in breast cancer cases. Annals of Oncology1995;6(Suppl 2):37‐9. Rosselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . Intensive diagnostic follow‐up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow‐up. JAMA1994;271(20):1593‐7. ">Rosselli Del Turco 1994</a>; <a href="./references#CD012425-bbs2-0041" title="GoodmanA . How often to follow up? Study shows two CT scans as good as five for low‐risk testicular cancer. Oncology Times2007;29(12):54‐5. NCT00003420 . CT scans in treating patients with stage I testicular cancer after undergoing orchiectomy. clinicaltrials.gov/ct2/show/NCT00003420 (first received 20 December 2016). RustinGJ , MeadGM , StenningSP , VaseyPA , AassN , HuddartRA , et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197‐‐the National Cancer Research Institute Testis Cancer Clinical Studies Group. Journal of Clinical Oncology2007;25(11):1310‐5. ">Rustin 2007</a>; <a href="./references#CD012425-bbs2-0044" title="SheppardC , HigginsB , WiseM , YiangouC , DuboisD , KilburnS . Breast cancer follow up: a randomised controlled trial comparing point of need access versus routine 6‐monthly clinical review. European Journal of Oncology Nursing2009;13(1):2‐8. [DOI: 10.1016/j.ejon.2008.11.005] ">Sheppard 2009</a>; <a href="./references#CD012425-bbs2-0046" title="NCT00624260 . Impact of PET Scan on the curative strategy of colo‐rectal cancers : a randomized study. clinicaltrials.gov/ct2/show/NCT00624260 (first received 20 December 2016). SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an openlabel multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology2017;35(15 Suppl 1):no pagination. SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal2017;5(5 Suppl 1):A13. SobhaniI , IttiE , LucianiA , BaumgaertnerI , LayeseR , AndreT , et al. Colorectal cancer (CRC) monitoring by 6‐monthly 18FDG‐PET/CT: an open‐label multicentre randomised trial. Annals of Oncology2018;29(4):931‐7. ">Sobhani 2018</a>; <a href="./references#CD012425-bbs2-0047" title="Van DerMeulenI , MayA , RosW , OosteromM , HordijkGJ , KooleR , et al. Effects of a nurse‐led psychosocial intervention on depressive symptoms and health‐related quality of life in patients with head and neck cancer: a randomized controlled trial. Psycho‐oncology2013;22(Suppl 3):17. Van derMeulenIC , MayAM , RosWJ , OosteromM , HordijkGJ , KooleR , et al. One‐year effect of a nurse‐led psychosocial intervention on depressive symptoms in patients with head and neck cancer: a randomized controlled trial. Oncologist2013;18(3):336‐44. [DOI: 10.1634/theoncologist.2012‐0299] ">Van der Meulen 2013</a>; <a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a>; <a href="./references#CD012425-bbs2-0049" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>; <a href="./references#CD012425-bbs2-0051" title="NCT00198341 . Post‐surgical non‐small cell lung cancer (NSCLC) follow‐up. clinicaltrials.gov/ct2/show/NCT00198341 (first received 20 December 2016). WesteelV . Follow‐up of the patient after curative treatment. Lung Cancer2011;71:S10‐1. WesteelV . Surveillance and second primary malignancies in lung cancer survivors. Journal of Thoracic Oncology2018;13(10 Suppl):S277‐8. WesteelV , BarlesiF , DomasJ , GirardP , FoucherP , LafitteJJ , et al. Postoperative follow‐up of lung cancer: randomized trial comparing two follow‐up programs in completely resected non‐small cell lung cancer (IFCT‐0302). Journal of Clinical Oncology2012;30(15 Suppl 1):no pagination. WesteelV , BarlesiF , FoucherP , LafitteJ , DomasJ , GirardP , et al. Recurrences and 2nd primary cancers in the IFCT‐0302 trial assessing a CT‐scan‐based follow‐up after lung cancer surgery. Journal of Thoracic Oncology2017;12(11 Suppl 2):S1788‐9. WesteelV , BarlesiF , FoucherP , LafitteJ‐J , DomasJ , GirardP , et al. Results of the phase III IFCT‐0302 trial assessing minimal versus CT‐scan‐based follow‐up for completely resected non‐small cell lung cancer (NSCLC). Annals of Oncology2017;28(Suppl 5):v452. WesteelV , BarlesiF , FoucherP , LafitteJJ , DomasJ , GirardP , et al. Compliance with follow‐up programs after surgery for non‐small cell lung cancer in the phase III IFCT‐0302 trial. Journal of Thoracic Oncology2015;10(9 Suppl 2):S239. WesteelV , LebitasyMP , MercierM , LafitteJJ , DomasJ , GirardPl . IFCT‐0302 trial: randomised study comparing two follow‐up schedules in completely resected non‐small cell lung cancer [Protocole IFCT‐0302 : essai randomisé de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués]. Revue des Maladies Respiratoires2007;2(5):645‐52. ">Westeel 2012</a>; <a href="./references#CD012425-bbs2-0052" title="NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00225641 (first received 20 December 2016). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PahlmanL , et al. Intensity of follow up after surgery for colorectal cancer. Colorectal Disease2014;16:93. Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA2018;319(20):2095‐103. ">Wille‐Jorgensen 2018</a>; <a href="./references#CD012425-bbs2-0053" title='ACTRN12608000252314 . Cancer care after surgery – the CONNECT study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82819 (first received 20 December 2016). HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Connect: a pilot RCT to improve outcomes for people with colorectal cancer. Asia‐Pacific Journal of Clinical Oncology2009;5:A159. HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Randomized pilot evaluation of the supportive care intervention "CONNECT" for people following surgery for colorectal cancer. Diseases of the Colon and Rectum2011;54(5):622‐31. YoungJM , ButowPN , WalshJ , DurcinoskaI , DobbinsTA , RodwellL , et al. Multicenter randomized trial of centralized nurse‐led telephone‐based care coordination to improve outcomes after surgical resection for colorectal cancer: the CONNECT intervention. Journal of Clinical Oncology2013;31(28):3585‐91. [DOI: 10.1200/JCO.2012.48.1036] '>Young 2013</a>). We judged studies that reported using a telephone‐, computer‐ or web‐based method of allocation to be at low risk of bias even if they did not specifically report that the allocation was concealed from the personnel involved in assigning participants to the treatment arms. Fifteen studies did not provide sufficient information for us to clearly judge whether allocation was adequately concealed prior to assignment (<a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a>; <a href="./references#CD012425-bbs2-0017" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14:260. [DOI: 10.1186/1745‐6215‐14‐260] JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a nurse‐led supportive care package (survivor care) for survivors of colorectal cancer. Cancer Nursing2015;38(4 Suppl 1):S16‐7. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (Survivor‐Care, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2015;33(15 Suppl 1):9566. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , SchofieldP , ArandaS , YoungJ , ButowP . Randomised controlled trial (RCT) of a comprehensive post‐treatment support package (survivor‐care) for bowel cancer survivors. Psycho‐oncology2010;19:S193. ">Jefford 2016</a>; <a href="./references#CD012425-bbs2-0019" title="JuarezG , HurriaA , FerrellB . Effectiveness of an education intervention on quality of life in Latina breast cancer survivors. Psycho‐oncology2012;21:110. JuarezG , HurriaA , UmanG , FerrellB . Impact of a bilingual education intervention on the quality of life of Latina breast cancer survivors. Oncology Nursing Forum2013;40(1):E50‐60. [DOI: 10.1188/13.ONF.E50‐E60] ">Juarez 2013</a>; <a href="./references#CD012425-bbs2-0021" title="DentJ , ToppingA , FergusonC , StephensonJ , McCoyM , AllinsonV , et al. To follow up or not? A new model of supportive care for early breast cancer. Journal of Clinical Oncology2011;29(15 Suppl 1):no pagination. KirshbaumMN , DentJ , StephensonJ , ToppingAE , AllinsonV , McCoyM , et al. Open access follow‐up care for early breast cancer: a randomised controlled quality of life analysis. European Journal of Cancer Care2017;26(4):e12577. [DOI: 10.1111/ecc.12577] ">Kirshbaum 2017</a>; <a href="./references#CD012425-bbs2-0022" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomized study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Gastroenterology1999;34(5):509‐15. KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;149:159‐62. ">Kjeldsen 1997</a>; <a href="./references#CD012425-bbs2-0024" title="KokkoR , HakamaM , HolliK . Follow‐up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Research and Treatment2005;93(3):255‐60. KokkoR , HakamaM , HolliK . Role of chest X‐ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Research and Treatment2003;81(1):33‐9. ">Kokko 2003</a>; <a href="./references#CD012425-bbs2-0025" title="KvaleEA , Demark‐WahnefriedW , MenesesK , BaeS , HuangCH , AzueroCB , et al. Patient centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer Research2015;75(9 Suppl 1):no pagination. KvaleEA , HuangCS , MenesesKM , Demark‐WahnefriedW , BaeS , AzueroCB , et al. Patient‐centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer2016;122(20):3232‐42. ">Kvale 2016</a>; <a href="./references#CD012425-bbs2-0026" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1992</a>; <a href="./references#CD012425-bbs2-0029" title="MonteilJ , VergnenègreA , BertinF , DalmayF , GaillardS , BonnaudF , et al. Randomized follow‐up study of resected NSCLC patients: conventional versus 18F‐DG coincidence imaging. Anticancer Research2010;30(9):3811‐6. NCT00199615 . Follow‐up of patients with curative‐intent surgical resection for NSCLC. clinicaltrials.gov/ct2/show/NCT00199615 (first received 20 December 2016). ">Monteil 2010</a>; <a href="./references#CD012425-bbs2-0032" title="OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD012425-bbs2-0033" title="OltraA , SantaballaA , MontalarJ , MunárrizB , PastorM , MeseguerA , et al. Cost‐benefit evaluation of a follow‐up program in patients with advanced breast cancer. Randomized study. Revista de Oncología1999;1(Suppl 1):165. OltraA , SantaballaA , MunárrizB , PastorM , MontalarJ . Cost‐benefit analysis of a follow‐up program in patients with breast cancer: a randomized prospective study. Breast Journal2007;13(6):571‐4. ">Oltra 2007</a>; <a href="./references#CD012425-bbs2-0035" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA , et al. Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD012425-bbs2-0040" title="RuddyKJ , BakerEL , GuoH , GoldsteinMJ , WinerEP , ShulmanLN , et al. Randomized trial evaluating a coordinated survivorship care program for early stage breast cancer. Cancer Research2013;73(24 Suppl 1):OT2‐5‐02. RuddyKJ , GuoH , BakerE , GoldsteinM , MullaneyEE , ShulmanLN , et al. Coordinated follow‐up breast cancer survivorship care program study. Journal of Clinical Oncology2015;33(15 Suppl 1):e17727. RuddyKJ , GuoH , BakerEL , GoldsteinMJ , MullaneyEE , ShulmanLN , et al. Randomized phase 2 trial of a coordinated breast cancer follow‐up care program. Cancer2016;122:3546‐54. ">Ruddy 2016</a>; <a href="./references#CD012425-bbs2-0043" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk‐adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD012425-bbs2-0045" title="SobhaniI , TiretE , LebtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>). We judged one study to be at high risk of selection bias (<a href="./references#CD012425-bbs2-0042" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gastroenterology1998;114(1):7‐14. SchoemakerD , BlackR , GilesL , ToouliJ , AlcornJ . Addition of intensive follow‐up procedures to standard follow‐up did not improve survival in patients with colorectal cancer. Evidence‐Based Medicine1998;3(5):140. ">Schoemaker 1998</a>), as participants were reported to be allocated by the assigner, "choosing the next card from a box of cards indicating the type of follow‐up". </p> </section> </section> <section id="CD012425-sec-0082"> <h4 class="title">Blinding</h4> <p>Given the nature of this type of intervention, it is usually not possible to blind participants and personnel to intervention arms. Following recommendations from the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012425-bbs2-0156" title="HigginsJP , AltmanDG , Sterne JA(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>), we assessed the domains of performance bias and detection bias by outcome group: objective outcomes (survival, recurrence and costs) and patient‐reported outcomes (health‐related quality of life, depression and anxiety). </p> <section id="CD012425-sec-0083"> <h5 class="title">Blinding of participants and personnel (performance bias)</h5> <p>Performance bias refers to systematic differences between groups in the care that is provided or received and requested (<a href="./references#CD012425-bbs2-0156" title="HigginsJP , AltmanDG , Sterne JA(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). We judged all studies that reported on the objective outcomes of survival and time to detection of recurrence to be at unclear risk of bias, as blinding was either not possible or not done. All the studies reporting on patient‐reported outcomes we judged to be at unclear risk of bias except three, which we judged to be at low risk of bias, as these three studies reported that participants were blinded (<a href="./references#CD012425-bbs2-0016" title="HershmanDL , GreenleeH , AwadD , KalinskyK , MaurerM , KranwinkelG , et al. Randomized controlled trial of a clinic‐based survivorship intervention following adjuvant therapy in breast cancer survivors. Breast Cancer Research and Treatment2013;138(3):795‐806. ">Hershman 2013</a>; <a href="./references#CD012425-bbs2-0038" title="DeRooijBH , EzendamNP , NicolaijeKA , LodderP , VosMC , PijnenborgJM , et al. Survivorship care plans have a negative impact on long‐term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. Quality of Life Research2018;27(6):1533‐44. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2‐year follow‐up ‐ The ROGY care trial. Gynecologic Oncology2017;145(2):319‐28. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Long‐term impact of survivorship care plans on ovarian cancer patient reported outcomes‐new results of the ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):64‐5. DeRooijBH , EzendamNP , NicolaijeKA , VosMC , PijnenborgJM , BollD , et al. The indirect effects of survivorship care plans on quality of life, anxiety and depression‐the ROGY care trial. Supportive Care in Cancer2017;25(2 Suppl 1):S53‐4. DeRooijBH , EzendamNP , VosMC , PijnenborgJM , BollD , KruitwagenRF , et al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. Cancer Epub 2018 Nov 30;125(5):788‐97. [DOI: 10.1002/cncr.31844] EzendamN , DeRooijB , NicolaijeK , VosC , PijnenborgJ , BollD , et al. Long‐term impact of cancer survivorship care plans on patient outcomes‐the randomized controlled ROGY care trial. International Journal of Gynecological Cancer2016;26:91. EzendamNP , VanBroekhovenM , Van DePoll‐FranseLV , DeRooijBH . The role of illness perceptions in smoking, alcohol consumption and weight changes among gynaecological cancer survivors. Quality of Life Research2016;25(1 Suppl 1):114. JeppesenMM , EzendamNP , PijnenborgJM , VosMC , BollD , KruitwagenRF , et al. The impact of the survivorship care plan on health care use: 2‐year follow‐up results of the ROGY care trial. Journal of Cancer Survivorship2018;12(1):18‐27. NicolaijeKA , EzendamNP , VosMC , PijnenborgJM , BollD , BossEA , et al. Impact of an automatically generated cancer survivorship care plan on patient‐reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial. Journal of Clinical Oncology2015;33(31):3550‐9. Van dePoll‐FranseL , NicolaijeK , EzendamN , VosC , BollD , PijnenborgJ , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY CARE): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Psycho‐oncology2013;22:341‐2. Van dePoll‐FranseLV , JeppesenMM , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. The survivorship care plan increases the use of primary care in anxious and irradiated endometrial cancer patients. Two year outcomes of the pragmatic cluster randomized ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):164. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosCM , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY Care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosMC , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. European Journal of Cancer2013;49:S720. Van dePoll‐FranseLV , NicolaijeKA , VosMC , PijnenborgJM , BollD , HussonO , et al. The impact of a cancer survivorship care plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials2011;12:256. ">ROGY 2015</a>; <a href="./references#CD012425-bbs2-0047" title="Van DerMeulenI , MayA , RosW , OosteromM , HordijkGJ , KooleR , et al. Effects of a nurse‐led psychosocial intervention on depressive symptoms and health‐related quality of life in patients with head and neck cancer: a randomized controlled trial. Psycho‐oncology2013;22(Suppl 3):17. Van derMeulenIC , MayAM , RosWJ , OosteromM , HordijkGJ , KooleR , et al. One‐year effect of a nurse‐led psychosocial intervention on depressive symptoms in patients with head and neck cancer: a randomized controlled trial. Oncologist2013;18(3):336‐44. [DOI: 10.1634/theoncologist.2012‐0299] ">Van der Meulen 2013</a>). </p> </section> <section id="CD012425-sec-0084"> <h5 class="title">Blinding of outcome assessment (detection bias)</h5> <p>Detection bias refers to systematic differences between groups in how outcomes are determined (<a href="./references#CD012425-bbs2-0156" title="HigginsJP , AltmanDG , Sterne JA(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). Here, we assessed the risk separately for the objective outcomes of survival and time to detection of recurrence. Since there can be no doubt whether a person is dead or alive, we judged all the studies reporting on overall survival to be at low risk of bias with regards to this outcome (<a href="./references#CD012425-bbs2-0011" title="GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata). A randomized trial of intensive versus minimalist follow‐up of patients with resected Dukes B‐C colorectal cancer: the pilot phase. Tumori1998;84(Suppl):89. GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. NCT02409472 . Intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. clinicaltrials.gov/ct2/show/NCT02409472 (first received 20 December 2016). RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] ">GILDA 2016</a>; <a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a>; <a href="./references#CD012425-bbs2-0022" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomized study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Gastroenterology1999;34(5):509‐15. KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;149:159‐62. ">Kjeldsen 1997</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0024" title="KokkoR , HakamaM , HolliK . Follow‐up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Research and Treatment2005;93(3):255‐60. KokkoR , HakamaM , HolliK . Role of chest X‐ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Research and Treatment2003;81(1):33‐9. ">Kokko 2003</a>; <a href="./references#CD012425-bbs2-0026" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1992</a>; <a href="./references#CD012425-bbs2-0029" title="MonteilJ , VergnenègreA , BertinF , DalmayF , GaillardS , BonnaudF , et al. Randomized follow‐up study of resected NSCLC patients: conventional versus 18F‐DG coincidence imaging. Anticancer Research2010;30(9):3811‐6. NCT00199615 . Follow‐up of patients with curative‐intent surgical resection for NSCLC. clinicaltrials.gov/ct2/show/NCT00199615 (first received 20 December 2016). ">Monteil 2010</a>; <a href="./references#CD012425-bbs2-0032" title="OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD012425-bbs2-0035" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA , et al. Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD012425-bbs2-0036" title="MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017;21(32):1‐86. MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00560365 (first received 20 December 2016). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology2011;29(15 Suppl 1):3521. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. [DOI: 10.1001/jama.2013.285718] PughSA , FullerA , PereraR , GeorgeS , MantD , PrimroseJ . The follow‐up after colorectal cancer surgery trial: randomised trial of follow‐up after colorectal cancer surgery and outcome following recurrence. Journal of the American College of Surgeons2014;219(4 Suppl 1):e46‐7. PughSA , MantD , ShinkinsB , MellorJ , PereraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology2016;27(Suppl 6):no pagination. ShinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PloS One2017;12(3):e0171810. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;105(6):658‐62. ">Primrose 2014</a>; <a href="./references#CD012425-bbs2-0037" title="BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial [Efectividad del seguimiento postoperatorio en los pacientes con cáncer colorrectal para la detección de recidivas curables. Análisis preliminar de un estudio multicéntrico, controlado y aleatorizado]. Gastroenterologia y Hepatologia2001;24(2):92, abstract no: 13. BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Preliminary analysis of a multicenter controlled trial to evaluate the effectiveness of postoperative follow‐up to detect curable recurrences in patients with colorectal cancer [Análisis preliminar de un estudio multicéntrico controlado y aleatorizado destinado a evaluar la efectividad del seguimiento postoperatorio en la detección de recidivas curables en los pacientes con cáncer colorrectal]. Gastroenterologia y Hepatologia2001;24(3):150. Rodriguez‐MorantaF , CastellsA , SaloJ , ArcusaA , BoadasJ , BessaV , et al. Efficacy of postoperative surveillance after radical surgery for colorectal cancer (CRC). Analysis of a prospective, multicenter, randomized controlled trial. Journal of Gastroenterology2005;128(4 Suppl 2):Abstract W967. Rodríguez‐MorantaF , SalóJ , AcrusaA , BoadasJ , BessaX , PiñolV , et al. Efficacy of postoperative surveillance in patients with colorectal cancer after radical surgery. A prospective, multicenter, randomized study. Gastroenterologia y Hepatologia2005;28(3):197‐8, abstract no: 126. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , Bessa , X , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD012425-bbs2-0039" title="PalliD , RussoA , SaievaC , CiattoS , Rosselli Del TurcoM , DistanteV , et al. Intensive vs clinical follow‐up after treatment of primary breast cancer: 10‐year update of a randomized trial. National Research Council Project on Breast Cancer Follow‐up. JAMA1999;281(17):1586. Roselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . The efficacy of intensive follow‐up testing in breast cancer cases. Annals of Oncology1995;6(Suppl 2):37‐9. Rosselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . Intensive diagnostic follow‐up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow‐up. JAMA1994;271(20):1593‐7. ">Rosselli Del Turco 1994</a>; <a href="./references#CD012425-bbs2-0042" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gastroenterology1998;114(1):7‐14. SchoemakerD , BlackR , GilesL , ToouliJ , AlcornJ . Addition of intensive follow‐up procedures to standard follow‐up did not improve survival in patients with colorectal cancer. Evidence‐Based Medicine1998;3(5):140. ">Schoemaker 1998</a>; <a href="./references#CD012425-bbs2-0043" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk‐adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD012425-bbs2-0046" title="NCT00624260 . Impact of PET Scan on the curative strategy of colo‐rectal cancers : a randomized study. clinicaltrials.gov/ct2/show/NCT00624260 (first received 20 December 2016). SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an openlabel multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology2017;35(15 Suppl 1):no pagination. SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal2017;5(5 Suppl 1):A13. SobhaniI , IttiE , LucianiA , BaumgaertnerI , LayeseR , AndreT , et al. Colorectal cancer (CRC) monitoring by 6‐monthly 18FDG‐PET/CT: an open‐label multicentre randomised trial. Annals of Oncology2018;29(4):931‐7. ">Sobhani 2018</a>; <a href="./references#CD012425-bbs2-0049" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>; <a href="./references#CD012425-bbs2-0051" title="NCT00198341 . Post‐surgical non‐small cell lung cancer (NSCLC) follow‐up. clinicaltrials.gov/ct2/show/NCT00198341 (first received 20 December 2016). WesteelV . Follow‐up of the patient after curative treatment. Lung Cancer2011;71:S10‐1. WesteelV . Surveillance and second primary malignancies in lung cancer survivors. Journal of Thoracic Oncology2018;13(10 Suppl):S277‐8. WesteelV , BarlesiF , DomasJ , GirardP , FoucherP , LafitteJJ , et al. Postoperative follow‐up of lung cancer: randomized trial comparing two follow‐up programs in completely resected non‐small cell lung cancer (IFCT‐0302). Journal of Clinical Oncology2012;30(15 Suppl 1):no pagination. WesteelV , BarlesiF , FoucherP , LafitteJ , DomasJ , GirardP , et al. Recurrences and 2nd primary cancers in the IFCT‐0302 trial assessing a CT‐scan‐based follow‐up after lung cancer surgery. Journal of Thoracic Oncology2017;12(11 Suppl 2):S1788‐9. WesteelV , BarlesiF , FoucherP , LafitteJ‐J , DomasJ , GirardP , et al. Results of the phase III IFCT‐0302 trial assessing minimal versus CT‐scan‐based follow‐up for completely resected non‐small cell lung cancer (NSCLC). Annals of Oncology2017;28(Suppl 5):v452. WesteelV , BarlesiF , FoucherP , LafitteJJ , DomasJ , GirardP , et al. Compliance with follow‐up programs after surgery for non‐small cell lung cancer in the phase III IFCT‐0302 trial. Journal of Thoracic Oncology2015;10(9 Suppl 2):S239. WesteelV , LebitasyMP , MercierM , LafitteJJ , DomasJ , GirardPl . IFCT‐0302 trial: randomised study comparing two follow‐up schedules in completely resected non‐small cell lung cancer [Protocole IFCT‐0302 : essai randomisé de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués]. Revue des Maladies Respiratoires2007;2(5):645‐52. ">Westeel 2012</a>; <a href="./references#CD012425-bbs2-0052" title="NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00225641 (first received 20 December 2016). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PahlmanL , et al. Intensity of follow up after surgery for colorectal cancer. Colorectal Disease2014;16:93. Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA2018;319(20):2095‐103. ">Wille‐Jorgensen 2018</a>). With regards to time to detection of recurrence, we judged the risk to be unclear, as we cannot rule out the possibility that the lack of blinding may influence judgement regarding clinical tests and assessments, which might influence the outcome. However, one study (<a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>), reported that, "the outcome was assessed by a committee that was blinded to treatment allocation" so we judged it as low risk of detection bias for this outcome. With regards to patient‐reported outcomes, all of which were collected through self‐reported questionnaires, we judged all the studies, except the three mentioned above (<a href="./references#CD012425-bbs2-0016" title="HershmanDL , GreenleeH , AwadD , KalinskyK , MaurerM , KranwinkelG , et al. Randomized controlled trial of a clinic‐based survivorship intervention following adjuvant therapy in breast cancer survivors. Breast Cancer Research and Treatment2013;138(3):795‐806. ">Hershman 2013</a>; <a href="./references#CD012425-bbs2-0038" title="DeRooijBH , EzendamNP , NicolaijeKA , LodderP , VosMC , PijnenborgJM , et al. Survivorship care plans have a negative impact on long‐term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. Quality of Life Research2018;27(6):1533‐44. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2‐year follow‐up ‐ The ROGY care trial. Gynecologic Oncology2017;145(2):319‐28. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Long‐term impact of survivorship care plans on ovarian cancer patient reported outcomes‐new results of the ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):64‐5. DeRooijBH , EzendamNP , NicolaijeKA , VosMC , PijnenborgJM , BollD , et al. The indirect effects of survivorship care plans on quality of life, anxiety and depression‐the ROGY care trial. Supportive Care in Cancer2017;25(2 Suppl 1):S53‐4. DeRooijBH , EzendamNP , VosMC , PijnenborgJM , BollD , KruitwagenRF , et al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. Cancer Epub 2018 Nov 30;125(5):788‐97. [DOI: 10.1002/cncr.31844] EzendamN , DeRooijB , NicolaijeK , VosC , PijnenborgJ , BollD , et al. Long‐term impact of cancer survivorship care plans on patient outcomes‐the randomized controlled ROGY care trial. International Journal of Gynecological Cancer2016;26:91. EzendamNP , VanBroekhovenM , Van DePoll‐FranseLV , DeRooijBH . The role of illness perceptions in smoking, alcohol consumption and weight changes among gynaecological cancer survivors. Quality of Life Research2016;25(1 Suppl 1):114. JeppesenMM , EzendamNP , PijnenborgJM , VosMC , BollD , KruitwagenRF , et al. The impact of the survivorship care plan on health care use: 2‐year follow‐up results of the ROGY care trial. Journal of Cancer Survivorship2018;12(1):18‐27. NicolaijeKA , EzendamNP , VosMC , PijnenborgJM , BollD , BossEA , et al. Impact of an automatically generated cancer survivorship care plan on patient‐reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial. Journal of Clinical Oncology2015;33(31):3550‐9. Van dePoll‐FranseL , NicolaijeK , EzendamN , VosC , BollD , PijnenborgJ , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY CARE): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Psycho‐oncology2013;22:341‐2. Van dePoll‐FranseLV , JeppesenMM , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. The survivorship care plan increases the use of primary care in anxious and irradiated endometrial cancer patients. Two year outcomes of the pragmatic cluster randomized ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):164. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosCM , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY Care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosMC , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. European Journal of Cancer2013;49:S720. Van dePoll‐FranseLV , NicolaijeKA , VosMC , PijnenborgJM , BollD , HussonO , et al. The impact of a cancer survivorship care plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials2011;12:256. ">ROGY 2015</a>; <a href="./references#CD012425-bbs2-0047" title="Van DerMeulenI , MayA , RosW , OosteromM , HordijkGJ , KooleR , et al. Effects of a nurse‐led psychosocial intervention on depressive symptoms and health‐related quality of life in patients with head and neck cancer: a randomized controlled trial. Psycho‐oncology2013;22(Suppl 3):17. Van derMeulenIC , MayAM , RosWJ , OosteromM , HordijkGJ , KooleR , et al. One‐year effect of a nurse‐led psychosocial intervention on depressive symptoms in patients with head and neck cancer: a randomized controlled trial. Oncologist2013;18(3):336‐44. [DOI: 10.1634/theoncologist.2012‐0299] ">Van der Meulen 2013</a>), to be at unclear risk because participants were self‐assessors and were not blinded. </p> </section> </section> <section id="CD012425-sec-0085"> <h4 class="title">Incomplete outcome data</h4> <p>Attrition bias refers to systematic differences between groups in withdrawals from a study (<a href="./references#CD012425-bbs2-0156" title="HigginsJP , AltmanDG , Sterne JA(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). Following recommendations from the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012425-bbs2-0156" title="HigginsJP , AltmanDG , Sterne JA(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>), we assessed the domain of attrition bias by outcome group as the same study may have low risk of bias for objective outcomes (where information on death or recurrence is available from hospital records) but a high risk of bias for patient‐reported outcomes (due to unreturned questionnaires). </p> <p>Studies reporting on objective outcomes where missing outcome data were balanced and due to similar reasons in both groups, we judged to be at low risk of bias (<a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad 2013</a>; <a href="./references#CD012425-bbs2-0003" title="BeaverK , CampbellM , WilliamsonS , ProcterD , SheridanJ , HeathJ , et al. An exploratory randomized controlled trial comparing telephone and hospital follow‐up after treatment for colorectal cancer. Colorectal Disease2012;14(10):1201‐9. [DOI: 10.1111/j.1463‐1318.2012.02936.x] ">Beaver 2012</a>; <a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a>; <a href="./references#CD012425-bbs2-0006" title="D'CruzA , VaishR , GuptaS , AryaS , HawaldarRW , ShahS . Does addition of neck ultrasonography to physical examination, in follow‐up of patients with early stage, clinically node negative oral cancers, influence outcome? A randomized control trial (RCT). Journal of Clinical Oncology2016;34(15 Suppl 6):no pagination. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node‐negative oral cancer. New England Journal of Medicine2015;373(6):521‐9. NCT00193765 . Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. clinicaltrials.gov/ct2/show/NCT00193765 (first received 20 December 2016). ">D'Cruz 2016</a>; <a href="./references#CD012425-bbs2-0007" title="DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . Prospective randomized clinical trial for the evaluation of a stage adjusted reduced follow‐up schedule in cutaneous melanoma patients: results after one year. Annals of Surgical Oncology2016;23(1 Suppl 1):S30. DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . The MELFO‐study: prospective randomized clinical trial for the evaluation of a stage‐adjusted reduced follow‐up schedule in cutaneous melanoma patients ‐ results after 1 year. Annals of Surgical Oncology2016;23(9):2762‐71. [DOI: 10.1245/s10434‐016‐5263‐7] DeckersE , Hoekstra‐WeebersJ , DamudeS , FranckenA , Ter MeulenS , BastiaannetE , et al. The MELFO‐study: a multi‐center prospective randomized clinical trial on the effects of a reduced stage‐adjusted follow‐up schedule on cutaneous melanoma IB‐IIC patients: results after 3‐years. Annals of Surgical Oncology2018;25(1 Suppl 1):S40. NCT01018004 . Comparing follow‐up schedules in patients with newly diagnosed stage IB or stage II melanoma. clinicaltrials.gov/ct2/show/NCT01018004 (first received 20 December 2016). ">Damude 2016</a>; <a href="./references#CD012425-bbs2-0009" title="ACTRN12610000938000 . The ProCare Trial: a randomised controlled trial of follow up of men with prostate cancer in primary care. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336116 (first received 20 December 2016). EmeryJ , DooreyJ , JeffordM , KingM , PirottaM , HayneD , et al. Protocol for the ProCare Trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. BMJ Open2014;4(3):e004972. [DOI: 10.1136/bmjopen‐2014‐004972] EmeryJ , SchofieldP , JeffordM , KingM , PirottaM , HayneD , et al. The ProCare trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. Asia‐Pacific Journal of Clinical Oncology2014;10:157. EmeryJD , JeffordM , KingM , HayneD , MartinA , DooreyJ , et al. ProCare Trial: a phase II randomized controlled trial of shared care for follow‐up of men with prostate cancer. BJU International2016;119(3):381‐89. [DOI: 10.1111/bju.13593] KingM . Procare/PC4 study update. Asia‐Pacific Journal of Clinical Oncology2012;8:23. ">Emery 2016</a>; <a href="./references#CD012425-bbs2-0010" title="GambazziF , FreyLD , BruehlmeierM , JanthurWD , GraberSM , HeubergerJ , et al. Comparing two imaging methods for follow‐up of lung cancer treatment: a randomized pilot study. Annals of Thoracic Surgery2018;107(2):430‐5. [DOI: 10.1016/j.athoracsur.2018.08.015] ">Gambazzi 2018</a>; <a href="./references#CD012425-bbs2-0011" title="GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata). A randomized trial of intensive versus minimalist follow‐up of patients with resected Dukes B‐C colorectal cancer: the pilot phase. Tumori1998;84(Suppl):89. GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. NCT02409472 . Intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. clinicaltrials.gov/ct2/show/NCT02409472 (first received 20 December 2016). RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] ">GILDA 2016</a>; <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a>; <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>; <a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a>; <a href="./references#CD012425-bbs2-0022" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomized study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Gastroenterology1999;34(5):509‐15. KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;149:159‐62. ">Kjeldsen 1997</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0024" title="KokkoR , HakamaM , HolliK . Follow‐up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Research and Treatment2005;93(3):255‐60. KokkoR , HakamaM , HolliK . Role of chest X‐ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Research and Treatment2003;81(1):33‐9. ">Kokko 2003</a>; <a href="./references#CD012425-bbs2-0026" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1992</a>; <a href="./references#CD012425-bbs2-0031" title="MurchieP , NicolsonMC , HannafordPC , RajaEA , LeeAJ , CampbellNC . Patient satisfaction with GP‐led melanoma follow‐up: a randomised controlled trial. British Journal of Cancer2010;102(10):1447‐55. ">Murchie 2010</a>; <a href="./references#CD012425-bbs2-0032" title="OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD012425-bbs2-0033" title="OltraA , SantaballaA , MontalarJ , MunárrizB , PastorM , MeseguerA , et al. Cost‐benefit evaluation of a follow‐up program in patients with advanced breast cancer. Randomized study. Revista de Oncología1999;1(Suppl 1):165. OltraA , SantaballaA , MunárrizB , PastorM , MontalarJ . Cost‐benefit analysis of a follow‐up program in patients with breast cancer: a randomized prospective study. Breast Journal2007;13(6):571‐4. ">Oltra 2007</a>; <a href="./references#CD012425-bbs2-0034" title="PicardiM , PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , et al. Advanced‐stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission‐‐a randomized trial of routine surveillance imaging procedures. Radiology2014;272(1):262‐74. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: Ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2015;100:7‐8. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2014;99:398‐9. ">Picardi 2014</a>; <a href="./references#CD012425-bbs2-0035" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA , et al. Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD012425-bbs2-0036" title="MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017;21(32):1‐86. MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00560365 (first received 20 December 2016). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology2011;29(15 Suppl 1):3521. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. [DOI: 10.1001/jama.2013.285718] PughSA , FullerA , PereraR , GeorgeS , MantD , PrimroseJ . The follow‐up after colorectal cancer surgery trial: randomised trial of follow‐up after colorectal cancer surgery and outcome following recurrence. Journal of the American College of Surgeons2014;219(4 Suppl 1):e46‐7. PughSA , MantD , ShinkinsB , MellorJ , PereraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology2016;27(Suppl 6):no pagination. ShinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PloS One2017;12(3):e0171810. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;105(6):658‐62. ">Primrose 2014</a>; <a href="./references#CD012425-bbs2-0037" title="BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial [Efectividad del seguimiento postoperatorio en los pacientes con cáncer colorrectal para la detección de recidivas curables. Análisis preliminar de un estudio multicéntrico, controlado y aleatorizado]. Gastroenterologia y Hepatologia2001;24(2):92, abstract no: 13. BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Preliminary analysis of a multicenter controlled trial to evaluate the effectiveness of postoperative follow‐up to detect curable recurrences in patients with colorectal cancer [Análisis preliminar de un estudio multicéntrico controlado y aleatorizado destinado a evaluar la efectividad del seguimiento postoperatorio en la detección de recidivas curables en los pacientes con cáncer colorrectal]. Gastroenterologia y Hepatologia2001;24(3):150. Rodriguez‐MorantaF , CastellsA , SaloJ , ArcusaA , BoadasJ , BessaV , et al. Efficacy of postoperative surveillance after radical surgery for colorectal cancer (CRC). Analysis of a prospective, multicenter, randomized controlled trial. Journal of Gastroenterology2005;128(4 Suppl 2):Abstract W967. Rodríguez‐MorantaF , SalóJ , AcrusaA , BoadasJ , BessaX , PiñolV , et al. Efficacy of postoperative surveillance in patients with colorectal cancer after radical surgery. A prospective, multicenter, randomized study. Gastroenterologia y Hepatologia2005;28(3):197‐8, abstract no: 126. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , Bessa , X , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD012425-bbs2-0040" title="RuddyKJ , BakerEL , GuoH , GoldsteinMJ , WinerEP , ShulmanLN , et al. Randomized trial evaluating a coordinated survivorship care program for early stage breast cancer. Cancer Research2013;73(24 Suppl 1):OT2‐5‐02. RuddyKJ , GuoH , BakerE , GoldsteinM , MullaneyEE , ShulmanLN , et al. Coordinated follow‐up breast cancer survivorship care program study. Journal of Clinical Oncology2015;33(15 Suppl 1):e17727. RuddyKJ , GuoH , BakerEL , GoldsteinMJ , MullaneyEE , ShulmanLN , et al. Randomized phase 2 trial of a coordinated breast cancer follow‐up care program. Cancer2016;122:3546‐54. ">Ruddy 2016</a>; <a href="./references#CD012425-bbs2-0041" title="GoodmanA . How often to follow up? Study shows two CT scans as good as five for low‐risk testicular cancer. Oncology Times2007;29(12):54‐5. NCT00003420 . CT scans in treating patients with stage I testicular cancer after undergoing orchiectomy. clinicaltrials.gov/ct2/show/NCT00003420 (first received 20 December 2016). RustinGJ , MeadGM , StenningSP , VaseyPA , AassN , HuddartRA , et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197‐‐the National Cancer Research Institute Testis Cancer Clinical Studies Group. Journal of Clinical Oncology2007;25(11):1310‐5. ">Rustin 2007</a>; <a href="./references#CD012425-bbs2-0042" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gastroenterology1998;114(1):7‐14. SchoemakerD , BlackR , GilesL , ToouliJ , AlcornJ . Addition of intensive follow‐up procedures to standard follow‐up did not improve survival in patients with colorectal cancer. Evidence‐Based Medicine1998;3(5):140. ">Schoemaker 1998</a>; <a href="./references#CD012425-bbs2-0045" title="SobhaniI , TiretE , LebtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>; <a href="./references#CD012425-bbs2-0046" title="NCT00624260 . Impact of PET Scan on the curative strategy of colo‐rectal cancers : a randomized study. clinicaltrials.gov/ct2/show/NCT00624260 (first received 20 December 2016). SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an openlabel multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology2017;35(15 Suppl 1):no pagination. SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal2017;5(5 Suppl 1):A13. SobhaniI , IttiE , LucianiA , BaumgaertnerI , LayeseR , AndreT , et al. Colorectal cancer (CRC) monitoring by 6‐monthly 18FDG‐PET/CT: an open‐label multicentre randomised trial. Annals of Oncology2018;29(4):931‐7. ">Sobhani 2018</a>; <a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a>; <a href="./references#CD012425-bbs2-0049" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>; <a href="./references#CD012425-bbs2-0051" title="NCT00198341 . Post‐surgical non‐small cell lung cancer (NSCLC) follow‐up. clinicaltrials.gov/ct2/show/NCT00198341 (first received 20 December 2016). WesteelV . Follow‐up of the patient after curative treatment. Lung Cancer2011;71:S10‐1. WesteelV . Surveillance and second primary malignancies in lung cancer survivors. Journal of Thoracic Oncology2018;13(10 Suppl):S277‐8. WesteelV , BarlesiF , DomasJ , GirardP , FoucherP , LafitteJJ , et al. Postoperative follow‐up of lung cancer: randomized trial comparing two follow‐up programs in completely resected non‐small cell lung cancer (IFCT‐0302). Journal of Clinical Oncology2012;30(15 Suppl 1):no pagination. WesteelV , BarlesiF , FoucherP , LafitteJ , DomasJ , GirardP , et al. Recurrences and 2nd primary cancers in the IFCT‐0302 trial assessing a CT‐scan‐based follow‐up after lung cancer surgery. Journal of Thoracic Oncology2017;12(11 Suppl 2):S1788‐9. WesteelV , BarlesiF , FoucherP , LafitteJ‐J , DomasJ , GirardP , et al. Results of the phase III IFCT‐0302 trial assessing minimal versus CT‐scan‐based follow‐up for completely resected non‐small cell lung cancer (NSCLC). Annals of Oncology2017;28(Suppl 5):v452. WesteelV , BarlesiF , FoucherP , LafitteJJ , DomasJ , GirardP , et al. Compliance with follow‐up programs after surgery for non‐small cell lung cancer in the phase III IFCT‐0302 trial. Journal of Thoracic Oncology2015;10(9 Suppl 2):S239. WesteelV , LebitasyMP , MercierM , LafitteJJ , DomasJ , GirardPl . IFCT‐0302 trial: randomised study comparing two follow‐up schedules in completely resected non‐small cell lung cancer [Protocole IFCT‐0302 : essai randomisé de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués]. Revue des Maladies Respiratoires2007;2(5):645‐52. ">Westeel 2012</a>; <a href="./references#CD012425-bbs2-0052" title="NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00225641 (first received 20 December 2016). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PahlmanL , et al. Intensity of follow up after surgery for colorectal cancer. Colorectal Disease2014;16:93. Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA2018;319(20):2095‐103. ">Wille‐Jorgensen 2018</a>). Five studies did not report reasons for dropout and we judged them to be at unclear risk of bias (<a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a>; <a href="./references#CD012425-bbs2-0029" title="MonteilJ , VergnenègreA , BertinF , DalmayF , GaillardS , BonnaudF , et al. Randomized follow‐up study of resected NSCLC patients: conventional versus 18F‐DG coincidence imaging. Anticancer Research2010;30(9):3811‐6. NCT00199615 . Follow‐up of patients with curative‐intent surgical resection for NSCLC. clinicaltrials.gov/ct2/show/NCT00199615 (first received 20 December 2016). ">Monteil 2010</a>; <a href="./references#CD012425-bbs2-0039" title="PalliD , RussoA , SaievaC , CiattoS , Rosselli Del TurcoM , DistanteV , et al. Intensive vs clinical follow‐up after treatment of primary breast cancer: 10‐year update of a randomized trial. National Research Council Project on Breast Cancer Follow‐up. JAMA1999;281(17):1586. Roselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . The efficacy of intensive follow‐up testing in breast cancer cases. Annals of Oncology1995;6(Suppl 2):37‐9. Rosselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . Intensive diagnostic follow‐up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow‐up. JAMA1994;271(20):1593‐7. ">Rosselli Del Turco 1994</a>; <a href="./references#CD012425-bbs2-0043" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk‐adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD012425-bbs2-0044" title="SheppardC , HigginsB , WiseM , YiangouC , DuboisD , KilburnS . Breast cancer follow up: a randomised controlled trial comparing point of need access versus routine 6‐monthly clinical review. European Journal of Oncology Nursing2009;13(1):2‐8. [DOI: 10.1016/j.ejon.2008.11.005] ">Sheppard 2009</a>). We judged one study (<a href="./references#CD012425-bbs2-0002" title="BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Economic evaluation of a randomized clinical trial of hospital versus telephone follow‐up after treatment for breast cancer. British Journal of Surgery2009;96(12):1406‐15. [DOI: 10.1002/bjs.6753] BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Is telephone follow‐up by specialist nurses a cost effective approach?. European Journal of Cancer Supplements2009;7(2‐3):230‐1. BeaverK , Tysver‐RobinsonD , CampbellM , TwomeyM , WilliamsonS , HindleyA , et al. Comparing hospital and telephone follow‐up after treatment for breast cancer: randomised equivalence trial. BMJ2009;338:a3147. [DOI: 10.1136/bmj.a3147] ">Beaver 2009</a>), to be at high risk of bias, as more participants in the intervention group did not receive the intervention or wanted to change group and were lost to follow‐up compared to the comparison group. </p> <p>We judged studies reporting on patient‐reported outcomes, where response rates were balanced and missing data were due to similar reasons in both groups, to be at low risk of bias (<a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad 2013</a>; <a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a>; <a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a>; <a href="./references#CD012425-bbs2-0007" title="DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . Prospective randomized clinical trial for the evaluation of a stage adjusted reduced follow‐up schedule in cutaneous melanoma patients: results after one year. Annals of Surgical Oncology2016;23(1 Suppl 1):S30. DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . The MELFO‐study: prospective randomized clinical trial for the evaluation of a stage‐adjusted reduced follow‐up schedule in cutaneous melanoma patients ‐ results after 1 year. Annals of Surgical Oncology2016;23(9):2762‐71. [DOI: 10.1245/s10434‐016‐5263‐7] DeckersE , Hoekstra‐WeebersJ , DamudeS , FranckenA , Ter MeulenS , BastiaannetE , et al. The MELFO‐study: a multi‐center prospective randomized clinical trial on the effects of a reduced stage‐adjusted follow‐up schedule on cutaneous melanoma IB‐IIC patients: results after 3‐years. Annals of Surgical Oncology2018;25(1 Suppl 1):S40. NCT01018004 . Comparing follow‐up schedules in patients with newly diagnosed stage IB or stage II melanoma. clinicaltrials.gov/ct2/show/NCT01018004 (first received 20 December 2016). ">Damude 2016</a>; <a href="./references#CD012425-bbs2-0008" title="DavisKM , DawsonD , KellyS , RedS , PenekS , LynchJ , et al. Monitoring of health‐related quality of life and symptoms in prostate cancer survivors: a randomized trial. Journal of Supportive Oncology2013;11(4):174‐82. ">Davis 2013</a>; <a href="./references#CD012425-bbs2-0009" title="ACTRN12610000938000 . The ProCare Trial: a randomised controlled trial of follow up of men with prostate cancer in primary care. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336116 (first received 20 December 2016). EmeryJ , DooreyJ , JeffordM , KingM , PirottaM , HayneD , et al. Protocol for the ProCare Trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. BMJ Open2014;4(3):e004972. [DOI: 10.1136/bmjopen‐2014‐004972] EmeryJ , SchofieldP , JeffordM , KingM , PirottaM , HayneD , et al. The ProCare trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. Asia‐Pacific Journal of Clinical Oncology2014;10:157. EmeryJD , JeffordM , KingM , HayneD , MartinA , DooreyJ , et al. ProCare Trial: a phase II randomized controlled trial of shared care for follow‐up of men with prostate cancer. BJU International2016;119(3):381‐89. [DOI: 10.1111/bju.13593] KingM . Procare/PC4 study update. Asia‐Pacific Journal of Clinical Oncology2012;8:23. ">Emery 2016</a>; <a href="./references#CD012425-bbs2-0011" title="GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata). A randomized trial of intensive versus minimalist follow‐up of patients with resected Dukes B‐C colorectal cancer: the pilot phase. Tumori1998;84(Suppl):89. GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. NCT02409472 . Intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. clinicaltrials.gov/ct2/show/NCT02409472 (first received 20 December 2016). RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] ">GILDA 2016</a>; <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a>; <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>; <a href="./references#CD012425-bbs2-0015" title="BoekhoutAH , MaunsellE , PondGR , JulianJA , CoyleD , LevineMN , et al. A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial. Journal of Cancer Survivorship2015;9(4):683‐91. CoyleD , GrunfeldE , CoyleK , JulianJA , PondGR , FolkesA , et al. Cost‐effectiveness of a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):6082. CoyleD , GrunfeldE , CoyleK , PondG , JulianJA , LevineMN . Cost effectiveness of a survivorship care plan for breast cancer survivors. Journal of Oncology Practice2014;10(2):e86‐92. GrunfeldE , JulianJA , PondG , MaunsellE , CoyleD , FolkesA , et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. Journal of Clinical Oncology2011;29(36):4755‐62. GrunfeldE , LevineMN , JulianJA , PondGR , MaunsellE , FolkesA , et al. Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):9005. GrunfeldE , PondG , MaunsellE , LevineMN , JulianJA , CoyleD . Impact of survivorship care plans (SCP) on adherence to guidelines, health service measures, and patient‐reported outcomes (PRO): extended results of a multicenter randomized clinical trial (RCT) with breast cancer survivors. European Journal of Cancer2012;48:S147. ">Grunfeld 2011</a>; <a href="./references#CD012425-bbs2-0016" title="HershmanDL , GreenleeH , AwadD , KalinskyK , MaurerM , KranwinkelG , et al. Randomized controlled trial of a clinic‐based survivorship intervention following adjuvant therapy in breast cancer survivors. Breast Cancer Research and Treatment2013;138(3):795‐806. ">Hershman 2013</a>; <a href="./references#CD012425-bbs2-0017" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14:260. [DOI: 10.1186/1745‐6215‐14‐260] JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a nurse‐led supportive care package (survivor care) for survivors of colorectal cancer. Cancer Nursing2015;38(4 Suppl 1):S16‐7. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (Survivor‐Care, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2015;33(15 Suppl 1):9566. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , SchofieldP , ArandaS , YoungJ , ButowP . Randomised controlled trial (RCT) of a comprehensive post‐treatment support package (survivor‐care) for bowel cancer survivors. Psycho‐oncology2010;19:S193. ">Jefford 2016</a>; <a href="./references#CD012425-bbs2-0018" title="JeppesenMM , JensenPT , GilsaD , DePont ChristensenR , JensenMM , MogensenO . The effect of patient‐initiated follow‐up on fear of recurrence and health care use: a randomized trial in early‐stage endometrial cancer. International Journal of Gynecological Cancer2017;27(Supplement 4):1107. JeppesenMM , JensenPT , HansenDG , ChristensenRD , MogensenO . Authors' reply re: Patient‐initiated follow‐up affects fear of recurrence and health care use: a randomised trial in early‐stage endometrial cancer. BJOG2018;125(13):1778‐9. JeppesenMM , JensenPT , HansenDG , ChristensenRD , MogensenO . Patient‐initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early‐stage endometrial cancer. BJOG2018;125(13):1705‐14. TegnerowiczJ . Re: Patient‐initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early‐stage endometrial cancer. BJOG2018;1125(13):1778. ">Jeppesen 2018</a>; <a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a>; <a href="./references#CD012425-bbs2-0022" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomized study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Gastroenterology1999;34(5):509‐15. KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;149:159‐62. ">Kjeldsen 1997</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0025" title="KvaleEA , Demark‐WahnefriedW , MenesesK , BaeS , HuangCH , AzueroCB , et al. Patient centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer Research2015;75(9 Suppl 1):no pagination. KvaleEA , HuangCS , MenesesKM , Demark‐WahnefriedW , BaeS , AzueroCB , et al. Patient‐centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer2016;122(20):3232‐42. ">Kvale 2016</a>; <a href="./references#CD012425-bbs2-0027" title="MalmströmM , IvarssonB , KlefsgårdR , PerssonK , JakobssonU , JohanssonJ . The effect of a nurse led telephone supportive care programme on patients' quality of life, received information and health care contacts after oesophageal cancer surgery‐a six month RCT‐follow‐up study. International Journal of Nursing Studies2016;64:86‐95. [DOI: 10.1016/j.ijnurstu.2016.09.009] ">Malmstrom 2016</a>; <a href="./references#CD012425-bbs2-0028" title="MalyRC , GriggsJJ , LiuY , LiangLJ , GanzPA . A randomized controlled trial of survivorship care plans among low‐income breast cancer survivors. Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. MalyRC , LiangLJ , LiuY , GriggsJJ , GanzPA . Randomized controlled trial of survivorship care plans among low‐income, predominant Latina breast cancer survivors. Journal of Clinical Oncology2017;35(16):1814‐21. NCT01627366 . Study of survivorship care plans and outcomes in underserved breast cancer survivors. clinicaltrials.gov/ct2/show/NCT01627366 (first received 17 December 2018). ">Maly 2017</a>; <a href="./references#CD012425-bbs2-0030" title="MorrisonV , SpencerLH , LeesonS . Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a randomised feasibility trial. Psycho‐oncology2017;26(Suppl 2):3‐4. MorrisonV , SpencerLH , TottonN , PyeK , YeoST , ButterworthC , et al. Trial of optimal personalised care after treatment‐gynaecological cancer (TOPCAT‐G): a randomized feasibility trial. International Journal of Gynecological Cancer2018;28(2):401‐11. PyeK , TottonN , StuartN , WhitakerR , MorrisonV , EdwardsRT , et al. Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a study protocol for a randomised feasibility trial. Pilot and Feasibility Studies2016;2:67. [DOI 10.1186/s40814‐016‐0108‐5] ">Morrison 2018</a>; <a href="./references#CD012425-bbs2-0031" title="MurchieP , NicolsonMC , HannafordPC , RajaEA , LeeAJ , CampbellNC . Patient satisfaction with GP‐led melanoma follow‐up: a randomised controlled trial. British Journal of Cancer2010;102(10):1447‐55. ">Murchie 2010</a>; <a href="./references#CD012425-bbs2-0040" title="RuddyKJ , BakerEL , GuoH , GoldsteinMJ , WinerEP , ShulmanLN , et al. Randomized trial evaluating a coordinated survivorship care program for early stage breast cancer. Cancer Research2013;73(24 Suppl 1):OT2‐5‐02. RuddyKJ , GuoH , BakerE , GoldsteinM , MullaneyEE , ShulmanLN , et al. Coordinated follow‐up breast cancer survivorship care program study. Journal of Clinical Oncology2015;33(15 Suppl 1):e17727. RuddyKJ , GuoH , BakerEL , GoldsteinMJ , MullaneyEE , ShulmanLN , et al. Randomized phase 2 trial of a coordinated breast cancer follow‐up care program. Cancer2016;122:3546‐54. ">Ruddy 2016</a>; <a href="./references#CD012425-bbs2-0047" title="Van DerMeulenI , MayA , RosW , OosteromM , HordijkGJ , KooleR , et al. Effects of a nurse‐led psychosocial intervention on depressive symptoms and health‐related quality of life in patients with head and neck cancer: a randomized controlled trial. Psycho‐oncology2013;22(Suppl 3):17. Van derMeulenIC , MayAM , RosWJ , OosteromM , HordijkGJ , KooleR , et al. One‐year effect of a nurse‐led psychosocial intervention on depressive symptoms in patients with head and neck cancer: a randomized controlled trial. Oncologist2013;18(3):336‐44. [DOI: 10.1634/theoncologist.2012‐0299] ">Van der Meulen 2013</a>; <a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a>; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>; <a href="./references#CD012425-bbs2-0053" title='ACTRN12608000252314 . Cancer care after surgery – the CONNECT study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82819 (first received 20 December 2016). HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Connect: a pilot RCT to improve outcomes for people with colorectal cancer. Asia‐Pacific Journal of Clinical Oncology2009;5:A159. HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Randomized pilot evaluation of the supportive care intervention "CONNECT" for people following surgery for colorectal cancer. Diseases of the Colon and Rectum2011;54(5):622‐31. YoungJM , ButowPN , WalshJ , DurcinoskaI , DobbinsTA , RodwellL , et al. Multicenter randomized trial of centralized nurse‐led telephone‐based care coordination to improve outcomes after surgical resection for colorectal cancer: the CONNECT intervention. Journal of Clinical Oncology2013;31(28):3585‐91. [DOI: 10.1200/JCO.2012.48.1036] '>Young 2013</a>). Three studies insufficiently reported reasons for loss to follow‐up or information on whether attrition was equally distributed between the groups, and we judged the risk of bias to be unclear (<a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a>; <a href="./references#CD012425-bbs2-0021" title="DentJ , ToppingA , FergusonC , StephensonJ , McCoyM , AllinsonV , et al. To follow up or not? A new model of supportive care for early breast cancer. Journal of Clinical Oncology2011;29(15 Suppl 1):no pagination. KirshbaumMN , DentJ , StephensonJ , ToppingAE , AllinsonV , McCoyM , et al. Open access follow‐up care for early breast cancer: a randomised controlled quality of life analysis. European Journal of Cancer Care2017;26(4):e12577. [DOI: 10.1111/ecc.12577] ">Kirshbaum 2017</a>; <a href="./references#CD012425-bbs2-0044" title="SheppardC , HigginsB , WiseM , YiangouC , DuboisD , KilburnS . Breast cancer follow up: a randomised controlled trial comparing point of need access versus routine 6‐monthly clinical review. European Journal of Oncology Nursing2009;13(1):2‐8. [DOI: 10.1016/j.ejon.2008.11.005] ">Sheppard 2009</a>). We judged four studies to be at high risk of bias due to high attrition, imbalance in numbers or different reasons for attrition between the two groups (<a href="./references#CD012425-bbs2-0002" title="BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Economic evaluation of a randomized clinical trial of hospital versus telephone follow‐up after treatment for breast cancer. British Journal of Surgery2009;96(12):1406‐15. [DOI: 10.1002/bjs.6753] BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Is telephone follow‐up by specialist nurses a cost effective approach?. European Journal of Cancer Supplements2009;7(2‐3):230‐1. BeaverK , Tysver‐RobinsonD , CampbellM , TwomeyM , WilliamsonS , HindleyA , et al. Comparing hospital and telephone follow‐up after treatment for breast cancer: randomised equivalence trial. BMJ2009;338:a3147. [DOI: 10.1136/bmj.a3147] ">Beaver 2009</a>; <a href="./references#CD012425-bbs2-0003" title="BeaverK , CampbellM , WilliamsonS , ProcterD , SheridanJ , HeathJ , et al. An exploratory randomized controlled trial comparing telephone and hospital follow‐up after treatment for colorectal cancer. Colorectal Disease2012;14(10):1201‐9. [DOI: 10.1111/j.1463‐1318.2012.02936.x] ">Beaver 2012</a>; <a href="./references#CD012425-bbs2-0019" title="JuarezG , HurriaA , FerrellB . Effectiveness of an education intervention on quality of life in Latina breast cancer survivors. Psycho‐oncology2012;21:110. JuarezG , HurriaA , UmanG , FerrellB . Impact of a bilingual education intervention on the quality of life of Latina breast cancer survivors. Oncology Nursing Forum2013;40(1):E50‐60. [DOI: 10.1188/13.ONF.E50‐E60] ">Juarez 2013</a>; <a href="./references#CD012425-bbs2-0038" title="DeRooijBH , EzendamNP , NicolaijeKA , LodderP , VosMC , PijnenborgJM , et al. Survivorship care plans have a negative impact on long‐term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. Quality of Life Research2018;27(6):1533‐44. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2‐year follow‐up ‐ The ROGY care trial. Gynecologic Oncology2017;145(2):319‐28. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Long‐term impact of survivorship care plans on ovarian cancer patient reported outcomes‐new results of the ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):64‐5. DeRooijBH , EzendamNP , NicolaijeKA , VosMC , PijnenborgJM , BollD , et al. The indirect effects of survivorship care plans on quality of life, anxiety and depression‐the ROGY care trial. Supportive Care in Cancer2017;25(2 Suppl 1):S53‐4. DeRooijBH , EzendamNP , VosMC , PijnenborgJM , BollD , KruitwagenRF , et al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. Cancer Epub 2018 Nov 30;125(5):788‐97. [DOI: 10.1002/cncr.31844] EzendamN , DeRooijB , NicolaijeK , VosC , PijnenborgJ , BollD , et al. Long‐term impact of cancer survivorship care plans on patient outcomes‐the randomized controlled ROGY care trial. International Journal of Gynecological Cancer2016;26:91. EzendamNP , VanBroekhovenM , Van DePoll‐FranseLV , DeRooijBH . The role of illness perceptions in smoking, alcohol consumption and weight changes among gynaecological cancer survivors. Quality of Life Research2016;25(1 Suppl 1):114. JeppesenMM , EzendamNP , PijnenborgJM , VosMC , BollD , KruitwagenRF , et al. The impact of the survivorship care plan on health care use: 2‐year follow‐up results of the ROGY care trial. Journal of Cancer Survivorship2018;12(1):18‐27. NicolaijeKA , EzendamNP , VosMC , PijnenborgJM , BollD , BossEA , et al. Impact of an automatically generated cancer survivorship care plan on patient‐reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial. Journal of Clinical Oncology2015;33(31):3550‐9. Van dePoll‐FranseL , NicolaijeK , EzendamN , VosC , BollD , PijnenborgJ , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY CARE): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Psycho‐oncology2013;22:341‐2. Van dePoll‐FranseLV , JeppesenMM , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. The survivorship care plan increases the use of primary care in anxious and irradiated endometrial cancer patients. Two year outcomes of the pragmatic cluster randomized ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):164. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosCM , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY Care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosMC , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. European Journal of Cancer2013;49:S720. Van dePoll‐FranseLV , NicolaijeKA , VosMC , PijnenborgJM , BollD , HussonO , et al. The impact of a cancer survivorship care plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials2011;12:256. ">ROGY 2015</a>). </p> </section> <section id="CD012425-sec-0086"> <h4 class="title">Selective reporting</h4> <p>Sixteen studies had available study protocols or prospectively registered clinical trial entries where all of the studies' prespecified outcomes had been reported and we judged these studies to be at low risk of reporting bias (<a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad 2013</a>; <a href="./references#CD012425-bbs2-0006" title="D'CruzA , VaishR , GuptaS , AryaS , HawaldarRW , ShahS . Does addition of neck ultrasonography to physical examination, in follow‐up of patients with early stage, clinically node negative oral cancers, influence outcome? A randomized control trial (RCT). Journal of Clinical Oncology2016;34(15 Suppl 6):no pagination. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node‐negative oral cancer. New England Journal of Medicine2015;373(6):521‐9. NCT00193765 . Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. clinicaltrials.gov/ct2/show/NCT00193765 (first received 20 December 2016). ">D'Cruz 2016</a>; <a href="./references#CD012425-bbs2-0009" title="ACTRN12610000938000 . The ProCare Trial: a randomised controlled trial of follow up of men with prostate cancer in primary care. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336116 (first received 20 December 2016). EmeryJ , DooreyJ , JeffordM , KingM , PirottaM , HayneD , et al. Protocol for the ProCare Trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. BMJ Open2014;4(3):e004972. [DOI: 10.1136/bmjopen‐2014‐004972] EmeryJ , SchofieldP , JeffordM , KingM , PirottaM , HayneD , et al. The ProCare trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. Asia‐Pacific Journal of Clinical Oncology2014;10:157. EmeryJD , JeffordM , KingM , HayneD , MartinA , DooreyJ , et al. ProCare Trial: a phase II randomized controlled trial of shared care for follow‐up of men with prostate cancer. BJU International2016;119(3):381‐89. [DOI: 10.1111/bju.13593] KingM . Procare/PC4 study update. Asia‐Pacific Journal of Clinical Oncology2012;8:23. ">Emery 2016</a>; <a href="./references#CD012425-bbs2-0011" title="GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata). A randomized trial of intensive versus minimalist follow‐up of patients with resected Dukes B‐C colorectal cancer: the pilot phase. Tumori1998;84(Suppl):89. GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. NCT02409472 . Intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. clinicaltrials.gov/ct2/show/NCT02409472 (first received 20 December 2016). RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] ">GILDA 2016</a>; <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>; <a href="./references#CD012425-bbs2-0017" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14:260. [DOI: 10.1186/1745‐6215‐14‐260] JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a nurse‐led supportive care package (survivor care) for survivors of colorectal cancer. Cancer Nursing2015;38(4 Suppl 1):S16‐7. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (Survivor‐Care, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2015;33(15 Suppl 1):9566. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , SchofieldP , ArandaS , YoungJ , ButowP . Randomised controlled trial (RCT) of a comprehensive post‐treatment support package (survivor‐care) for bowel cancer survivors. Psycho‐oncology2010;19:S193. ">Jefford 2016</a>; <a href="./references#CD012425-bbs2-0018" title="JeppesenMM , JensenPT , GilsaD , DePont ChristensenR , JensenMM , MogensenO . The effect of patient‐initiated follow‐up on fear of recurrence and health care use: a randomized trial in early‐stage endometrial cancer. International Journal of Gynecological Cancer2017;27(Supplement 4):1107. JeppesenMM , JensenPT , HansenDG , ChristensenRD , MogensenO . Authors' reply re: Patient‐initiated follow‐up affects fear of recurrence and health care use: a randomised trial in early‐stage endometrial cancer. BJOG2018;125(13):1778‐9. JeppesenMM , JensenPT , HansenDG , ChristensenRD , MogensenO . Patient‐initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early‐stage endometrial cancer. BJOG2018;125(13):1705‐14. TegnerowiczJ . Re: Patient‐initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early‐stage endometrial cancer. BJOG2018;1125(13):1778. ">Jeppesen 2018</a>; <a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a>; <a href="./references#CD012425-bbs2-0029" title="MonteilJ , VergnenègreA , BertinF , DalmayF , GaillardS , BonnaudF , et al. Randomized follow‐up study of resected NSCLC patients: conventional versus 18F‐DG coincidence imaging. Anticancer Research2010;30(9):3811‐6. NCT00199615 . Follow‐up of patients with curative‐intent surgical resection for NSCLC. clinicaltrials.gov/ct2/show/NCT00199615 (first received 20 December 2016). ">Monteil 2010</a>; <a href="./references#CD012425-bbs2-0030" title="MorrisonV , SpencerLH , LeesonS . Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a randomised feasibility trial. Psycho‐oncology2017;26(Suppl 2):3‐4. MorrisonV , SpencerLH , TottonN , PyeK , YeoST , ButterworthC , et al. Trial of optimal personalised care after treatment‐gynaecological cancer (TOPCAT‐G): a randomized feasibility trial. International Journal of Gynecological Cancer2018;28(2):401‐11. PyeK , TottonN , StuartN , WhitakerR , MorrisonV , EdwardsRT , et al. Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a study protocol for a randomised feasibility trial. Pilot and Feasibility Studies2016;2:67. [DOI 10.1186/s40814‐016‐0108‐5] ">Morrison 2018</a>; <a href="./references#CD012425-bbs2-0038" title="DeRooijBH , EzendamNP , NicolaijeKA , LodderP , VosMC , PijnenborgJM , et al. Survivorship care plans have a negative impact on long‐term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. Quality of Life Research2018;27(6):1533‐44. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2‐year follow‐up ‐ The ROGY care trial. Gynecologic Oncology2017;145(2):319‐28. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Long‐term impact of survivorship care plans on ovarian cancer patient reported outcomes‐new results of the ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):64‐5. DeRooijBH , EzendamNP , NicolaijeKA , VosMC , PijnenborgJM , BollD , et al. The indirect effects of survivorship care plans on quality of life, anxiety and depression‐the ROGY care trial. Supportive Care in Cancer2017;25(2 Suppl 1):S53‐4. DeRooijBH , EzendamNP , VosMC , PijnenborgJM , BollD , KruitwagenRF , et al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. Cancer Epub 2018 Nov 30;125(5):788‐97. [DOI: 10.1002/cncr.31844] EzendamN , DeRooijB , NicolaijeK , VosC , PijnenborgJ , BollD , et al. Long‐term impact of cancer survivorship care plans on patient outcomes‐the randomized controlled ROGY care trial. International Journal of Gynecological Cancer2016;26:91. EzendamNP , VanBroekhovenM , Van DePoll‐FranseLV , DeRooijBH . The role of illness perceptions in smoking, alcohol consumption and weight changes among gynaecological cancer survivors. Quality of Life Research2016;25(1 Suppl 1):114. JeppesenMM , EzendamNP , PijnenborgJM , VosMC , BollD , KruitwagenRF , et al. The impact of the survivorship care plan on health care use: 2‐year follow‐up results of the ROGY care trial. Journal of Cancer Survivorship2018;12(1):18‐27. NicolaijeKA , EzendamNP , VosMC , PijnenborgJM , BollD , BossEA , et al. Impact of an automatically generated cancer survivorship care plan on patient‐reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial. Journal of Clinical Oncology2015;33(31):3550‐9. Van dePoll‐FranseL , NicolaijeK , EzendamN , VosC , BollD , PijnenborgJ , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY CARE): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Psycho‐oncology2013;22:341‐2. Van dePoll‐FranseLV , JeppesenMM , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. The survivorship care plan increases the use of primary care in anxious and irradiated endometrial cancer patients. Two year outcomes of the pragmatic cluster randomized ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):164. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosCM , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY Care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosMC , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. European Journal of Cancer2013;49:S720. Van dePoll‐FranseLV , NicolaijeKA , VosMC , PijnenborgJM , BollD , HussonO , et al. The impact of a cancer survivorship care plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials2011;12:256. ">ROGY 2015</a>; <a href="./references#CD012425-bbs2-0041" title="GoodmanA . How often to follow up? Study shows two CT scans as good as five for low‐risk testicular cancer. Oncology Times2007;29(12):54‐5. NCT00003420 . CT scans in treating patients with stage I testicular cancer after undergoing orchiectomy. clinicaltrials.gov/ct2/show/NCT00003420 (first received 20 December 2016). RustinGJ , MeadGM , StenningSP , VaseyPA , AassN , HuddartRA , et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197‐‐the National Cancer Research Institute Testis Cancer Clinical Studies Group. Journal of Clinical Oncology2007;25(11):1310‐5. ">Rustin 2007</a>; <a href="./references#CD012425-bbs2-0046" title="NCT00624260 . Impact of PET Scan on the curative strategy of colo‐rectal cancers : a randomized study. clinicaltrials.gov/ct2/show/NCT00624260 (first received 20 December 2016). SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an openlabel multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology2017;35(15 Suppl 1):no pagination. SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal2017;5(5 Suppl 1):A13. SobhaniI , IttiE , LucianiA , BaumgaertnerI , LayeseR , AndreT , et al. Colorectal cancer (CRC) monitoring by 6‐monthly 18FDG‐PET/CT: an open‐label multicentre randomised trial. Annals of Oncology2018;29(4):931‐7. ">Sobhani 2018</a>; <a href="./references#CD012425-bbs2-0051" title="NCT00198341 . Post‐surgical non‐small cell lung cancer (NSCLC) follow‐up. clinicaltrials.gov/ct2/show/NCT00198341 (first received 20 December 2016). WesteelV . Follow‐up of the patient after curative treatment. Lung Cancer2011;71:S10‐1. WesteelV . Surveillance and second primary malignancies in lung cancer survivors. Journal of Thoracic Oncology2018;13(10 Suppl):S277‐8. WesteelV , BarlesiF , DomasJ , GirardP , FoucherP , LafitteJJ , et al. Postoperative follow‐up of lung cancer: randomized trial comparing two follow‐up programs in completely resected non‐small cell lung cancer (IFCT‐0302). Journal of Clinical Oncology2012;30(15 Suppl 1):no pagination. WesteelV , BarlesiF , FoucherP , LafitteJ , DomasJ , GirardP , et al. Recurrences and 2nd primary cancers in the IFCT‐0302 trial assessing a CT‐scan‐based follow‐up after lung cancer surgery. Journal of Thoracic Oncology2017;12(11 Suppl 2):S1788‐9. WesteelV , BarlesiF , FoucherP , LafitteJ‐J , DomasJ , GirardP , et al. Results of the phase III IFCT‐0302 trial assessing minimal versus CT‐scan‐based follow‐up for completely resected non‐small cell lung cancer (NSCLC). Annals of Oncology2017;28(Suppl 5):v452. WesteelV , BarlesiF , FoucherP , LafitteJJ , DomasJ , GirardP , et al. Compliance with follow‐up programs after surgery for non‐small cell lung cancer in the phase III IFCT‐0302 trial. Journal of Thoracic Oncology2015;10(9 Suppl 2):S239. WesteelV , LebitasyMP , MercierM , LafitteJJ , DomasJ , GirardPl . IFCT‐0302 trial: randomised study comparing two follow‐up schedules in completely resected non‐small cell lung cancer [Protocole IFCT‐0302 : essai randomisé de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués]. Revue des Maladies Respiratoires2007;2(5):645‐52. ">Westeel 2012</a>; <a href="./references#CD012425-bbs2-0052" title="NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00225641 (first received 20 December 2016). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PahlmanL , et al. Intensity of follow up after surgery for colorectal cancer. Colorectal Disease2014;16:93. Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA2018;319(20):2095‐103. ">Wille‐Jorgensen 2018</a>; <a href="./references#CD012425-bbs2-0053" title='ACTRN12608000252314 . Cancer care after surgery – the CONNECT study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82819 (first received 20 December 2016). HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Connect: a pilot RCT to improve outcomes for people with colorectal cancer. Asia‐Pacific Journal of Clinical Oncology2009;5:A159. HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Randomized pilot evaluation of the supportive care intervention "CONNECT" for people following surgery for colorectal cancer. Diseases of the Colon and Rectum2011;54(5):622‐31. YoungJM , ButowPN , WalshJ , DurcinoskaI , DobbinsTA , RodwellL , et al. Multicenter randomized trial of centralized nurse‐led telephone‐based care coordination to improve outcomes after surgical resection for colorectal cancer: the CONNECT intervention. Journal of Clinical Oncology2013;31(28):3585‐91. [DOI: 10.1200/JCO.2012.48.1036] '>Young 2013</a>). We judged one study (<a href="./references#CD012425-bbs2-0040" title="RuddyKJ , BakerEL , GuoH , GoldsteinMJ , WinerEP , ShulmanLN , et al. Randomized trial evaluating a coordinated survivorship care program for early stage breast cancer. Cancer Research2013;73(24 Suppl 1):OT2‐5‐02. RuddyKJ , GuoH , BakerE , GoldsteinM , MullaneyEE , ShulmanLN , et al. Coordinated follow‐up breast cancer survivorship care program study. Journal of Clinical Oncology2015;33(15 Suppl 1):e17727. RuddyKJ , GuoH , BakerEL , GoldsteinMJ , MullaneyEE , ShulmanLN , et al. Randomized phase 2 trial of a coordinated breast cancer follow‐up care program. Cancer2016;122:3546‐54. ">Ruddy 2016</a>), as being at high risk of reporting bias, as they did not report results for anxiety and depression in the publication, even though it was an outcome that was specified in the methods section. The remaining studies received a judgement of unclear risk, either because no study protocol was available for these studies or because they did not report all the outcomes specified in the protocol. </p> </section> <section id="CD012425-sec-0087"> <h4 class="title">Other potential sources of bias</h4> <p>We judged four studies to be at high risk of bias due to the potential risk of contamination, the risk of surveillance bias, significant baseline imbalances, or a combination of two or all of these (<a href="./references#CD012425-bbs2-0003" title="BeaverK , CampbellM , WilliamsonS , ProcterD , SheridanJ , HeathJ , et al. An exploratory randomized controlled trial comparing telephone and hospital follow‐up after treatment for colorectal cancer. Colorectal Disease2012;14(10):1201‐9. [DOI: 10.1111/j.1463‐1318.2012.02936.x] ">Beaver 2012</a>; <a href="./references#CD012425-bbs2-0019" title="JuarezG , HurriaA , FerrellB . Effectiveness of an education intervention on quality of life in Latina breast cancer survivors. Psycho‐oncology2012;21:110. JuarezG , HurriaA , UmanG , FerrellB . Impact of a bilingual education intervention on the quality of life of Latina breast cancer survivors. Oncology Nursing Forum2013;40(1):E50‐60. [DOI: 10.1188/13.ONF.E50‐E60] ">Juarez 2013</a>; <a href="./references#CD012425-bbs2-0031" title="MurchieP , NicolsonMC , HannafordPC , RajaEA , LeeAJ , CampbellNC . Patient satisfaction with GP‐led melanoma follow‐up: a randomised controlled trial. British Journal of Cancer2010;102(10):1447‐55. ">Murchie 2010</a>; <a href="./references#CD012425-bbs2-0040" title="RuddyKJ , BakerEL , GuoH , GoldsteinMJ , WinerEP , ShulmanLN , et al. Randomized trial evaluating a coordinated survivorship care program for early stage breast cancer. Cancer Research2013;73(24 Suppl 1):OT2‐5‐02. RuddyKJ , GuoH , BakerE , GoldsteinM , MullaneyEE , ShulmanLN , et al. Coordinated follow‐up breast cancer survivorship care program study. Journal of Clinical Oncology2015;33(15 Suppl 1):e17727. RuddyKJ , GuoH , BakerEL , GoldsteinMJ , MullaneyEE , ShulmanLN , et al. Randomized phase 2 trial of a coordinated breast cancer follow‐up care program. Cancer2016;122:3546‐54. ">Ruddy 2016</a>). Four other studies also reported baseline imbalances but we had difficulty identifying whether the imbalance would introduce bias and thus, judged them to be at unclear risk: <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a> had more stage I participants in the hospital group compared to the GP group (50.3% versus 40.4%); <a href="./references#CD012425-bbs2-0032" title="OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a> had fewer women and more men in the control group compared to the intervention group (23 versus 33 women, 31 versus 20 men); <a href="./references#CD012425-bbs2-0033" title="OltraA , SantaballaA , MontalarJ , MunárrizB , PastorM , MeseguerA , et al. Cost‐benefit evaluation of a follow‐up program in patients with advanced breast cancer. Randomized study. Revista de Oncología1999;1(Suppl 1):165. OltraA , SantaballaA , MunárrizB , PastorM , MontalarJ . Cost‐benefit analysis of a follow‐up program in patients with breast cancer: a randomized prospective study. Breast Journal2007;13(6):571‐4. ">Oltra 2007</a> had more disease stage I participants in the intervention group (28 versus 17) and more stage IIA participants in the comparison group (24 versus 11); and <a href="./references#CD012425-bbs2-0043" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk‐adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a> had more participants with higher levels of pre‐operative carcinoembryonic antigen (CEA) and fewer participants with lower levels of pre‐operative CEA in the intervention group compared to the comparison group (31.5% versus 9.5%, 68.5% versus 90.5%). <a href="./references#CD012425-bbs2-0021" title="DentJ , ToppingA , FergusonC , StephensonJ , McCoyM , AllinsonV , et al. To follow up or not? A new model of supportive care for early breast cancer. Journal of Clinical Oncology2011;29(15 Suppl 1):no pagination. KirshbaumMN , DentJ , StephensonJ , ToppingAE , AllinsonV , McCoyM , et al. Open access follow‐up care for early breast cancer: a randomised controlled quality of life analysis. European Journal of Cancer Care2017;26(4):e12577. [DOI: 10.1111/ecc.12577] ">Kirshbaum 2017</a> did not record any baseline information other than age of the participants and we also judged the risk to be unclear. We judged the remaining studies to be at unclear risk of other bias. </p> </section> </section> <section id="CD012425-sec-0088"> <h3 class="title" id="CD012425-sec-0088">Effects of interventions</h3> <p>See: <a href="./full#CD012425-tbl-0001"><b>Summary of findings for the main comparison</b> Non‐specialist‐led versus specialist‐led follow‐up after primary cancer treatment</a>; <a href="./full#CD012425-tbl-0002"><b>Summary of findings 2</b> Less intensive versus more intensive follow‐up after primary cancer treatment</a>; <a href="./full#CD012425-tbl-0003"><b>Summary of findings 3</b> Follow‐up integrating additional patient symptom education or monitoring, or survivorship care plans versus usual care</a> </p> <p>Below, we present the effects of the interventions by outcome for each comparison group. For each outcome, we present the results of the meta‐analyses, the meta‐regression and sensitivity analyses for overall survival and time to detection of recurrence (if carried out) and a narrative synthesis of the studies with results that we could not pool. </p> <section id="CD012425-sec-0089"> <h4 class="title">Comparison 1: non‐specialist‐led versus specialist‐led follow‐up</h4> <p>We included 17 studies for this comparison (<a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad 2013</a>; <a href="./references#CD012425-bbs2-0002" title="BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Economic evaluation of a randomized clinical trial of hospital versus telephone follow‐up after treatment for breast cancer. British Journal of Surgery2009;96(12):1406‐15. [DOI: 10.1002/bjs.6753] BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Is telephone follow‐up by specialist nurses a cost effective approach?. European Journal of Cancer Supplements2009;7(2‐3):230‐1. BeaverK , Tysver‐RobinsonD , CampbellM , TwomeyM , WilliamsonS , HindleyA , et al. Comparing hospital and telephone follow‐up after treatment for breast cancer: randomised equivalence trial. BMJ2009;338:a3147. [DOI: 10.1136/bmj.a3147] ">Beaver 2009</a>; <a href="./references#CD012425-bbs2-0003" title="BeaverK , CampbellM , WilliamsonS , ProcterD , SheridanJ , HeathJ , et al. An exploratory randomized controlled trial comparing telephone and hospital follow‐up after treatment for colorectal cancer. Colorectal Disease2012;14(10):1201‐9. [DOI: 10.1111/j.1463‐1318.2012.02936.x] ">Beaver 2012</a>; <a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a>; <a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a>; <a href="./references#CD012425-bbs2-0009" title="ACTRN12610000938000 . The ProCare Trial: a randomised controlled trial of follow up of men with prostate cancer in primary care. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336116 (first received 20 December 2016). EmeryJ , DooreyJ , JeffordM , KingM , PirottaM , HayneD , et al. Protocol for the ProCare Trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. BMJ Open2014;4(3):e004972. [DOI: 10.1136/bmjopen‐2014‐004972] EmeryJ , SchofieldP , JeffordM , KingM , PirottaM , HayneD , et al. The ProCare trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. Asia‐Pacific Journal of Clinical Oncology2014;10:157. EmeryJD , JeffordM , KingM , HayneD , MartinA , DooreyJ , et al. ProCare Trial: a phase II randomized controlled trial of shared care for follow‐up of men with prostate cancer. BJU International2016;119(3):381‐89. [DOI: 10.1111/bju.13593] KingM . Procare/PC4 study update. Asia‐Pacific Journal of Clinical Oncology2012;8:23. ">Emery 2016</a>; <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a>; <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>; <a href="./references#CD012425-bbs2-0018" title="JeppesenMM , JensenPT , GilsaD , DePont ChristensenR , JensenMM , MogensenO . The effect of patient‐initiated follow‐up on fear of recurrence and health care use: a randomized trial in early‐stage endometrial cancer. International Journal of Gynecological Cancer2017;27(Supplement 4):1107. JeppesenMM , JensenPT , HansenDG , ChristensenRD , MogensenO . Authors' reply re: Patient‐initiated follow‐up affects fear of recurrence and health care use: a randomised trial in early‐stage endometrial cancer. BJOG2018;125(13):1778‐9. JeppesenMM , JensenPT , HansenDG , ChristensenRD , MogensenO . Patient‐initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early‐stage endometrial cancer. BJOG2018;125(13):1705‐14. TegnerowiczJ . Re: Patient‐initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early‐stage endometrial cancer. BJOG2018;1125(13):1778. ">Jeppesen 2018</a>; <a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a>; <a href="./references#CD012425-bbs2-0021" title="DentJ , ToppingA , FergusonC , StephensonJ , McCoyM , AllinsonV , et al. To follow up or not? A new model of supportive care for early breast cancer. Journal of Clinical Oncology2011;29(15 Suppl 1):no pagination. KirshbaumMN , DentJ , StephensonJ , ToppingAE , AllinsonV , McCoyM , et al. Open access follow‐up care for early breast cancer: a randomised controlled quality of life analysis. European Journal of Cancer Care2017;26(4):e12577. [DOI: 10.1111/ecc.12577] ">Kirshbaum 2017</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0030" title="MorrisonV , SpencerLH , LeesonS . Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a randomised feasibility trial. Psycho‐oncology2017;26(Suppl 2):3‐4. MorrisonV , SpencerLH , TottonN , PyeK , YeoST , ButterworthC , et al. Trial of optimal personalised care after treatment‐gynaecological cancer (TOPCAT‐G): a randomized feasibility trial. International Journal of Gynecological Cancer2018;28(2):401‐11. PyeK , TottonN , StuartN , WhitakerR , MorrisonV , EdwardsRT , et al. Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a study protocol for a randomised feasibility trial. Pilot and Feasibility Studies2016;2:67. [DOI 10.1186/s40814‐016‐0108‐5] ">Morrison 2018</a>; <a href="./references#CD012425-bbs2-0031" title="MurchieP , NicolsonMC , HannafordPC , RajaEA , LeeAJ , CampbellNC . Patient satisfaction with GP‐led melanoma follow‐up: a randomised controlled trial. British Journal of Cancer2010;102(10):1447‐55. ">Murchie 2010</a>; <a href="./references#CD012425-bbs2-0044" title="SheppardC , HigginsB , WiseM , YiangouC , DuboisD , KilburnS . Breast cancer follow up: a randomised controlled trial comparing point of need access versus routine 6‐monthly clinical review. European Journal of Oncology Nursing2009;13(1):2‐8. [DOI: 10.1016/j.ejon.2008.11.005] ">Sheppard 2009</a>; <a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a>; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>). </p> <section id="CD012425-sec-0090"> <h5 class="title">Overall survival</h5> <p>Four studies reported on the outcome of survival (<a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a>; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>). </p> <p>Two studies reported data that we could pool in a meta‐analysis investigating nurse‐led follow‐up after breast cancer (<a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>), and GP‐led follow‐up after colon cancer (<a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>). It is uncertain how non‐specialist‐led follow‐up affects overall survival as the certainty of the evidence is very low (HR 1.21, 95% CI 0.68 to 2.15; P = 0.07; 2 studies; 603 participants; <a href="./references#CD012425-fig-0007" title="">Analysis 1.1</a>; <a href="#CD012425-fig-0004">Figure 4</a>). The anticipated absolute effect was 2 fewer survivors per 100 patients (ranging from 10 fewer to 4 more). There was no statistical heterogeneity (I<sup>2</sup> = 0) and we could not carry out meta‐regression or sensitivity analyses. We downgraded the certainty of evidence by three levels for very serious concerns regarding indirectness and imprecision, as representativeness is limited with only two studies, the HRs were not reported but indirectly estimated and the confidence interval was very wide. </p> <div class="figure" id="CD012425-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison 1. Non‐specialist‐led versus specialist‐led follow‐up, outcome: 1.1 overall survivalA HR greater than 1 indicates a higher hazard of death (worse survival) in the non‐specialist arm and a lower hazard of death (better survival) in the specialist‐led arm" data-id="CD012425-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 1. Non‐specialist‐led versus specialist‐led follow‐up, outcome: 1.1 overall survival </p> <p>A HR greater than 1 indicates a higher hazard of death (worse survival) in the non‐specialist arm and a lower hazard of death (better survival) in the specialist‐led arm </p> </div> </div> </div> <p>The remaining two studies (1077 participants) reported little or no difference in survival for GP‐led follow‐up after breast cancer (risk difference 0.18%, 95% CI −2.90 to 3.26; <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>) or nurse‐led follow‐up after oesophageal cancer ("7 died in each group"; P = 0.41; <a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a>). </p> </section> <section id="CD012425-sec-0091"> <h5 class="title">Time to detection of recurrence</h5> <p>Four studies reported on time to detection of recurrence (<a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a>; <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>), but we could not use the reported data to indirectly estimate HRs and we could not pool the results. Thus, it is uncertain how non‐specialist‐led follow‐up affects time to detection of recurrence </p> <p>Three studies (1435 participants) reported little or no difference in time to detection of recurrence for: GP‐led follow‐up after breast cancer (risk difference 2.02%, 95% CI −2.13 to 6.16; <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>); GP‐led follow‐up after colon cancer (log‐rank P = 0.76; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>); and nurse‐led follow‐up after breast cancer (risk difference −0.3%, 95% CI −10 to 9; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>). The final study (<a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a>; 259 participants), investigated follow‐up after endometrial cancer and reported median time to recurrence in the nurse‐led arm (307 days; range 48 to 662) versus the hospital arm (172 days; range 99 to 436) but did not carry out any statistical analysis. We judged the certainty of evidence to be very low and downgraded by three levels for serious concerns regarding inconsistency, indirectness and imprecision due to few studies, reporting of results by different estimates that could not be pooled and high variance of the result estimates. </p> </section> <section id="CD012425-sec-0092"> <h5 class="title">Health‐related quality of life</h5> <p>Thirteen studies reported on health‐related quality of life using a variety of measurement scales and with varying follow‐up periods (<a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad 2013</a>; <a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a>; <a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a>; <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a>; <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>; <a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a>; <a href="./references#CD012425-bbs2-0021" title="DentJ , ToppingA , FergusonC , StephensonJ , McCoyM , AllinsonV , et al. To follow up or not? A new model of supportive care for early breast cancer. Journal of Clinical Oncology2011;29(15 Suppl 1):no pagination. KirshbaumMN , DentJ , StephensonJ , ToppingAE , AllinsonV , McCoyM , et al. Open access follow‐up care for early breast cancer: a randomised controlled quality of life analysis. European Journal of Cancer Care2017;26(4):e12577. [DOI: 10.1111/ecc.12577] ">Kirshbaum 2017</a>; <a href="./references#CD012425-bbs2-0028" title="MalyRC , GriggsJJ , LiuY , LiangLJ , GanzPA . A randomized controlled trial of survivorship care plans among low‐income breast cancer survivors. Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. MalyRC , LiangLJ , LiuY , GriggsJJ , GanzPA . Randomized controlled trial of survivorship care plans among low‐income, predominant Latina breast cancer survivors. Journal of Clinical Oncology2017;35(16):1814‐21. NCT01627366 . Study of survivorship care plans and outcomes in underserved breast cancer survivors. clinicaltrials.gov/ct2/show/NCT01627366 (first received 17 December 2018). ">Maly 2017</a>; <a href="./references#CD012425-bbs2-0030" title="MorrisonV , SpencerLH , LeesonS . Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a randomised feasibility trial. Psycho‐oncology2017;26(Suppl 2):3‐4. MorrisonV , SpencerLH , TottonN , PyeK , YeoST , ButterworthC , et al. Trial of optimal personalised care after treatment‐gynaecological cancer (TOPCAT‐G): a randomized feasibility trial. International Journal of Gynecological Cancer2018;28(2):401‐11. PyeK , TottonN , StuartN , WhitakerR , MorrisonV , EdwardsRT , et al. Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a study protocol for a randomised feasibility trial. Pilot and Feasibility Studies2016;2:67. [DOI 10.1186/s40814‐016‐0108‐5] ">Morrison 2018</a>; <a href="./references#CD012425-bbs2-0031" title="MurchieP , NicolsonMC , HannafordPC , RajaEA , LeeAJ , CampbellNC . Patient satisfaction with GP‐led melanoma follow‐up: a randomised controlled trial. British Journal of Cancer2010;102(10):1447‐55. ">Murchie 2010</a>; <a href="./references#CD012425-bbs2-0044" title="SheppardC , HigginsB , WiseM , YiangouC , DuboisD , KilburnS . Breast cancer follow up: a randomised controlled trial comparing point of need access versus routine 6‐monthly clinical review. European Journal of Oncology Nursing2009;13(1):2‐8. [DOI: 10.1016/j.ejon.2008.11.005] ">Sheppard 2009</a>; <a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a>; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>). We present results below, according to measurement scale. </p> <section id="CD012425-sec-0093"> <h6 class="title">The Medical Outcomes Study Short Form Health Survey (SF‐36)</h6> <p>The SF‐36 (<a href="./references#CD012425-bbs2-0190" title="WareJE , KosinskiMA , KellerSD . SF‐36 physical and mental health summary scales: a user’s manual. Boston, Mass: The Health Institute, New England Medical Center, 1994. ">Ware 1994</a>), is a 36‐item self‐reported questionnaire consisting of eight subscales (physical functioning, physical role functioning, bodily pain, general health, vitality, social functioning, emotional role functioning and mental health) that can be grouped into two dimensions: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). All scales have transformed scores from 0‐100, with higher scores indicating better health. The MCID for the SF‐36 has been estimated to be approximately five points (<a href="./references#CD012425-bbs2-0194" title="WyrwichKW , TierneyWM , BabuAN , KroenkeK , WolinskyFD . A comparison of clinically important differences in health‐related quality of life for patients with chronic lung disease, asthma, or heart disease. Health Services Research2005;40(2):577‐91. [PUBMED: 15762908] ">Wyrwich 2005</a>). </p> <p>Three studies (1406 participants) used the SF‐36 (<a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a>; <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>; <a href="./references#CD012425-bbs2-0031" title="MurchieP , NicolsonMC , HannafordPC , RajaEA , LeeAJ , CampbellNC . Patient satisfaction with GP‐led melanoma follow‐up: a randomised controlled trial. British Journal of Cancer2010;102(10):1447‐55. ">Murchie 2010</a>). We were unable to pool the data for meta‐analysis as the three studies did not report on the same subscales at 12 months of follow‐up (criteria prespecified in the <a href="#CD012425-sec-0059">Data synthesis</a> section). However, all three studies reported that non‐specialist‐led follow‐up may make little or no difference to health‐related quality of life. Two studies (1264 participants) investigated GP‐led follow‐up after breast cancer. <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a> reported small differences between groups in mean change scores from baseline to trial end at 18 months' follow‐up for social functioning (−1.8, 95% CI −7.2 to 3.5), mental health (0.5, 95% CI −4.1 to 5.1) and general health (0.6, 95% CI −3.6 to 4.8). <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a> reported a figure showing similar mean scores between groups over time for SF‐36 MCS and PCS with up to 60 months' follow‐up. <a href="./references#CD012425-bbs2-0031" title="MurchieP , NicolsonMC , HannafordPC , RajaEA , LeeAJ , CampbellNC . Patient satisfaction with GP‐led melanoma follow‐up: a randomised controlled trial. British Journal of Cancer2010;102(10):1447‐55. ">Murchie 2010</a> reported little or no effect of GP‐led follow‐up after melanoma on SF‐36 scores for all subscales at 12 months' follow‐up with P values ranging from P = 0.149 to P = 1.000 (142 participants). </p> </section> <section id="CD012425-sec-0094"> <h6 class="title">European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC‐C30) </h6> <p>The EORTC‐C30 is a 30‐item, self‐reported questionnaire consisting of six subscales (physical functioning, role functioning, social functioning, emotional functioning, cognitive functioning and global health status) and other single items on symptoms (<a href="./references#CD012425-bbs2-0131" title="AaronsonNK , AhmedzaiS , BergmanB , BullingerM , CullA , DuezNJ , et al. The European Organization for Research and Treatment of Cancer QLQ‐C30: a quality‐of‐life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute1993;85(5):365‐76. [PUBMED: 8433390] ">Aaronson 1993</a>). All scales have scores from 0 to 100, with higher scores indicating better health. The MCID for the EORTC‐C30 has been estimated to be approximately 10 points (<a href="./references#CD012425-bbs2-0169" title="OsobaD , RodriguesG , MylesJ , ZeeB , PaterJ . Interpreting the significance of changes in health‐related quality‐of‐life scores. Journal of Clinical Oncology1998;16(1):139‐44. [PUBMED: 9440735] ">Osoba 1998</a>). </p> <p>Seven studies reported on quality of life using the EORTC‐C30 (<a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad 2013</a>; <a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a>; <a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a>; <a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a>; <a href="./references#CD012425-bbs2-0021" title="DentJ , ToppingA , FergusonC , StephensonJ , McCoyM , AllinsonV , et al. To follow up or not? A new model of supportive care for early breast cancer. Journal of Clinical Oncology2011;29(15 Suppl 1):no pagination. KirshbaumMN , DentJ , StephensonJ , ToppingAE , AllinsonV , McCoyM , et al. Open access follow‐up care for early breast cancer: a randomised controlled quality of life analysis. European Journal of Cancer Care2017;26(4):e12577. [DOI: 10.1111/ecc.12577] ">Kirshbaum 2017</a>; <a href="./references#CD012425-bbs2-0030" title="MorrisonV , SpencerLH , LeesonS . Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a randomised feasibility trial. Psycho‐oncology2017;26(Suppl 2):3‐4. MorrisonV , SpencerLH , TottonN , PyeK , YeoST , ButterworthC , et al. Trial of optimal personalised care after treatment‐gynaecological cancer (TOPCAT‐G): a randomized feasibility trial. International Journal of Gynecological Cancer2018;28(2):401‐11. PyeK , TottonN , StuartN , WhitakerR , MorrisonV , EdwardsRT , et al. Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a study protocol for a randomised feasibility trial. Pilot and Feasibility Studies2016;2:67. [DOI 10.1186/s40814‐016‐0108‐5] ">Morrison 2018</a>; <a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a>). We were able to pool data from four studies investigating GP‐led follow‐up after colon cancer (<a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad 2013</a>), nurse‐led follow‐up after breast cancer (<a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a>), patient‐initiated follow‐up after breast cancer (<a href="./references#CD012425-bbs2-0021" title="DentJ , ToppingA , FergusonC , StephensonJ , McCoyM , AllinsonV , et al. To follow up or not? A new model of supportive care for early breast cancer. Journal of Clinical Oncology2011;29(15 Suppl 1):no pagination. KirshbaumMN , DentJ , StephensonJ , ToppingAE , AllinsonV , McCoyM , et al. Open access follow‐up care for early breast cancer: a randomised controlled quality of life analysis. European Journal of Cancer Care2017;26(4):e12577. [DOI: 10.1111/ecc.12577] ">Kirshbaum 2017</a>), and nurse‐led follow‐up after oesophageal cancer (<a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a>). We carried out meta‐analyses for all six subscales, although <a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a> did not report data for the subscales physical functioning, cognitive functioning and social functioning. Compared to specialist‐led follow‐up, non‐specialist‐led follow‐up may make little or no difference at 12 months to: global health status (MD 1.06, 95% CI −1.83 to 3.95; P = 0.47, I<sup>2</sup> = 32%; 4 studies, 605 participants; <a href="./references#CD012425-fig-0008" title="">Analysis 1.2</a>); physical functioning (MD 1.65, 95% CI −2.35 to 5.64; P = 0.42, I<sup>2</sup> = 47%; 3 studies, 306 participants; <a href="./references#CD012425-fig-0009" title="">Analysis 1.3</a>); role functioning (MD 2.36, 95% CI −2.75 to 7.47; P = 0.36, I<sup>2</sup> = 48%; 4 studies; participants = 605; <a href="./references#CD012425-fig-0010" title="">Analysis 1.4</a>); emotional functioning (MD 0.52, 95% CI −2.06 to 3.09; P = 0.69, I<sup>2</sup> = 0%; 4 studies, 605 participants; <a href="./references#CD012425-fig-0011" title="">Analysis 1.5</a>); and cognitive functioning (MD 4.41, 95% CI −1.52 to 10.34; P = 0.14, I<sup>2</sup> = 54%; 3 studies, 306 participants; <a href="./references#CD012425-fig-0012" title="">Analysis 1.6</a>). However, non‐specialist‐led follow‐up may slightly improve social functioning (MD 5.39, 95% CI 1.60 to 9.17; P = 0.005; I<sup>2</sup> = 0%; 3 studies, 306 participants; <a href="./references#CD012425-fig-0013" title="">Analysis 1.7</a>), but this difference was not large enough to be clinically meaningful. We judged the certainty of evidence to be low and downgraded by two levels for serious concerns regarding inconsistency and imprecision due to differing estimates of effect and wide confidence intervals. </p> <p>Of the remaining three studies, two studies (320 participants) did not contradict the results of the meta‐analyses. <a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a> reported little or no effect of nurse‐led telephone follow‐up after endometrial cancer on all six subscales at time points ranging from 3 to 12 months after baseline data collection, and <a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a> investigated patient‐initiated follow‐up after breast cancer and reported similar median scores between groups on all subscales after 12 months of follow‐up. The third study (<a href="./references#CD012425-bbs2-0030" title="MorrisonV , SpencerLH , LeesonS . Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a randomised feasibility trial. Psycho‐oncology2017;26(Suppl 2):3‐4. MorrisonV , SpencerLH , TottonN , PyeK , YeoST , ButterworthC , et al. Trial of optimal personalised care after treatment‐gynaecological cancer (TOPCAT‐G): a randomized feasibility trial. International Journal of Gynecological Cancer2018;28(2):401‐11. PyeK , TottonN , StuartN , WhitakerR , MorrisonV , EdwardsRT , et al. Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a study protocol for a randomised feasibility trial. Pilot and Feasibility Studies2016;2:67. [DOI 10.1186/s40814‐016‐0108‐5] ">Morrison 2018</a>; 24 participants), reported improved health‐related quality of life for nurse‐led telephone follow‐up after gynaecological cancer at six months for global health (MD 4.2, no 95% CI)<i>,</i> physical functioning (MD 14.3, no 95% CI) and emotional functioning (MD 1.6, no 95% CI). </p> </section> <section id="CD012425-sec-0095"> <h6 class="title">Other measures of health‐related quality of life</h6> <p>Four studies also reported that non‐specialist‐led follow‐up made little or no difference to health‐related quality of life using other measures than the above (659 participants). <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a> reported on health‐related quality of life using the 12‐item Short Form Health Survey (SF‐12; <a href="./references#CD012425-bbs2-0191" title="WareJ , KosinskiM , KellerS . SF‐12: how to score the SF‐12 physical and mental health summary scales. 2nd Edition. Boston Massachusetts: The Health Institute, New England Medical Centre, 1995. ">Ware 1995</a>), and reported little or no effect of GP‐led follow‐up after colon cancer on the median scores for both subscales at 12 months (PCS, P = 0.887; MCS, P = 0.510). Two studies reported on health‐related quality of life using the EuroQol‐5D (<a href="./references#CD012425-bbs2-0149" title="EuroQoL Group. EuroQol ‐ a new facility for the measurement of health‐related quality of life. Health Policy1990;16(3):199‐208. ">EuroQoL 1990</a>). <a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad 2013</a> reported little or no effect of GP‐led follow‐up after colon cancer in mean differences from baseline to 24 months (P = 0.48) and <a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a> reported little or no effect of nurse‐led follow‐up after oesophageal cancer on mean scores at 13 months (P = 0.58). Using the Functional Assessment of Cancer Therapy (FACT) scale, <a href="./references#CD012425-bbs2-0044" title="SheppardC , HigginsB , WiseM , YiangouC , DuboisD , KilburnS . Breast cancer follow up: a randomised controlled trial comparing point of need access versus routine 6‐monthly clinical review. European Journal of Oncology Nursing2009;13(1):2‐8. [DOI: 10.1016/j.ejon.2008.11.005] ">Sheppard 2009</a> reported little or no effect of nurse‐led patient‐initiated follow‐up after breast cancer on mean scores at 18 months of follow‐up (P = 0.952). </p> </section> </section> <section id="CD012425-sec-0096"> <h5 class="title">Anxiety</h5> <p>Twelve studies reported on the outcome of anxiety using a variety of measurement scales and with varying follow‐up periods (<a href="./references#CD012425-bbs2-0002" title="BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Economic evaluation of a randomized clinical trial of hospital versus telephone follow‐up after treatment for breast cancer. British Journal of Surgery2009;96(12):1406‐15. [DOI: 10.1002/bjs.6753] BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Is telephone follow‐up by specialist nurses a cost effective approach?. European Journal of Cancer Supplements2009;7(2‐3):230‐1. BeaverK , Tysver‐RobinsonD , CampbellM , TwomeyM , WilliamsonS , HindleyA , et al. Comparing hospital and telephone follow‐up after treatment for breast cancer: randomised equivalence trial. BMJ2009;338:a3147. [DOI: 10.1136/bmj.a3147] ">Beaver 2009</a>; <a href="./references#CD012425-bbs2-0003" title="BeaverK , CampbellM , WilliamsonS , ProcterD , SheridanJ , HeathJ , et al. An exploratory randomized controlled trial comparing telephone and hospital follow‐up after treatment for colorectal cancer. Colorectal Disease2012;14(10):1201‐9. [DOI: 10.1111/j.1463‐1318.2012.02936.x] ">Beaver 2012</a>; <a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a>; <a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a>; <a href="./references#CD012425-bbs2-0009" title="ACTRN12610000938000 . The ProCare Trial: a randomised controlled trial of follow up of men with prostate cancer in primary care. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336116 (first received 20 December 2016). EmeryJ , DooreyJ , JeffordM , KingM , PirottaM , HayneD , et al. Protocol for the ProCare Trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. BMJ Open2014;4(3):e004972. [DOI: 10.1136/bmjopen‐2014‐004972] EmeryJ , SchofieldP , JeffordM , KingM , PirottaM , HayneD , et al. The ProCare trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. Asia‐Pacific Journal of Clinical Oncology2014;10:157. EmeryJD , JeffordM , KingM , HayneD , MartinA , DooreyJ , et al. ProCare Trial: a phase II randomized controlled trial of shared care for follow‐up of men with prostate cancer. BJU International2016;119(3):381‐89. [DOI: 10.1111/bju.13593] KingM . Procare/PC4 study update. Asia‐Pacific Journal of Clinical Oncology2012;8:23. ">Emery 2016</a>; <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a>; <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>; <a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a>; <a href="./references#CD012425-bbs2-0021" title="DentJ , ToppingA , FergusonC , StephensonJ , McCoyM , AllinsonV , et al. To follow up or not? A new model of supportive care for early breast cancer. Journal of Clinical Oncology2011;29(15 Suppl 1):no pagination. KirshbaumMN , DentJ , StephensonJ , ToppingAE , AllinsonV , McCoyM , et al. Open access follow‐up care for early breast cancer: a randomised controlled quality of life analysis. European Journal of Cancer Care2017;26(4):e12577. [DOI: 10.1111/ecc.12577] ">Kirshbaum 2017</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0031" title="MurchieP , NicolsonMC , HannafordPC , RajaEA , LeeAJ , CampbellNC . Patient satisfaction with GP‐led melanoma follow‐up: a randomised controlled trial. British Journal of Cancer2010;102(10):1447‐55. ">Murchie 2010</a>; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>), and two studies reported on fear of recurrence (<a href="./references#CD012425-bbs2-0018" title="JeppesenMM , JensenPT , GilsaD , DePont ChristensenR , JensenMM , MogensenO . The effect of patient‐initiated follow‐up on fear of recurrence and health care use: a randomized trial in early‐stage endometrial cancer. International Journal of Gynecological Cancer2017;27(Supplement 4):1107. JeppesenMM , JensenPT , HansenDG , ChristensenRD , MogensenO . Authors' reply re: Patient‐initiated follow‐up affects fear of recurrence and health care use: a randomised trial in early‐stage endometrial cancer. BJOG2018;125(13):1778‐9. JeppesenMM , JensenPT , HansenDG , ChristensenRD , MogensenO . Patient‐initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early‐stage endometrial cancer. BJOG2018;125(13):1705‐14. TegnerowiczJ . Re: Patient‐initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early‐stage endometrial cancer. BJOG2018;1125(13):1778. ">Jeppesen 2018</a>; <a href="./references#CD012425-bbs2-0044" title="SheppardC , HigginsB , WiseM , YiangouC , DuboisD , KilburnS . Breast cancer follow up: a randomised controlled trial comparing point of need access versus routine 6‐monthly clinical review. European Journal of Oncology Nursing2009;13(1):2‐8. [DOI: 10.1016/j.ejon.2008.11.005] ">Sheppard 2009</a>). We present below results according to measurement scale. </p> <section id="CD012425-sec-0097"> <h6 class="title">State Trait Anxiety Inventory (STAI) ‐ state subscale</h6> <p>The STAI is a 40‐item, self‐reported questionnaire consisting of two subscales (state anxiety and trait anxiety; <a href="./references#CD012425-bbs2-0185" title="SpielbergerCD , GorsuchRL , LusheneR , VaggPR , JacobsGA . Manual for the State‐Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press, 1983. ">Spielberger 1983</a>). Subscales have scores ranging from 20 to 80, with higher scores indicating greater anxiety. The MCID for the STAI has been estimated to be approximately 10 points (<a href="./references#CD012425-bbs2-0139" title="CorsalettiBF , ProencaMG , BiscaGK , LeiteJC , BellinettiLM , PittaF . Minimal important difference for anxiety and depression surveys after intervention to increase daily physical activity in smokers. Fisioterapia e Pesquisa2014;21(4):359‐64. ">Corsaletti 2014</a>). </p> <p>Four studies reported on state anxiety using STAI (<a href="./references#CD012425-bbs2-0002" title="BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Economic evaluation of a randomized clinical trial of hospital versus telephone follow‐up after treatment for breast cancer. British Journal of Surgery2009;96(12):1406‐15. [DOI: 10.1002/bjs.6753] BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Is telephone follow‐up by specialist nurses a cost effective approach?. European Journal of Cancer Supplements2009;7(2‐3):230‐1. BeaverK , Tysver‐RobinsonD , CampbellM , TwomeyM , WilliamsonS , HindleyA , et al. Comparing hospital and telephone follow‐up after treatment for breast cancer: randomised equivalence trial. BMJ2009;338:a3147. [DOI: 10.1136/bmj.a3147] ">Beaver 2009</a>; <a href="./references#CD012425-bbs2-0003" title="BeaverK , CampbellM , WilliamsonS , ProcterD , SheridanJ , HeathJ , et al. An exploratory randomized controlled trial comparing telephone and hospital follow‐up after treatment for colorectal cancer. Colorectal Disease2012;14(10):1201‐9. [DOI: 10.1111/j.1463‐1318.2012.02936.x] ">Beaver 2012</a>; <a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a>; <a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a>), and three reported data that we could pool in a meta‐analysis (<a href="./references#CD012425-bbs2-0002" title="BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Economic evaluation of a randomized clinical trial of hospital versus telephone follow‐up after treatment for breast cancer. British Journal of Surgery2009;96(12):1406‐15. [DOI: 10.1002/bjs.6753] BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Is telephone follow‐up by specialist nurses a cost effective approach?. European Journal of Cancer Supplements2009;7(2‐3):230‐1. BeaverK , Tysver‐RobinsonD , CampbellM , TwomeyM , WilliamsonS , HindleyA , et al. Comparing hospital and telephone follow‐up after treatment for breast cancer: randomised equivalence trial. BMJ2009;338:a3147. [DOI: 10.1136/bmj.a3147] ">Beaver 2009</a>; <a href="./references#CD012425-bbs2-0003" title="BeaverK , CampbellM , WilliamsonS , ProcterD , SheridanJ , HeathJ , et al. An exploratory randomized controlled trial comparing telephone and hospital follow‐up after treatment for colorectal cancer. Colorectal Disease2012;14(10):1201‐9. [DOI: 10.1111/j.1463‐1318.2012.02936.x] ">Beaver 2012</a>; <a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a>). Compared to specialist‐led follow‐up, non‐specialist‐led follow‐up may make little or no difference to anxiety at 12 months' follow‐up as measured by STAI state subscale (MD −0.55, 95% CI −2.41 to 1.32; P = 0.57; I<sup>2</sup> = 0%; 3 studies, 602 participants; <a href="./references#CD012425-fig-0014" title="">Analysis 1.8</a>). We judged the certainty of evidence to be low as we downgraded by two levels for serious concerns regarding study limitations (high risk of attrition bias for two of the studies) and indirectness due to only three studies. </p> <p>We did not include results from <a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a> in the meta‐analysis as the reported final scores included follow‐up periods of 3, 6 and 12 months (259 participants). However, the study reported the non‐inferiority of nurse‐led follow‐up in endometrial cancer (MD 0.7, 95% CI −1.9 to 3.3). </p> </section> <section id="CD012425-sec-0098"> <h6 class="title">Hospital Anxiety and Depression Scale (HADS)‐Anxiety subscale</h6> <p>The HADS is a 14‐item, self‐reported questionnaire consisting of two subscales (anxiety and depression; <a href="./references#CD012425-bbs2-0182" title="SnaithRP . The Hospital Anxiety And Depression Scale. Health and Quality of Life Outcomes2003;1:29. [PUBMED: 12914662] ">Snaith 2003</a>). Subscales have scores from 0 to 21, with higher scores indicating greater anxiety or depression. The MCID for the HADS has been estimated to be approximately 1.5 points (<a href="./references#CD012425-bbs2-0173" title="PuhanMA , FreyM , BuchiS , SchunemannHJ . The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health and Quality of Life Outcomes2008;6:46. [PUBMED: 18597689] ">Puhan 2008</a>). </p> <p>Eight studies reported on anxiety using the HADS‐Anxiety subscale (<a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a>; <a href="./references#CD012425-bbs2-0009" title="ACTRN12610000938000 . The ProCare Trial: a randomised controlled trial of follow up of men with prostate cancer in primary care. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336116 (first received 20 December 2016). EmeryJ , DooreyJ , JeffordM , KingM , PirottaM , HayneD , et al. Protocol for the ProCare Trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. BMJ Open2014;4(3):e004972. [DOI: 10.1136/bmjopen‐2014‐004972] EmeryJ , SchofieldP , JeffordM , KingM , PirottaM , HayneD , et al. The ProCare trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. Asia‐Pacific Journal of Clinical Oncology2014;10:157. EmeryJD , JeffordM , KingM , HayneD , MartinA , DooreyJ , et al. ProCare Trial: a phase II randomized controlled trial of shared care for follow‐up of men with prostate cancer. BJU International2016;119(3):381‐89. [DOI: 10.1111/bju.13593] KingM . Procare/PC4 study update. Asia‐Pacific Journal of Clinical Oncology2012;8:23. ">Emery 2016</a>; <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a>; <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>; <a href="./references#CD012425-bbs2-0021" title="DentJ , ToppingA , FergusonC , StephensonJ , McCoyM , AllinsonV , et al. To follow up or not? A new model of supportive care for early breast cancer. Journal of Clinical Oncology2011;29(15 Suppl 1):no pagination. KirshbaumMN , DentJ , StephensonJ , ToppingAE , AllinsonV , McCoyM , et al. Open access follow‐up care for early breast cancer: a randomised controlled quality of life analysis. European Journal of Cancer Care2017;26(4):e12577. [DOI: 10.1111/ecc.12577] ">Kirshbaum 2017</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0031" title="MurchieP , NicolsonMC , HannafordPC , RajaEA , LeeAJ , CampbellNC . Patient satisfaction with GP‐led melanoma follow‐up: a randomised controlled trial. British Journal of Cancer2010;102(10):1447‐55. ">Murchie 2010</a>; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>). Five studies contributed data to the meta‐analysis investigating patient‐initiated follow‐up after breast cancer (<a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a>), shared‐care after prostate cancer (<a href="./references#CD012425-bbs2-0009" title="ACTRN12610000938000 . The ProCare Trial: a randomised controlled trial of follow up of men with prostate cancer in primary care. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336116 (first received 20 December 2016). EmeryJ , DooreyJ , JeffordM , KingM , PirottaM , HayneD , et al. Protocol for the ProCare Trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. BMJ Open2014;4(3):e004972. [DOI: 10.1136/bmjopen‐2014‐004972] EmeryJ , SchofieldP , JeffordM , KingM , PirottaM , HayneD , et al. The ProCare trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. Asia‐Pacific Journal of Clinical Oncology2014;10:157. EmeryJD , JeffordM , KingM , HayneD , MartinA , DooreyJ , et al. ProCare Trial: a phase II randomized controlled trial of shared care for follow‐up of men with prostate cancer. BJU International2016;119(3):381‐89. [DOI: 10.1111/bju.13593] KingM . Procare/PC4 study update. Asia‐Pacific Journal of Clinical Oncology2012;8:23. ">Emery 2016</a>), GP‐led follow‐up after breast cancer (<a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>), patient‐initiated follow‐up after breast cancer (<a href="./references#CD012425-bbs2-0021" title="DentJ , ToppingA , FergusonC , StephensonJ , McCoyM , AllinsonV , et al. To follow up or not? A new model of supportive care for early breast cancer. Journal of Clinical Oncology2011;29(15 Suppl 1):no pagination. KirshbaumMN , DentJ , StephensonJ , ToppingAE , AllinsonV , McCoyM , et al. Open access follow‐up care for early breast cancer: a randomised controlled quality of life analysis. European Journal of Cancer Care2017;26(4):e12577. [DOI: 10.1111/ecc.12577] ">Kirshbaum 2017</a>), and GP‐led follow‐up after colon cancer (<a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>). Compared to specialist‐led follow‐up, non‐specialist‐led follow‐up probably makes little or no difference to anxiety at 12 months' follow‐up as measured by HADS‐Anxiety subscale (MD −0.03, 95% CI −0.73 to 0.67; P = 0.94, I<sup>2</sup> = 51%; 5 studies, 1266 participants; <a href="./references#CD012425-fig-0015" title="">Analysis 1.9</a>). Sensitivity analysis (where we removed estimates that were indirectly derived from <a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a>) did not change our conclusion (MD 0.27, 95% CI −0.15 to 0.69; P = 0.21; 4 studies, 1210 participants). We judged the certainty of evidence to be moderate as we downgraded by one level for concerns regarding inconsistency of results (I<sup>2</sup> = 51%) and indirectness due to few studies. </p> <p>The remaining three studies did not contradict the results of the meta‐analyses (702 participants). <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a> reported little or no effect of GP‐led follow‐up after breast cancer on mean change from baseline to the end of the study (MD 0.4, 95% CI −0.3 to 1.2). <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a> and <a href="./references#CD012425-bbs2-0031" title="MurchieP , NicolsonMC , HannafordPC , RajaEA , LeeAJ , CampbellNC . Patient satisfaction with GP‐led melanoma follow‐up: a randomised controlled trial. British Journal of Cancer2010;102(10):1447‐55. ">Murchie 2010</a> reported dichotomised results with little or no effect of nurse‐led follow‐up after breast cancer at 18 months (RR 1.2, 95% CI 0.4 to 3.1) and GP‐led follow‐up after melanoma at 12 months (P = 0.87) respectively. </p> </section> <section id="CD012425-sec-0099"> <h6 class="title">Fear of recurrence</h6> <p>Two studies reported conflicting results on fear of recurrence. <a href="./references#CD012425-bbs2-0018" title="JeppesenMM , JensenPT , GilsaD , DePont ChristensenR , JensenMM , MogensenO . The effect of patient‐initiated follow‐up on fear of recurrence and health care use: a randomized trial in early‐stage endometrial cancer. International Journal of Gynecological Cancer2017;27(Supplement 4):1107. JeppesenMM , JensenPT , HansenDG , ChristensenRD , MogensenO . Authors' reply re: Patient‐initiated follow‐up affects fear of recurrence and health care use: a randomised trial in early‐stage endometrial cancer. BJOG2018;125(13):1778‐9. JeppesenMM , JensenPT , HansenDG , ChristensenRD , MogensenO . Patient‐initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early‐stage endometrial cancer. BJOG2018;125(13):1705‐14. TegnerowiczJ . Re: Patient‐initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early‐stage endometrial cancer. BJOG2018;1125(13):1778. ">Jeppesen 2018</a> reported that fear of recurrence decreased more in the comparison group than in the patient‐initiated group at 10 months' follow‐up (MD −5.9, 95% CI −10.9 to −0.9; P = 0.02; 214 participants) as measured by the Fear of Cancer Recurrence Inventory (<a href="./references#CD012425-bbs2-0181" title="SimardS , SavardJ . Fear of Cancer Recurrence Inventory: development and initial validation of a multidimensional measure of fear of cancer recurrence. Supportive Care in Cancer2009;17:241‐51. ">Simard 2009</a>), while <a href="./references#CD012425-bbs2-0044" title="SheppardC , HigginsB , WiseM , YiangouC , DuboisD , KilburnS . Breast cancer follow up: a randomised controlled trial comparing point of need access versus routine 6‐monthly clinical review. European Journal of Oncology Nursing2009;13(1):2‐8. [DOI: 10.1016/j.ejon.2008.11.005] ">Sheppard 2009</a> reported little or no effect of nurse‐led patient‐initiated follow‐up after breast cancer on fear of recurrence at 18‐months (MD 0.5 95% CI −0.3 to 1.0; 237 participants) using a three‐item questionnaire that was yet to be tested at that time. </p> </section> </section> <section id="CD012425-sec-0100"> <h5 class="title">Depression</h5> <p>Eleven studies reported on the outcome of depression or psychological distress using a variety of measurement scales and with varying follow‐up periods (<a href="./references#CD012425-bbs2-0002" title="BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Economic evaluation of a randomized clinical trial of hospital versus telephone follow‐up after treatment for breast cancer. British Journal of Surgery2009;96(12):1406‐15. [DOI: 10.1002/bjs.6753] BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Is telephone follow‐up by specialist nurses a cost effective approach?. European Journal of Cancer Supplements2009;7(2‐3):230‐1. BeaverK , Tysver‐RobinsonD , CampbellM , TwomeyM , WilliamsonS , HindleyA , et al. Comparing hospital and telephone follow‐up after treatment for breast cancer: randomised equivalence trial. BMJ2009;338:a3147. [DOI: 10.1136/bmj.a3147] ">Beaver 2009</a>; <a href="./references#CD012425-bbs2-0003" title="BeaverK , CampbellM , WilliamsonS , ProcterD , SheridanJ , HeathJ , et al. An exploratory randomized controlled trial comparing telephone and hospital follow‐up after treatment for colorectal cancer. Colorectal Disease2012;14(10):1201‐9. [DOI: 10.1111/j.1463‐1318.2012.02936.x] ">Beaver 2012</a>; <a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a>; <a href="./references#CD012425-bbs2-0009" title="ACTRN12610000938000 . The ProCare Trial: a randomised controlled trial of follow up of men with prostate cancer in primary care. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336116 (first received 20 December 2016). EmeryJ , DooreyJ , JeffordM , KingM , PirottaM , HayneD , et al. Protocol for the ProCare Trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. BMJ Open2014;4(3):e004972. [DOI: 10.1136/bmjopen‐2014‐004972] EmeryJ , SchofieldP , JeffordM , KingM , PirottaM , HayneD , et al. The ProCare trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. Asia‐Pacific Journal of Clinical Oncology2014;10:157. EmeryJD , JeffordM , KingM , HayneD , MartinA , DooreyJ , et al. ProCare Trial: a phase II randomized controlled trial of shared care for follow‐up of men with prostate cancer. BJU International2016;119(3):381‐89. [DOI: 10.1111/bju.13593] KingM . Procare/PC4 study update. Asia‐Pacific Journal of Clinical Oncology2012;8:23. ">Emery 2016</a>; <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a>; <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>; <a href="./references#CD012425-bbs2-0021" title="DentJ , ToppingA , FergusonC , StephensonJ , McCoyM , AllinsonV , et al. To follow up or not? A new model of supportive care for early breast cancer. Journal of Clinical Oncology2011;29(15 Suppl 1):no pagination. KirshbaumMN , DentJ , StephensonJ , ToppingAE , AllinsonV , McCoyM , et al. Open access follow‐up care for early breast cancer: a randomised controlled quality of life analysis. European Journal of Cancer Care2017;26(4):e12577. [DOI: 10.1111/ecc.12577] ">Kirshbaum 2017</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0031" title="MurchieP , NicolsonMC , HannafordPC , RajaEA , LeeAJ , CampbellNC . Patient satisfaction with GP‐led melanoma follow‐up: a randomised controlled trial. British Journal of Cancer2010;102(10):1447‐55. ">Murchie 2010</a>; <a href="./references#CD012425-bbs2-0044" title="SheppardC , HigginsB , WiseM , YiangouC , DuboisD , KilburnS . Breast cancer follow up: a randomised controlled trial comparing point of need access versus routine 6‐monthly clinical review. European Journal of Oncology Nursing2009;13(1):2‐8. [DOI: 10.1016/j.ejon.2008.11.005] ">Sheppard 2009</a>; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>). We present a synthesis according to measurement scale below: </p> <section id="CD012425-sec-0101"> <h6 class="title">Hospital Anxiety and Depression Scale (HADS)‐Depression subscale</h6> <p>Eight studies reported on depression using the HADS‐Depression subscale (<a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a>; <a href="./references#CD012425-bbs2-0009" title="ACTRN12610000938000 . The ProCare Trial: a randomised controlled trial of follow up of men with prostate cancer in primary care. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336116 (first received 20 December 2016). EmeryJ , DooreyJ , JeffordM , KingM , PirottaM , HayneD , et al. Protocol for the ProCare Trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. BMJ Open2014;4(3):e004972. [DOI: 10.1136/bmjopen‐2014‐004972] EmeryJ , SchofieldP , JeffordM , KingM , PirottaM , HayneD , et al. The ProCare trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. Asia‐Pacific Journal of Clinical Oncology2014;10:157. EmeryJD , JeffordM , KingM , HayneD , MartinA , DooreyJ , et al. ProCare Trial: a phase II randomized controlled trial of shared care for follow‐up of men with prostate cancer. BJU International2016;119(3):381‐89. [DOI: 10.1111/bju.13593] KingM . Procare/PC4 study update. Asia‐Pacific Journal of Clinical Oncology2012;8:23. ">Emery 2016</a>; <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a>; <a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>; <a href="./references#CD012425-bbs2-0021" title="DentJ , ToppingA , FergusonC , StephensonJ , McCoyM , AllinsonV , et al. To follow up or not? A new model of supportive care for early breast cancer. Journal of Clinical Oncology2011;29(15 Suppl 1):no pagination. KirshbaumMN , DentJ , StephensonJ , ToppingAE , AllinsonV , McCoyM , et al. Open access follow‐up care for early breast cancer: a randomised controlled quality of life analysis. European Journal of Cancer Care2017;26(4):e12577. [DOI: 10.1111/ecc.12577] ">Kirshbaum 2017</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0031" title="MurchieP , NicolsonMC , HannafordPC , RajaEA , LeeAJ , CampbellNC . Patient satisfaction with GP‐led melanoma follow‐up: a randomised controlled trial. British Journal of Cancer2010;102(10):1447‐55. ">Murchie 2010</a>; <a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>). Five studies contributed data to the meta‐analysis investigating patient‐initiated follow‐up after breast cancer (<a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a>), shared‐care after prostate cancer (<a href="./references#CD012425-bbs2-0009" title="ACTRN12610000938000 . The ProCare Trial: a randomised controlled trial of follow up of men with prostate cancer in primary care. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336116 (first received 20 December 2016). EmeryJ , DooreyJ , JeffordM , KingM , PirottaM , HayneD , et al. Protocol for the ProCare Trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. BMJ Open2014;4(3):e004972. [DOI: 10.1136/bmjopen‐2014‐004972] EmeryJ , SchofieldP , JeffordM , KingM , PirottaM , HayneD , et al. The ProCare trial: a phase II randomised controlled trial of shared care for follow‐up of men with prostate cancer. Asia‐Pacific Journal of Clinical Oncology2014;10:157. EmeryJD , JeffordM , KingM , HayneD , MartinA , DooreyJ , et al. ProCare Trial: a phase II randomized controlled trial of shared care for follow‐up of men with prostate cancer. BJU International2016;119(3):381‐89. [DOI: 10.1111/bju.13593] KingM . Procare/PC4 study update. Asia‐Pacific Journal of Clinical Oncology2012;8:23. ">Emery 2016</a>), GP‐led follow‐up after breast cancer (<a href="./references#CD012425-bbs2-0014" title="GrunfeldE , JulianJ , LevineM , PritchardK . A randomized controlled trial (RCT) of long‐term follow‐up for early stage breast cancer comparing family physician to specialist care: a report of secondary outcomes. Journal of Clinical Oncology2006;24(18 Suppl):301s. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Journal of Clinical Oncology2004;22(14):665. GrunfeldE , LevineM , JulianJ , PritchardK , CoyleD , MirskyD . A randomized controlled trial (RCT) of routine follow‐up for early stage breast cancer: a comparison of primary care versus specialist care. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 22:13 Suppl. GrunfeldE , LevineMN , JulianJA , CoyleD , SzechtmanB , MirskyD , et al. Randomized trial of long‐term follow‐up for early‐stage breast cancer: a comparison of family physician versus specialist care. Journal of Clinical Oncology2006;24(6):848‐55. NCT00156039 . Randomized trial of follow‐up strategies in breast cancer. clinicaltrials.gov/ct2/show/NCT00156039 (first received 20 December 2016). WarnerE , WeinrothJ . Family physician versus specialist care for breast cancer follow‐up. Journal of Clinical Oncology2006;24(22):3710. ">Grunfeld 2006</a>), patient‐initiated follow‐up after breast cancer (<a href="./references#CD012425-bbs2-0021" title="DentJ , ToppingA , FergusonC , StephensonJ , McCoyM , AllinsonV , et al. To follow up or not? A new model of supportive care for early breast cancer. Journal of Clinical Oncology2011;29(15 Suppl 1):no pagination. KirshbaumMN , DentJ , StephensonJ , ToppingAE , AllinsonV , McCoyM , et al. Open access follow‐up care for early breast cancer: a randomised controlled quality of life analysis. European Journal of Cancer Care2017;26(4):e12577. [DOI: 10.1111/ecc.12577] ">Kirshbaum 2017</a>) and GP‐led follow‐up after colon cancer (<a href="./references#CD012425-bbs2-0050" title="GallCA , WellerD , EstermanA , PilottoL , McGormK , HammettZ , et al. Patient satisfaction and health‐related quality of life after treatment for colon cancer. Diseases of the Colon and Rectum2007;50(6):801‐9. WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. ANZ Journal of Surgery2002;72 (Suppl):A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. WattchowDA , WellerDP , LewisMC , EstermanA , PilottoLS , McGormK , et al. Randomised controlled trial of general practitioner compared to surgeon follow‐up of patients with colon cancer. Colorectal Disease2005;7(Suppl 1):82. ">Wattchow 2006</a>). Compared to specialist‐led follow‐up, non‐specialist‐led follow‐up makes little or no difference to depression at 12‐months as measured by HADS‐Depression subscale (MD 0.03, 95% CI ‐0.35 to 0.42; P = 0.86; I<sup>2</sup> = 8%; 5 studies, 1266 participants; <a href="./references#CD012425-fig-0016" title="">Analysis 1.10</a>). Sensitivity analysis (where we removed estimates that were indirectly derived from <a href="./references#CD012425-bbs2-0005" title="BrownL , PayneS , RoyleG . Patient‐initiated follow‐up of breast cancer. Psycho‐oncology2002;11(4):346‐55. ">Brown 2002</a>) did not change our conclusion (MD 0.19, 95% CI ‐0.18 to 0.56; P = 0.30; 4 studies, 1210 participants). We judged the certainty of evidence to be high although we had some concerns regarding indirectness due to few studies, but we did not judge it serious enough to warrant downgrading the evidence by a whole level. </p> <p>The remaining three studies did not contradict the results of the meta‐analyses (702 participants). <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a> reported little or no effect on depression for GP‐led follow‐up after breast cancer on mean change from baseline to the end of the trial (MD 0.4, 95% CI −0.2 to 1.1). <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a> and <a href="./references#CD012425-bbs2-0031" title="MurchieP , NicolsonMC , HannafordPC , RajaEA , LeeAJ , CampbellNC . Patient satisfaction with GP‐led melanoma follow‐up: a randomised controlled trial. British Journal of Cancer2010;102(10):1447‐55. ">Murchie 2010</a> reported little or no effect on depression for nurse‐led follow‐up after breast cancer at 18 months (RR 0.5, 95% CI 0.0 to 5.8) and GP‐led follow‐up after melanoma at 12 months (P = 0.91) respectively. </p> </section> <section id="CD012425-sec-0102"> <h6 class="title">Other measures of depression</h6> <p>The remaining three studies (676 participants) also reported that non‐specialist‐led follow‐up may make little or no difference to depression. The studies reported using the General Heath Questionnaire (GHQ‐12; <a href="./references#CD012425-bbs2-0150" title="GoldbergDP . Manual of the General Health Questionnaire. Windsor, UK: NFER Nelson, 1978. ">Goldberg 1978</a>). <a href="./references#CD012425-bbs2-0002" title="BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Economic evaluation of a randomized clinical trial of hospital versus telephone follow‐up after treatment for breast cancer. British Journal of Surgery2009;96(12):1406‐15. [DOI: 10.1002/bjs.6753] BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Is telephone follow‐up by specialist nurses a cost effective approach?. European Journal of Cancer Supplements2009;7(2‐3):230‐1. BeaverK , Tysver‐RobinsonD , CampbellM , TwomeyM , WilliamsonS , HindleyA , et al. Comparing hospital and telephone follow‐up after treatment for breast cancer: randomised equivalence trial. BMJ2009;338:a3147. [DOI: 10.1136/bmj.a3147] ">Beaver 2009</a> reported that, "Although the percentage of cases (scores ≥4) was consistently higher in the hospital group at the start, middle, and end of the trial, differences between the groups at each time point were not significant". <a href="./references#CD012425-bbs2-0003" title="BeaverK , CampbellM , WilliamsonS , ProcterD , SheridanJ , HeathJ , et al. An exploratory randomized controlled trial comparing telephone and hospital follow‐up after treatment for colorectal cancer. Colorectal Disease2012;14(10):1201‐9. [DOI: 10.1111/j.1463‐1318.2012.02936.x] ">Beaver 2012</a> reported that mean GHQ‐12 score was slightly higher in the hospital arm (Cohen’s d = 0.11), and <a href="./references#CD012425-bbs2-0044" title="SheppardC , HigginsB , WiseM , YiangouC , DuboisD , KilburnS . Breast cancer follow up: a randomised controlled trial comparing point of need access versus routine 6‐monthly clinical review. European Journal of Oncology Nursing2009;13(1):2‐8. [DOI: 10.1016/j.ejon.2008.11.005] ">Sheppard 2009</a> reported little or no differences between the point‐of‐need (patient‐initiated) and routine follow‐up (MD 0.1, 95% CI −1.4 to 1.0, P = 0.767). </p> </section> </section> <section id="CD012425-sec-0103"> <h5 class="title">Cost</h5> <p>Eight studies reported cost outcomes (<a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad 2013</a>; <a href="./references#CD012425-bbs2-0002" title="BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Economic evaluation of a randomized clinical trial of hospital versus telephone follow‐up after treatment for breast cancer. British Journal of Surgery2009;96(12):1406‐15. [DOI: 10.1002/bjs.6753] BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Is telephone follow‐up by specialist nurses a cost effective approach?. European Journal of Cancer Supplements2009;7(2‐3):230‐1. BeaverK , Tysver‐RobinsonD , CampbellM , TwomeyM , WilliamsonS , HindleyA , et al. Comparing hospital and telephone follow‐up after treatment for breast cancer: randomised equivalence trial. BMJ2009;338:a3147. [DOI: 10.1136/bmj.a3147] ">Beaver 2009</a>; <a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a>; <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a>; <a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0030" title="MorrisonV , SpencerLH , LeesonS . Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a randomised feasibility trial. Psycho‐oncology2017;26(Suppl 2):3‐4. MorrisonV , SpencerLH , TottonN , PyeK , YeoST , ButterworthC , et al. Trial of optimal personalised care after treatment‐gynaecological cancer (TOPCAT‐G): a randomized feasibility trial. International Journal of Gynecological Cancer2018;28(2):401‐11. PyeK , TottonN , StuartN , WhitakerR , MorrisonV , EdwardsRT , et al. Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a study protocol for a randomised feasibility trial. Pilot and Feasibility Studies2016;2:67. [DOI 10.1186/s40814‐016‐0108‐5] ">Morrison 2018</a>; <a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a>), but due to the substantial heterogeneity in how the outcome was measured and reported, we could not pool the results in a meta‐analysis (1756 participants). Details of how each study measured and reported cost outcomes are summarised in <a href="#CD012425-tbl-0004">Table 1</a>. In general, <a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad 2013</a>; <a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a>; <a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a>; <a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a>; <a href="./references#CD012425-bbs2-0030" title="MorrisonV , SpencerLH , LeesonS . Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a randomised feasibility trial. Psycho‐oncology2017;26(Suppl 2):3‐4. MorrisonV , SpencerLH , TottonN , PyeK , YeoST , ButterworthC , et al. Trial of optimal personalised care after treatment‐gynaecological cancer (TOPCAT‐G): a randomized feasibility trial. International Journal of Gynecological Cancer2018;28(2):401‐11. PyeK , TottonN , StuartN , WhitakerR , MorrisonV , EdwardsRT , et al. Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a study protocol for a randomised feasibility trial. Pilot and Feasibility Studies2016;2:67. [DOI 10.1186/s40814‐016‐0108‐5] ">Morrison 2018</a>; and <a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a> reported lower cost per participant in the non‐specialist‐led group, while <a href="./references#CD012425-bbs2-0002" title="BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Economic evaluation of a randomized clinical trial of hospital versus telephone follow‐up after treatment for breast cancer. British Journal of Surgery2009;96(12):1406‐15. [DOI: 10.1002/bjs.6753] BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Is telephone follow‐up by specialist nurses a cost effective approach?. European Journal of Cancer Supplements2009;7(2‐3):230‐1. BeaverK , Tysver‐RobinsonD , CampbellM , TwomeyM , WilliamsonS , HindleyA , et al. Comparing hospital and telephone follow‐up after treatment for breast cancer: randomised equivalence trial. BMJ2009;338:a3147. [DOI: 10.1136/bmj.a3147] ">Beaver 2009</a> and <a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a> reported higher cost per participant in the non‐specialist‐led group. We judged the certainty of evidence to be very low and downgraded by three levels as the substantial heterogeneity led to serious concerns regarding inconsistency, indirectness and imprecision in the way cost was measured and reported across studies. </p> <div class="table" id="CD012425-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of cost outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcome measurement</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GP‐led vs surgeon‐led follow‐up after colon cancer</b> </p> <p> <ul id="CD012425-list-0016"> <li> <p>The cost elements included costs related to hospital visits, GP visits, laboratory tests, radiology examinations, colonoscopy, examinations owing to suspected relapse treatment of recurrence, travelling/transportation, production losses, co‐payments and other participant/family expenses. </p> </li> <li> <p>Cost minimisation analysis was carried out and reported as:</p> <ul id="CD012425-list-0017"> <li> <p>cost per participant per 3‐month follow‐up cycle in GBP</p> </li> <li> <p>mean societal cost in GBP for 24 months' follow‐up: mean (95% CI)</p> </li> </ul> </li> <li> <p>The follow‐up programme initiated 1186 healthcare contacts (GP 678 vs surgeon 508), 1105 diagnostic tests (GP 592 vs surgeon 513) and 778 hospital travels (GP 250 vs surgeon 528). GP‐organised follow‐up was associated with societal cost savings (GBP 8233 vs GBP 9889, P &lt; 0.001). </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cost per participant</p> <p>GBP 292 (255 to 327)</p> <p>Mean societal cost</p> <p>GBP 8233 (7904 to 8619)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cost per participant</p> <p>GBP 351 (315 to 386)</p> <p>Mean societal cost</p> <p>GBP 9889 (9569 to 10194)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0002" title="BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Economic evaluation of a randomized clinical trial of hospital versus telephone follow‐up after treatment for breast cancer. British Journal of Surgery2009;96(12):1406‐15. [DOI: 10.1002/bjs.6753] BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Is telephone follow‐up by specialist nurses a cost effective approach?. European Journal of Cancer Supplements2009;7(2‐3):230‐1. BeaverK , Tysver‐RobinsonD , CampbellM , TwomeyM , WilliamsonS , HindleyA , et al. Comparing hospital and telephone follow‐up after treatment for breast cancer: randomised equivalence trial. BMJ2009;338:a3147. [DOI: 10.1136/bmj.a3147] ">Beaver 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nurse‐led telephone vs hospital follow‐up after breast cancer</b> </p> <p> <ul id="CD012425-list-0018"> <li> <p>Resource use included training of nurses in telephone follow‐up, routine follow‐up consultations and diagnostic tests ordered, participant travel, and time of work and unit costs (e.g. salary, qualifications, ongoing training and clinic overhead) </p> </li> <li> <p>Cost was reported as total NHS (UK) cost per participant in GBP (mean/SD) over a mean of 24 months </p> </li> <li> <p>Owing to the cost of nurse training, greater frequency and longer duration of the telephone consultations, and the frequent use of junior medical staff in hospital clinics, the mean costs of follow‐up consultations were higher with telephone follow‐up (MD GBP 55, bias‐corrected 95% CI GBP 29 to GBP 77). </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GBP 179 (118)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GBP 24 (116)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nurse‐led telephone vs hospital follow‐up after endometrial cancer</b> </p> <p> <ul id="CD012425-list-0019"> <li> <p>Unit cost data were drawn primarily from the unit costs of health and social care and NHS Reference Costs. The cost of a nurse or doctor contact hour included salary (excluding overtime and shift payments), on‐costs (e.g. national insurance contributions), qualifications, the ratio of participant contact to non‐contact time, and overheads. </p> </li> <li> <p>Unit cost data were collected from 2012/13 and inflated from the time of the study using the most recent (2016/17) UK GBP deflator so that costs were expressed in GBP at 2016/17 prices. </p> </li> <li> <p>Reported as total health service mean cost per participant costs at 6 months or 12 months </p> </li> <li> <p>Differences between groups: 6 months, GBP 8 (bias‐corrected 95% GBP −147 to GBP 141); 12 months, GBP −77 (GBP −334 to GBP 154) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months: GBP 434</p> <p>12 months: GBP 746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months: GBP 426</p> <p>12 months: GBP 823</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0007" title="DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . Prospective randomized clinical trial for the evaluation of a stage adjusted reduced follow‐up schedule in cutaneous melanoma patients: results after one year. Annals of Surgical Oncology2016;23(1 Suppl 1):S30. DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . The MELFO‐study: prospective randomized clinical trial for the evaluation of a stage‐adjusted reduced follow‐up schedule in cutaneous melanoma patients ‐ results after 1 year. Annals of Surgical Oncology2016;23(9):2762‐71. [DOI: 10.1245/s10434‐016‐5263‐7] DeckersE , Hoekstra‐WeebersJ , DamudeS , FranckenA , Ter MeulenS , BastiaannetE , et al. The MELFO‐study: a multi‐center prospective randomized clinical trial on the effects of a reduced stage‐adjusted follow‐up schedule on cutaneous melanoma IB‐IIC patients: results after 3‐years. Annals of Surgical Oncology2018;25(1 Suppl 1):S40. NCT01018004 . Comparing follow‐up schedules in patients with newly diagnosed stage IB or stage II melanoma. clinicaltrials.gov/ct2/show/NCT01018004 (first received 20 December 2016). ">Damude 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Less frequent vs conventional follow‐up schedule after melanoma</b> </p> <p> <ul id="CD012425-list-0020"> <li> <p>Study authors calculated total follow‐up costs of the first year for all participants from University Medical Center Groningen, Netherlands (UMCG) based on data from the UMCG financial administration. </p> </li> <li> <p>Cost was reported as total cost per participant (EUR; mean/SD)</p> </li> <li> <p>Study reported a reduction in hospital costs at 1‐year follow‐up of 45% in the intervention group compared to the conventional schedule group. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 417.66 (452.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 761.97 (683.37)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GP‐led vs hospital follow‐up after breast cancer</b> </p> <p> <ul id="CD012425-list-0021"> <li> <p>The economic evaluation considered costs to the health service (particularly, the costs of follow‐up visits and diagnostic tests) and costs to the participants (such as lost earnings and out‐of‐pocket expenses) over 18 months. All costs were expressed in 1994 GBP. </p> </li> <li> <p>Cost was reported as average cost per participant in GBP (95% CI)</p> </li> <li> <p>GP participants were seen significantly more frequently and each follow‐up visit lasted longer. GPs ordered more diagnostic tests than did specialists. Although the mean cost per visit in general practice was significantly less, the mean cost of diagnostic tests per visit was similar in the 2 groups. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GBP 64.70 (5.80 to 301.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GBP 195.10 (62 to 737.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0015" title="BoekhoutAH , MaunsellE , PondGR , JulianJA , CoyleD , LevineMN , et al. A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial. Journal of Cancer Survivorship2015;9(4):683‐91. CoyleD , GrunfeldE , CoyleK , JulianJA , PondGR , FolkesA , et al. Cost‐effectiveness of a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):6082. CoyleD , GrunfeldE , CoyleK , PondG , JulianJA , LevineMN . Cost effectiveness of a survivorship care plan for breast cancer survivors. Journal of Oncology Practice2014;10(2):e86‐92. GrunfeldE , JulianJA , PondG , MaunsellE , CoyleD , FolkesA , et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. Journal of Clinical Oncology2011;29(36):4755‐62. GrunfeldE , LevineMN , JulianJA , PondGR , MaunsellE , FolkesA , et al. Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):9005. GrunfeldE , PondG , MaunsellE , LevineMN , JulianJA , CoyleD . Impact of survivorship care plans (SCP) on adherence to guidelines, health service measures, and patient‐reported outcomes (PRO): extended results of a multicenter randomized clinical trial (RCT) with breast cancer survivors. European Journal of Cancer2012;48:S147. ">Grunfeld 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SCP vs no SCP after breast cancer</b> </p> <p> <ul id="CD012425-list-0022"> <li> <p>Analysis assessed the healthcare and societal costs (physician visits, diagnostic and laboratory tests, participant travel costs and lost productivity, and additional costs associated with the SCP) and QALYs over the 2‐year follow‐up of the randomised trial. </p> </li> <li> <p>Cost was reported as:</p> <ul id="CD012425-list-0023"> <li> <p>total cost per participant in 2011 CAD</p> </li> <li> <p>QALY</p> </li> </ul> </li> <li> <p>The SCP is not cost‐effective. Total costs per participant were lower for standard care (CAD 698 vs CAD 765), and total QALYs were almost equivalent (1.42 for standard care vs 1.41 for the SCP). The probability that the SCP was cost effective was 0.26 at a threshold value of a QALY of CAD 50,000. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAD 765</p> <p>QALY 1.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAD 698</p> <p>QALY 1.42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nurse‐led telephone vs hospital follow‐up after breast cancer</b> </p> <p> <ul id="CD012425-list-0024"> <li> <p>Analysis included health care (e.g. diagnostic procedures, outpatient clinic visits, telephone interviews) and non‐healthcare‐related costs (e.g. productivity loss, informal care). Cost prices were obtained from the Dutch Governmental manual for healthcare cost analysis. </p> </li> <li> <p>Costs were reported by treatment arm (see note) as:</p> <ul id="CD012425-list-0025"> <li> <p>mean annual costs per participant in 2008 Euros (95% CI) over 12 months</p> </li> <li> <p>QALY (95% CI)</p> </li> </ul> </li> </ul> </p> <p>Note: this study was a 4‐armed 2 x 2 design that also compared the use of an educational group programme (EGP) vs no EGP. We only included the nurse‐led vs hospital follow‐up comparison for this review. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 4672 (3489 to 6033)</p> <p>QALY 0.769 (0.746 to 0.794)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 4419 (3410 to 5501)</p> <p>QALY 0.747 (0.707 to 0.778)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nurse‐led on demand vs standard hospital follow‐up after breast cancer</b> </p> <p> <ul id="CD012425-list-0026"> <li> <p>Cost elements included medical examinations (e.g. mammography, pulmonary X‐ray, scintigraphy, CT scans, US, biopsies), visits (nurse, physician, social worker, physiotherapist and breast prosthetic technician visits) and telephone contacts. </p> </li> <li> <p>Costs are reported as mean cost per participant per year of follow‐up by intervention arm in 2006 Euros (95% CI) in Sweden. </p> </li> <li> <p>Specialist nurse intervention with check‐ups on demand was 20% less expensive than routine follow‐up visits to the physician, explained by the numbers of visits to the physician in the respective study arms. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 495 (410 to 797)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 630 (557 to 1055)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0024" title="KokkoR , HakamaM , HolliK . Follow‐up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Research and Treatment2005;93(3):255‐60. KokkoR , HakamaM , HolliK . Role of chest X‐ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Research and Treatment2003;81(1):33‐9. ">Kokko 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Less intensive (CXR only when indicated) vs regular X‐rays after breast cancer</b> </p> <p> <ul id="CD012425-list-0027"> <li> <p>Costs from the hospital perspective (no. of contacts (visits and phone calls) and diagnostic tests) were compared during the first 5 years of follow‐up </p> </li> <li> <p>Mean cost of follow‐up per participant in 2003‐2004 Euros were reported for 4 arms (see note): </p> <ul id="CD012425-list-0028"> <li> <p>A: every 3 months, routine tests (X‐ray every 6 months)</p> </li> <li> <p>B: every 3 months, no routine tests</p> </li> <li> <p>C: every 6 months, routine tests</p> </li> <li> <p>D: every 6 months, no routine tests</p> </li> </ul> </li> <li> <p>Routine examinations in the follow‐up of asymptomatic primary breast cancer participants increase the costs of follow‐up 2.2 times. </p> </li> </ul> </p> <p>Note: the clinical outcomes of this study (survival and recurrence) were reported in a separate paper according to 2 groups: 1 group had regular CXRs every 6 months while the other group had CXR only when clinically needed. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arm B: EUR 1493</p> <p>Arm D: EUR 1050</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arm A: EUR 2269</p> <p>Arm C: EUR 1656</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0029" title="MonteilJ , VergnenègreA , BertinF , DalmayF , GaillardS , BonnaudF , et al. Randomized follow‐up study of resected NSCLC patients: conventional versus 18F‐DG coincidence imaging. Anticancer Research2010;30(9):3811‐6. NCT00199615 . Follow‐up of patients with curative‐intent surgical resection for NSCLC. clinicaltrials.gov/ct2/show/NCT00199615 (first received 20 December 2016). ">Monteil 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>More intensive (CDET) vs CT scans after lung cancer</b> </p> <p> <ul id="CD012425-list-0029"> <li> <p>The analysis included only direct medical costs for each participant (imaging procedure, fixed hospital and patient transportation costs) over 2 years. Reimbursement prices were determined for each procedure by the French Healthcare system using 2002 repayment tariffs. </p> </li> <li> <p>Costs were reported as average cost of follow‐up visits and imaging per participant in Euros (95% CI) </p> </li> <li> <p>CDET imaging was more expensive, provided earlier detection of recurrence, but did not modify survival outcome. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 1104.96</p> <p>(954 to 1240)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 755.47 (640 to 864)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0030" title="MorrisonV , SpencerLH , LeesonS . Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a randomised feasibility trial. Psycho‐oncology2017;26(Suppl 2):3‐4. MorrisonV , SpencerLH , TottonN , PyeK , YeoST , ButterworthC , et al. Trial of optimal personalised care after treatment‐gynaecological cancer (TOPCAT‐G): a randomized feasibility trial. International Journal of Gynecological Cancer2018;28(2):401‐11. PyeK , TottonN , StuartN , WhitakerR , MorrisonV , EdwardsRT , et al. Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a study protocol for a randomised feasibility trial. Pilot and Feasibility Studies2016;2:67. [DOI 10.1186/s40814‐016‐0108‐5] ">Morrison 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nurse‐led telephone vs hospital follow‐up after gynaecological cancer</b> </p> <p> <ul id="CD012425-list-0030"> <li> <p>Mean total cost per participant (SD) of all contacts with NHS primary and secondary care services and other cancer services over the 6‐month follow‐up period were calculated. </p> </li> <li> <p>Difference between groups: GBP 26.60 (bootstrapped 95% CI GBP −290.37 to GBP 240.42)</p> </li> <li> <p>Although this difference is not statistically significant, the mean total costs of service use were lower in the intervention group. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GBP 388.84 (320.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GBP 415.44</p> <p>(329.08)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0033" title="OltraA , SantaballaA , MontalarJ , MunárrizB , PastorM , MeseguerA , et al. Cost‐benefit evaluation of a follow‐up program in patients with advanced breast cancer. Randomized study. Revista de Oncología1999;1(Suppl 1):165. OltraA , SantaballaA , MunárrizB , PastorM , MontalarJ . Cost‐benefit analysis of a follow‐up program in patients with breast cancer: a randomized prospective study. Breast Journal2007;13(6):571‐4. ">Oltra 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>More intensive (additional diagnostic tests) vs standard follow‐up after breast cancer</b> </p> <p> <ul id="CD012425-list-0031"> <li> <p>Cost elements were not specified but were calculated over a median of 3 years of follow‐up in a hospital in Spain where participants were recruited from 1997‐1999. </p> </li> <li> <p>Cost reported as:</p> <ul id="CD012425-list-0032"> <li> <p>total cost of follow‐up in Euros</p> </li> <li> <p>mean costs per participant in Euros</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 74,171</p> <p>EUR 1278 per participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 24,567</p> <p>EUR 390 per participant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0034" title="PicardiM , PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , et al. Advanced‐stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission‐‐a randomized trial of routine surveillance imaging procedures. Radiology2014;272(1):262‐74. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: Ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2015;100:7‐8. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2014;99:398‐9. ">Picardi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Less intensive (US/chest radiography) vs standard (PET/CT scans) follow‐up after Hodgkin lymphoma</b> </p> <p> <ul id="CD012425-list-0033"> <li> <p>Cost was calculated from the perspective of the Italian National Healthcare System including costs of imaging procedures and surgical biopsies over median follow‐up of 60 months. </p> </li> <li> <p>Costs were reported as average cost of follow‐up per participant in 2010 Euros</p> </li> <li> <p>Estimated cost per relapse diagnosed with routine PET/CT was 10‐fold higher compared with that diagnosed with routine US/chest radiography (P &lt; 0.0001 for difference between groups). </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 8818</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0037" title="BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial [Efectividad del seguimiento postoperatorio en los pacientes con cáncer colorrectal para la detección de recidivas curables. Análisis preliminar de un estudio multicéntrico, controlado y aleatorizado]. Gastroenterologia y Hepatologia2001;24(2):92, abstract no: 13. BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Preliminary analysis of a multicenter controlled trial to evaluate the effectiveness of postoperative follow‐up to detect curable recurrences in patients with colorectal cancer [Análisis preliminar de un estudio multicéntrico controlado y aleatorizado destinado a evaluar la efectividad del seguimiento postoperatorio en la detección de recidivas curables en los pacientes con cáncer colorrectal]. Gastroenterologia y Hepatologia2001;24(3):150. Rodriguez‐MorantaF , CastellsA , SaloJ , ArcusaA , BoadasJ , BessaV , et al. Efficacy of postoperative surveillance after radical surgery for colorectal cancer (CRC). Analysis of a prospective, multicenter, randomized controlled trial. Journal of Gastroenterology2005;128(4 Suppl 2):Abstract W967. Rodríguez‐MorantaF , SalóJ , AcrusaA , BoadasJ , BessaX , PiñolV , et al. Efficacy of postoperative surveillance in patients with colorectal cancer after radical surgery. A prospective, multicenter, randomized study. Gastroenterologia y Hepatologia2005;28(3):197‐8, abstract no: 126. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , Bessa , X , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>More intensive (CT scan plus colonoscopy) vs simple follow‐up after colorectal cancer</b> </p> <p> <ul id="CD012425-list-0034"> <li> <p>Costs were calculated for all procedures performed during the scheduled follow‐up or as a result of additional work‐up for any suspected recurrence according to Hospital Clinic current billing (participants recruited from 1997‐2001). Indirect costs, such as time lost from work or transportation charges, were not factored into the analysis. </p> </li> <li> <p>Cost were reported as:</p> <ul id="CD012425-list-0035"> <li> <p>cost per participant in Euros for median follow‐up of up to 49 months</p> </li> <li> <p>Cost per resectable tumour recurrence in Euros</p> </li> </ul> </li> <li> <p>Although overall cost of follow‐up was higher in the intensive strategy group (EUR 300,315) than in simple strategy group (EUR 188,630), the intensive surveillance strategy was more efficient when resectability was considered. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 300,315 per participant</p> <p>EUR 16,684 per tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 188,630 per participant</p> <p>EUR 18,863 per tumour</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0046" title="NCT00624260 . Impact of PET Scan on the curative strategy of colo‐rectal cancers : a randomized study. clinicaltrials.gov/ct2/show/NCT00624260 (first received 20 December 2016). SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an openlabel multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology2017;35(15 Suppl 1):no pagination. SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal2017;5(5 Suppl 1):A13. SobhaniI , IttiE , LucianiA , BaumgaertnerI , LayeseR , AndreT , et al. Colorectal cancer (CRC) monitoring by 6‐monthly 18FDG‐PET/CT: an open‐label multicentre randomised trial. Annals of Oncology2018;29(4):931‐7. ">Sobhani 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>More intensive (18FDG‐PET) vs conventional follow‐up after colorectal cancer</b> </p> <p> <ul id="CD012425-list-0036"> <li> <p>Costs were assessed in accordance with the Consolidated Health Economic Evaluation Reporting Standards statement for single‐trial‐based studies. </p> </li> <li> <p>The prospective analysis determined the cost per life‐year gained with 18FDG‐PET/CT vs the standard of care over the 3‐year trial period. Hospital inpatient costs were estimated and average cost for each study group determined with adjustment for the actual length of stay and resources used during the admission including the cost of imaging studies. Discounting was not performed. Total cost (mean/SD) was computed both with and without the cost of 18FDG‐PET/CT in 2016 EUROS. Costs were compared between groups using the Wilcoxon test. </p> </li> <li> <p>Difference between groups P value: without imaging: P = 0.23; with imaging: P = 0.033</p> </li> <li> <p>The probabilistic sensitivity analysis suggested that the intervention strategy increased costs without improving participant outcomes, with a likelihood of 87% for the survival end point </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Without imaging: EUR 14,573 (27,531)</p> <p>With imaging: EUR 18,192 (27,679)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 11,131 (13,254)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nurse‐led vs surgeon‐led follow‐up after oesophageal cancer</b> </p> <p> <ul id="CD012425-list-0037"> <li> <p>Cost elements included comprehensive data on hospital costs (inpatient days, health practitioner care, medical treatment), diagnostic interventions and extramural care (GP‐care) for a period of 12 months' follow‐up </p> </li> <li> <p>Costs were reported as total costs per participant, reported in 2006 Euros in the Netherlands </p> </li> <li> <p>The total average costs per participant were not statistically significantly higher for standard follow‐up than nurse‐led follow‐up (EUR 3798 vs EUR 2592; P = 0.11). Costs of nurse‐led follow‐up visits were lower than those of standard follow‐up visits (EUR 234 vs EUR 503; P &lt; 0.001). </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 2592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 3798</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>18FDG:</b> 18F‐fluoro‐2‐deoxy‐D‐glucose; <b>CAD:</b> Canadian Dollar ; <b>CI:</b> confidence interval; <b>CDET:</b> coincidence detection system imaging; <b>CT:</b> computed tomography; EUR: Euro; <b>CXR:</b> chest X‐ray; <b>GBP:</b> Pound Sterling; <b>GP:</b> general practitioner; <b>MD:</b> mean difference; <b>NHS:</b> National Health Service; <b>PET:</b> positron emission tomography; <b>QALY:</b> quality‐adjusted life year; <b>SCP:</b> survivorship care plan; <b>SD:</b> standard deviation; <b>US:</b> ultrasound </p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD012425-sec-0104"> <h4 class="title">Comparison 2: less intensive versus more intensive follow‐up</h4> <p>We included 24 studies for this comparison (<a href="./references#CD012425-bbs2-0006" title="D'CruzA , VaishR , GuptaS , AryaS , HawaldarRW , ShahS . Does addition of neck ultrasonography to physical examination, in follow‐up of patients with early stage, clinically node negative oral cancers, influence outcome? A randomized control trial (RCT). Journal of Clinical Oncology2016;34(15 Suppl 6):no pagination. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node‐negative oral cancer. New England Journal of Medicine2015;373(6):521‐9. NCT00193765 . Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. clinicaltrials.gov/ct2/show/NCT00193765 (first received 20 December 2016). ">D'Cruz 2016</a>; <a href="./references#CD012425-bbs2-0007" title="DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . Prospective randomized clinical trial for the evaluation of a stage adjusted reduced follow‐up schedule in cutaneous melanoma patients: results after one year. Annals of Surgical Oncology2016;23(1 Suppl 1):S30. DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . The MELFO‐study: prospective randomized clinical trial for the evaluation of a stage‐adjusted reduced follow‐up schedule in cutaneous melanoma patients ‐ results after 1 year. Annals of Surgical Oncology2016;23(9):2762‐71. [DOI: 10.1245/s10434‐016‐5263‐7] DeckersE , Hoekstra‐WeebersJ , DamudeS , FranckenA , Ter MeulenS , BastiaannetE , et al. The MELFO‐study: a multi‐center prospective randomized clinical trial on the effects of a reduced stage‐adjusted follow‐up schedule on cutaneous melanoma IB‐IIC patients: results after 3‐years. Annals of Surgical Oncology2018;25(1 Suppl 1):S40. NCT01018004 . Comparing follow‐up schedules in patients with newly diagnosed stage IB or stage II melanoma. clinicaltrials.gov/ct2/show/NCT01018004 (first received 20 December 2016). ">Damude 2016</a>; <a href="./references#CD012425-bbs2-0010" title="GambazziF , FreyLD , BruehlmeierM , JanthurWD , GraberSM , HeubergerJ , et al. Comparing two imaging methods for follow‐up of lung cancer treatment: a randomized pilot study. Annals of Thoracic Surgery2018;107(2):430‐5. [DOI: 10.1016/j.athoracsur.2018.08.015] ">Gambazzi 2018</a>; <a href="./references#CD012425-bbs2-0011" title="GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata). A randomized trial of intensive versus minimalist follow‐up of patients with resected Dukes B‐C colorectal cancer: the pilot phase. Tumori1998;84(Suppl):89. GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. NCT02409472 . Intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. clinicaltrials.gov/ct2/show/NCT02409472 (first received 20 December 2016). RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] ">GILDA 2016</a>; <a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a>; <a href="./references#CD012425-bbs2-0022" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomized study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Gastroenterology1999;34(5):509‐15. KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;149:159‐62. ">Kjeldsen 1997</a>; <a href="./references#CD012425-bbs2-0024" title="KokkoR , HakamaM , HolliK . Follow‐up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Research and Treatment2005;93(3):255‐60. KokkoR , HakamaM , HolliK . Role of chest X‐ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Research and Treatment2003;81(1):33‐9. ">Kokko 2003</a>; <a href="./references#CD012425-bbs2-0026" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1992</a>; <a href="./references#CD012425-bbs2-0029" title="MonteilJ , VergnenègreA , BertinF , DalmayF , GaillardS , BonnaudF , et al. Randomized follow‐up study of resected NSCLC patients: conventional versus 18F‐DG coincidence imaging. Anticancer Research2010;30(9):3811‐6. NCT00199615 . Follow‐up of patients with curative‐intent surgical resection for NSCLC. clinicaltrials.gov/ct2/show/NCT00199615 (first received 20 December 2016). ">Monteil 2010</a>; <a href="./references#CD012425-bbs2-0032" title="OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD012425-bbs2-0033" title="OltraA , SantaballaA , MontalarJ , MunárrizB , PastorM , MeseguerA , et al. Cost‐benefit evaluation of a follow‐up program in patients with advanced breast cancer. Randomized study. Revista de Oncología1999;1(Suppl 1):165. OltraA , SantaballaA , MunárrizB , PastorM , MontalarJ . Cost‐benefit analysis of a follow‐up program in patients with breast cancer: a randomized prospective study. Breast Journal2007;13(6):571‐4. ">Oltra 2007</a>; <a href="./references#CD012425-bbs2-0034" title="PicardiM , PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , et al. Advanced‐stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission‐‐a randomized trial of routine surveillance imaging procedures. Radiology2014;272(1):262‐74. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: Ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2015;100:7‐8. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2014;99:398‐9. ">Picardi 2014</a>; <a href="./references#CD012425-bbs2-0035" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA , et al. Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD012425-bbs2-0036" title="MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017;21(32):1‐86. MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00560365 (first received 20 December 2016). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology2011;29(15 Suppl 1):3521. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. [DOI: 10.1001/jama.2013.285718] PughSA , FullerA , PereraR , GeorgeS , MantD , PrimroseJ . The follow‐up after colorectal cancer surgery trial: randomised trial of follow‐up after colorectal cancer surgery and outcome following recurrence. Journal of the American College of Surgeons2014;219(4 Suppl 1):e46‐7. PughSA , MantD , ShinkinsB , MellorJ , PereraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology2016;27(Suppl 6):no pagination. ShinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PloS One2017;12(3):e0171810. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;105(6):658‐62. ">Primrose 2014</a>; <a href="./references#CD012425-bbs2-0037" title="BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial [Efectividad del seguimiento postoperatorio en los pacientes con cáncer colorrectal para la detección de recidivas curables. Análisis preliminar de un estudio multicéntrico, controlado y aleatorizado]. Gastroenterologia y Hepatologia2001;24(2):92, abstract no: 13. BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Preliminary analysis of a multicenter controlled trial to evaluate the effectiveness of postoperative follow‐up to detect curable recurrences in patients with colorectal cancer [Análisis preliminar de un estudio multicéntrico controlado y aleatorizado destinado a evaluar la efectividad del seguimiento postoperatorio en la detección de recidivas curables en los pacientes con cáncer colorrectal]. Gastroenterologia y Hepatologia2001;24(3):150. Rodriguez‐MorantaF , CastellsA , SaloJ , ArcusaA , BoadasJ , BessaV , et al. Efficacy of postoperative surveillance after radical surgery for colorectal cancer (CRC). Analysis of a prospective, multicenter, randomized controlled trial. Journal of Gastroenterology2005;128(4 Suppl 2):Abstract W967. Rodríguez‐MorantaF , SalóJ , AcrusaA , BoadasJ , BessaX , PiñolV , et al. Efficacy of postoperative surveillance in patients with colorectal cancer after radical surgery. A prospective, multicenter, randomized study. Gastroenterologia y Hepatologia2005;28(3):197‐8, abstract no: 126. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , Bessa , X , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD012425-bbs2-0039" title="PalliD , RussoA , SaievaC , CiattoS , Rosselli Del TurcoM , DistanteV , et al. Intensive vs clinical follow‐up after treatment of primary breast cancer: 10‐year update of a randomized trial. National Research Council Project on Breast Cancer Follow‐up. JAMA1999;281(17):1586. Roselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . The efficacy of intensive follow‐up testing in breast cancer cases. Annals of Oncology1995;6(Suppl 2):37‐9. Rosselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . Intensive diagnostic follow‐up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow‐up. JAMA1994;271(20):1593‐7. ">Rosselli Del Turco 1994</a>; <a href="./references#CD012425-bbs2-0041" title="GoodmanA . How often to follow up? Study shows two CT scans as good as five for low‐risk testicular cancer. Oncology Times2007;29(12):54‐5. NCT00003420 . CT scans in treating patients with stage I testicular cancer after undergoing orchiectomy. clinicaltrials.gov/ct2/show/NCT00003420 (first received 20 December 2016). RustinGJ , MeadGM , StenningSP , VaseyPA , AassN , HuddartRA , et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197‐‐the National Cancer Research Institute Testis Cancer Clinical Studies Group. Journal of Clinical Oncology2007;25(11):1310‐5. ">Rustin 2007</a>; <a href="./references#CD012425-bbs2-0042" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gastroenterology1998;114(1):7‐14. SchoemakerD , BlackR , GilesL , ToouliJ , AlcornJ . Addition of intensive follow‐up procedures to standard follow‐up did not improve survival in patients with colorectal cancer. Evidence‐Based Medicine1998;3(5):140. ">Schoemaker 1998</a>; <a href="./references#CD012425-bbs2-0043" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk‐adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD012425-bbs2-0045" title="SobhaniI , TiretE , LebtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>; <a href="./references#CD012425-bbs2-0046" title="NCT00624260 . Impact of PET Scan on the curative strategy of colo‐rectal cancers : a randomized study. clinicaltrials.gov/ct2/show/NCT00624260 (first received 20 December 2016). SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an openlabel multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology2017;35(15 Suppl 1):no pagination. SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal2017;5(5 Suppl 1):A13. SobhaniI , IttiE , LucianiA , BaumgaertnerI , LayeseR , AndreT , et al. Colorectal cancer (CRC) monitoring by 6‐monthly 18FDG‐PET/CT: an open‐label multicentre randomised trial. Annals of Oncology2018;29(4):931‐7. ">Sobhani 2018</a>; <a href="./references#CD012425-bbs2-0049" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>; <a href="./references#CD012425-bbs2-0051" title="NCT00198341 . Post‐surgical non‐small cell lung cancer (NSCLC) follow‐up. clinicaltrials.gov/ct2/show/NCT00198341 (first received 20 December 2016). WesteelV . Follow‐up of the patient after curative treatment. Lung Cancer2011;71:S10‐1. WesteelV . Surveillance and second primary malignancies in lung cancer survivors. Journal of Thoracic Oncology2018;13(10 Suppl):S277‐8. WesteelV , BarlesiF , DomasJ , GirardP , FoucherP , LafitteJJ , et al. Postoperative follow‐up of lung cancer: randomized trial comparing two follow‐up programs in completely resected non‐small cell lung cancer (IFCT‐0302). Journal of Clinical Oncology2012;30(15 Suppl 1):no pagination. WesteelV , BarlesiF , FoucherP , LafitteJ , DomasJ , GirardP , et al. Recurrences and 2nd primary cancers in the IFCT‐0302 trial assessing a CT‐scan‐based follow‐up after lung cancer surgery. Journal of Thoracic Oncology2017;12(11 Suppl 2):S1788‐9. WesteelV , BarlesiF , FoucherP , LafitteJ‐J , DomasJ , GirardP , et al. Results of the phase III IFCT‐0302 trial assessing minimal versus CT‐scan‐based follow‐up for completely resected non‐small cell lung cancer (NSCLC). Annals of Oncology2017;28(Suppl 5):v452. WesteelV , BarlesiF , FoucherP , LafitteJJ , DomasJ , GirardP , et al. Compliance with follow‐up programs after surgery for non‐small cell lung cancer in the phase III IFCT‐0302 trial. Journal of Thoracic Oncology2015;10(9 Suppl 2):S239. WesteelV , LebitasyMP , MercierM , LafitteJJ , DomasJ , GirardPl . IFCT‐0302 trial: randomised study comparing two follow‐up schedules in completely resected non‐small cell lung cancer [Protocole IFCT‐0302 : essai randomisé de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués]. Revue des Maladies Respiratoires2007;2(5):645‐52. ">Westeel 2012</a>; <a href="./references#CD012425-bbs2-0052" title="NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00225641 (first received 20 December 2016). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PahlmanL , et al. Intensity of follow up after surgery for colorectal cancer. Colorectal Disease2014;16:93. Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA2018;319(20):2095‐103. ">Wille‐Jorgensen 2018</a>). </p> <section id="CD012425-sec-0105"> <h5 class="title">Overall survival</h5> <p>Eighteen studies reported on the outcome of survival (<a href="./references#CD012425-bbs2-0006" title="D'CruzA , VaishR , GuptaS , AryaS , HawaldarRW , ShahS . Does addition of neck ultrasonography to physical examination, in follow‐up of patients with early stage, clinically node negative oral cancers, influence outcome? A randomized control trial (RCT). Journal of Clinical Oncology2016;34(15 Suppl 6):no pagination. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node‐negative oral cancer. New England Journal of Medicine2015;373(6):521‐9. NCT00193765 . Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. clinicaltrials.gov/ct2/show/NCT00193765 (first received 20 December 2016). ">D'Cruz 2016</a>; <a href="./references#CD012425-bbs2-0011" title="GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata). A randomized trial of intensive versus minimalist follow‐up of patients with resected Dukes B‐C colorectal cancer: the pilot phase. Tumori1998;84(Suppl):89. GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. NCT02409472 . Intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. clinicaltrials.gov/ct2/show/NCT02409472 (first received 20 December 2016). RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] ">GILDA 2016</a>; <a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a>; <a href="./references#CD012425-bbs2-0022" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomized study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Gastroenterology1999;34(5):509‐15. KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;149:159‐62. ">Kjeldsen 1997</a>; <a href="./references#CD012425-bbs2-0024" title="KokkoR , HakamaM , HolliK . Follow‐up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Research and Treatment2005;93(3):255‐60. KokkoR , HakamaM , HolliK . Role of chest X‐ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Research and Treatment2003;81(1):33‐9. ">Kokko 2003</a>; <a href="./references#CD012425-bbs2-0026" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1992</a>; <a href="./references#CD012425-bbs2-0029" title="MonteilJ , VergnenègreA , BertinF , DalmayF , GaillardS , BonnaudF , et al. Randomized follow‐up study of resected NSCLC patients: conventional versus 18F‐DG coincidence imaging. Anticancer Research2010;30(9):3811‐6. NCT00199615 . Follow‐up of patients with curative‐intent surgical resection for NSCLC. clinicaltrials.gov/ct2/show/NCT00199615 (first received 20 December 2016). ">Monteil 2010</a>; <a href="./references#CD012425-bbs2-0032" title="OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD012425-bbs2-0035" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA , et al. Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD012425-bbs2-0036" title="MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017;21(32):1‐86. MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00560365 (first received 20 December 2016). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology2011;29(15 Suppl 1):3521. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. [DOI: 10.1001/jama.2013.285718] PughSA , FullerA , PereraR , GeorgeS , MantD , PrimroseJ . The follow‐up after colorectal cancer surgery trial: randomised trial of follow‐up after colorectal cancer surgery and outcome following recurrence. Journal of the American College of Surgeons2014;219(4 Suppl 1):e46‐7. PughSA , MantD , ShinkinsB , MellorJ , PereraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology2016;27(Suppl 6):no pagination. ShinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PloS One2017;12(3):e0171810. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;105(6):658‐62. ">Primrose 2014</a>; <a href="./references#CD012425-bbs2-0037" title="BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial [Efectividad del seguimiento postoperatorio en los pacientes con cáncer colorrectal para la detección de recidivas curables. Análisis preliminar de un estudio multicéntrico, controlado y aleatorizado]. Gastroenterologia y Hepatologia2001;24(2):92, abstract no: 13. BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Preliminary analysis of a multicenter controlled trial to evaluate the effectiveness of postoperative follow‐up to detect curable recurrences in patients with colorectal cancer [Análisis preliminar de un estudio multicéntrico controlado y aleatorizado destinado a evaluar la efectividad del seguimiento postoperatorio en la detección de recidivas curables en los pacientes con cáncer colorrectal]. Gastroenterologia y Hepatologia2001;24(3):150. Rodriguez‐MorantaF , CastellsA , SaloJ , ArcusaA , BoadasJ , BessaV , et al. Efficacy of postoperative surveillance after radical surgery for colorectal cancer (CRC). Analysis of a prospective, multicenter, randomized controlled trial. Journal of Gastroenterology2005;128(4 Suppl 2):Abstract W967. Rodríguez‐MorantaF , SalóJ , AcrusaA , BoadasJ , BessaX , PiñolV , et al. Efficacy of postoperative surveillance in patients with colorectal cancer after radical surgery. A prospective, multicenter, randomized study. Gastroenterologia y Hepatologia2005;28(3):197‐8, abstract no: 126. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , Bessa , X , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD012425-bbs2-0039" title="PalliD , RussoA , SaievaC , CiattoS , Rosselli Del TurcoM , DistanteV , et al. Intensive vs clinical follow‐up after treatment of primary breast cancer: 10‐year update of a randomized trial. National Research Council Project on Breast Cancer Follow‐up. JAMA1999;281(17):1586. Roselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . The efficacy of intensive follow‐up testing in breast cancer cases. Annals of Oncology1995;6(Suppl 2):37‐9. Rosselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . Intensive diagnostic follow‐up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow‐up. JAMA1994;271(20):1593‐7. ">Rosselli Del Turco 1994</a>; <a href="./references#CD012425-bbs2-0042" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gastroenterology1998;114(1):7‐14. SchoemakerD , BlackR , GilesL , ToouliJ , AlcornJ . Addition of intensive follow‐up procedures to standard follow‐up did not improve survival in patients with colorectal cancer. Evidence‐Based Medicine1998;3(5):140. ">Schoemaker 1998</a>; <a href="./references#CD012425-bbs2-0043" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk‐adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD012425-bbs2-0046" title="NCT00624260 . Impact of PET Scan on the curative strategy of colo‐rectal cancers : a randomized study. clinicaltrials.gov/ct2/show/NCT00624260 (first received 20 December 2016). SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an openlabel multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology2017;35(15 Suppl 1):no pagination. SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal2017;5(5 Suppl 1):A13. SobhaniI , IttiE , LucianiA , BaumgaertnerI , LayeseR , AndreT , et al. Colorectal cancer (CRC) monitoring by 6‐monthly 18FDG‐PET/CT: an open‐label multicentre randomised trial. Annals of Oncology2018;29(4):931‐7. ">Sobhani 2018</a>; <a href="./references#CD012425-bbs2-0049" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>; <a href="./references#CD012425-bbs2-0051" title="NCT00198341 . Post‐surgical non‐small cell lung cancer (NSCLC) follow‐up. clinicaltrials.gov/ct2/show/NCT00198341 (first received 20 December 2016). WesteelV . Follow‐up of the patient after curative treatment. Lung Cancer2011;71:S10‐1. WesteelV . Surveillance and second primary malignancies in lung cancer survivors. Journal of Thoracic Oncology2018;13(10 Suppl):S277‐8. WesteelV , BarlesiF , DomasJ , GirardP , FoucherP , LafitteJJ , et al. Postoperative follow‐up of lung cancer: randomized trial comparing two follow‐up programs in completely resected non‐small cell lung cancer (IFCT‐0302). Journal of Clinical Oncology2012;30(15 Suppl 1):no pagination. WesteelV , BarlesiF , FoucherP , LafitteJ , DomasJ , GirardP , et al. Recurrences and 2nd primary cancers in the IFCT‐0302 trial assessing a CT‐scan‐based follow‐up after lung cancer surgery. Journal of Thoracic Oncology2017;12(11 Suppl 2):S1788‐9. WesteelV , BarlesiF , FoucherP , LafitteJ‐J , DomasJ , GirardP , et al. Results of the phase III IFCT‐0302 trial assessing minimal versus CT‐scan‐based follow‐up for completely resected non‐small cell lung cancer (NSCLC). Annals of Oncology2017;28(Suppl 5):v452. WesteelV , BarlesiF , FoucherP , LafitteJJ , DomasJ , GirardP , et al. Compliance with follow‐up programs after surgery for non‐small cell lung cancer in the phase III IFCT‐0302 trial. Journal of Thoracic Oncology2015;10(9 Suppl 2):S239. WesteelV , LebitasyMP , MercierM , LafitteJJ , DomasJ , GirardPl . IFCT‐0302 trial: randomised study comparing two follow‐up schedules in completely resected non‐small cell lung cancer [Protocole IFCT‐0302 : essai randomisé de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués]. Revue des Maladies Respiratoires2007;2(5):645‐52. ">Westeel 2012</a>; <a href="./references#CD012425-bbs2-0052" title="NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00225641 (first received 20 December 2016). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PahlmanL , et al. Intensity of follow up after surgery for colorectal cancer. Colorectal Disease2014;16:93. Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA2018;319(20):2095‐103. ">Wille‐Jorgensen 2018</a>). </p> <p>Thirteen studies reported data that we could pool for meta‐analysis investigating less versus more intensive follow‐up after oral cancer (<a href="./references#CD012425-bbs2-0006" title="D'CruzA , VaishR , GuptaS , AryaS , HawaldarRW , ShahS . Does addition of neck ultrasonography to physical examination, in follow‐up of patients with early stage, clinically node negative oral cancers, influence outcome? A randomized control trial (RCT). Journal of Clinical Oncology2016;34(15 Suppl 6):no pagination. D'CruzAK , VaishR , KapreN , DandekarM , GuptaS , HawaldarR , et al. Elective versus therapeutic neck dissection in node‐negative oral cancer. New England Journal of Medicine2015;373(6):521‐9. NCT00193765 . Elective vs therapeutic neck dissection in treatment of early node negative squamous carcinoma of oral cavity. clinicaltrials.gov/ct2/show/NCT00193765 (first received 20 December 2016). ">D'Cruz 2016</a>), breast cancer (<a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a>; <a href="./references#CD012425-bbs2-0039" title="PalliD , RussoA , SaievaC , CiattoS , Rosselli Del TurcoM , DistanteV , et al. Intensive vs clinical follow‐up after treatment of primary breast cancer: 10‐year update of a randomized trial. National Research Council Project on Breast Cancer Follow‐up. JAMA1999;281(17):1586. Roselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . The efficacy of intensive follow‐up testing in breast cancer cases. Annals of Oncology1995;6(Suppl 2):37‐9. Rosselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . Intensive diagnostic follow‐up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow‐up. JAMA1994;271(20):1593‐7. ">Rosselli Del Turco 1994</a>), non‐small cell lung cancer (<a href="./references#CD012425-bbs2-0051" title="NCT00198341 . Post‐surgical non‐small cell lung cancer (NSCLC) follow‐up. clinicaltrials.gov/ct2/show/NCT00198341 (first received 20 December 2016). WesteelV . Follow‐up of the patient after curative treatment. Lung Cancer2011;71:S10‐1. WesteelV . Surveillance and second primary malignancies in lung cancer survivors. Journal of Thoracic Oncology2018;13(10 Suppl):S277‐8. WesteelV , BarlesiF , DomasJ , GirardP , FoucherP , LafitteJJ , et al. Postoperative follow‐up of lung cancer: randomized trial comparing two follow‐up programs in completely resected non‐small cell lung cancer (IFCT‐0302). Journal of Clinical Oncology2012;30(15 Suppl 1):no pagination. WesteelV , BarlesiF , FoucherP , LafitteJ , DomasJ , GirardP , et al. Recurrences and 2nd primary cancers in the IFCT‐0302 trial assessing a CT‐scan‐based follow‐up after lung cancer surgery. Journal of Thoracic Oncology2017;12(11 Suppl 2):S1788‐9. WesteelV , BarlesiF , FoucherP , LafitteJ‐J , DomasJ , GirardP , et al. Results of the phase III IFCT‐0302 trial assessing minimal versus CT‐scan‐based follow‐up for completely resected non‐small cell lung cancer (NSCLC). Annals of Oncology2017;28(Suppl 5):v452. WesteelV , BarlesiF , FoucherP , LafitteJJ , DomasJ , GirardP , et al. Compliance with follow‐up programs after surgery for non‐small cell lung cancer in the phase III IFCT‐0302 trial. Journal of Thoracic Oncology2015;10(9 Suppl 2):S239. WesteelV , LebitasyMP , MercierM , LafitteJJ , DomasJ , GirardPl . IFCT‐0302 trial: randomised study comparing two follow‐up schedules in completely resected non‐small cell lung cancer [Protocole IFCT‐0302 : essai randomisé de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués]. Revue des Maladies Respiratoires2007;2(5):645‐52. ">Westeel 2012</a>), and colorectal cancer (<a href="./references#CD012425-bbs2-0011" title="GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata). A randomized trial of intensive versus minimalist follow‐up of patients with resected Dukes B‐C colorectal cancer: the pilot phase. Tumori1998;84(Suppl):89. GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. NCT02409472 . Intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. clinicaltrials.gov/ct2/show/NCT02409472 (first received 20 December 2016). RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] ">GILDA 2016</a>; <a href="./references#CD012425-bbs2-0022" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomized study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Gastroenterology1999;34(5):509‐15. KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;149:159‐62. ">Kjeldsen 1997</a>; <a href="./references#CD012425-bbs2-0026" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1992</a>; <a href="./references#CD012425-bbs2-0032" title="OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD012425-bbs2-0037" title="BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial [Efectividad del seguimiento postoperatorio en los pacientes con cáncer colorrectal para la detección de recidivas curables. Análisis preliminar de un estudio multicéntrico, controlado y aleatorizado]. Gastroenterologia y Hepatologia2001;24(2):92, abstract no: 13. BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Preliminary analysis of a multicenter controlled trial to evaluate the effectiveness of postoperative follow‐up to detect curable recurrences in patients with colorectal cancer [Análisis preliminar de un estudio multicéntrico controlado y aleatorizado destinado a evaluar la efectividad del seguimiento postoperatorio en la detección de recidivas curables en los pacientes con cáncer colorrectal]. Gastroenterologia y Hepatologia2001;24(3):150. Rodriguez‐MorantaF , CastellsA , SaloJ , ArcusaA , BoadasJ , BessaV , et al. Efficacy of postoperative surveillance after radical surgery for colorectal cancer (CRC). Analysis of a prospective, multicenter, randomized controlled trial. Journal of Gastroenterology2005;128(4 Suppl 2):Abstract W967. Rodríguez‐MorantaF , SalóJ , AcrusaA , BoadasJ , BessaX , PiñolV , et al. Efficacy of postoperative surveillance in patients with colorectal cancer after radical surgery. A prospective, multicenter, randomized study. Gastroenterologia y Hepatologia2005;28(3):197‐8, abstract no: 126. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , Bessa , X , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD012425-bbs2-0042" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gastroenterology1998;114(1):7‐14. SchoemakerD , BlackR , GilesL , ToouliJ , AlcornJ . Addition of intensive follow‐up procedures to standard follow‐up did not improve survival in patients with colorectal cancer. Evidence‐Based Medicine1998;3(5):140. ">Schoemaker 1998</a>; <a href="./references#CD012425-bbs2-0046" title="NCT00624260 . Impact of PET Scan on the curative strategy of colo‐rectal cancers : a randomized study. clinicaltrials.gov/ct2/show/NCT00624260 (first received 20 December 2016). SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an openlabel multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology2017;35(15 Suppl 1):no pagination. SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal2017;5(5 Suppl 1):A13. SobhaniI , IttiE , LucianiA , BaumgaertnerI , LayeseR , AndreT , et al. Colorectal cancer (CRC) monitoring by 6‐monthly 18FDG‐PET/CT: an open‐label multicentre randomised trial. Annals of Oncology2018;29(4):931‐7. ">Sobhani 2018</a>; <a href="./references#CD012425-bbs2-0049" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>; <a href="./references#CD012425-bbs2-0052" title="NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00225641 (first received 20 December 2016). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PahlmanL , et al. Intensity of follow up after surgery for colorectal cancer. Colorectal Disease2014;16:93. Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA2018;319(20):2095‐103. ">Wille‐Jorgensen 2018</a>). </p> <p>Compared to more intensive follow‐up, we found that less intensive follow‐up may make little or no difference to overall survival (HR 1.05, 95% CI 0.96 to 1.14; P = 0.29, I<sup>2</sup> = 8%; 13 studies, 10,726 participants; <a href="./references#CD012425-fig-0017" title="">Analysis 2.1</a>; <a href="#CD012425-fig-0005">Figure 5</a>). The anticipated absolute effect was 1 fewer survivor per 100 patients (ranging from 3 fewer to 1 more). A funnel plot showed no detectable publication bias. We judged the certainty of evidence to be low as we downgraded by two levels for some concerns regarding study limitations (lack of allocation concealment in one study, <a href="./references#CD012425-bbs2-0042" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gastroenterology1998;114(1):7‐14. SchoemakerD , BlackR , GilesL , ToouliJ , AlcornJ . Addition of intensive follow‐up procedures to standard follow‐up did not improve survival in patients with colorectal cancer. Evidence‐Based Medicine1998;3(5):140. ">Schoemaker 1998</a>) and indirectness as the studies were primarily investigating follow‐up after colorectal and breast cancer, and serious concerns regarding imprecision as the confidence interval includes effects that are not trivial (potentially up to 3 fewer survivors per 100 patients). Sensitivity analysis (where we removed estimates that were indirectly derived from the following studies <a href="./references#CD012425-bbs2-0022" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomized study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Gastroenterology1999;34(5):509‐15. KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;149:159‐62. ">Kjeldsen 1997</a>; <a href="./references#CD012425-bbs2-0026" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1992</a>; <a href="./references#CD012425-bbs2-0032" title="OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD012425-bbs2-0039" title="PalliD , RussoA , SaievaC , CiattoS , Rosselli Del TurcoM , DistanteV , et al. Intensive vs clinical follow‐up after treatment of primary breast cancer: 10‐year update of a randomized trial. National Research Council Project on Breast Cancer Follow‐up. JAMA1999;281(17):1586. Roselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . The efficacy of intensive follow‐up testing in breast cancer cases. Annals of Oncology1995;6(Suppl 2):37‐9. Rosselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . Intensive diagnostic follow‐up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow‐up. JAMA1994;271(20):1593‐7. ">Rosselli Del Turco 1994</a>; <a href="./references#CD012425-bbs2-0046" title="NCT00624260 . Impact of PET Scan on the curative strategy of colo‐rectal cancers : a randomized study. clinicaltrials.gov/ct2/show/NCT00624260 (first received 20 December 2016). SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an openlabel multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology2017;35(15 Suppl 1):no pagination. SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal2017;5(5 Suppl 1):A13. SobhaniI , IttiE , LucianiA , BaumgaertnerI , LayeseR , AndreT , et al. Colorectal cancer (CRC) monitoring by 6‐monthly 18FDG‐PET/CT: an open‐label multicentre randomised trial. Annals of Oncology2018;29(4):931‐7. ">Sobhani 2018</a>), gave a similar result (HR 1.07, 95% CI 0.96 to 1.19; P = 0.24; 8 studies, 9037 participants). </p> <div class="figure" id="CD012425-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison 2. Less intensive versus more intensive follow‐up, outcome: 2.1 overall survivalA HR greater than 1 indicates a higher hazard of death (worse survival) in the less intensive arm and a lower hazard of death (better survival) in more intensive arm" data-id="CD012425-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 2. Less intensive versus more intensive follow‐up, outcome: 2.1 overall survival </p> <p>A HR greater than 1 indicates a higher hazard of death (worse survival) in the less intensive arm and a lower hazard of death (better survival) in more intensive arm </p> </div> </div> </div> <p>We carried out meta‐regression analysis to quantify clinical heterogeneity and found little or no difference in the intervention effect by cancer site (breast, colorectal, lung, oral), P = 0.32; year of publication (before 2000, from 2000 onwards), P = 0.87; or study quality (high, moderate, low), P = 0.71. We did not carry out meta‐regression for participant age or sex, as age was similar across studies (approximately 60 to 65 years) and sex was either associated with cancer site (e.g. breast cancer) or effects were not reported separately by sex in studies with both men and women. </p> <p>We could not incorporate data from five other studies (<a href="./references#CD012425-bbs2-0024" title="KokkoR , HakamaM , HolliK . Follow‐up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Research and Treatment2005;93(3):255‐60. KokkoR , HakamaM , HolliK . Role of chest X‐ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Research and Treatment2003;81(1):33‐9. ">Kokko 2003</a>; <a href="./references#CD012425-bbs2-0029" title="MonteilJ , VergnenègreA , BertinF , DalmayF , GaillardS , BonnaudF , et al. Randomized follow‐up study of resected NSCLC patients: conventional versus 18F‐DG coincidence imaging. Anticancer Research2010;30(9):3811‐6. NCT00199615 . Follow‐up of patients with curative‐intent surgical resection for NSCLC. clinicaltrials.gov/ct2/show/NCT00199615 (first received 20 December 2016). ">Monteil 2010</a>; <a href="./references#CD012425-bbs2-0035" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA , et al. Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD012425-bbs2-0036" title="MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017;21(32):1‐86. MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00560365 (first received 20 December 2016). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology2011;29(15 Suppl 1):3521. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. [DOI: 10.1001/jama.2013.285718] PughSA , FullerA , PereraR , GeorgeS , MantD , PrimroseJ . The follow‐up after colorectal cancer surgery trial: randomised trial of follow‐up after colorectal cancer surgery and outcome following recurrence. Journal of the American College of Surgeons2014;219(4 Suppl 1):e46‐7. PughSA , MantD , ShinkinsB , MellorJ , PereraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology2016;27(Suppl 6):no pagination. ShinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PloS One2017;12(3):e0171810. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;105(6):658‐62. ">Primrose 2014</a>; <a href="./references#CD012425-bbs2-0043" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk‐adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>). Three of these studies (1752 participants) reported no difference between less and more intensive follow‐up on overall survival after breast cancer (five‐year survival rate = 85% versus 85%, no P‐value; <a href="./references#CD012425-bbs2-0024" title="KokkoR , HakamaM , HolliK . Follow‐up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Research and Treatment2005;93(3):255‐60. KokkoR , HakamaM , HolliK . Role of chest X‐ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Research and Treatment2003;81(1):33‐9. ">Kokko 2003</a>), lung cancer ("overall survival" = 26,5 months ± 19.6 versus 29 months ± 17.1, no P‐value; <a href="./references#CD012425-bbs2-0029" title="MonteilJ , VergnenègreA , BertinF , DalmayF , GaillardS , BonnaudF , et al. Randomized follow‐up study of resected NSCLC patients: conventional versus 18F‐DG coincidence imaging. Anticancer Research2010;30(9):3811‐6. NCT00199615 . Follow‐up of patients with curative‐intent surgical resection for NSCLC. clinicaltrials.gov/ct2/show/NCT00199615 (first received 20 December 2016). ">Monteil 2010</a>), and colorectal cancer (survival curves comparing all four arms, log‐rank P = 0.56; <a href="./references#CD012425-bbs2-0036" title="MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017;21(32):1‐86. MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00560365 (first received 20 December 2016). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology2011;29(15 Suppl 1):3521. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. [DOI: 10.1001/jama.2013.285718] PughSA , FullerA , PereraR , GeorgeS , MantD , PrimroseJ . The follow‐up after colorectal cancer surgery trial: randomised trial of follow‐up after colorectal cancer surgery and outcome following recurrence. Journal of the American College of Surgeons2014;219(4 Suppl 1):e46‐7. PughSA , MantD , ShinkinsB , MellorJ , PereraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology2016;27(Suppl 6):no pagination. ShinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PloS One2017;12(3):e0171810. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;105(6):658‐62. ">Primrose 2014</a>). The remaining two studies (544 participants) reported improved survival outcomes with more intensive follow‐up after colorectal cancer. <a href="./references#CD012425-bbs2-0035" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA , et al. Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a> reported improved cumulative survival rates (73% versus 58%, log‐rank P &lt; 0.02) and <a href="./references#CD012425-bbs2-0043" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk‐adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a> reported improved actuarial five‐year survival rates (for high‐risk patients: Chi<sup>2</sup> = 4.97, P &lt; 0.05 and for low‐risk patients: Chi<sup>2</sup> = 7.90, P &lt; 0.01). </p> </section> <section id="CD012425-sec-0106"> <h5 class="title">Time to detection of recurrence</h5> <p>Twenty‐two studies reported on time to detection of recurrence (<a href="./references#CD012425-bbs2-0007" title="DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . Prospective randomized clinical trial for the evaluation of a stage adjusted reduced follow‐up schedule in cutaneous melanoma patients: results after one year. Annals of Surgical Oncology2016;23(1 Suppl 1):S30. DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . The MELFO‐study: prospective randomized clinical trial for the evaluation of a stage‐adjusted reduced follow‐up schedule in cutaneous melanoma patients ‐ results after 1 year. Annals of Surgical Oncology2016;23(9):2762‐71. [DOI: 10.1245/s10434‐016‐5263‐7] DeckersE , Hoekstra‐WeebersJ , DamudeS , FranckenA , Ter MeulenS , BastiaannetE , et al. The MELFO‐study: a multi‐center prospective randomized clinical trial on the effects of a reduced stage‐adjusted follow‐up schedule on cutaneous melanoma IB‐IIC patients: results after 3‐years. Annals of Surgical Oncology2018;25(1 Suppl 1):S40. NCT01018004 . Comparing follow‐up schedules in patients with newly diagnosed stage IB or stage II melanoma. clinicaltrials.gov/ct2/show/NCT01018004 (first received 20 December 2016). ">Damude 2016</a>; <a href="./references#CD012425-bbs2-0010" title="GambazziF , FreyLD , BruehlmeierM , JanthurWD , GraberSM , HeubergerJ , et al. Comparing two imaging methods for follow‐up of lung cancer treatment: a randomized pilot study. Annals of Thoracic Surgery2018;107(2):430‐5. [DOI: 10.1016/j.athoracsur.2018.08.015] ">Gambazzi 2018</a>; <a href="./references#CD012425-bbs2-0011" title="GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata). A randomized trial of intensive versus minimalist follow‐up of patients with resected Dukes B‐C colorectal cancer: the pilot phase. Tumori1998;84(Suppl):89. GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. NCT02409472 . Intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. clinicaltrials.gov/ct2/show/NCT02409472 (first received 20 December 2016). RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] ">GILDA 2016</a>; <a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a>; <a href="./references#CD012425-bbs2-0022" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomized study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Gastroenterology1999;34(5):509‐15. KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;149:159‐62. ">Kjeldsen 1997</a>; <a href="./references#CD012425-bbs2-0024" title="KokkoR , HakamaM , HolliK . Follow‐up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Research and Treatment2005;93(3):255‐60. KokkoR , HakamaM , HolliK . Role of chest X‐ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Research and Treatment2003;81(1):33‐9. ">Kokko 2003</a>; <a href="./references#CD012425-bbs2-0026" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1992</a>; <a href="./references#CD012425-bbs2-0029" title="MonteilJ , VergnenègreA , BertinF , DalmayF , GaillardS , BonnaudF , et al. Randomized follow‐up study of resected NSCLC patients: conventional versus 18F‐DG coincidence imaging. Anticancer Research2010;30(9):3811‐6. NCT00199615 . Follow‐up of patients with curative‐intent surgical resection for NSCLC. clinicaltrials.gov/ct2/show/NCT00199615 (first received 20 December 2016). ">Monteil 2010</a>; <a href="./references#CD012425-bbs2-0032" title="OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD012425-bbs2-0033" title="OltraA , SantaballaA , MontalarJ , MunárrizB , PastorM , MeseguerA , et al. Cost‐benefit evaluation of a follow‐up program in patients with advanced breast cancer. Randomized study. Revista de Oncología1999;1(Suppl 1):165. OltraA , SantaballaA , MunárrizB , PastorM , MontalarJ . Cost‐benefit analysis of a follow‐up program in patients with breast cancer: a randomized prospective study. Breast Journal2007;13(6):571‐4. ">Oltra 2007</a>; <a href="./references#CD012425-bbs2-0034" title="PicardiM , PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , et al. Advanced‐stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission‐‐a randomized trial of routine surveillance imaging procedures. Radiology2014;272(1):262‐74. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: Ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2015;100:7‐8. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2014;99:398‐9. ">Picardi 2014</a>; <a href="./references#CD012425-bbs2-0035" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA , et al. Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD012425-bbs2-0036" title="MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017;21(32):1‐86. MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00560365 (first received 20 December 2016). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology2011;29(15 Suppl 1):3521. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. [DOI: 10.1001/jama.2013.285718] PughSA , FullerA , PereraR , GeorgeS , MantD , PrimroseJ . The follow‐up after colorectal cancer surgery trial: randomised trial of follow‐up after colorectal cancer surgery and outcome following recurrence. Journal of the American College of Surgeons2014;219(4 Suppl 1):e46‐7. PughSA , MantD , ShinkinsB , MellorJ , PereraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology2016;27(Suppl 6):no pagination. ShinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PloS One2017;12(3):e0171810. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;105(6):658‐62. ">Primrose 2014</a>; <a href="./references#CD012425-bbs2-0037" title="BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial [Efectividad del seguimiento postoperatorio en los pacientes con cáncer colorrectal para la detección de recidivas curables. Análisis preliminar de un estudio multicéntrico, controlado y aleatorizado]. Gastroenterologia y Hepatologia2001;24(2):92, abstract no: 13. BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Preliminary analysis of a multicenter controlled trial to evaluate the effectiveness of postoperative follow‐up to detect curable recurrences in patients with colorectal cancer [Análisis preliminar de un estudio multicéntrico controlado y aleatorizado destinado a evaluar la efectividad del seguimiento postoperatorio en la detección de recidivas curables en los pacientes con cáncer colorrectal]. Gastroenterologia y Hepatologia2001;24(3):150. Rodriguez‐MorantaF , CastellsA , SaloJ , ArcusaA , BoadasJ , BessaV , et al. Efficacy of postoperative surveillance after radical surgery for colorectal cancer (CRC). Analysis of a prospective, multicenter, randomized controlled trial. Journal of Gastroenterology2005;128(4 Suppl 2):Abstract W967. Rodríguez‐MorantaF , SalóJ , AcrusaA , BoadasJ , BessaX , PiñolV , et al. Efficacy of postoperative surveillance in patients with colorectal cancer after radical surgery. A prospective, multicenter, randomized study. Gastroenterologia y Hepatologia2005;28(3):197‐8, abstract no: 126. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , Bessa , X , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD012425-bbs2-0039" title="PalliD , RussoA , SaievaC , CiattoS , Rosselli Del TurcoM , DistanteV , et al. Intensive vs clinical follow‐up after treatment of primary breast cancer: 10‐year update of a randomized trial. National Research Council Project on Breast Cancer Follow‐up. JAMA1999;281(17):1586. Roselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . The efficacy of intensive follow‐up testing in breast cancer cases. Annals of Oncology1995;6(Suppl 2):37‐9. Rosselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . Intensive diagnostic follow‐up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow‐up. JAMA1994;271(20):1593‐7. ">Rosselli Del Turco 1994</a>; <a href="./references#CD012425-bbs2-0041" title="GoodmanA . How often to follow up? Study shows two CT scans as good as five for low‐risk testicular cancer. Oncology Times2007;29(12):54‐5. NCT00003420 . CT scans in treating patients with stage I testicular cancer after undergoing orchiectomy. clinicaltrials.gov/ct2/show/NCT00003420 (first received 20 December 2016). RustinGJ , MeadGM , StenningSP , VaseyPA , AassN , HuddartRA , et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197‐‐the National Cancer Research Institute Testis Cancer Clinical Studies Group. Journal of Clinical Oncology2007;25(11):1310‐5. ">Rustin 2007</a>; <a href="./references#CD012425-bbs2-0043" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk‐adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD012425-bbs2-0045" title="SobhaniI , TiretE , LebtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>; <a href="./references#CD012425-bbs2-0046" title="NCT00624260 . Impact of PET Scan on the curative strategy of colo‐rectal cancers : a randomized study. clinicaltrials.gov/ct2/show/NCT00624260 (first received 20 December 2016). SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an openlabel multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology2017;35(15 Suppl 1):no pagination. SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal2017;5(5 Suppl 1):A13. SobhaniI , IttiE , LucianiA , BaumgaertnerI , LayeseR , AndreT , et al. Colorectal cancer (CRC) monitoring by 6‐monthly 18FDG‐PET/CT: an open‐label multicentre randomised trial. Annals of Oncology2018;29(4):931‐7. ">Sobhani 2018</a>; <a href="./references#CD012425-bbs2-0049" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>; <a href="./references#CD012425-bbs2-0051" title="NCT00198341 . Post‐surgical non‐small cell lung cancer (NSCLC) follow‐up. clinicaltrials.gov/ct2/show/NCT00198341 (first received 20 December 2016). WesteelV . Follow‐up of the patient after curative treatment. Lung Cancer2011;71:S10‐1. WesteelV . Surveillance and second primary malignancies in lung cancer survivors. Journal of Thoracic Oncology2018;13(10 Suppl):S277‐8. WesteelV , BarlesiF , DomasJ , GirardP , FoucherP , LafitteJJ , et al. Postoperative follow‐up of lung cancer: randomized trial comparing two follow‐up programs in completely resected non‐small cell lung cancer (IFCT‐0302). Journal of Clinical Oncology2012;30(15 Suppl 1):no pagination. WesteelV , BarlesiF , FoucherP , LafitteJ , DomasJ , GirardP , et al. Recurrences and 2nd primary cancers in the IFCT‐0302 trial assessing a CT‐scan‐based follow‐up after lung cancer surgery. Journal of Thoracic Oncology2017;12(11 Suppl 2):S1788‐9. WesteelV , BarlesiF , FoucherP , LafitteJ‐J , DomasJ , GirardP , et al. Results of the phase III IFCT‐0302 trial assessing minimal versus CT‐scan‐based follow‐up for completely resected non‐small cell lung cancer (NSCLC). Annals of Oncology2017;28(Suppl 5):v452. WesteelV , BarlesiF , FoucherP , LafitteJJ , DomasJ , GirardP , et al. Compliance with follow‐up programs after surgery for non‐small cell lung cancer in the phase III IFCT‐0302 trial. Journal of Thoracic Oncology2015;10(9 Suppl 2):S239. WesteelV , LebitasyMP , MercierM , LafitteJJ , DomasJ , GirardPl . IFCT‐0302 trial: randomised study comparing two follow‐up schedules in completely resected non‐small cell lung cancer [Protocole IFCT‐0302 : essai randomisé de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués]. Revue des Maladies Respiratoires2007;2(5):645‐52. ">Westeel 2012</a>; <a href="./references#CD012425-bbs2-0052" title="NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00225641 (first received 20 December 2016). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PahlmanL , et al. Intensity of follow up after surgery for colorectal cancer. Colorectal Disease2014;16:93. Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA2018;319(20):2095‐103. ">Wille‐Jorgensen 2018</a>). </p> <p>Twelve studies reported data that we were able to pool for meta‐analysis investigating less versus more intensive follow‐up after colorectal cancer (<a href="./references#CD012425-bbs2-0011" title="GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata). A randomized trial of intensive versus minimalist follow‐up of patients with resected Dukes B‐C colorectal cancer: the pilot phase. Tumori1998;84(Suppl):89. GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. NCT02409472 . Intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. clinicaltrials.gov/ct2/show/NCT02409472 (first received 20 December 2016). RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] ">GILDA 2016</a>; <a href="./references#CD012425-bbs2-0022" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomized study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Gastroenterology1999;34(5):509‐15. KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;149:159‐62. ">Kjeldsen 1997</a>; <a href="./references#CD012425-bbs2-0036" title="MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017;21(32):1‐86. MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00560365 (first received 20 December 2016). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology2011;29(15 Suppl 1):3521. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. [DOI: 10.1001/jama.2013.285718] PughSA , FullerA , PereraR , GeorgeS , MantD , PrimroseJ . The follow‐up after colorectal cancer surgery trial: randomised trial of follow‐up after colorectal cancer surgery and outcome following recurrence. Journal of the American College of Surgeons2014;219(4 Suppl 1):e46‐7. PughSA , MantD , ShinkinsB , MellorJ , PereraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology2016;27(Suppl 6):no pagination. ShinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PloS One2017;12(3):e0171810. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;105(6):658‐62. ">Primrose 2014</a>; <a href="./references#CD012425-bbs2-0037" title="BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial [Efectividad del seguimiento postoperatorio en los pacientes con cáncer colorrectal para la detección de recidivas curables. Análisis preliminar de un estudio multicéntrico, controlado y aleatorizado]. Gastroenterologia y Hepatologia2001;24(2):92, abstract no: 13. BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Preliminary analysis of a multicenter controlled trial to evaluate the effectiveness of postoperative follow‐up to detect curable recurrences in patients with colorectal cancer [Análisis preliminar de un estudio multicéntrico controlado y aleatorizado destinado a evaluar la efectividad del seguimiento postoperatorio en la detección de recidivas curables en los pacientes con cáncer colorrectal]. Gastroenterologia y Hepatologia2001;24(3):150. Rodriguez‐MorantaF , CastellsA , SaloJ , ArcusaA , BoadasJ , BessaV , et al. Efficacy of postoperative surveillance after radical surgery for colorectal cancer (CRC). Analysis of a prospective, multicenter, randomized controlled trial. Journal of Gastroenterology2005;128(4 Suppl 2):Abstract W967. Rodríguez‐MorantaF , SalóJ , AcrusaA , BoadasJ , BessaX , PiñolV , et al. Efficacy of postoperative surveillance in patients with colorectal cancer after radical surgery. A prospective, multicenter, randomized study. Gastroenterologia y Hepatologia2005;28(3):197‐8, abstract no: 126. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , Bessa , X , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD012425-bbs2-0045" title="SobhaniI , TiretE , LebtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>; <a href="./references#CD012425-bbs2-0052" title="NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00225641 (first received 20 December 2016). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PahlmanL , et al. Intensity of follow up after surgery for colorectal cancer. Colorectal Disease2014;16:93. Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA2018;319(20):2095‐103. ">Wille‐Jorgensen 2018</a>), breast cancer (<a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a>; <a href="./references#CD012425-bbs2-0039" title="PalliD , RussoA , SaievaC , CiattoS , Rosselli Del TurcoM , DistanteV , et al. Intensive vs clinical follow‐up after treatment of primary breast cancer: 10‐year update of a randomized trial. National Research Council Project on Breast Cancer Follow‐up. JAMA1999;281(17):1586. Roselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . The efficacy of intensive follow‐up testing in breast cancer cases. Annals of Oncology1995;6(Suppl 2):37‐9. Rosselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . Intensive diagnostic follow‐up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow‐up. JAMA1994;271(20):1593‐7. ">Rosselli Del Turco 1994</a>), non‐small cell lung cancer (<a href="./references#CD012425-bbs2-0010" title="GambazziF , FreyLD , BruehlmeierM , JanthurWD , GraberSM , HeubergerJ , et al. Comparing two imaging methods for follow‐up of lung cancer treatment: a randomized pilot study. Annals of Thoracic Surgery2018;107(2):430‐5. [DOI: 10.1016/j.athoracsur.2018.08.015] ">Gambazzi 2018</a>; <a href="./references#CD012425-bbs2-0051" title="NCT00198341 . Post‐surgical non‐small cell lung cancer (NSCLC) follow‐up. clinicaltrials.gov/ct2/show/NCT00198341 (first received 20 December 2016). WesteelV . Follow‐up of the patient after curative treatment. Lung Cancer2011;71:S10‐1. WesteelV . Surveillance and second primary malignancies in lung cancer survivors. Journal of Thoracic Oncology2018;13(10 Suppl):S277‐8. WesteelV , BarlesiF , DomasJ , GirardP , FoucherP , LafitteJJ , et al. Postoperative follow‐up of lung cancer: randomized trial comparing two follow‐up programs in completely resected non‐small cell lung cancer (IFCT‐0302). Journal of Clinical Oncology2012;30(15 Suppl 1):no pagination. WesteelV , BarlesiF , FoucherP , LafitteJ , DomasJ , GirardP , et al. Recurrences and 2nd primary cancers in the IFCT‐0302 trial assessing a CT‐scan‐based follow‐up after lung cancer surgery. Journal of Thoracic Oncology2017;12(11 Suppl 2):S1788‐9. WesteelV , BarlesiF , FoucherP , LafitteJ‐J , DomasJ , GirardP , et al. Results of the phase III IFCT‐0302 trial assessing minimal versus CT‐scan‐based follow‐up for completely resected non‐small cell lung cancer (NSCLC). Annals of Oncology2017;28(Suppl 5):v452. WesteelV , BarlesiF , FoucherP , LafitteJJ , DomasJ , GirardP , et al. Compliance with follow‐up programs after surgery for non‐small cell lung cancer in the phase III IFCT‐0302 trial. Journal of Thoracic Oncology2015;10(9 Suppl 2):S239. WesteelV , LebitasyMP , MercierM , LafitteJJ , DomasJ , GirardPl . IFCT‐0302 trial: randomised study comparing two follow‐up schedules in completely resected non‐small cell lung cancer [Protocole IFCT‐0302 : essai randomisé de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués]. Revue des Maladies Respiratoires2007;2(5):645‐52. ">Westeel 2012</a>), Hodgkin lymphoma (<a href="./references#CD012425-bbs2-0034" title="PicardiM , PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , et al. Advanced‐stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission‐‐a randomized trial of routine surveillance imaging procedures. Radiology2014;272(1):262‐74. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: Ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2015;100:7‐8. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2014;99:398‐9. ">Picardi 2014</a>) and testicular cancer (<a href="./references#CD012425-bbs2-0041" title="GoodmanA . How often to follow up? Study shows two CT scans as good as five for low‐risk testicular cancer. Oncology Times2007;29(12):54‐5. NCT00003420 . CT scans in treating patients with stage I testicular cancer after undergoing orchiectomy. clinicaltrials.gov/ct2/show/NCT00003420 (first received 20 December 2016). RustinGJ , MeadGM , StenningSP , VaseyPA , AassN , HuddartRA , et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197‐‐the National Cancer Research Institute Testis Cancer Clinical Studies Group. Journal of Clinical Oncology2007;25(11):1310‐5. ">Rustin 2007</a>). </p> <p>Compared to more intensive follow‐up, less intensive follow‐up probably increases time to detection of recurrence (HR 0.85, 95% CI 0.79 to 0.92; P &lt; 0.0001, I<sup>2</sup> = 0; 12 studies, 11,276 participants; <a href="./references#CD012425-fig-0018" title="">Analysis 2.2</a>, <a href="#CD012425-fig-0006">Figure 6</a>). The anticipated absolute effect was 3 fewer detected recurrences per 100 patients (ranging between 5 to 2 fewer). A funnel plot showed no detectable publication bias. We judged the certainty of evidence to be moderate as we downgraded by one level for serious concerns regarding indirectness as HRs for eight of the studies were not reported but indirectly estimated from published data. Sensitivity analysis (where we removed all the studies except <a href="./references#CD012425-bbs2-0011" title="GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata). A randomized trial of intensive versus minimalist follow‐up of patients with resected Dukes B‐C colorectal cancer: the pilot phase. Tumori1998;84(Suppl):89. GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. NCT02409472 . Intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. clinicaltrials.gov/ct2/show/NCT02409472 (first received 20 December 2016). RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] ">GILDA 2016</a>; <a href="./references#CD012425-bbs2-0034" title="PicardiM , PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , et al. Advanced‐stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission‐‐a randomized trial of routine surveillance imaging procedures. Radiology2014;272(1):262‐74. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: Ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2015;100:7‐8. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2014;99:398‐9. ">Picardi 2014</a>; <a href="./references#CD012425-bbs2-0051" title="NCT00198341 . Post‐surgical non‐small cell lung cancer (NSCLC) follow‐up. clinicaltrials.gov/ct2/show/NCT00198341 (first received 20 December 2016). WesteelV . Follow‐up of the patient after curative treatment. Lung Cancer2011;71:S10‐1. WesteelV . Surveillance and second primary malignancies in lung cancer survivors. Journal of Thoracic Oncology2018;13(10 Suppl):S277‐8. WesteelV , BarlesiF , DomasJ , GirardP , FoucherP , LafitteJJ , et al. Postoperative follow‐up of lung cancer: randomized trial comparing two follow‐up programs in completely resected non‐small cell lung cancer (IFCT‐0302). Journal of Clinical Oncology2012;30(15 Suppl 1):no pagination. WesteelV , BarlesiF , FoucherP , LafitteJ , DomasJ , GirardP , et al. Recurrences and 2nd primary cancers in the IFCT‐0302 trial assessing a CT‐scan‐based follow‐up after lung cancer surgery. Journal of Thoracic Oncology2017;12(11 Suppl 2):S1788‐9. WesteelV , BarlesiF , FoucherP , LafitteJ‐J , DomasJ , GirardP , et al. Results of the phase III IFCT‐0302 trial assessing minimal versus CT‐scan‐based follow‐up for completely resected non‐small cell lung cancer (NSCLC). Annals of Oncology2017;28(Suppl 5):v452. WesteelV , BarlesiF , FoucherP , LafitteJJ , DomasJ , GirardP , et al. Compliance with follow‐up programs after surgery for non‐small cell lung cancer in the phase III IFCT‐0302 trial. Journal of Thoracic Oncology2015;10(9 Suppl 2):S239. WesteelV , LebitasyMP , MercierM , LafitteJJ , DomasJ , GirardPl . IFCT‐0302 trial: randomised study comparing two follow‐up schedules in completely resected non‐small cell lung cancer [Protocole IFCT‐0302 : essai randomisé de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués]. Revue des Maladies Respiratoires2007;2(5):645‐52. ">Westeel 2012</a>; <a href="./references#CD012425-bbs2-0052" title="NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer. clinicaltrials.gov/ct2/show/NCT00225641 (first received 20 December 2016). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PahlmanL , et al. Intensity of follow up after surgery for colorectal cancer. Colorectal Disease2014;16:93. Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA2018;319(20):2095‐103. ">Wille‐Jorgensen 2018</a>), showed that less intensive follow‐up may still delay detection of recurrence (HR 0.87, 95% CI 0.79 to 0.96; P = 0.006; 4 studies, 5872 participants). </p> <div class="figure" id="CD012425-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison 2. Less intensive versus more intensive follow‐up, outcome: 2.2 time‐to‐detection of recurrenceA HR less than 1 indicates a lower hazard of detecting recurrence (delay in detection of recurrence) in the less intensive arm and a higher hazard of detecting recurrence (better detection of recurrence) in the more intensive arm." data-id="CD012425-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 2. Less intensive versus more intensive follow‐up, outcome: 2.2 time‐to‐detection of recurrence </p> <p>A HR less than 1 indicates a lower hazard of detecting recurrence (delay in detection of recurrence) in the less intensive arm and a higher hazard of detecting recurrence (better detection of recurrence) in the more intensive arm. </p> </div> </div> </div> <p>We carried out meta‐regression analysis to quantify clinical heterogeneity and found little or no difference in the intervention effect by cancer site (breast, colorectal, lung, other), P = 0.81; year of publication (before 2000, from 2000 onwards), P = 0.89 or study quality (high, moderate, low), P = 0.42. We did not carry out meta‐regression for participant age or sex, as age was similar across studies (approximately 60 to 65 years) and sex was either associated with cancer site (e.g. breast cancer) or effects were not reported separately by sex in studies with both men and women. </p> <p>We could not incorporate data from 10 other studies (<a href="./references#CD012425-bbs2-0007" title="DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . Prospective randomized clinical trial for the evaluation of a stage adjusted reduced follow‐up schedule in cutaneous melanoma patients: results after one year. Annals of Surgical Oncology2016;23(1 Suppl 1):S30. DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . The MELFO‐study: prospective randomized clinical trial for the evaluation of a stage‐adjusted reduced follow‐up schedule in cutaneous melanoma patients ‐ results after 1 year. Annals of Surgical Oncology2016;23(9):2762‐71. [DOI: 10.1245/s10434‐016‐5263‐7] DeckersE , Hoekstra‐WeebersJ , DamudeS , FranckenA , Ter MeulenS , BastiaannetE , et al. The MELFO‐study: a multi‐center prospective randomized clinical trial on the effects of a reduced stage‐adjusted follow‐up schedule on cutaneous melanoma IB‐IIC patients: results after 3‐years. Annals of Surgical Oncology2018;25(1 Suppl 1):S40. NCT01018004 . Comparing follow‐up schedules in patients with newly diagnosed stage IB or stage II melanoma. clinicaltrials.gov/ct2/show/NCT01018004 (first received 20 December 2016). ">Damude 2016</a>; <a href="./references#CD012425-bbs2-0024" title="KokkoR , HakamaM , HolliK . Follow‐up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Research and Treatment2005;93(3):255‐60. KokkoR , HakamaM , HolliK . Role of chest X‐ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Research and Treatment2003;81(1):33‐9. ">Kokko 2003</a>; <a href="./references#CD012425-bbs2-0026" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1992</a>; <a href="./references#CD012425-bbs2-0029" title="MonteilJ , VergnenègreA , BertinF , DalmayF , GaillardS , BonnaudF , et al. Randomized follow‐up study of resected NSCLC patients: conventional versus 18F‐DG coincidence imaging. Anticancer Research2010;30(9):3811‐6. NCT00199615 . Follow‐up of patients with curative‐intent surgical resection for NSCLC. clinicaltrials.gov/ct2/show/NCT00199615 (first received 20 December 2016). ">Monteil 2010</a>; <a href="./references#CD012425-bbs2-0032" title="OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD012425-bbs2-0033" title="OltraA , SantaballaA , MontalarJ , MunárrizB , PastorM , MeseguerA , et al. Cost‐benefit evaluation of a follow‐up program in patients with advanced breast cancer. Randomized study. Revista de Oncología1999;1(Suppl 1):165. OltraA , SantaballaA , MunárrizB , PastorM , MontalarJ . Cost‐benefit analysis of a follow‐up program in patients with breast cancer: a randomized prospective study. Breast Journal2007;13(6):571‐4. ">Oltra 2007</a>; <a href="./references#CD012425-bbs2-0035" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA , et al. Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD012425-bbs2-0043" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk‐adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD012425-bbs2-0046" title="NCT00624260 . Impact of PET Scan on the curative strategy of colo‐rectal cancers : a randomized study. clinicaltrials.gov/ct2/show/NCT00624260 (first received 20 December 2016). SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an openlabel multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology2017;35(15 Suppl 1):no pagination. SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal2017;5(5 Suppl 1):A13. SobhaniI , IttiE , LucianiA , BaumgaertnerI , LayeseR , AndreT , et al. Colorectal cancer (CRC) monitoring by 6‐monthly 18FDG‐PET/CT: an open‐label multicentre randomised trial. Annals of Oncology2018;29(4):931‐7. ">Sobhani 2018</a>; <a href="./references#CD012425-bbs2-0049" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>). Four of these studies (854 participants) reported shorter time to detection of recurrence for more intensive follow‐up after colorectal cancer (mean/SD 10 ± 5 versus 15 ± 10 months, P = 0.002; <a href="./references#CD012425-bbs2-0026" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1992</a> and mean/SD 10.3 ± 2.7 versus 20.2 ± 6.1 months, P &lt; .0003; <a href="./references#CD012425-bbs2-0035" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA , et al. Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>), lung cancer (mean/SD 12 ± 9.9 versus 18 ± 11.8 months, no P‐value; <a href="./references#CD012425-bbs2-0029" title="MonteilJ , VergnenègreA , BertinF , DalmayF , GaillardS , BonnaudF , et al. Randomized follow‐up study of resected NSCLC patients: conventional versus 18F‐DG coincidence imaging. Anticancer Research2010;30(9):3811‐6. NCT00199615 . Follow‐up of patients with curative‐intent surgical resection for NSCLC. clinicaltrials.gov/ct2/show/NCT00199615 (first received 20 December 2016). ">Monteil 2010</a>) and breast cancer (mean 1.9 versus 2.1 years, no P‐value; <a href="./references#CD012425-bbs2-0024" title="KokkoR , HakamaM , HolliK . Follow‐up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Research and Treatment2005;93(3):255‐60. KokkoR , HakamaM , HolliK . Role of chest X‐ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Research and Treatment2003;81(1):33‐9. ">Kokko 2003</a>). Four other studies (734 participants) reported little or no difference between groups on time to recurrence after melanoma (no estimate reported by the authors, only Chi<sup>2</sup> P‐value = 0.893; <a href="./references#CD012425-bbs2-0007" title="DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . Prospective randomized clinical trial for the evaluation of a stage adjusted reduced follow‐up schedule in cutaneous melanoma patients: results after one year. Annals of Surgical Oncology2016;23(1 Suppl 1):S30. DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . The MELFO‐study: prospective randomized clinical trial for the evaluation of a stage‐adjusted reduced follow‐up schedule in cutaneous melanoma patients ‐ results after 1 year. Annals of Surgical Oncology2016;23(9):2762‐71. [DOI: 10.1245/s10434‐016‐5263‐7] DeckersE , Hoekstra‐WeebersJ , DamudeS , FranckenA , Ter MeulenS , BastiaannetE , et al. The MELFO‐study: a multi‐center prospective randomized clinical trial on the effects of a reduced stage‐adjusted follow‐up schedule on cutaneous melanoma IB‐IIC patients: results after 3‐years. Annals of Surgical Oncology2018;25(1 Suppl 1):S40. NCT01018004 . Comparing follow‐up schedules in patients with newly diagnosed stage IB or stage II melanoma. clinicaltrials.gov/ct2/show/NCT01018004 (first received 20 December 2016). ">Damude 2016</a>), colorectal cancer (median 1.7 (range 0.3 to 7.6) years versus 2.0 (range 0.8 ‐ 5.6) years, P &gt; 0.05; <a href="./references#CD012425-bbs2-0032" title="OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>), (mean/SD 22 ± 17.6 months versus 35 ± 23.9 months, P = 0.49; <a href="./references#CD012425-bbs2-0049" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>), and detection of recurrence after breast cancer at three years' follow‐up (22.41%, 90% CI 13.40 to 31.42 versus 17.46%, 90% CI 9.59 to 25.30; <a href="./references#CD012425-bbs2-0033" title="OltraA , SantaballaA , MontalarJ , MunárrizB , PastorM , MeseguerA , et al. Cost‐benefit evaluation of a follow‐up program in patients with advanced breast cancer. Randomized study. Revista de Oncología1999;1(Suppl 1):165. OltraA , SantaballaA , MunárrizB , PastorM , MontalarJ . Cost‐benefit analysis of a follow‐up program in patients with breast cancer: a randomized prospective study. Breast Journal2007;13(6):571‐4. ">Oltra 2007</a>). One final study, <a href="./references#CD012425-bbs2-0043" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk‐adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>, also reported on "disease‐free intervals" but the outcome data were not relevant for this review as the study compared high‐risk patients with low‐risk patients instead of patients in the intensive treatment group with patients in the minimal treatment group (337 participants). Finally, <a href="./references#CD012425-bbs2-0046" title="NCT00624260 . Impact of PET Scan on the curative strategy of colo‐rectal cancers : a randomized study. clinicaltrials.gov/ct2/show/NCT00624260 (first received 20 December 2016). SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an openlabel multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology2017;35(15 Suppl 1):no pagination. SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal2017;5(5 Suppl 1):A13. SobhaniI , IttiE , LucianiA , BaumgaertnerI , LayeseR , AndreT , et al. Colorectal cancer (CRC) monitoring by 6‐monthly 18FDG‐PET/CT: an open‐label multicentre randomised trial. Annals of Oncology2018;29(4):931‐7. ">Sobhani 2018</a> only reported on detection of unresectable recurrence in colorectal cancer (7.0 versus 14.3 months in favour of the more intensive arm; 239 participants). </p> <p>The delay in detection of recurrence between the two arms ranged from 2 to 10 months in the studies that reported the outcome in time. However, the clinical relevance of this delay on patient outcomes, such as survival, is uncertain as this depends on multiple factors, such as cancer site, treatment received or the patient’s disease burden, and the studies included were not designed to address this. </p> </section> <section id="CD012425-sec-0107"> <h5 class="title">Health‐related quality of life</h5> <p>Three studies reported on health‐related quality of life (<a href="./references#CD012425-bbs2-0007" title="DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . Prospective randomized clinical trial for the evaluation of a stage adjusted reduced follow‐up schedule in cutaneous melanoma patients: results after one year. Annals of Surgical Oncology2016;23(1 Suppl 1):S30. DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . The MELFO‐study: prospective randomized clinical trial for the evaluation of a stage‐adjusted reduced follow‐up schedule in cutaneous melanoma patients ‐ results after 1 year. Annals of Surgical Oncology2016;23(9):2762‐71. [DOI: 10.1245/s10434‐016‐5263‐7] DeckersE , Hoekstra‐WeebersJ , DamudeS , FranckenA , Ter MeulenS , BastiaannetE , et al. The MELFO‐study: a multi‐center prospective randomized clinical trial on the effects of a reduced stage‐adjusted follow‐up schedule on cutaneous melanoma IB‐IIC patients: results after 3‐years. Annals of Surgical Oncology2018;25(1 Suppl 1):S40. NCT01018004 . Comparing follow‐up schedules in patients with newly diagnosed stage IB or stage II melanoma. clinicaltrials.gov/ct2/show/NCT01018004 (first received 20 December 2016). ">Damude 2016</a>; <a href="./references#CD012425-bbs2-0011" title="GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata). A randomized trial of intensive versus minimalist follow‐up of patients with resected Dukes B‐C colorectal cancer: the pilot phase. Tumori1998;84(Suppl):89. GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. NCT02409472 . Intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. clinicaltrials.gov/ct2/show/NCT02409472 (first received 20 December 2016). RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] ">GILDA 2016</a>; <a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a>), but we could not pool the reported data due to the different measures used and varying follow‐up periods. However, all three studies (2742 participants) reported that less intensive follow‐up made little or no difference in health‐related quality of life when compared to more intensive follow‐up. <a href="./references#CD012425-bbs2-0007" title="DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . Prospective randomized clinical trial for the evaluation of a stage adjusted reduced follow‐up schedule in cutaneous melanoma patients: results after one year. Annals of Surgical Oncology2016;23(1 Suppl 1):S30. DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . The MELFO‐study: prospective randomized clinical trial for the evaluation of a stage‐adjusted reduced follow‐up schedule in cutaneous melanoma patients ‐ results after 1 year. Annals of Surgical Oncology2016;23(9):2762‐71. [DOI: 10.1245/s10434‐016‐5263‐7] DeckersE , Hoekstra‐WeebersJ , DamudeS , FranckenA , Ter MeulenS , BastiaannetE , et al. The MELFO‐study: a multi‐center prospective randomized clinical trial on the effects of a reduced stage‐adjusted follow‐up schedule on cutaneous melanoma IB‐IIC patients: results after 3‐years. Annals of Surgical Oncology2018;25(1 Suppl 1):S40. NCT01018004 . Comparing follow‐up schedules in patients with newly diagnosed stage IB or stage II melanoma. clinicaltrials.gov/ct2/show/NCT01018004 (first received 20 December 2016). ">Damude 2016</a> used the MCS subscale of the RAND‐36 (a version of the SF‐36) and reported that less intensive follow‐up after melanoma had no effect on health‐related quality of life at 12 months (mean/SD 54.3 (7.6) versus 52.5 (8.8); P = 0.62). <a href="./references#CD012425-bbs2-0011" title="GILDA (Gruppo Italiano di Lavoro per la Diagnosi Anticipata). A randomized trial of intensive versus minimalist follow‐up of patients with resected Dukes B‐C colorectal cancer: the pilot phase. Tumori1998;84(Suppl):89. GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. NCT02409472 . Intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. clinicaltrials.gov/ct2/show/NCT02409472 (first received 20 December 2016). RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] ">GILDA 2016</a> used the SF‐12 and reported graphs showing no difference between less intensive and more intensive follow‐up after colorectal cancer on the PCS and MCS subscales of the SF‐36 for up to 60 months of follow‐up. <a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a> measured quality of life using a compilation of items selected from several quality‐of‐life instruments and reported that, "type of follow‐up did not affect various dimensions of health‐related quality of life" after breast cancer for up to five years' follow‐up. We judged the certainty of evidence to be very low and downgraded by three levels for serious concerns regarding inconsistency, indirectness and imprecision due to the few studies, heterogeneous measures and reporting of results by different estimates that we could not pool. </p> </section> <section id="CD012425-sec-0108"> <h5 class="title">Anxiety</h5> <p>Only <a href="./references#CD012425-bbs2-0007" title="DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . Prospective randomized clinical trial for the evaluation of a stage adjusted reduced follow‐up schedule in cutaneous melanoma patients: results after one year. Annals of Surgical Oncology2016;23(1 Suppl 1):S30. DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . The MELFO‐study: prospective randomized clinical trial for the evaluation of a stage‐adjusted reduced follow‐up schedule in cutaneous melanoma patients ‐ results after 1 year. Annals of Surgical Oncology2016;23(9):2762‐71. [DOI: 10.1245/s10434‐016‐5263‐7] DeckersE , Hoekstra‐WeebersJ , DamudeS , FranckenA , Ter MeulenS , BastiaannetE , et al. The MELFO‐study: a multi‐center prospective randomized clinical trial on the effects of a reduced stage‐adjusted follow‐up schedule on cutaneous melanoma IB‐IIC patients: results after 3‐years. Annals of Surgical Oncology2018;25(1 Suppl 1):S40. NCT01018004 . Comparing follow‐up schedules in patients with newly diagnosed stage IB or stage II melanoma. clinicaltrials.gov/ct2/show/NCT01018004 (first received 20 December 2016). ">Damude 2016</a> reported on anxiety using STAI and showed that less intensive follow‐up after melanoma made little or no difference to anxiety at 12 months (mean/SD 29.5 (8.8) versus 31.0 (9.9); P = 0.54; 180 participants). We judged the certainty of evidence to be very low and downgraded by three levels for serious concerns regarding inconsistency, indirectness and imprecision since there was only one study. </p> </section> <section id="CD012425-sec-0109"> <h5 class="title">Depression</h5> <p>None of the studies reported on depression. Thus, there is a lack of evidence for the effect of less intensive versus more intensive follow‐up on depression following completion of primary cancer treatment in adult cancer survivors. </p> </section> <section id="CD012425-sec-0110"> <h5 class="title">Cost</h5> <p>Six studies (1412 participants) reported cost outcomes (<a href="./references#CD012425-bbs2-0007" title="DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . Prospective randomized clinical trial for the evaluation of a stage adjusted reduced follow‐up schedule in cutaneous melanoma patients: results after one year. Annals of Surgical Oncology2016;23(1 Suppl 1):S30. DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . The MELFO‐study: prospective randomized clinical trial for the evaluation of a stage‐adjusted reduced follow‐up schedule in cutaneous melanoma patients ‐ results after 1 year. Annals of Surgical Oncology2016;23(9):2762‐71. [DOI: 10.1245/s10434‐016‐5263‐7] DeckersE , Hoekstra‐WeebersJ , DamudeS , FranckenA , Ter MeulenS , BastiaannetE , et al. The MELFO‐study: a multi‐center prospective randomized clinical trial on the effects of a reduced stage‐adjusted follow‐up schedule on cutaneous melanoma IB‐IIC patients: results after 3‐years. Annals of Surgical Oncology2018;25(1 Suppl 1):S40. NCT01018004 . Comparing follow‐up schedules in patients with newly diagnosed stage IB or stage II melanoma. clinicaltrials.gov/ct2/show/NCT01018004 (first received 20 December 2016). ">Damude 2016</a>; <a href="./references#CD012425-bbs2-0024" title="KokkoR , HakamaM , HolliK . Follow‐up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Research and Treatment2005;93(3):255‐60. KokkoR , HakamaM , HolliK . Role of chest X‐ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Research and Treatment2003;81(1):33‐9. ">Kokko 2003</a>; <a href="./references#CD012425-bbs2-0029" title="MonteilJ , VergnenègreA , BertinF , DalmayF , GaillardS , BonnaudF , et al. Randomized follow‐up study of resected NSCLC patients: conventional versus 18F‐DG coincidence imaging. Anticancer Research2010;30(9):3811‐6. NCT00199615 . Follow‐up of patients with curative‐intent surgical resection for NSCLC. clinicaltrials.gov/ct2/show/NCT00199615 (first received 20 December 2016). ">Monteil 2010</a>; <a href="./references#CD012425-bbs2-0033" title="OltraA , SantaballaA , MontalarJ , MunárrizB , PastorM , MeseguerA , et al. Cost‐benefit evaluation of a follow‐up program in patients with advanced breast cancer. Randomized study. Revista de Oncología1999;1(Suppl 1):165. OltraA , SantaballaA , MunárrizB , PastorM , MontalarJ . Cost‐benefit analysis of a follow‐up program in patients with breast cancer: a randomized prospective study. Breast Journal2007;13(6):571‐4. ">Oltra 2007</a>; <a href="./references#CD012425-bbs2-0034" title="PicardiM , PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , et al. Advanced‐stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission‐‐a randomized trial of routine surveillance imaging procedures. Radiology2014;272(1):262‐74. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: Ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2015;100:7‐8. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2014;99:398‐9. ">Picardi 2014</a>; <a href="./references#CD012425-bbs2-0037" title="BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial [Efectividad del seguimiento postoperatorio en los pacientes con cáncer colorrectal para la detección de recidivas curables. Análisis preliminar de un estudio multicéntrico, controlado y aleatorizado]. Gastroenterologia y Hepatologia2001;24(2):92, abstract no: 13. BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Preliminary analysis of a multicenter controlled trial to evaluate the effectiveness of postoperative follow‐up to detect curable recurrences in patients with colorectal cancer [Análisis preliminar de un estudio multicéntrico controlado y aleatorizado destinado a evaluar la efectividad del seguimiento postoperatorio en la detección de recidivas curables en los pacientes con cáncer colorrectal]. Gastroenterologia y Hepatologia2001;24(3):150. Rodriguez‐MorantaF , CastellsA , SaloJ , ArcusaA , BoadasJ , BessaV , et al. Efficacy of postoperative surveillance after radical surgery for colorectal cancer (CRC). Analysis of a prospective, multicenter, randomized controlled trial. Journal of Gastroenterology2005;128(4 Suppl 2):Abstract W967. Rodríguez‐MorantaF , SalóJ , AcrusaA , BoadasJ , BessaX , PiñolV , et al. Efficacy of postoperative surveillance in patients with colorectal cancer after radical surgery. A prospective, multicenter, randomized study. Gastroenterologia y Hepatologia2005;28(3):197‐8, abstract no: 126. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , Bessa , X , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>), but due to the substantial heterogeneity in how studies measured and reported the outcome, we could not pool the results in a meta‐analysis. We have summarised details of how each study measured and reported cost outcomes in <a href="#CD012425-tbl-0004">Table 1</a>. One study (<a href="./references#CD012425-bbs2-0043" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk‐adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>) reported carrying out cost analysis but did not report any data. All studies reported lower costs for the less intensive arm from the perspective of the patient or healthcare system but the difference in cost varied considerably depending on the components of or procedures used in the different interventions. We judged the certainty of evidence to be very low and downgraded by three levels as the substantial heterogeneity led to serious concerns regarding inconsistency, indirectness and imprecision in the way cost was measured and reported across studies. </p> </section> </section> <section id="CD012425-sec-0111"> <h4 class="title">Comparison 3: follow‐up integrating additional patient symptom education or monitoring, or survivorship care plans versus usual care </h4> <p>We included 12 studies for this comparison (<a href="./references#CD012425-bbs2-0008" title="DavisKM , DawsonD , KellyS , RedS , PenekS , LynchJ , et al. Monitoring of health‐related quality of life and symptoms in prostate cancer survivors: a randomized trial. Journal of Supportive Oncology2013;11(4):174‐82. ">Davis 2013</a>; <a href="./references#CD012425-bbs2-0015" title="BoekhoutAH , MaunsellE , PondGR , JulianJA , CoyleD , LevineMN , et al. A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial. Journal of Cancer Survivorship2015;9(4):683‐91. CoyleD , GrunfeldE , CoyleK , JulianJA , PondGR , FolkesA , et al. Cost‐effectiveness of a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):6082. CoyleD , GrunfeldE , CoyleK , PondG , JulianJA , LevineMN . Cost effectiveness of a survivorship care plan for breast cancer survivors. Journal of Oncology Practice2014;10(2):e86‐92. GrunfeldE , JulianJA , PondG , MaunsellE , CoyleD , FolkesA , et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. Journal of Clinical Oncology2011;29(36):4755‐62. GrunfeldE , LevineMN , JulianJA , PondGR , MaunsellE , FolkesA , et al. Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):9005. GrunfeldE , PondG , MaunsellE , LevineMN , JulianJA , CoyleD . Impact of survivorship care plans (SCP) on adherence to guidelines, health service measures, and patient‐reported outcomes (PRO): extended results of a multicenter randomized clinical trial (RCT) with breast cancer survivors. European Journal of Cancer2012;48:S147. ">Grunfeld 2011</a>; <a href="./references#CD012425-bbs2-0016" title="HershmanDL , GreenleeH , AwadD , KalinskyK , MaurerM , KranwinkelG , et al. Randomized controlled trial of a clinic‐based survivorship intervention following adjuvant therapy in breast cancer survivors. Breast Cancer Research and Treatment2013;138(3):795‐806. ">Hershman 2013</a>; <a href="./references#CD012425-bbs2-0017" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14:260. [DOI: 10.1186/1745‐6215‐14‐260] JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a nurse‐led supportive care package (survivor care) for survivors of colorectal cancer. Cancer Nursing2015;38(4 Suppl 1):S16‐7. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (Survivor‐Care, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2015;33(15 Suppl 1):9566. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , SchofieldP , ArandaS , YoungJ , ButowP . Randomised controlled trial (RCT) of a comprehensive post‐treatment support package (survivor‐care) for bowel cancer survivors. Psycho‐oncology2010;19:S193. ">Jefford 2016</a>; <a href="./references#CD012425-bbs2-0019" title="JuarezG , HurriaA , FerrellB . Effectiveness of an education intervention on quality of life in Latina breast cancer survivors. Psycho‐oncology2012;21:110. JuarezG , HurriaA , UmanG , FerrellB . Impact of a bilingual education intervention on the quality of life of Latina breast cancer survivors. Oncology Nursing Forum2013;40(1):E50‐60. [DOI: 10.1188/13.ONF.E50‐E60] ">Juarez 2013</a>; <a href="./references#CD012425-bbs2-0025" title="KvaleEA , Demark‐WahnefriedW , MenesesK , BaeS , HuangCH , AzueroCB , et al. Patient centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer Research2015;75(9 Suppl 1):no pagination. KvaleEA , HuangCS , MenesesKM , Demark‐WahnefriedW , BaeS , AzueroCB , et al. Patient‐centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer2016;122(20):3232‐42. ">Kvale 2016</a>; <a href="./references#CD012425-bbs2-0027" title="MalmströmM , IvarssonB , KlefsgårdR , PerssonK , JakobssonU , JohanssonJ . The effect of a nurse led telephone supportive care programme on patients' quality of life, received information and health care contacts after oesophageal cancer surgery‐a six month RCT‐follow‐up study. International Journal of Nursing Studies2016;64:86‐95. [DOI: 10.1016/j.ijnurstu.2016.09.009] ">Malmstrom 2016</a>; <a href="./references#CD012425-bbs2-0028" title="MalyRC , GriggsJJ , LiuY , LiangLJ , GanzPA . A randomized controlled trial of survivorship care plans among low‐income breast cancer survivors. Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. MalyRC , LiangLJ , LiuY , GriggsJJ , GanzPA . Randomized controlled trial of survivorship care plans among low‐income, predominant Latina breast cancer survivors. Journal of Clinical Oncology2017;35(16):1814‐21. NCT01627366 . Study of survivorship care plans and outcomes in underserved breast cancer survivors. clinicaltrials.gov/ct2/show/NCT01627366 (first received 17 December 2018). ">Maly 2017</a>; <a href="./references#CD012425-bbs2-0038" title="DeRooijBH , EzendamNP , NicolaijeKA , LodderP , VosMC , PijnenborgJM , et al. Survivorship care plans have a negative impact on long‐term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. Quality of Life Research2018;27(6):1533‐44. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2‐year follow‐up ‐ The ROGY care trial. Gynecologic Oncology2017;145(2):319‐28. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Long‐term impact of survivorship care plans on ovarian cancer patient reported outcomes‐new results of the ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):64‐5. DeRooijBH , EzendamNP , NicolaijeKA , VosMC , PijnenborgJM , BollD , et al. The indirect effects of survivorship care plans on quality of life, anxiety and depression‐the ROGY care trial. Supportive Care in Cancer2017;25(2 Suppl 1):S53‐4. DeRooijBH , EzendamNP , VosMC , PijnenborgJM , BollD , KruitwagenRF , et al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. Cancer Epub 2018 Nov 30;125(5):788‐97. [DOI: 10.1002/cncr.31844] EzendamN , DeRooijB , NicolaijeK , VosC , PijnenborgJ , BollD , et al. Long‐term impact of cancer survivorship care plans on patient outcomes‐the randomized controlled ROGY care trial. International Journal of Gynecological Cancer2016;26:91. EzendamNP , VanBroekhovenM , Van DePoll‐FranseLV , DeRooijBH . The role of illness perceptions in smoking, alcohol consumption and weight changes among gynaecological cancer survivors. Quality of Life Research2016;25(1 Suppl 1):114. JeppesenMM , EzendamNP , PijnenborgJM , VosMC , BollD , KruitwagenRF , et al. The impact of the survivorship care plan on health care use: 2‐year follow‐up results of the ROGY care trial. Journal of Cancer Survivorship2018;12(1):18‐27. NicolaijeKA , EzendamNP , VosMC , PijnenborgJM , BollD , BossEA , et al. Impact of an automatically generated cancer survivorship care plan on patient‐reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial. Journal of Clinical Oncology2015;33(31):3550‐9. Van dePoll‐FranseL , NicolaijeK , EzendamN , VosC , BollD , PijnenborgJ , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY CARE): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Psycho‐oncology2013;22:341‐2. Van dePoll‐FranseLV , JeppesenMM , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. The survivorship care plan increases the use of primary care in anxious and irradiated endometrial cancer patients. Two year outcomes of the pragmatic cluster randomized ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):164. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosCM , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY Care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosMC , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. European Journal of Cancer2013;49:S720. Van dePoll‐FranseLV , NicolaijeKA , VosMC , PijnenborgJM , BollD , HussonO , et al. The impact of a cancer survivorship care plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials2011;12:256. ">ROGY 2015</a>; <a href="./references#CD012425-bbs2-0040" title="RuddyKJ , BakerEL , GuoH , GoldsteinMJ , WinerEP , ShulmanLN , et al. Randomized trial evaluating a coordinated survivorship care program for early stage breast cancer. Cancer Research2013;73(24 Suppl 1):OT2‐5‐02. RuddyKJ , GuoH , BakerE , GoldsteinM , MullaneyEE , ShulmanLN , et al. Coordinated follow‐up breast cancer survivorship care program study. Journal of Clinical Oncology2015;33(15 Suppl 1):e17727. RuddyKJ , GuoH , BakerEL , GoldsteinMJ , MullaneyEE , ShulmanLN , et al. Randomized phase 2 trial of a coordinated breast cancer follow‐up care program. Cancer2016;122:3546‐54. ">Ruddy 2016</a>; <a href="./references#CD012425-bbs2-0047" title="Van DerMeulenI , MayA , RosW , OosteromM , HordijkGJ , KooleR , et al. Effects of a nurse‐led psychosocial intervention on depressive symptoms and health‐related quality of life in patients with head and neck cancer: a randomized controlled trial. Psycho‐oncology2013;22(Suppl 3):17. Van derMeulenIC , MayAM , RosWJ , OosteromM , HordijkGJ , KooleR , et al. One‐year effect of a nurse‐led psychosocial intervention on depressive symptoms in patients with head and neck cancer: a randomized controlled trial. Oncologist2013;18(3):336‐44. [DOI: 10.1634/theoncologist.2012‐0299] ">Van der Meulen 2013</a>; <a href="./references#CD012425-bbs2-0053" title='ACTRN12608000252314 . Cancer care after surgery – the CONNECT study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82819 (first received 20 December 2016). HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Connect: a pilot RCT to improve outcomes for people with colorectal cancer. Asia‐Pacific Journal of Clinical Oncology2009;5:A159. HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Randomized pilot evaluation of the supportive care intervention "CONNECT" for people following surgery for colorectal cancer. Diseases of the Colon and Rectum2011;54(5):622‐31. YoungJM , ButowPN , WalshJ , DurcinoskaI , DobbinsTA , RodwellL , et al. Multicenter randomized trial of centralized nurse‐led telephone‐based care coordination to improve outcomes after surgical resection for colorectal cancer: the CONNECT intervention. Journal of Clinical Oncology2013;31(28):3585‐91. [DOI: 10.1200/JCO.2012.48.1036] '>Young 2013</a>). </p> <section id="CD012425-sec-0112"> <h5 class="title">Overall survival</h5> <p>None of the studies reported on overall survival. Thus, there is a lack of evidence for the effect of follow‐up integrating patient education/survivorship care plans versus usual care on survival following completion of primary cancer treatment in adult cancer survivors. </p> </section> <section id="CD012425-sec-0113"> <h5 class="title">Time to detection of recurrence</h5> <p>None of the studies reported on time to detection of recurrence. Thus, there is a lack of evidence for the effect of follow‐up integrating patient education/survivorship care plans versus usual care on detection of recurrence following completion of primary cancer treatment in adult cancer survivors. </p> </section> <section id="CD012425-sec-0114"> <h5 class="title">Health‐related quality of life</h5> <p>All twelve studies (2846 participants) reported on health‐related quality of life using a variety of measurement scales and with varying follow‐up periods. (<a href="./references#CD012425-bbs2-0008" title="DavisKM , DawsonD , KellyS , RedS , PenekS , LynchJ , et al. Monitoring of health‐related quality of life and symptoms in prostate cancer survivors: a randomized trial. Journal of Supportive Oncology2013;11(4):174‐82. ">Davis 2013</a>; <a href="./references#CD012425-bbs2-0015" title="BoekhoutAH , MaunsellE , PondGR , JulianJA , CoyleD , LevineMN , et al. A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial. Journal of Cancer Survivorship2015;9(4):683‐91. CoyleD , GrunfeldE , CoyleK , JulianJA , PondGR , FolkesA , et al. Cost‐effectiveness of a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):6082. CoyleD , GrunfeldE , CoyleK , PondG , JulianJA , LevineMN . Cost effectiveness of a survivorship care plan for breast cancer survivors. Journal of Oncology Practice2014;10(2):e86‐92. GrunfeldE , JulianJA , PondG , MaunsellE , CoyleD , FolkesA , et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. Journal of Clinical Oncology2011;29(36):4755‐62. GrunfeldE , LevineMN , JulianJA , PondGR , MaunsellE , FolkesA , et al. Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):9005. GrunfeldE , PondG , MaunsellE , LevineMN , JulianJA , CoyleD . Impact of survivorship care plans (SCP) on adherence to guidelines, health service measures, and patient‐reported outcomes (PRO): extended results of a multicenter randomized clinical trial (RCT) with breast cancer survivors. European Journal of Cancer2012;48:S147. ">Grunfeld 2011</a>; <a href="./references#CD012425-bbs2-0016" title="HershmanDL , GreenleeH , AwadD , KalinskyK , MaurerM , KranwinkelG , et al. Randomized controlled trial of a clinic‐based survivorship intervention following adjuvant therapy in breast cancer survivors. Breast Cancer Research and Treatment2013;138(3):795‐806. ">Hershman 2013</a>; <a href="./references#CD012425-bbs2-0017" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14:260. [DOI: 10.1186/1745‐6215‐14‐260] JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a nurse‐led supportive care package (survivor care) for survivors of colorectal cancer. Cancer Nursing2015;38(4 Suppl 1):S16‐7. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (Survivor‐Care, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2015;33(15 Suppl 1):9566. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , SchofieldP , ArandaS , YoungJ , ButowP . Randomised controlled trial (RCT) of a comprehensive post‐treatment support package (survivor‐care) for bowel cancer survivors. Psycho‐oncology2010;19:S193. ">Jefford 2016</a>; <a href="./references#CD012425-bbs2-0019" title="JuarezG , HurriaA , FerrellB . Effectiveness of an education intervention on quality of life in Latina breast cancer survivors. Psycho‐oncology2012;21:110. JuarezG , HurriaA , UmanG , FerrellB . Impact of a bilingual education intervention on the quality of life of Latina breast cancer survivors. Oncology Nursing Forum2013;40(1):E50‐60. [DOI: 10.1188/13.ONF.E50‐E60] ">Juarez 2013</a>; <a href="./references#CD012425-bbs2-0025" title="KvaleEA , Demark‐WahnefriedW , MenesesK , BaeS , HuangCH , AzueroCB , et al. Patient centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer Research2015;75(9 Suppl 1):no pagination. KvaleEA , HuangCS , MenesesKM , Demark‐WahnefriedW , BaeS , AzueroCB , et al. Patient‐centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer2016;122(20):3232‐42. ">Kvale 2016</a>; <a href="./references#CD012425-bbs2-0027" title="MalmströmM , IvarssonB , KlefsgårdR , PerssonK , JakobssonU , JohanssonJ . The effect of a nurse led telephone supportive care programme on patients' quality of life, received information and health care contacts after oesophageal cancer surgery‐a six month RCT‐follow‐up study. International Journal of Nursing Studies2016;64:86‐95. [DOI: 10.1016/j.ijnurstu.2016.09.009] ">Malmstrom 2016</a>; <a href="./references#CD012425-bbs2-0028" title="MalyRC , GriggsJJ , LiuY , LiangLJ , GanzPA . A randomized controlled trial of survivorship care plans among low‐income breast cancer survivors. Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. MalyRC , LiangLJ , LiuY , GriggsJJ , GanzPA . Randomized controlled trial of survivorship care plans among low‐income, predominant Latina breast cancer survivors. Journal of Clinical Oncology2017;35(16):1814‐21. NCT01627366 . Study of survivorship care plans and outcomes in underserved breast cancer survivors. clinicaltrials.gov/ct2/show/NCT01627366 (first received 17 December 2018). ">Maly 2017</a>; <a href="./references#CD012425-bbs2-0038" title="DeRooijBH , EzendamNP , NicolaijeKA , LodderP , VosMC , PijnenborgJM , et al. Survivorship care plans have a negative impact on long‐term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. Quality of Life Research2018;27(6):1533‐44. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2‐year follow‐up ‐ The ROGY care trial. Gynecologic Oncology2017;145(2):319‐28. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Long‐term impact of survivorship care plans on ovarian cancer patient reported outcomes‐new results of the ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):64‐5. DeRooijBH , EzendamNP , NicolaijeKA , VosMC , PijnenborgJM , BollD , et al. The indirect effects of survivorship care plans on quality of life, anxiety and depression‐the ROGY care trial. Supportive Care in Cancer2017;25(2 Suppl 1):S53‐4. DeRooijBH , EzendamNP , VosMC , PijnenborgJM , BollD , KruitwagenRF , et al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. Cancer Epub 2018 Nov 30;125(5):788‐97. [DOI: 10.1002/cncr.31844] EzendamN , DeRooijB , NicolaijeK , VosC , PijnenborgJ , BollD , et al. Long‐term impact of cancer survivorship care plans on patient outcomes‐the randomized controlled ROGY care trial. International Journal of Gynecological Cancer2016;26:91. EzendamNP , VanBroekhovenM , Van DePoll‐FranseLV , DeRooijBH . The role of illness perceptions in smoking, alcohol consumption and weight changes among gynaecological cancer survivors. Quality of Life Research2016;25(1 Suppl 1):114. JeppesenMM , EzendamNP , PijnenborgJM , VosMC , BollD , KruitwagenRF , et al. The impact of the survivorship care plan on health care use: 2‐year follow‐up results of the ROGY care trial. Journal of Cancer Survivorship2018;12(1):18‐27. NicolaijeKA , EzendamNP , VosMC , PijnenborgJM , BollD , BossEA , et al. Impact of an automatically generated cancer survivorship care plan on patient‐reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial. Journal of Clinical Oncology2015;33(31):3550‐9. Van dePoll‐FranseL , NicolaijeK , EzendamN , VosC , BollD , PijnenborgJ , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY CARE): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Psycho‐oncology2013;22:341‐2. Van dePoll‐FranseLV , JeppesenMM , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. The survivorship care plan increases the use of primary care in anxious and irradiated endometrial cancer patients. Two year outcomes of the pragmatic cluster randomized ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):164. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosCM , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY Care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosMC , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. European Journal of Cancer2013;49:S720. Van dePoll‐FranseLV , NicolaijeKA , VosMC , PijnenborgJM , BollD , HussonO , et al. The impact of a cancer survivorship care plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials2011;12:256. ">ROGY 2015</a>; <a href="./references#CD012425-bbs2-0040" title="RuddyKJ , BakerEL , GuoH , GoldsteinMJ , WinerEP , ShulmanLN , et al. Randomized trial evaluating a coordinated survivorship care program for early stage breast cancer. Cancer Research2013;73(24 Suppl 1):OT2‐5‐02. RuddyKJ , GuoH , BakerE , GoldsteinM , MullaneyEE , ShulmanLN , et al. Coordinated follow‐up breast cancer survivorship care program study. Journal of Clinical Oncology2015;33(15 Suppl 1):e17727. RuddyKJ , GuoH , BakerEL , GoldsteinMJ , MullaneyEE , ShulmanLN , et al. Randomized phase 2 trial of a coordinated breast cancer follow‐up care program. Cancer2016;122:3546‐54. ">Ruddy 2016</a>; <a href="./references#CD012425-bbs2-0047" title="Van DerMeulenI , MayA , RosW , OosteromM , HordijkGJ , KooleR , et al. Effects of a nurse‐led psychosocial intervention on depressive symptoms and health‐related quality of life in patients with head and neck cancer: a randomized controlled trial. Psycho‐oncology2013;22(Suppl 3):17. Van derMeulenIC , MayAM , RosWJ , OosteromM , HordijkGJ , KooleR , et al. One‐year effect of a nurse‐led psychosocial intervention on depressive symptoms in patients with head and neck cancer: a randomized controlled trial. Oncologist2013;18(3):336‐44. [DOI: 10.1634/theoncologist.2012‐0299] ">Van der Meulen 2013</a>; <a href="./references#CD012425-bbs2-0053" title='ACTRN12608000252314 . Cancer care after surgery – the CONNECT study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82819 (first received 20 December 2016). HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Connect: a pilot RCT to improve outcomes for people with colorectal cancer. Asia‐Pacific Journal of Clinical Oncology2009;5:A159. HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Randomized pilot evaluation of the supportive care intervention "CONNECT" for people following surgery for colorectal cancer. Diseases of the Colon and Rectum2011;54(5):622‐31. YoungJM , ButowPN , WalshJ , DurcinoskaI , DobbinsTA , RodwellL , et al. Multicenter randomized trial of centralized nurse‐led telephone‐based care coordination to improve outcomes after surgical resection for colorectal cancer: the CONNECT intervention. Journal of Clinical Oncology2013;31(28):3585‐91. [DOI: 10.1200/JCO.2012.48.1036] '>Young 2013</a>). We were unable to pool the reported data in a meta‐analysis as there was no scale or subscale that at least three studies reported at 12 months of follow‐up (criteria prespecified in the <a href="#CD012425-sec-0059">Data synthesis</a> section). However, all the studies except <a href="./references#CD012425-bbs2-0025" title="KvaleEA , Demark‐WahnefriedW , MenesesK , BaeS , HuangCH , AzueroCB , et al. Patient centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer Research2015;75(9 Suppl 1):no pagination. KvaleEA , HuangCS , MenesesKM , Demark‐WahnefriedW , BaeS , AzueroCB , et al. Patient‐centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer2016;122(20):3232‐42. ">Kvale 2016</a> reported little or no difference in health‐related quality of life between the intervention and usual care groups. We present results below according to measurement scale. </p> <p>Two studies used the SF‐36. <a href="./references#CD012425-bbs2-0015" title="BoekhoutAH , MaunsellE , PondGR , JulianJA , CoyleD , LevineMN , et al. A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial. Journal of Cancer Survivorship2015;9(4):683‐91. CoyleD , GrunfeldE , CoyleK , JulianJA , PondGR , FolkesA , et al. Cost‐effectiveness of a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):6082. CoyleD , GrunfeldE , CoyleK , PondG , JulianJA , LevineMN . Cost effectiveness of a survivorship care plan for breast cancer survivors. Journal of Oncology Practice2014;10(2):e86‐92. GrunfeldE , JulianJA , PondG , MaunsellE , CoyleD , FolkesA , et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. Journal of Clinical Oncology2011;29(36):4755‐62. GrunfeldE , LevineMN , JulianJA , PondGR , MaunsellE , FolkesA , et al. Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):9005. GrunfeldE , PondG , MaunsellE , LevineMN , JulianJA , CoyleD . Impact of survivorship care plans (SCP) on adherence to guidelines, health service measures, and patient‐reported outcomes (PRO): extended results of a multicenter randomized clinical trial (RCT) with breast cancer survivors. European Journal of Cancer2012;48:S147. ">Grunfeld 2011</a> investigated a survivorship care plan intervention after breast cancer and unpublished results showed similar mean scores between groups at 12 months for both the PCS subscale (mean/SD 48.2 (8.8) versus 48.4 (9.4)) and MCS subscale (,mean/SD 51.4 (9.4) versus 49.5 (10.7)). <a href="./references#CD012425-bbs2-0025" title="KvaleEA , Demark‐WahnefriedW , MenesesK , BaeS , HuangCH , AzueroCB , et al. Patient centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer Research2015;75(9 Suppl 1):no pagination. KvaleEA , HuangCS , MenesesKM , Demark‐WahnefriedW , BaeS , AzueroCB , et al. Patient‐centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer2016;122(20):3232‐42. ">Kvale 2016</a> investigated the POSTCARE intervention (survivorship care plan and patient coaching) after breast cancer and reported clinically meaningful improvement for physical role functioning (P = 0.0009), bodily pain (P = 0.03) and emotional role functioning (P = 0.04) at three months' follow‐up. </p> <p>Three studies used the EORTC‐C30. <a href="./references#CD012425-bbs2-0017" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14:260. [DOI: 10.1186/1745‐6215‐14‐260] JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a nurse‐led supportive care package (survivor care) for survivors of colorectal cancer. Cancer Nursing2015;38(4 Suppl 1):S16‐7. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (Survivor‐Care, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2015;33(15 Suppl 1):9566. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , SchofieldP , ArandaS , YoungJ , ButowP . Randomised controlled trial (RCT) of a comprehensive post‐treatment support package (survivor‐care) for bowel cancer survivors. Psycho‐oncology2010;19:S193. ">Jefford 2016</a> (the SurvivorCare intervention) and <a href="./references#CD012425-bbs2-0027" title="MalmströmM , IvarssonB , KlefsgårdR , PerssonK , JakobssonU , JohanssonJ . The effect of a nurse led telephone supportive care programme on patients' quality of life, received information and health care contacts after oesophageal cancer surgery‐a six month RCT‐follow‐up study. International Journal of Nursing Studies2016;64:86‐95. [DOI: 10.1016/j.ijnurstu.2016.09.009] ">Malmstrom 2016</a> investigated the addition of patient supportive education or care packages to usual care after colorectal and oesophageal cancer respectively and both reported little or no difference on all subscales at six months between the intervention group and the usual care group. Unpublished results from <a href="./references#CD012425-bbs2-0038" title="DeRooijBH , EzendamNP , NicolaijeKA , LodderP , VosMC , PijnenborgJM , et al. Survivorship care plans have a negative impact on long‐term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. Quality of Life Research2018;27(6):1533‐44. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2‐year follow‐up ‐ The ROGY care trial. Gynecologic Oncology2017;145(2):319‐28. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Long‐term impact of survivorship care plans on ovarian cancer patient reported outcomes‐new results of the ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):64‐5. DeRooijBH , EzendamNP , NicolaijeKA , VosMC , PijnenborgJM , BollD , et al. The indirect effects of survivorship care plans on quality of life, anxiety and depression‐the ROGY care trial. Supportive Care in Cancer2017;25(2 Suppl 1):S53‐4. DeRooijBH , EzendamNP , VosMC , PijnenborgJM , BollD , KruitwagenRF , et al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. Cancer Epub 2018 Nov 30;125(5):788‐97. [DOI: 10.1002/cncr.31844] EzendamN , DeRooijB , NicolaijeK , VosC , PijnenborgJ , BollD , et al. Long‐term impact of cancer survivorship care plans on patient outcomes‐the randomized controlled ROGY care trial. International Journal of Gynecological Cancer2016;26:91. EzendamNP , VanBroekhovenM , Van DePoll‐FranseLV , DeRooijBH . The role of illness perceptions in smoking, alcohol consumption and weight changes among gynaecological cancer survivors. Quality of Life Research2016;25(1 Suppl 1):114. JeppesenMM , EzendamNP , PijnenborgJM , VosMC , BollD , KruitwagenRF , et al. The impact of the survivorship care plan on health care use: 2‐year follow‐up results of the ROGY care trial. Journal of Cancer Survivorship2018;12(1):18‐27. NicolaijeKA , EzendamNP , VosMC , PijnenborgJM , BollD , BossEA , et al. Impact of an automatically generated cancer survivorship care plan on patient‐reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial. Journal of Clinical Oncology2015;33(31):3550‐9. Van dePoll‐FranseL , NicolaijeK , EzendamN , VosC , BollD , PijnenborgJ , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY CARE): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Psycho‐oncology2013;22:341‐2. Van dePoll‐FranseLV , JeppesenMM , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. The survivorship care plan increases the use of primary care in anxious and irradiated endometrial cancer patients. Two year outcomes of the pragmatic cluster randomized ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):164. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosCM , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY Care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosMC , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. European Journal of Cancer2013;49:S720. Van dePoll‐FranseLV , NicolaijeKA , VosMC , PijnenborgJM , BollD , HussonO , et al. The impact of a cancer survivorship care plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials2011;12:256. ">ROGY 2015</a>, investigating survivorship care plan after endometrial and ovarian cancer, also showed little or no difference on all subscales at 12 months between the survivorship care plan group and the usual care group. </p> <p>Three studies used the SF‐12. <a href="./references#CD012425-bbs2-0008" title="DavisKM , DawsonD , KellyS , RedS , PenekS , LynchJ , et al. Monitoring of health‐related quality of life and symptoms in prostate cancer survivors: a randomized trial. Journal of Supportive Oncology2013;11(4):174‐82. ">Davis 2013</a> investigated the addition of patient symptom education and monitoring after prostate cancer and reported, "no significant group differences at 7 months" (P &gt; 0.10), <a href="./references#CD012425-bbs2-0028" title="MalyRC , GriggsJJ , LiuY , LiangLJ , GanzPA . A randomized controlled trial of survivorship care plans among low‐income breast cancer survivors. Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. MalyRC , LiangLJ , LiuY , GriggsJJ , GanzPA . Randomized controlled trial of survivorship care plans among low‐income, predominant Latina breast cancer survivors. Journal of Clinical Oncology2017;35(16):1814‐21. NCT01627366 . Study of survivorship care plans and outcomes in underserved breast cancer survivors. clinicaltrials.gov/ct2/show/NCT01627366 (first received 17 December 2018). ">Maly 2017</a> investigated the addition of treatment summaries and survivorship care plan after breast cancer and reported, "no significant differences in SF‐12 scores from baseline to 12 months between groups (data not shown)", while <a href="./references#CD012425-bbs2-0040" title="RuddyKJ , BakerEL , GuoH , GoldsteinMJ , WinerEP , ShulmanLN , et al. Randomized trial evaluating a coordinated survivorship care program for early stage breast cancer. Cancer Research2013;73(24 Suppl 1):OT2‐5‐02. RuddyKJ , GuoH , BakerE , GoldsteinM , MullaneyEE , ShulmanLN , et al. Coordinated follow‐up breast cancer survivorship care program study. Journal of Clinical Oncology2015;33(15 Suppl 1):e17727. RuddyKJ , GuoH , BakerEL , GoldsteinMJ , MullaneyEE , ShulmanLN , et al. Randomized phase 2 trial of a coordinated breast cancer follow‐up care program. Cancer2016;122:3546‐54. ">Ruddy 2016</a> investigated a survivorship care plan with patient navigator intervention after breast cancer and reported similar medians and interquartile ranges in both groups at 12 months, but did not carry out any statistical analyses. </p> <p>Three studies used various versions of the FACT scale. In addition to reporting on the SF‐12 above, <a href="./references#CD012425-bbs2-0008" title="DavisKM , DawsonD , KellyS , RedS , PenekS , LynchJ , et al. Monitoring of health‐related quality of life and symptoms in prostate cancer survivors: a randomized trial. Journal of Supportive Oncology2013;11(4):174‐82. ">Davis 2013</a> also reported little or no effect as measured by FACT‐G at seven months (P &gt; 0.10). <a href="./references#CD012425-bbs2-0053" title='ACTRN12608000252314 . Cancer care after surgery – the CONNECT study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82819 (first received 20 December 2016). HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Connect: a pilot RCT to improve outcomes for people with colorectal cancer. Asia‐Pacific Journal of Clinical Oncology2009;5:A159. HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Randomized pilot evaluation of the supportive care intervention "CONNECT" for people following surgery for colorectal cancer. Diseases of the Colon and Rectum2011;54(5):622‐31. YoungJM , ButowPN , WalshJ , DurcinoskaI , DobbinsTA , RodwellL , et al. Multicenter randomized trial of centralized nurse‐led telephone‐based care coordination to improve outcomes after surgical resection for colorectal cancer: the CONNECT intervention. Journal of Clinical Oncology2013;31(28):3585‐91. [DOI: 10.1200/JCO.2012.48.1036] '>Young 2013</a> investigated the CONNECT intervention (additional patient education through structured telephone calls by trained nurses) after colorectal cancer and reported little or no effect as measured by the FACT‐C at six months (P = 0.58), and <a href="./references#CD012425-bbs2-0016" title="HershmanDL , GreenleeH , AwadD , KalinskyK , MaurerM , KranwinkelG , et al. Randomized controlled trial of a clinic‐based survivorship intervention following adjuvant therapy in breast cancer survivors. Breast Cancer Research and Treatment2013;138(3):795‐806. ">Hershman 2013</a> investigated survivorship care plan with patient‐nurse sessions after breast cancer and reported little or no effect as measured by the FACT‐B at six months for the physical well‐being subscale (P = 0.93) and functional well‐being subscale (P = 0.83). </p> <p><a href="./references#CD012425-bbs2-0019" title="JuarezG , HurriaA , FerrellB . Effectiveness of an education intervention on quality of life in Latina breast cancer survivors. Psycho‐oncology2012;21:110. JuarezG , HurriaA , UmanG , FerrellB . Impact of a bilingual education intervention on the quality of life of Latina breast cancer survivors. Oncology Nursing Forum2013;40(1):E50‐60. [DOI: 10.1188/13.ONF.E50‐E60] ">Juarez 2013</a> investigated an individualised bilingual patient education programme after breast cancer and used the City of Hope Quality of Life Questionnaire to measure quality of life at three and six months and reported that, "QoL [quality of life] increased slightly in both groups or remained unchanged, without significant group by time interaction." </p> <p>Although all the studies but one reported consistent results, we judged the overall certainty of evidence to be very low and downgraded by three levels for serious concerns regarding study limitations, indirectness and imprecision due to studies being at high risk of bias, the heterogeneous measures and reporting of results by different estimates that could not be pooled. </p> </section> <section id="CD012425-sec-0115"> <h5 class="title">Anxiety</h5> <p>Only <a href="./references#CD012425-bbs2-0038" title="DeRooijBH , EzendamNP , NicolaijeKA , LodderP , VosMC , PijnenborgJM , et al. Survivorship care plans have a negative impact on long‐term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. Quality of Life Research2018;27(6):1533‐44. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2‐year follow‐up ‐ The ROGY care trial. Gynecologic Oncology2017;145(2):319‐28. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Long‐term impact of survivorship care plans on ovarian cancer patient reported outcomes‐new results of the ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):64‐5. DeRooijBH , EzendamNP , NicolaijeKA , VosMC , PijnenborgJM , BollD , et al. The indirect effects of survivorship care plans on quality of life, anxiety and depression‐the ROGY care trial. Supportive Care in Cancer2017;25(2 Suppl 1):S53‐4. DeRooijBH , EzendamNP , VosMC , PijnenborgJM , BollD , KruitwagenRF , et al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. Cancer Epub 2018 Nov 30;125(5):788‐97. [DOI: 10.1002/cncr.31844] EzendamN , DeRooijB , NicolaijeK , VosC , PijnenborgJ , BollD , et al. Long‐term impact of cancer survivorship care plans on patient outcomes‐the randomized controlled ROGY care trial. International Journal of Gynecological Cancer2016;26:91. EzendamNP , VanBroekhovenM , Van DePoll‐FranseLV , DeRooijBH . The role of illness perceptions in smoking, alcohol consumption and weight changes among gynaecological cancer survivors. Quality of Life Research2016;25(1 Suppl 1):114. JeppesenMM , EzendamNP , PijnenborgJM , VosMC , BollD , KruitwagenRF , et al. The impact of the survivorship care plan on health care use: 2‐year follow‐up results of the ROGY care trial. Journal of Cancer Survivorship2018;12(1):18‐27. NicolaijeKA , EzendamNP , VosMC , PijnenborgJM , BollD , BossEA , et al. Impact of an automatically generated cancer survivorship care plan on patient‐reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial. Journal of Clinical Oncology2015;33(31):3550‐9. Van dePoll‐FranseL , NicolaijeK , EzendamN , VosC , BollD , PijnenborgJ , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY CARE): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Psycho‐oncology2013;22:341‐2. Van dePoll‐FranseLV , JeppesenMM , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. The survivorship care plan increases the use of primary care in anxious and irradiated endometrial cancer patients. Two year outcomes of the pragmatic cluster randomized ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):164. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosCM , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY Care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosMC , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. European Journal of Cancer2013;49:S720. Van dePoll‐FranseLV , NicolaijeKA , VosMC , PijnenborgJM , BollD , HussonO , et al. The impact of a cancer survivorship care plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials2011;12:256. ">ROGY 2015</a> reported on anxiety (470 participants). Unpublished data showed similar scores for both the survivorship care plan and usual care group on the HADS‐Anxiety subscale at 12 months for endometrial cancer survivors (mean/SD 5 (4) versus 4.2 (3.6)) and ovarian cancer survivors (mean/SD 5.4 (3.9) versus 6.2 (4.5)). We judged the certainty of evidence to be very low and downgraded by three levels for serious concerns regarding inconsistency, indirectness and imprecision since there was only one study. </p> </section> <section id="CD012425-sec-0116"> <h5 class="title">Depression</h5> <p>Eight studies (2351 participants) reported on depression or psychological distress using a variety of measurement scales and with varying follow‐up periods. (<a href="./references#CD012425-bbs2-0015" title="BoekhoutAH , MaunsellE , PondGR , JulianJA , CoyleD , LevineMN , et al. A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial. Journal of Cancer Survivorship2015;9(4):683‐91. CoyleD , GrunfeldE , CoyleK , JulianJA , PondGR , FolkesA , et al. Cost‐effectiveness of a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):6082. CoyleD , GrunfeldE , CoyleK , PondG , JulianJA , LevineMN . Cost effectiveness of a survivorship care plan for breast cancer survivors. Journal of Oncology Practice2014;10(2):e86‐92. GrunfeldE , JulianJA , PondG , MaunsellE , CoyleD , FolkesA , et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. Journal of Clinical Oncology2011;29(36):4755‐62. GrunfeldE , LevineMN , JulianJA , PondGR , MaunsellE , FolkesA , et al. Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):9005. GrunfeldE , PondG , MaunsellE , LevineMN , JulianJA , CoyleD . Impact of survivorship care plans (SCP) on adherence to guidelines, health service measures, and patient‐reported outcomes (PRO): extended results of a multicenter randomized clinical trial (RCT) with breast cancer survivors. European Journal of Cancer2012;48:S147. ">Grunfeld 2011</a>; <a href="./references#CD012425-bbs2-0016" title="HershmanDL , GreenleeH , AwadD , KalinskyK , MaurerM , KranwinkelG , et al. Randomized controlled trial of a clinic‐based survivorship intervention following adjuvant therapy in breast cancer survivors. Breast Cancer Research and Treatment2013;138(3):795‐806. ">Hershman 2013</a>; <a href="./references#CD012425-bbs2-0017" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14:260. [DOI: 10.1186/1745‐6215‐14‐260] JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a nurse‐led supportive care package (survivor care) for survivors of colorectal cancer. Cancer Nursing2015;38(4 Suppl 1):S16‐7. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (Survivor‐Care, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2015;33(15 Suppl 1):9566. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , SchofieldP , ArandaS , YoungJ , ButowP . Randomised controlled trial (RCT) of a comprehensive post‐treatment support package (survivor‐care) for bowel cancer survivors. Psycho‐oncology2010;19:S193. ">Jefford 2016</a>; <a href="./references#CD012425-bbs2-0019" title="JuarezG , HurriaA , FerrellB . Effectiveness of an education intervention on quality of life in Latina breast cancer survivors. Psycho‐oncology2012;21:110. JuarezG , HurriaA , UmanG , FerrellB . Impact of a bilingual education intervention on the quality of life of Latina breast cancer survivors. Oncology Nursing Forum2013;40(1):E50‐60. [DOI: 10.1188/13.ONF.E50‐E60] ">Juarez 2013</a>; <a href="./references#CD012425-bbs2-0025" title="KvaleEA , Demark‐WahnefriedW , MenesesK , BaeS , HuangCH , AzueroCB , et al. Patient centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer Research2015;75(9 Suppl 1):no pagination. KvaleEA , HuangCS , MenesesKM , Demark‐WahnefriedW , BaeS , AzueroCB , et al. Patient‐centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer2016;122(20):3232‐42. ">Kvale 2016</a>; <a href="./references#CD012425-bbs2-0038" title="DeRooijBH , EzendamNP , NicolaijeKA , LodderP , VosMC , PijnenborgJM , et al. Survivorship care plans have a negative impact on long‐term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. Quality of Life Research2018;27(6):1533‐44. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2‐year follow‐up ‐ The ROGY care trial. Gynecologic Oncology2017;145(2):319‐28. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Long‐term impact of survivorship care plans on ovarian cancer patient reported outcomes‐new results of the ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):64‐5. DeRooijBH , EzendamNP , NicolaijeKA , VosMC , PijnenborgJM , BollD , et al. The indirect effects of survivorship care plans on quality of life, anxiety and depression‐the ROGY care trial. Supportive Care in Cancer2017;25(2 Suppl 1):S53‐4. DeRooijBH , EzendamNP , VosMC , PijnenborgJM , BollD , KruitwagenRF , et al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. Cancer Epub 2018 Nov 30;125(5):788‐97. [DOI: 10.1002/cncr.31844] EzendamN , DeRooijB , NicolaijeK , VosC , PijnenborgJ , BollD , et al. Long‐term impact of cancer survivorship care plans on patient outcomes‐the randomized controlled ROGY care trial. International Journal of Gynecological Cancer2016;26:91. EzendamNP , VanBroekhovenM , Van DePoll‐FranseLV , DeRooijBH . The role of illness perceptions in smoking, alcohol consumption and weight changes among gynaecological cancer survivors. Quality of Life Research2016;25(1 Suppl 1):114. JeppesenMM , EzendamNP , PijnenborgJM , VosMC , BollD , KruitwagenRF , et al. The impact of the survivorship care plan on health care use: 2‐year follow‐up results of the ROGY care trial. Journal of Cancer Survivorship2018;12(1):18‐27. NicolaijeKA , EzendamNP , VosMC , PijnenborgJM , BollD , BossEA , et al. Impact of an automatically generated cancer survivorship care plan on patient‐reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial. Journal of Clinical Oncology2015;33(31):3550‐9. Van dePoll‐FranseL , NicolaijeK , EzendamN , VosC , BollD , PijnenborgJ , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY CARE): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Psycho‐oncology2013;22:341‐2. Van dePoll‐FranseLV , JeppesenMM , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. The survivorship care plan increases the use of primary care in anxious and irradiated endometrial cancer patients. Two year outcomes of the pragmatic cluster randomized ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):164. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosCM , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY Care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosMC , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. European Journal of Cancer2013;49:S720. Van dePoll‐FranseLV , NicolaijeKA , VosMC , PijnenborgJM , BollD , HussonO , et al. The impact of a cancer survivorship care plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials2011;12:256. ">ROGY 2015</a>; <a href="./references#CD012425-bbs2-0047" title="Van DerMeulenI , MayA , RosW , OosteromM , HordijkGJ , KooleR , et al. Effects of a nurse‐led psychosocial intervention on depressive symptoms and health‐related quality of life in patients with head and neck cancer: a randomized controlled trial. Psycho‐oncology2013;22(Suppl 3):17. Van derMeulenIC , MayAM , RosWJ , OosteromM , HordijkGJ , KooleR , et al. One‐year effect of a nurse‐led psychosocial intervention on depressive symptoms in patients with head and neck cancer: a randomized controlled trial. Oncologist2013;18(3):336‐44. [DOI: 10.1634/theoncologist.2012‐0299] ">Van der Meulen 2013</a>; <a href="./references#CD012425-bbs2-0053" title='ACTRN12608000252314 . Cancer care after surgery – the CONNECT study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82819 (first received 20 December 2016). HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Connect: a pilot RCT to improve outcomes for people with colorectal cancer. Asia‐Pacific Journal of Clinical Oncology2009;5:A159. HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Randomized pilot evaluation of the supportive care intervention "CONNECT" for people following surgery for colorectal cancer. Diseases of the Colon and Rectum2011;54(5):622‐31. YoungJM , ButowPN , WalshJ , DurcinoskaI , DobbinsTA , RodwellL , et al. Multicenter randomized trial of centralized nurse‐led telephone‐based care coordination to improve outcomes after surgical resection for colorectal cancer: the CONNECT intervention. Journal of Clinical Oncology2013;31(28):3585‐91. [DOI: 10.1200/JCO.2012.48.1036] '>Young 2013</a>). We were unable to pool the reported data in a meta‐analysis as there was no scale or subscale that at least three studies reported at 12 months of follow‐up (criteria prespecified in the <a href="#CD012425-sec-0059">Data synthesis</a> section). However, all the studies except <a href="./references#CD012425-bbs2-0047" title="Van DerMeulenI , MayA , RosW , OosteromM , HordijkGJ , KooleR , et al. Effects of a nurse‐led psychosocial intervention on depressive symptoms and health‐related quality of life in patients with head and neck cancer: a randomized controlled trial. Psycho‐oncology2013;22(Suppl 3):17. Van derMeulenIC , MayAM , RosWJ , OosteromM , HordijkGJ , KooleR , et al. One‐year effect of a nurse‐led psychosocial intervention on depressive symptoms in patients with head and neck cancer: a randomized controlled trial. Oncologist2013;18(3):336‐44. [DOI: 10.1634/theoncologist.2012‐0299] ">Van der Meulen 2013</a> reported little or no difference in depression between the intervention and usual care groups. We present results below according to measurement scale. </p> <p>One study used the HADS‐Depression subscale. Unpublished results from <a href="./references#CD012425-bbs2-0038" title="DeRooijBH , EzendamNP , NicolaijeKA , LodderP , VosMC , PijnenborgJM , et al. Survivorship care plans have a negative impact on long‐term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. Quality of Life Research2018;27(6):1533‐44. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2‐year follow‐up ‐ The ROGY care trial. Gynecologic Oncology2017;145(2):319‐28. DeRooijBH , EzendamNP , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. Long‐term impact of survivorship care plans on ovarian cancer patient reported outcomes‐new results of the ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):64‐5. DeRooijBH , EzendamNP , NicolaijeKA , VosMC , PijnenborgJM , BollD , et al. The indirect effects of survivorship care plans on quality of life, anxiety and depression‐the ROGY care trial. Supportive Care in Cancer2017;25(2 Suppl 1):S53‐4. DeRooijBH , EzendamNP , VosMC , PijnenborgJM , BollD , KruitwagenRF , et al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. Cancer Epub 2018 Nov 30;125(5):788‐97. [DOI: 10.1002/cncr.31844] EzendamN , DeRooijB , NicolaijeK , VosC , PijnenborgJ , BollD , et al. Long‐term impact of cancer survivorship care plans on patient outcomes‐the randomized controlled ROGY care trial. International Journal of Gynecological Cancer2016;26:91. EzendamNP , VanBroekhovenM , Van DePoll‐FranseLV , DeRooijBH . The role of illness perceptions in smoking, alcohol consumption and weight changes among gynaecological cancer survivors. Quality of Life Research2016;25(1 Suppl 1):114. JeppesenMM , EzendamNP , PijnenborgJM , VosMC , BollD , KruitwagenRF , et al. The impact of the survivorship care plan on health care use: 2‐year follow‐up results of the ROGY care trial. Journal of Cancer Survivorship2018;12(1):18‐27. NicolaijeKA , EzendamNP , VosMC , PijnenborgJM , BollD , BossEA , et al. Impact of an automatically generated cancer survivorship care plan on patient‐reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial. Journal of Clinical Oncology2015;33(31):3550‐9. Van dePoll‐FranseL , NicolaijeK , EzendamN , VosC , BollD , PijnenborgJ , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY CARE): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Psycho‐oncology2013;22:341‐2. Van dePoll‐FranseLV , JeppesenMM , NicolaijeKA , VosC , PijnenborgJM , BollD , et al. The survivorship care plan increases the use of primary care in anxious and irradiated endometrial cancer patients. Two year outcomes of the pragmatic cluster randomized ROGY care trial. Quality of Life Research2016;25(1 Suppl 1):164. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosCM , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY Care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. Journal of Clinical Oncology2013;31(15 Suppl 1):no pagination. Van dePoll‐FranseLV , NicolaijeKA , EzendamNP , VosMC , BollD , PijnenborgJM , et al. The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY care): results of a pragmatic cluster randomized controlled trial among endometrial cancer patients. European Journal of Cancer2013;49:S720. Van dePoll‐FranseLV , NicolaijeKA , VosMC , PijnenborgJM , BollD , HussonO , et al. The impact of a cancer survivorship care plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials2011;12:256. ">ROGY 2015</a> showed similar mean scores for both the survivorship care plan and usual care groups at 12 months' follow‐up among endometrial cancer survivors (mean/SD 3.8 (3.9) versus 3.7 (3.5)) and ovarian cancer survivors (mean/SD 3.5 (3.6) versus 4.4 (4.4)). </p> <p>One study used the Profile of Mood States (POMS). <a href="./references#CD012425-bbs2-0015" title="BoekhoutAH , MaunsellE , PondGR , JulianJA , CoyleD , LevineMN , et al. A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial. Journal of Cancer Survivorship2015;9(4):683‐91. CoyleD , GrunfeldE , CoyleK , JulianJA , PondGR , FolkesA , et al. Cost‐effectiveness of a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):6082. CoyleD , GrunfeldE , CoyleK , PondG , JulianJA , LevineMN . Cost effectiveness of a survivorship care plan for breast cancer survivors. Journal of Oncology Practice2014;10(2):e86‐92. GrunfeldE , JulianJA , PondG , MaunsellE , CoyleD , FolkesA , et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. Journal of Clinical Oncology2011;29(36):4755‐62. GrunfeldE , LevineMN , JulianJA , PondGR , MaunsellE , FolkesA , et al. Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):9005. GrunfeldE , PondG , MaunsellE , LevineMN , JulianJA , CoyleD . Impact of survivorship care plans (SCP) on adherence to guidelines, health service measures, and patient‐reported outcomes (PRO): extended results of a multicenter randomized clinical trial (RCT) with breast cancer survivors. European Journal of Cancer2012;48:S147. ">Grunfeld 2011</a> reported little or no mean difference between the survivorship care plan and usual care groups at 12 months' follow‐up among breast cancer survivors (MD 2.6, 95% CI 5.6 to 0.5). </p> <p>One study used the Patient Health Questionnaine (PHQ‐9). <a href="./references#CD012425-bbs2-0025" title="KvaleEA , Demark‐WahnefriedW , MenesesK , BaeS , HuangCH , AzueroCB , et al. Patient centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer Research2015;75(9 Suppl 1):no pagination. KvaleEA , HuangCS , MenesesKM , Demark‐WahnefriedW , BaeS , AzueroCB , et al. Patient‐centered support in the survivorship care transition: outcomes from the patient‐owned survivorship care plan intervention. Cancer2016;122(20):3232‐42. ">Kvale 2016</a> reported no difference between the POSTCARE and usual care groups in change scores from baseline to three‐month follow‐up among breast cancer survivors (P = 0.376). </p> <p>One study used the Brief Symptom Inventory (BSI‐18). <a href="./references#CD012425-bbs2-0017" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14:260. [DOI: 10.1186/1745‐6215‐14‐260] JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a nurse‐led supportive care package (survivor care) for survivors of colorectal cancer. Cancer Nursing2015;38(4 Suppl 1):S16‐7. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (Survivor‐Care, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2015;33(15 Suppl 1):9566. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3 Suppl 1):no pagination. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , SchofieldP , ArandaS , YoungJ , ButowP . Randomised controlled trial (RCT) of a comprehensive post‐treatment support package (survivor‐care) for bowel cancer survivors. Psycho‐oncology2010;19:S193. ">Jefford 2016</a> reported little or no difference between the SurvivorCare and usual care groups at six months' follow‐up among colorectal cancer survivors (MD −0.9, 95% CI −3.7 to 1.9). </p> <p>Two studies each used the Center for Epidemiological Studies‐Depression scale (CES‐D). <a href="./references#CD012425-bbs2-0016" title="HershmanDL , GreenleeH , AwadD , KalinskyK , MaurerM , KranwinkelG , et al. Randomized controlled trial of a clinic‐based survivorship intervention following adjuvant therapy in breast cancer survivors. Breast Cancer Research and Treatment2013;138(3):795‐806. ">Hershman 2013</a> reported little or no difference between the survivorship care plan and usual care groups at six months' follow‐up among breast cancer survivors (P = 0.83), while <a href="./references#CD012425-bbs2-0047" title="Van DerMeulenI , MayA , RosW , OosteromM , HordijkGJ , KooleR , et al. Effects of a nurse‐led psychosocial intervention on depressive symptoms and health‐related quality of life in patients with head and neck cancer: a randomized controlled trial. Psycho‐oncology2013;22(Suppl 3):17. Van derMeulenIC , MayAM , RosWJ , OosteromM , HordijkGJ , KooleR , et al. One‐year effect of a nurse‐led psychosocial intervention on depressive symptoms in patients with head and neck cancer: a randomized controlled trial. Oncologist2013;18(3):336‐44. [DOI: 10.1634/theoncologist.2012‐0299] ">Van der Meulen 2013</a> reported a decrease in depressive symptoms in the 'NUCAI' survivorship care group compared with the usual care group at 12 months among head and neck cancer survivors (MD 2.8, 95% CI 5.2 to 0.3). </p> <p>Two studies used the distress thermometer, a single‐question screening instrument to evaluate patient’s distress based on a scale of 1 to 10 during the past week. Both studies reported little or no difference between groups at six months among breast cancer and colorectal cancer survivors respectively: <a href="./references#CD012425-bbs2-0019" title="JuarezG , HurriaA , FerrellB . Effectiveness of an education intervention on quality of life in Latina breast cancer survivors. Psycho‐oncology2012;21:110. JuarezG , HurriaA , UmanG , FerrellB . Impact of a bilingual education intervention on the quality of life of Latina breast cancer survivors. Oncology Nursing Forum2013;40(1):E50‐60. [DOI: 10.1188/13.ONF.E50‐E60] ">Juarez 2013</a> (P = 0.305) and <a href="./references#CD012425-bbs2-0053" title='ACTRN12608000252314 . Cancer care after surgery – the CONNECT study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82819 (first received 20 December 2016). HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Connect: a pilot RCT to improve outcomes for people with colorectal cancer. Asia‐Pacific Journal of Clinical Oncology2009;5:A159. HarrisonJD , YoungJM , SolomonMJ , ButowPN , SecombR , MasyaL . Randomized pilot evaluation of the supportive care intervention "CONNECT" for people following surgery for colorectal cancer. Diseases of the Colon and Rectum2011;54(5):622‐31. YoungJM , ButowPN , WalshJ , DurcinoskaI , DobbinsTA , RodwellL , et al. Multicenter randomized trial of centralized nurse‐led telephone‐based care coordination to improve outcomes after surgical resection for colorectal cancer: the CONNECT intervention. Journal of Clinical Oncology2013;31(28):3585‐91. [DOI: 10.1200/JCO.2012.48.1036] '>Young 2013</a> (MD 0.3, 95% CI 0.8 to 0.2). </p> <p>Although all the studies but one reported consistent results, we judged the overall certainty of evidence to be very low and downgraded by three levels for serious concerns regarding study limitations, indirectness and imprecision due to one study (<a href="./references#CD012425-bbs2-0019" title="JuarezG , HurriaA , FerrellB . Effectiveness of an education intervention on quality of life in Latina breast cancer survivors. Psycho‐oncology2012;21:110. JuarezG , HurriaA , UmanG , FerrellB . Impact of a bilingual education intervention on the quality of life of Latina breast cancer survivors. Oncology Nursing Forum2013;40(1):E50‐60. [DOI: 10.1188/13.ONF.E50‐E60] ">Juarez 2013</a>), at high risk of bias (as the principal investigator was responsible for all aspects of study, including implementation and follow‐up for both the experimental and attention control groups, which were also highly imbalanced), the heterogeneous measures and reporting of results by different estimates that could not be pooled. </p> </section> <section id="CD012425-sec-0117"> <h5 class="title">Cost</h5> <p>Only <a href="./references#CD012425-bbs2-0015" title="BoekhoutAH , MaunsellE , PondGR , JulianJA , CoyleD , LevineMN , et al. A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial. Journal of Cancer Survivorship2015;9(4):683‐91. CoyleD , GrunfeldE , CoyleK , JulianJA , PondGR , FolkesA , et al. Cost‐effectiveness of a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):6082. CoyleD , GrunfeldE , CoyleK , PondG , JulianJA , LevineMN . Cost effectiveness of a survivorship care plan for breast cancer survivors. Journal of Oncology Practice2014;10(2):e86‐92. GrunfeldE , JulianJA , PondG , MaunsellE , CoyleD , FolkesA , et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. Journal of Clinical Oncology2011;29(36):4755‐62. GrunfeldE , LevineMN , JulianJA , PondGR , MaunsellE , FolkesA , et al. Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):9005. GrunfeldE , PondG , MaunsellE , LevineMN , JulianJA , CoyleD . Impact of survivorship care plans (SCP) on adherence to guidelines, health service measures, and patient‐reported outcomes (PRO): extended results of a multicenter randomized clinical trial (RCT) with breast cancer survivors. European Journal of Cancer2012;48:S147. ">Grunfeld 2011</a> reported cost outcomes using quality‐adjusted life years (QALY) to calculate the cost effectiveness of the use of a survivorship care plan after two years of follow‐up among breast cancer survivors (408 participants). One QALY is equivalent to one year in perfect health and this study reported 1.42 QALY for the survivorship care plan arm and 1.41 QALY for the usual care only arm. We judged the certainty of evidence to be very low and downgraded by three levels for serious concerns regarding inconsistency, indirectness and imprecision since there was only one study. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012425-sec-0118" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012425-sec-0118">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012425-sec-0195">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012425-sec-0118"></div> <p>The aim of this systematic review was to summarise the available evidence regarding the effects of different follow‐up strategies after curative primary cancer treatment in adult cancer survivors on the outcomes of overall survival, time to detection of recurrence, health‐related quality of life, anxiety, depression and cost. Due to the wide range of follow‐up strategies available, we categorised interventions into three groups based on whether the study investigated: 1) who leads the follow‐up, 2) intensity of the follow‐up strategy with regards to clinical examinations and diagnostic procedures, or 3) integration of other components to usual care that may be relevant for detection of recurrence, such as patient symptom education/monitoring or information through survivorship care plans. This focus reflects the 'who', 'what' and 'when' elements in Box 1. The 'where' is implied by who leads the follow‐up (e.g. GP‐led follow‐up will take place in primary care), while the use of different formats/technologies to deliver care may vary across the same elements of follow‐up and was not addressed in this review. </p> <p>Although we were successful in pooling studies across cancer sites and were able to synthesise the evidence for different outcomes, we still could not provide conclusive evidence for the effect of certain intervention types on specific outcomes (e.g. effect of non‐specialist‐led follow‐up on survival and detection of recurrence) due to the lack of available studies. However, identification of this knowledge gap across cancer sites is also an important part of this review. Below, we summarise our findings, discuss the strengths and limitations of this review and point to implications for future research and practice. </p> <section id="CD012425-sec-0119"> <h3 class="title" id="CD012425-sec-0119">Summary of main results</h3> <p>We identified 53 studies that evaluated three broad types of follow‐up strategies.</p> <section id="CD012425-sec-0120"> <h4 class="title">Non‐specialist‐led follow‐up (i.e. GP‐led, nurse‐led, patient‐initiated or shared care) versus specialist‐led follow‐up </h4> <p>We included 17 studies for this comparison. Four studies reported on overall survival, four studies reported on detection of recurrence, 13 studies reported on health‐related quality of life, 14 studies reported on anxiety, 11 studies reported on depression and 8 studies reported cost. </p> <p>It is uncertain how this strategy affects overall survival (HR 1.21, 95% CI 0.68 to 2.15; very low‐certainty evidence) and time to detection of recurrence (data could not be pooled). This strategy may make little or no difference to health‐related quality of life at 12 months (MD 1.06, 95% CI −1.83 to 3.95; low‐certainty evidence), probably makes little or no difference to anxiety at 12 months (MD −0.03, 95% CI −0.73 to 0.67; moderate‐certainty evidence) and has little or no effect on depression at 12 months (MD 0.03, 95% CI −0.35 to 0.42; high‐certainty evidence). It is uncertain whether non‐specialist‐led follow‐up is as cost‐effective as specialist‐led follow‐up due to the substantial heterogeneity in how the included studies measured and reported this outcome. </p> </section> <section id="CD012425-sec-0121"> <h4 class="title">Less intensive versus more intensive follow‐up (based on clinical visits, examinations or diagnostic procedures) </h4> <p>We included 24 studies for this comparison. Eighteen studies reported on overall survival, 22 studies reported on time to detection of recurrence, three studies reported on health‐related quality of life, one study reported on anxiety, none of the studies reported on depression and six studies reported cost. </p> <p>Less intensive follow‐up may make little or no difference to overall survival (HR 1.05, 95% CI 0.96 to 1.14; low‐certainty evidence) but probably increases time to detection of recurrence (HR 0.85, 95% CI 0.79 to 0.92; moderate‐certainty evidence). Meta‐regression analysis for both outcomes showed little or no difference in the intervention effect by cancer site, year of publication or quality score. However, the clinical relevance of a delay in detection of recurrence on patient outcomes is unclear as we did not analyse the two outcomes together. Sensitivity analysis gave a similar result for both outcomes. It is uncertain whether less intensive follow‐up has an effect on health‐related quality of life, anxiety and depression because the certainty of evidence is very low (and non‐existent for the outcome of depression). All studies reported lower costs for the less intensive arm but there was substantial heterogeneity in how they measured and reported the outcome. </p> </section> <section id="CD012425-sec-0122"> <h4 class="title">Follow‐up integrating additional patient symptom education or monitoring, or survivorship care plans versus usual care </h4> <p>We included 12 studies for this comparison. None of the studies reported on overall survival or detection of recurrence, all 12 studies reported on health‐related quality of life, one study reported on anxiety, eight studies reported on depression and one study reported cost. </p> <p>There is a lack of evidence for the effect of follow‐up integrating additional patient symptom education or monitoring, or survivorship care plans on overall survival and time to detection of recurrence as none of the studies evaluated these outcomes. It is uncertain whether this strategy makes a difference to health‐related quality of life, anxiety, depression and cost as the certainty of evidence is very low. There was substantial heterogeneity in how the studies measured health‐related quality of life and depression and only single studies reported anxiety and cost. </p> </section> </section> <section id="CD012425-sec-0123"> <h3 class="title" id="CD012425-sec-0123">Overall completeness and applicability of evidence</h3> <p>Thanks to the comprehensive search strategy, we have been able to identify, to the best of our ability, almost all the studies available that address the objectives of this review. We have also been able to pool the results of diverse interventions by constructing what we hope are three meaningful comparisons: 1) non‐specialist‐led versus specialist‐led follow‐up, 2) less intensive versus more intensive follow‐up, and 3) follow‐up integrating patient symptom education or monitoring, or survivorship care plans versus usual care only. </p> <p>In this review, we include cancer sites that have not previously been represented. We also used more advanced statistical methods to include all possible data in the most appropriate way available (e.g. by estimating hazard ratios for time‐to‐event outcomes) and to investigate heterogeneity without splitting studies into subgroups and losing statistical power (e.g. using meta‐regression). Furthermore, we analysed what might be considered the most important outcomes for patients, clinicians and health services, namely overall survival, detection of recurrence, quality of life, anxiety, depression and cost. </p> <p>However, despite our efforts, the evidence presented in this review is limited by the fact that there is still a substantial lack of high‐quality research in many cancer sites and in many parts of the world. Although 12 cancer sites and 15 countries were represented in this review; the majority of the studies were in breast and colorectal cancer and almost all studies were carried out in high‐income countries with universal healthcare systems, where there is a direct incentive to find the best model balancing cost and effect. Reasons for this may include the fact that trials are very expensive to carry out and relatively long follow‐up periods are required for the outcomes of survival and recurrence, particularly in cancer sites with long survival and low recurrence rates. Thus, the evidence presented in this review may not be directly applicable in certain parts of the world and for certain cancer types. We also note that we only included studies carried out in participants with curatively‐treated cancer. This means that our results cannot be generalised to the care of patients with late‐stage or incurable cancer, which is characterised by further treatment and surveillance of progression rather than recurrence. </p> <p>Finally, the broadness of our aims could only be achieved at the expense of specificity. Thus, we did not investigate more detailed aspects of an intervention, such as the effectiveness of tumour markers or specific types of imaging, nor did we investigate other outcomes, such as cancer‐specific survival or the effects of early treatment for asymptomatic recurrences. We also did not investigate potential adverse effects of different follow‐up strategies. However, we hope that the framework presented in the introduction and the results of this comprehensive review can provide the foundation for further work investigating more specific aspects of cancer follow‐up. </p> <section id="CD012425-sec-0124"> <h4 class="title">Certainty of evidence</h4> <p>As the evidence came from randomised trials, our quality assessments began at the highest level of certainty. However, after the GRADE assessment, the final certainty of evidence ranged from high to very low (<a href="./references#CD012425-bbs2-0178" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s) . Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html. ">Schünemann 2013</a>). We have summarised the GRADE certainty of evidence for each outcome in the three 'Summary of findings' tables: <a href="./full#CD012425-tbl-0001">summary of findings Table for the main comparison</a> (non‐specialist‐led versus specialist‐led follow‐up), <a href="./full#CD012425-tbl-0002">summary of findings Table 2</a> (less intensive versus more intensive follow‐up) and <a href="./full#CD012425-tbl-0003">summary of findings Table 3</a> (follow‐up integrating additional patient symptom education or monitoring, or survivorship care plans versus usual care only). Details regarding the GRADE domains that we assessed and downgraded for each outcome are given in the footnotes of each 'Summary of findings' table and in the GRADE evidence profiles (<a href="./appendices#CD012425-sec-0148">Appendix 3</a>). </p> <p>It is worth noting that almost all the trials in this review were not blinded. In line with the judgement that the direction of bias is unclear (see <a href="#CD012425-sec-0082">Blinding (performance bias and detection bias)</a>), we did not consider lack of blinding a serious enough concern to downgrade the certainty of evidence. </p> <p>For non‐specialist‐led follow‐up, the certainty of evidence for the effect on overall survival and detection of recurrence was very low, meaning that the synthesized results do not provide a reliable indication of the likely effect of this intervention. The certainty of evidence for the effect of this intervention was low on health‐related quality of life, moderate for anxiety, high for depression and very low for cost. Thus, although we are relatively certain that this intervention does not worsen anxiety and depression for the patient, we are less certain about how it affects quality of life and cost. </p> <p>For less intensive follow‐up, the certainty of evidence for the effect on overall survival was low, mainly due to imprecision, as the confidence interval included a harm (potentially 3 extra deaths) that we judged to be important for patients and decision‐makers. For time to detection of recurrence, the certainty of evidence was moderate, meaning that the estimated effect is likely to be close to the true effect. The certainty of evidence for the effect of this intervention on the rest of the outcomes was very low, and nonexistent for depression, highlighting our lack of knowledge on how this intervention impacts the patient's well‐being. </p> <p>For follow‐up integrating patient education/monitoring and survivorship care plans, there was no evidence for the effect on overall survival and detection of recurrence, highlighting that we do not know how this newer type of follow‐up strategy affects patient prognostic outcomes. The certainty of evidence for the effect of this intervention on the rest of the outcomes was very low, mainly due to the heterogeneous measures and time‐points used in the different studies that could not be pooled in a meta‐analysis. </p> </section> </section> <section id="CD012425-sec-0125"> <h3 class="title" id="CD012425-sec-0125">Potential biases in the review process</h3> <p>We made several decisions and judgements in the review process that may have had an impact on our conclusions. Below, we identify and discuss the potential strengths and limitations of the review process using the domains identified in the tool to assess risk of bias in systematic reviews (ROBIS): study eligibility criteria, identification and selection of studies, data collection and study appraisal, synthesis and findings (<a href="./references#CD012425-bbs2-0192" title="WhitingP , SavovicJ , HigginsJP , CaldwellDM , ReevesBC , SheaB , et al. ROBIS: a new tool to assess risk of bias in systematic reviews was developed. Journal of Clinical Epidemiology2016;69:225‐34. [PUBMED: 26092286] ">Whiting 2016</a>). </p> <section id="CD012425-sec-0126"> <h4 class="title">Study eligibility criteria</h4> <p>Due to the broad objectives and research question of this review, all randomised trials comparing different types of follow‐up with potential impact on detection of recurrence in patients who have undergone curatively‐intended primary treatment were potentially eligible. This led to the retrieval of a large number of studies comparing a wide range of interventions and measuring a wide range of outcomes. We adhered to our protocol by including only studies that reported on one of our pre‐defined outcomes and we made the decision to exclude studies that did not integrate the intervention in clinical follow‐up care even though they reported carrying out the intervention in participants undergoing follow‐up after primary treatment. We based this decision on our judgement that outcomes in such studies were a measurement of purely the intervention (often a psychosocial or rehabilitation intervention), and not a measurement of a change in cancer follow‐up per se. Furthermore, we included studies investigating a supportive care intervention only if there was a component that could be relevant for detection of recurrence, for example, symptom education and monitoring or survivorship care plans, in accordance with the focus of our review. We report the intervention components in detail for all the included studies in the <a href="./references#CD012425-sec-0158" title="">Characteristics of included studies</a> tables to help the reader navigate the specific comparisons. </p> </section> <section id="CD012425-sec-0127"> <h4 class="title">Identification and selection of studies</h4> <p>We carried out the search with the support of our Cochrane editorial group, EPOC, and it included all the relevant databases. We did not place any restrictions on date, publication format or language. We also used additional searching methods, such as looking through references in commentaries, abstracts and articles, in order to retrieve as many potentially relevant studies as possible. In order to systematise the screening and selection process and minimise error in the inclusion of studies, we used the recommended software, <a href="./references#CD012425-bbs2-0140" title="Veritas Health Innovation. Covidence. Version accessed 19 December 2016. Melbourne, Australia: Veritas Health Innovation. ">Covidence</a>, to ensure independent screening of each study by at least two review authors and we held regular discussion meetings with the review author group to resolve any uncertainties. </p> </section> <section id="CD012425-sec-0128"> <h4 class="title">Data collection and study appraisal</h4> <p>In order to systematise and minimise error, we used standardised data collection forms based on the EPOC template that we piloted and subsequently refined on the first five studies. For each study, one review author extracted all the pre‐defined relevant data and another review author independently read all the publications from the same study and double‐checked the form to ensure accuracy and that there were no missing data. Several review authors were involved in this process. At least two review authors independently carried out 'Risk of bias' assessments for each study and all the review authors took the online interactive learning modules developed by Cochrane Training (<a href="./references#CD012425-bbs2-0170" title="PageMJ , HigginsJ , SambunjakD , CumpstonM , WattsC . Module 5: Introduction to study quality and risk of bias. In: Cochrane Interactive Learning: Conducting an intervention review, Cochrane, 2017. Available from training.cochrane.org/interactivelearning. ">Page 2017</a>; <a href="./references#CD012425-bbs2-0177" title="SambunjakD , CumpstonM , WattsC . Module 4: Selecting studies and collecting data. In: Cochrane Interactive Learning: Conducting an intervention review, Cochrane, 2017. Available from training.cochrane.org/interactivelearning. ">Sambunjak 2017</a>), and read the relevant chapters in the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> to minimise any error (<a href="./references#CD012425-bbs2-0155" title="HigginsJP , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>; <a href="./references#CD012425-bbs2-0156" title="HigginsJP , AltmanDG , Sterne JA(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). The review author group held regular discussion meetings regarding the studies and we resolved any issues through consensus. As we were interested in many outcomes, we also assessed the risk of bias in each domain by objective outcomes and patient‐reported outcomes, so that we could draw clearer conclusions about any study limitations once we had synthesised the findings. </p> </section> <section id="CD012425-sec-0129"> <h4 class="title">Synthesis and findings</h4> <p>We made substantial efforts to include all the studies possible for the synthesis of each outcome by contacting study authors and using statistical methods to convert published data into estimates that we could pool. We addressed heterogeneity statistically, where possible, and have reported all findings either as meta‐analyses or narrative summaries. We have reported the results of each meta‐analysis together with GRADE quality assessments and state MCIDs, where relevant, to help the reader draw the appropriate conclusions. At least two review authors carried out GRADE assessments for each outcome and the review authors took the online interactive learning modules developed by Cochrane Training (<a href="./references#CD012425-bbs2-0170" title="PageMJ , HigginsJ , SambunjakD , CumpstonM , WattsC . Module 5: Introduction to study quality and risk of bias. In: Cochrane Interactive Learning: Conducting an intervention review, Cochrane, 2017. Available from training.cochrane.org/interactivelearning. ">Page 2017</a>; <a href="./references#CD012425-bbs2-0177" title="SambunjakD , CumpstonM , WattsC . Module 4: Selecting studies and collecting data. In: Cochrane Interactive Learning: Conducting an intervention review, Cochrane, 2017. Available from training.cochrane.org/interactivelearning. ">Sambunjak 2017</a>), and read the relevant chapters in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to minimise any error (<a href="./references#CD012425-bbs2-0143" title="DeeksJJ , HigginsJP , Altman DG(editors) , on behalf of the Cochrane Statistical Methods Group. Deeks JJ, Higgins JPT, Altman DG Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). </p> </section> </section> <section id="CD012425-sec-0130"> <h3 class="title" id="CD012425-sec-0130">Agreements and disagreements with other studies or reviews</h3> <p>To our knowledge, this is the first systematic review that comprehensively includes studies across follow‐up interventions and across cancer sites, and pools their results for each outcome according to three groups of follow‐up strategy. Our results extend the findings of the available Cochrane Reviews on cancer follow‐up in breast, colorectal, cervical and ovarian cancer at the time of our search. However, although our findings regarding survival and quality of life are in line with the Cochrane Reviews on breast cancer and colorectal cancer follow‐up, our finding of an effect on detection of recurrence was not found in the other two reviews. </p> <p>In the Cochrane Review on follow‐up strategies for breast cancer based on five included studies, <a href="./references#CD012425-bbs2-0167" title="MoschettiI , CinquiniM , LambertiniM , LevaggiA , LiberatiA . Follow‐up strategies for women treated for early breast cancer. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD001768.pub3] ">Moschetti 2016</a> concluded that less intensive follow‐up is just as effective as more intensive follow‐up with regard to overall survival, time to detection of recurrence and quality of life. Their different result regarding time to detection of recurrence is probably due to the fact that they based their meta‐analysis on only two studies (<a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a>; <a href="./references#CD012425-bbs2-0039" title="PalliD , RussoA , SaievaC , CiattoS , Rosselli Del TurcoM , DistanteV , et al. Intensive vs clinical follow‐up after treatment of primary breast cancer: 10‐year update of a randomized trial. National Research Council Project on Breast Cancer Follow‐up. JAMA1999;281(17):1586. Roselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . The efficacy of intensive follow‐up testing in breast cancer cases. Annals of Oncology1995;6(Suppl 2):37‐9. Rosselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . Intensive diagnostic follow‐up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow‐up. JAMA1994;271(20):1593‐7. ">Rosselli Del Turco 1994</a>), and their result was borderline favouring more intensive follow‐up (HR 0.84, 95% CI 0.71 to 1.00). In another systematic review of randomised trials investigating intensive breast cancer follow‐up (<a href="./references#CD012425-bbs2-0160" title="LafranconiA , PylkkanenL , DeandreaS , BramesfeldA , LerdaD , NeamtiuL , et al. Intensive follow‐up for women with breast cancer: review of clinical, economic and patient's preference domains through evidence to decision framework. Health and Quality of Life Outcomes2017;15(1):206. [PUBMED: 29052503] ">Lafranconi 2017</a>), which included six randomised trials (all of which were included in this review except <a href="./references#CD012425-bbs2-0059" title="GullifordT , OpomuM , WilsonE , HanhamI , EpsteinR . Popularity of less frequent follow up for breast cancer in randomised study: initial findings from the hotline study. BMJ (Clinical Research Ed.)1997;314(7075):174‐7. ">Gulliford 1997</a>), the authors concluded that more frequent diagnostic tests or visits did not have effects on overall mortality or recurrences. However, they summarised effects as dichotomous outcomes and presented them as risk ratios, thus differing from our time‐to‐event analyses. </p> <p>In the Cochrane Review on follow‐up strategies for colorectal cancer based on 15 included studies, <a href="./references#CD012425-bbs2-0158" title="JefferyM , HickeyBE , HiderPN , SeeAM . Follow‐up strategies for patients treated for non‐metastatic colorectal cancer. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD002200.pub3] ">Jeffery 2016</a> concluded that there was no overall survival or relapse‐free survival benefit with more intensive follow‐up. Their different result regarding detection of recurrence is likely due to the fact that they based their meta‐analysis on different studies from ours. Five of our studies were from other cancer sites (<a href="./references#CD012425-bbs2-0012" title="ColemanEA . Commentary on impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial [original article appears in JAMA 1994;271(20):1587‐92]. ONS Nursing Scan in Oncology1994; Vol. 3, issue 5:8‐8. GIVIO Investigators. Impact of follow‐up testing on survival and health‐related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA1994;271(20):1587‐92. LiberatiA . The GIVIO trial on the impact of follow‐up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Annals of Oncology1995;6(Suppl 2):41‐6. ">GIVIO 1994</a>; <a href="./references#CD012425-bbs2-0034" title="PicardiM , PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , et al. Advanced‐stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission‐‐a randomized trial of routine surveillance imaging procedures. Radiology2014;272(1):262‐74. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: Ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2015;100:7‐8. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2014;99:398‐9. ">Picardi 2014</a>; <a href="./references#CD012425-bbs2-0039" title="PalliD , RussoA , SaievaC , CiattoS , Rosselli Del TurcoM , DistanteV , et al. Intensive vs clinical follow‐up after treatment of primary breast cancer: 10‐year update of a randomized trial. National Research Council Project on Breast Cancer Follow‐up. JAMA1999;281(17):1586. Roselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . The efficacy of intensive follow‐up testing in breast cancer cases. Annals of Oncology1995;6(Suppl 2):37‐9. Rosselli Del TurcoM , PalliD , CariddiA , CiattoS , PaciniP , DistanteV . Intensive diagnostic follow‐up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow‐up. JAMA1994;271(20):1593‐7. ">Rosselli Del Turco 1994</a>; <a href="./references#CD012425-bbs2-0041" title="GoodmanA . How often to follow up? Study shows two CT scans as good as five for low‐risk testicular cancer. Oncology Times2007;29(12):54‐5. NCT00003420 . CT scans in treating patients with stage I testicular cancer after undergoing orchiectomy. clinicaltrials.gov/ct2/show/NCT00003420 (first received 20 December 2016). RustinGJ , MeadGM , StenningSP , VaseyPA , AassN , HuddartRA , et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197‐‐the National Cancer Research Institute Testis Cancer Clinical Studies Group. Journal of Clinical Oncology2007;25(11):1310‐5. ">Rustin 2007</a>; <a href="./references#CD012425-bbs2-0051" title="NCT00198341 . Post‐surgical non‐small cell lung cancer (NSCLC) follow‐up. clinicaltrials.gov/ct2/show/NCT00198341 (first received 20 December 2016). WesteelV . Follow‐up of the patient after curative treatment. Lung Cancer2011;71:S10‐1. WesteelV . Surveillance and second primary malignancies in lung cancer survivors. Journal of Thoracic Oncology2018;13(10 Suppl):S277‐8. WesteelV , BarlesiF , DomasJ , GirardP , FoucherP , LafitteJJ , et al. Postoperative follow‐up of lung cancer: randomized trial comparing two follow‐up programs in completely resected non‐small cell lung cancer (IFCT‐0302). Journal of Clinical Oncology2012;30(15 Suppl 1):no pagination. WesteelV , BarlesiF , FoucherP , LafitteJ , DomasJ , GirardP , et al. Recurrences and 2nd primary cancers in the IFCT‐0302 trial assessing a CT‐scan‐based follow‐up after lung cancer surgery. Journal of Thoracic Oncology2017;12(11 Suppl 2):S1788‐9. WesteelV , BarlesiF , FoucherP , LafitteJ‐J , DomasJ , GirardP , et al. Results of the phase III IFCT‐0302 trial assessing minimal versus CT‐scan‐based follow‐up for completely resected non‐small cell lung cancer (NSCLC). Annals of Oncology2017;28(Suppl 5):v452. WesteelV , BarlesiF , FoucherP , LafitteJJ , DomasJ , GirardP , et al. Compliance with follow‐up programs after surgery for non‐small cell lung cancer in the phase III IFCT‐0302 trial. Journal of Thoracic Oncology2015;10(9 Suppl 2):S239. WesteelV , LebitasyMP , MercierM , LafitteJJ , DomasJ , GirardPl . IFCT‐0302 trial: randomised study comparing two follow‐up schedules in completely resected non‐small cell lung cancer [Protocole IFCT‐0302 : essai randomisé de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués]. Revue des Maladies Respiratoires2007;2(5):645‐52. ">Westeel 2012</a>) and we did not include seven of their studies (<a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad 2013</a>; <a href="./references#CD012425-bbs2-0026" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1992</a>; <a href="./references#CD012425-bbs2-0032" title="OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD012425-bbs2-0035" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA , et al. Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD012425-bbs2-0042" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gastroenterology1998;114(1):7‐14. SchoemakerD , BlackR , GilesL , ToouliJ , AlcornJ . Addition of intensive follow‐up procedures to standard follow‐up did not improve survival in patients with colorectal cancer. Evidence‐Based Medicine1998;3(5):140. ">Schoemaker 1998</a>; <a href="./references#CD012425-bbs2-0043" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk‐adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD012425-bbs2-0049" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>). <a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad 2013</a> calculated recurrence from the time of suspicion of recurrence instead of from randomisation and although the authors of <a href="./references#CD012425-bbs2-0158" title="JefferyM , HickeyBE , HiderPN , SeeAM . Follow‐up strategies for patients treated for non‐metastatic colorectal cancer. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD002200.pub3] ">Jeffery 2016</a> kindly provided the methods they used when we contacted them, we could not obtain enough information from the latter five studies to estimate hazard ratios (see <a href="#CD012425-sec-0088">Effects of interventions</a>, Comparison 2: less intensive versus more intensive follow‐up, Time to detection of recurrence). We did not identify any new systematic reviews of randomised trials investigating colorectal cancer follow‐up, other than the five that <a href="./references#CD012425-bbs2-0158" title="JefferyM , HickeyBE , HiderPN , SeeAM . Follow‐up strategies for patients treated for non‐metastatic colorectal cancer. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD002200.pub3] ">Jeffery 2016</a> identified, and we refer to the discussion in their review. </p> <p>In the Cochrane Review on follow‐up strategies for ovarian cancer, <a href="./references#CD012425-bbs2-0137" title="ClarkeT , GalaalK , BryantA , NaikR . Evaluation of follow‐up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD006119.pub3] ">Clarke 2014</a> identified one study that was not included in ours (<a href="./references#CD012425-bbs2-0092" title="RustinGJ , Van derBurgME , GriffinCL , GuthrieD , LamontA , JaysonGC , et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet2010;376(9747):1155‐63. ">Rustin 2010</a>). This study investigated early versus delayed treatment of relapsed ovarian cancer and found that there was no overall survival benefit from immediate treatment based on raised CA125 levels compared to delayed treatment until a woman develops symptoms. As patients were only randomised after elevated serum levels were detected, we did not include this study, as we judged that the outcomes were a measure of the effect of an early versus later intervention in patients with recurrence, rather than of change in follow‐up strategies among patients treated with curative intent. No studies were found in the Cochrane Review on follow‐up strategies for cervical cancer (<a href="./references#CD012425-bbs2-0161" title="LanceleyA , FianderA , McCormackM , BryantA . Follow‐up protocols for women with cervical cancer after primary treatment. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD008767.pub2] ">Lanceley 2013</a>), while a Cochrane Review is underway investigating follow‐up strategies for women with endometrial cancer (<a href="./references#CD012425-bbs2-0132" title="AslamRW , PyeKL , RaiTK , HallB , TimmisLJ , YeoS , et al. Follow‐up strategies for women with endometrial cancer after primary treatment. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD012386] ">Aslam 2016</a>). </p> <p>We did not find any other systematic reviews focusing on randomised trials of follow‐up strategies in specific cancer sites, but identified four other systematic reviews that included randomised trials across cancer sites. However, all four reviews did not carry out any meta‐analyses and reported the results of the individual studies in narrative form. <a href="./references#CD012425-bbs2-0163" title="LewisR , NealR , WilliamsN , FranceB , HendryM , RussellD , et al. Follow up of cancer in primary care versus secondary care: a systematic review. British Journal of General Practice2009;59:234‐47. [DOI: 10.3399/bjgp09X453567] ">Lewis 2009a</a> and <a href="./references#CD012425-bbs2-0164" title="LewisR , NealRD , WilliamsNH , FranceB , WilkinsonC , HendryM , et al. Nurse‐led vs. conventional physician‐led follow‐up for patients with cancer: systematic review. Journal of Advanced Nursing2009;65(4):706‐23. [PUBMED: 19278415] ">Lewis 2009b</a> reported on follow‐up in primary care versus secondary care (11 randomised trials) and nurse‐led versus conventional physician‐led follow‐up (four randomised trials) respectively. Conclusions in both publications are in line with our results except that they report "no statistically significant difference for recurrence rate." <a href="./references#CD012425-bbs2-0144" title="DickinsonR , HallS , SinclairJE , BondC , MurchieP . Using technology to deliver cancer follow‐up: a systematic review. BMC Cancer2014;14(311):1‐16. [DOI: 10.1186/1471‐2407‐14‐311] ">Dickinson 2014</a> carried out a systematic review on the use of technology to deliver cancer follow‐up care (13 randomised trials) and concluded that the use of telephone follow‐up or internet‐based educational programmes were acceptable and feasible, based on the outcomes of patient satisfaction, quality of life and psychological distress. <a href="./references#CD012425-bbs2-0134" title="BarbieriM , RichardsonG , PaisleyS . The cost‐effectiveness of follow‐up strategies after cancer treatment: a systematic literature review. British Medical Bulletin2018;126(1):85‐100. [PUBMED: 29659715] ">Barbieri 2018</a> carried out a systematic literature review on the cost‐effectiveness of follow‐up strategies after cancer treatment based on 44 articles (including non‐randomised trials). They concluded that intensive follow‐up is likely to be cost‐effective in colorectal cancer but not in breast cancer, and there was insufficient evidence to make conclusions for the other cancer sites. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012425-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/urn:x-wiley:14651858:media:CD012425:CD012425-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_t/tCD012425-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Proposed model of cancer follow‐up, mechanisms and possible outcomes" data-id="CD012425-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Proposed model of cancer follow‐up, mechanisms and possible outcomes</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/full#CD012425-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012425-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/urn:x-wiley:14651858:media:CD012425:CD012425-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_t/tCD012425-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD012425-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/full#CD012425-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012425-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/urn:x-wiley:14651858:media:CD012425:CD012425-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_t/tCD012425-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. Blank items indicate that this type of outcome was not reported by the study" data-id="CD012425-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. Blank items indicate that this type of outcome was not reported by the study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/full#CD012425-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012425-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/urn:x-wiley:14651858:media:CD012425:CD012425-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_t/tCD012425-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 1. Non‐specialist‐led versus specialist‐led follow‐up, outcome: 1.1 overall survivalA HR greater than 1 indicates a higher hazard of death (worse survival) in the non‐specialist arm and a lower hazard of death (better survival) in the specialist‐led arm" data-id="CD012425-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison 1. Non‐specialist‐led versus specialist‐led follow‐up, outcome: 1.1 overall survival </p> <p>A HR greater than 1 indicates a higher hazard of death (worse survival) in the non‐specialist arm and a lower hazard of death (better survival) in the specialist‐led arm </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/full#CD012425-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012425-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/urn:x-wiley:14651858:media:CD012425:CD012425-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_t/tCD012425-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 2. Less intensive versus more intensive follow‐up, outcome: 2.1 overall survivalA HR greater than 1 indicates a higher hazard of death (worse survival) in the less intensive arm and a lower hazard of death (better survival) in more intensive arm" data-id="CD012425-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison 2. Less intensive versus more intensive follow‐up, outcome: 2.1 overall survival </p> <p>A HR greater than 1 indicates a higher hazard of death (worse survival) in the less intensive arm and a lower hazard of death (better survival) in more intensive arm </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/full#CD012425-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012425-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/urn:x-wiley:14651858:media:CD012425:CD012425-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_t/tCD012425-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 2. Less intensive versus more intensive follow‐up, outcome: 2.2 time‐to‐detection of recurrenceA HR less than 1 indicates a lower hazard of detecting recurrence (delay in detection of recurrence) in the less intensive arm and a higher hazard of detecting recurrence (better detection of recurrence) in the more intensive arm." data-id="CD012425-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison 2. Less intensive versus more intensive follow‐up, outcome: 2.2 time‐to‐detection of recurrence </p> <p>A HR less than 1 indicates a lower hazard of detecting recurrence (delay in detection of recurrence) in the less intensive arm and a higher hazard of detecting recurrence (better detection of recurrence) in the more intensive arm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/full#CD012425-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012425-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/urn:x-wiley:14651858:media:CD012425:CD012425-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_t/tCD012425-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐specialist‐led versus specialist‐led follow‐up, Outcome 1 Overall Survival." data-id="CD012425-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Non‐specialist‐led versus specialist‐led follow‐up, Outcome 1 Overall Survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/references#CD012425-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012425-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/urn:x-wiley:14651858:media:CD012425:CD012425-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_t/tCD012425-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐specialist‐led versus specialist‐led follow‐up, Outcome 2 EORTC‐C30 ‐ Global health status." data-id="CD012425-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Non‐specialist‐led versus specialist‐led follow‐up, Outcome 2 EORTC‐C30 ‐ Global health status. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/references#CD012425-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012425-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/urn:x-wiley:14651858:media:CD012425:CD012425-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_t/tCD012425-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐specialist‐led versus specialist‐led follow‐up, Outcome 3 EORTC‐C30 ‐ Physical functioning." data-id="CD012425-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Non‐specialist‐led versus specialist‐led follow‐up, Outcome 3 EORTC‐C30 ‐ Physical functioning. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/references#CD012425-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012425-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/urn:x-wiley:14651858:media:CD012425:CD012425-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_t/tCD012425-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐specialist‐led versus specialist‐led follow‐up, Outcome 4 EORTC‐C30 ‐ Role functioning." data-id="CD012425-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Non‐specialist‐led versus specialist‐led follow‐up, Outcome 4 EORTC‐C30 ‐ Role functioning. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/references#CD012425-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012425-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/urn:x-wiley:14651858:media:CD012425:CD012425-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_t/tCD012425-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐specialist‐led versus specialist‐led follow‐up, Outcome 5 EORTC‐C30 ‐ Emotional functioning." data-id="CD012425-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Non‐specialist‐led versus specialist‐led follow‐up, Outcome 5 EORTC‐C30 ‐ Emotional functioning. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/references#CD012425-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012425-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/urn:x-wiley:14651858:media:CD012425:CD012425-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_t/tCD012425-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐specialist‐led versus specialist‐led follow‐up, Outcome 6 EORTC‐C30 ‐ Cognitive functioning." data-id="CD012425-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Non‐specialist‐led versus specialist‐led follow‐up, Outcome 6 EORTC‐C30 ‐ Cognitive functioning. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/references#CD012425-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012425-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/urn:x-wiley:14651858:media:CD012425:CD012425-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_t/tCD012425-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐specialist‐led versus specialist‐led follow‐up, Outcome 7 EORTC‐C30 ‐ Social functioning." data-id="CD012425-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Non‐specialist‐led versus specialist‐led follow‐up, Outcome 7 EORTC‐C30 ‐ Social functioning. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/references#CD012425-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012425-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/urn:x-wiley:14651858:media:CD012425:CD012425-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_t/tCD012425-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐specialist‐led versus specialist‐led follow‐up, Outcome 8 STAI ‐ State anxiety subscale." data-id="CD012425-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Non‐specialist‐led versus specialist‐led follow‐up, Outcome 8 STAI ‐ State anxiety subscale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/references#CD012425-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012425-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/urn:x-wiley:14651858:media:CD012425:CD012425-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_t/tCD012425-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐specialist‐led versus specialist‐led follow‐up, Outcome 9 HADS ‐ Anxiety subscale." data-id="CD012425-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Non‐specialist‐led versus specialist‐led follow‐up, Outcome 9 HADS ‐ Anxiety subscale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/references#CD012425-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012425-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/urn:x-wiley:14651858:media:CD012425:CD012425-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_t/tCD012425-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Non‐specialist‐led versus specialist‐led follow‐up, Outcome 10 HADS ‐ Depression subscale." data-id="CD012425-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Non‐specialist‐led versus specialist‐led follow‐up, Outcome 10 HADS ‐ Depression subscale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/references#CD012425-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012425-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/urn:x-wiley:14651858:media:CD012425:CD012425-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_t/tCD012425-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Less intensive versus more intensive follow‐up, Outcome 1 Overall survival." data-id="CD012425-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Less intensive versus more intensive follow‐up, Outcome 1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/references#CD012425-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012425-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/urn:x-wiley:14651858:media:CD012425:CD012425-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_t/tCD012425-CMP-002-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Less intensive versus more intensive follow‐up, Outcome 2 Time‐to‐detection of recurrence." data-id="CD012425-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Less intensive versus more intensive follow‐up, Outcome 2 Time‐to‐detection of recurrence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/references#CD012425-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/media/CDSR/CD012425/image_n/nCD012425-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012425-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Non‐specialist‐led versus specialist‐led follow‐up after primary cancer treatment</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Non‐specialist‐led versus specialist‐led follow‐up after primary cancer treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult cancer survivors from the following cancer sites: breast, colon, colorectal, endometrial, ovarian, cervical, melanoma and oesophageal<br/> <b>Setting</b> : outpatient treatment in hospitals or general practice in Australia, Canada, Denmark, Netherlands, Norway, Sweden and UK<br/> <b>Intervention</b> : non‐specialist‐led (i.e. GP‐led, nurse‐led, patient‐initiated or shared care) follow‐up<br/> <b>Comparison</b>: specialist‐led follow‐up </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effects (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<sup>a</sup> <br/> (Number of studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Risk with specialist‐led follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Risk with non‐specialist‐led follow‐up</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>Follow‐up range: 12 months to 60 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 100<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 100</p> <p>(79 to 93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.21<br/> (0.68 to 2.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>603 participants</p> <p>(2 randomised trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 studies reported on overall survival. It is uncertain how non‐specialist‐led follow‐up affects overall survival as the certainty of the evidence is very low. </p> <p>We could not incorporate data from 2 other studies (N =1077) in the meta‐analysis, both reported little or no difference in overall survival. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Difference:</b> 2 fewer survivors in the intervention group per 100 participants (between 10 fewer to 4 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to detection of recurrence</b> </p> <p>Follow‐up range: 3 months to 60 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1691 participants (4 randomised trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies reported on time to detection of recurrence. It is uncertain how non‐specialist‐led follow‐up affects time to detection of recurrence as the certainty of the evidence is very low and we could not pool the reported data. </p> <p>3 studies reported little or no difference in time to detection of recurrence and 1 study reported median time to recurrence but did not carry out any statistical analysis. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life, (at 12 months' follow‐up)</b> </p> <p>EORTC‐C30 global health status scale (higher scores indicate better HRQoL)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.06 higher<br/> (1.83 lower to 3.95 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>605 participants</p> <p>(4 randomised trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thirteen studies reported on HRQoL using EORTC‐C30, SF‐36, SF‐12, EuroQoL‐5D and FACT at different time points. Meta‐analysis of 4 studies showed that non‐specialist‐led follow‐up may make little or no difference in HRQoL at 12 months as measured by the EORTC‐C30 global health status scale. The mean difference did not reach the minimal clinically important difference of 10 points identified for this scale. </p> <p>Studies that we could not incorporate in the meta‐analysis (N = 2385) generally reported that non‐specialist‐led follow‐up made little or no difference to HRQoL. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anxiety (at 12 months' follow‐up)</b> </p> <p>HADS‐Anxiety subscale (higher scores indicate worse anxiety)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.03 lower<br/> (0.73 lower to 0.67 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1266 participants</p> <p>(5 randomised trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 studies reported on anxiety and 2 on fear of recurrence using STAI, HADS and FCRI at different time points. Meta‐analysis of 5 studies showed that non‐specialist‐led follow‐up probably makes little or no difference to anxiety at 12 months as measured by HADS‐Anxiety subscale. The mean difference did not reach the minimal clinically important difference of 1.5 points identified for this scale. </p> <p>Data from the studies that we could not incorporate in the meta‐analysis (N = 1755) generally reported that non‐specialist‐led follow‐up made little or no difference to anxiety and fear of recurrence, except 1 study reporting higher levels of fear of recurrence in the patient‐initiated follow‐up group. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Depression (at 12 months)</b> </p> <p>HADS‐Depression subscale (higher scores indicate worse depression)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.03 higher<br/> (0.35 lower to 0.42 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1266 participants</p> <p>(5 randomised trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eleven studies reported on depression using GHQ‐12 and HADS at different time points. Meta‐analysis of 5 studies showed that non‐specialist‐led follow‐up makes little or no difference to depression at 12 months as measured by HADS‐Depression subscale. The mean difference did not reach the minimal clinically important difference of 1.5 points identified for this scale. </p> <p>The studies that we could not incorporate in the meta‐analysis (N = 1378) generally reported that non‐specialist‐led follow‐up may make little or no difference to depression. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cost</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1756 participants (8 randomised trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eight studies reported cost outcomes but due to the substantial heterogeneity in how they measured and reported them, we could not pool the results in a meta‐analysis. It is uncertain whether non‐specialist‐led follow‐up has an effect on cost when compared with specialist‐led follow‐up, as the certainty of the evidence is very low. </p> <p>6 studies reported lower cost per participant in the non‐specialist‐led group, while 2 studies reported higher cost per participant in the non‐specialist‐led group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>*</b> The basis for the assumed risk in the comparison group (<b>assumed comparator risk, ACR</b> ) is provided in the footnotes. The <b>corresponding risk in the intervention group</b> (and its 95%confidence interval) is based on the ACR and the <b>relative effect</b> of the intervention (and its 95%CI). </p> <p><b>CI</b> : confidence interval; <b>EORTC‐C30:</b> European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; <b>FACT:</b> Functional Assessment of Cancer Therapy scale; <b>FCRI:</b> Fear of Cancer Recurrence Inventory; <b>GHQ‐12:</b> General Health Questionnaire‐12 items; <b>GP:</b> general practitioner; <b>HADS:</b> Hospital Anxiety and Depression Scale; <b>HR:</b> Hazard ratio; <b>HRQoL:</b> health‐related quality of life; <b>MD</b> : mean difference; <b>SF‐36:</b> Short Form Health Survey‐36 items; <b>SF‐12</b> : Short Form Health Survey‐12 items; <b>STAI:</b> State Trait Anxiety Inventory </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>From meta‐analysis if we pooled study results; for all studies if we did not pool study results.<br/> <sup>b</sup>The ACR is the assumed proportion of participants who are alive in the comparison group. <br/> <sup>c</sup>We judged the certainty of evidence to be very low and downgraded by three levels for very serious concerns regarding indirectness and imprecision, as representativeness is limited with only two studies, the HRs were not reported but indirectly estimated and the confidence interval was very wide.<br/> <sup>d</sup>We judged the certainty of evidence to be very low and downgraded by three levels for serious concerns regarding inconsistency, indirectness and imprecision due to few studies, reporting of results by different estimates that could not be pooled and high variance of the result estimates.<br/> <sup>e</sup>We judged the certainty of evidence to be low and downgraded by two levels for serious concerns regarding inconsistency and imprecision due to differing estimates of effect and wide confidence intervals.<br/> <sup>f</sup>We judged the certainty of evidence to be moderate as we downgraded by one level for concerns regarding inconsistency of results and indirectness due to few studies.<br/> <sup>g</sup>We judged the certainty of evidence to be high although we had some concerns regarding indirectness due to few studies.<br/> <sup>h</sup>We judged the certainty of evidence to be very low as the high heterogeneity led to serious concerns regarding inconsistency, indirectness and imprecision in the way cost outcomes were measured and reported across studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Non‐specialist‐led versus specialist‐led follow‐up after primary cancer treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/full#CD012425-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012425-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Less intensive versus more intensive follow‐up after primary cancer treatment</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Less compared with more intensive components in follow‐up after primary cancer treatment</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adult cancer survivors from the following cancer sites: breast, colorectal, head‐and‐neck, Hodgkin lymphoma, melanoma, non‐small cell lung cancer and testicular cancer<br/> <b>Setting</b> : outpatient treatment in hospitals in Australia, Denmark, China, Finland, France, India, Italy, Netherlands, Spain, Sweden, Switzerland and UK<br/> <b>Intervention</b> : less intensive follow‐up (based on fewer clinical visits, examinations or less intensive diagnostic procedures)<br/> <b>Comparison</b>: more intensive follow‐up </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effects<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<sup>a</sup><br/> (Number of studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Risk with more intensive follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Risk with less intensive follow‐up</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>Follow‐up range: 24 months to 120 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 per 100<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 100</p> <p>(72 to 76)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.05<br/> (0.96 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10,726 participants</p> <p>(13 randomised trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>18 studies reported on overall survival. Meta‐analysis of 13 studies showed that less intensive follow‐up may make little or no difference to overall survival. Meta‐regression analysis showed little or no difference in the intervention effects by cancer site, publication year or study quality. </p> <p>We could not incorporate data from 5 other studies. 3 of these studies reported little or no difference in overall survival (N = 1752), while 2 studies reported improved survival with more intensive follow‐up (N = 544). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Difference:</b> 1 fewer survivor in the intervention group per 100 participants (between 3 fewer to 1 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Time to detection of recurrence</b> </p> <p>Follow‐up range: 12 months to 120 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 100<sup>d</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 100</p> <p>(22 to 25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.85 (0.79 to 0.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>11,276 participants</p> <p>(12 randomised trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>22 studies reported on time to detection of recurrence. Meta‐analysis of 12 studies showed that less intensive follow‐up probably increases time to detection of recurrence. Meta‐regression analysis showed little or no difference in the intervention effects by cancer site, publication year or study quality. </p> <p>We could not incorporate data from 10 other studies. 4 of these studies reported shorter time to detection of recurrence for more intensive follow‐up (N = 854), while 4 other studies reported little or no difference in detection of recurrence (N = 734). 1 study reported results that we could not use for this comparison (N = 337) and 1 study reported results based on only unresectable recurrence (N = 239). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Difference: 3 fewer detected recurrence in the intervention group per 100 participants (between 5 to 2 fewer)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2742 participants (3 randomised trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies reported on HRQoL using SF‐36 and SF‐12 at varying time points. We could not pool the reported data. It is uncertain whether less intensive follow‐up has an effect on HRQoL when compared with more intensive follow‐up, as the certainty of the evidence is very low. </p> <p>All 3 studies reported that less intensive follow‐up may make little or no difference in HRQoL when compared to more intensive follow‐up at time points ranging from 12 months to 5 years. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Anxiety</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 participants (1 randomised trial)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One study reported that less intensive follow‐up may make little or no difference to anxiety at 12 months follow‐up using STAI. </p> <p>It is uncertain whether less intensive follow‐up has an effect on anxiety when compared with more intensive follow‐up, as the certainty of the evidence is very low. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Depression</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of the studies reported depression.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cost</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1412 participants (6 randomised trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 studies reported cost outcomes but due to the substantial heterogeneity in how they measured and reported this outcome, we could not pool the results in a meta‐analysis. It is uncertain whether less intensive follow‐up has an effect on cost when compared with more intensive follow‐up, as the certainty of the evidence is very low. </p> <p>All studies report lower costs for the less intensive arm from the perspective of the participant or healthcare system but the difference in cost varied considerably depending on the components/procedures used in the different interventions. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>*</b> The basis for the assumed risk in the comparison group (<b>assumed comparator risk, ACR</b> ) is provided in the footnotes. The <b>corresponding risk in the intervention group</b> (and its 95%confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95%CI). </p> <p><b>CI</b> : confidence interval; <b>HR:</b> hazard ratio; <b>HRQoL:</b> health‐related quality of life; <b>SF‐36:</b> Short Form Health Survey‐36 items; <b>SF‐12</b> : Short Form Health Survey‐12 items; <b>STAI:</b> State Trait Anxiety Inventory </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>From meta‐analysis if we pooled study results; for all studies if we did not pool study results.<br/> <sup>b</sup>The ACR is the assumed proportion of participants who are alive in the comparison group. <br/> <sup>c</sup>We judged the certainty of evidence to be low as we downgraded by two levels for some concerns regarding study limitations (lack of allocation concealment in one study) and indirectness as the studies were primarily investigating follow‐up after colorectal and breast cancer, and serious concerns regarding imprecision as the confidence interval includes effects that are not trivial (potentially up to 3 fewer survivors per 100 participants).<br/> <sup>d</sup>The ACR is the assumed proportion of participants with a detected recurrence in the comparison group.<br/> <sup>e</sup>We judged the certainty of evidence to be moderate as we downgraded by one level for serious concerns regarding indirectness as seven of the studies did not report hazard ratios, so we indirectly estimated them from published data.<br/> <sup>f</sup>We judged the certainty of evidence to be very low and downgraded by three levels for serious concerns regarding inconsistency, indirectness and imprecision due to the few studies, heterogeneous measures and reporting of results by different estimates that we could not pool.<br/> <sup>g</sup>We judged the certainty of evidence to be very low and downgraded by three levels for serious concerns regarding inconsistency, indirectness and imprecision since there was only one study.<br/> <sup>h</sup>We judged the certainty of evidence to be very low and downgraded by three levels as the substantial heterogeneity led to serious concerns regarding inconsistency, indirectness and imprecision in the way cost was measured and reported across studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Less intensive versus more intensive follow‐up after primary cancer treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/full#CD012425-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012425-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Follow‐up integrating additional patient symptom education or monitoring, or survivorship care plans versus usual care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Follow‐up integrating additional</b> patient symptom education or monitoring, or survivorship care plan<b>s versus usual care</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adult cancer survivors from the following cancer sites: breast, colorectal, endometrial, ovarian and prostate cancer<br/> <b>Setting</b> : outpatient treatment in hospitals or general practice in Australia, Canada, Netherlands, Sweden and USA<br/> <b>Intervention:</b> follow‐up integrating additional components relevant for detection of recurrence (e.g. patient symptom education or monitoring, or survivorship care plans (SCP))<br/> <b>Comparison</b>: usual care </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effects<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of studies</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Risk with usual care</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Risk with follow‐up integrating additional patient symptom education/monitoring or SCP</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the studies reported overall survival.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time‐to‐ detection of recurrence</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the studies reported detection of recurrence.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life, (HRQoL)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2846 participants (12 randomised trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 studies reported on HRQoL using EORTC‐C30, SF‐36, SF‐12, FACT and City of Hope QoL scale at varying time points. We could not pool the reported data. It is uncertain whether follow‐up integrating additional patient symptom education/monitoring or SCP has an effect on HRQoL when compared with usual care, as the certainty of the evidence is very low. </p> <p>11 studies reported that follow‐up integrating additional patient education/SCP may make little or no difference to HRQoL when compared to usual care at follow‐up ranging from 6 months to 12 months. 1 study reported that SCP and patient coaching improved HRQoL at 3 months' follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anxiety</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>470 participants (1 randomised trial)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One study reported that SCP may make little or no difference to anxiety at 12 months' follow‐up using HADS. </p> <p>It is uncertain whether follow‐up integrating additional patient symptom education/monitoring or SCP has an effect on anxiety when compared with usual care, as the certainty of the evidence is very low. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Depression</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2351 participants (8 randomised trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Very low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 studies reported on depression using HADS, POMS, PHQ‐9, BSI‐18, CES‐D and the distress thermometer at varying time points. We could not pool the reported data. It is uncertain whether follow‐up integrating additional patient symptom education/monitoring or SCP has an effect on depression when compared with usual care, as the certainty of the evidence is very low. </p> <p>7 studies reported that follow‐up integrating additional patient education/SCP may make little or no difference to depression when compared to usual care at follow‐up ranging from 3 months to 12 months. 1 study reported that the intervention improved symptoms of depression at 12 months' follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cost</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>408 participants (1 randomised trial)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One study reported that the use of SCP make little or no difference to cost at 2 years' follow‐up. </p> <p>It is uncertain whether follow‐up integrating additional patient symptom education/monitoring or SCP has an effect on cost when compared with usual care, as the certainty of the evidence is very low. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>*</b>The corresponding risk in the intervention group (and its 95%confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%CI). </p> <p><b>BSI‐18:</b> Brief Symptom Inventory‐18 items, <b>CES‐D:</b> Center for Epidemiological Studies‐Depression scale; <b>CI</b> : confidence interval; <b>EORTC‐C30:</b> European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; <b>FACT:</b> Functional Assessment of Cancer Therapy scale; <b>HADS:</b> Hospital Anxiety and Depression Scale; <b>HRQoL:</b> health‐related quality of life; <b>PHQ‐9:</b> Patient Health Questionaire‐9 items; <b>POMS:</b> Profile of Mood States; <b>QoL:</b> quality of life; <b>SCP:</b> survivorship care plans; <b>SF‐36:</b> Short Form Health Survey‐36 items; <b>SF‐12</b>: Short Form Health Survey‐12 items </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We judged the overall certainty of evidence to be very low and downgraded by three levels for serious concerns regarding study limitations, indirectness and imprecision due to studies being at high risk of bias, the heterogeneous measures and reporting of results by different estimates that could not be pooled.<br/> <sup>b</sup>We judged the certainty of evidence to be very low and downgraded by three levels for serious concerns regarding inconsistency, indirectness and imprecision since there was only one study.<br/> <sup>c</sup>We judged the overall certainty of evidence to be very low and downgraded by three levels for serious concerns regarding study limitations, indirectness and imprecision due to one study at high risk of bias, the heterogeneous measures and reporting of results by different estimates that could not be pooled.<br/> <sup>d</sup>We judged the certainty of evidence to be very low and downgraded by three levels for serious concerns regarding inconsistency, indirectness and imprecision since there was only one study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Follow‐up integrating additional patient symptom education or monitoring, or survivorship care plans versus usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/full#CD012425-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012425-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of cost outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcome measurement</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0001" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [DOI: 10.1136/bmjopen‐2012‐002391] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. [DOI: 10.1186/1472‐6963‐8‐137] NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up?. clinicaltrials.gov/ct2/show/NCT00572143 (first received 20 December 2016). ">Augestad</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GP‐led vs surgeon‐led follow‐up after colon cancer</b> </p> <p> <ul id="CD012425-list-0016"> <li> <p>The cost elements included costs related to hospital visits, GP visits, laboratory tests, radiology examinations, colonoscopy, examinations owing to suspected relapse treatment of recurrence, travelling/transportation, production losses, co‐payments and other participant/family expenses. </p> </li> <li> <p>Cost minimisation analysis was carried out and reported as:</p> <ul id="CD012425-list-0017"> <li> <p>cost per participant per 3‐month follow‐up cycle in GBP</p> </li> <li> <p>mean societal cost in GBP for 24 months' follow‐up: mean (95% CI)</p> </li> </ul> </li> <li> <p>The follow‐up programme initiated 1186 healthcare contacts (GP 678 vs surgeon 508), 1105 diagnostic tests (GP 592 vs surgeon 513) and 778 hospital travels (GP 250 vs surgeon 528). GP‐organised follow‐up was associated with societal cost savings (GBP 8233 vs GBP 9889, P &lt; 0.001). </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cost per participant</p> <p>GBP 292 (255 to 327)</p> <p>Mean societal cost</p> <p>GBP 8233 (7904 to 8619)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cost per participant</p> <p>GBP 351 (315 to 386)</p> <p>Mean societal cost</p> <p>GBP 9889 (9569 to 10194)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0002" title="BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Economic evaluation of a randomized clinical trial of hospital versus telephone follow‐up after treatment for breast cancer. British Journal of Surgery2009;96(12):1406‐15. [DOI: 10.1002/bjs.6753] BeaverK , HollingworthW , McDonaldR , DunnG , Tysver‐RobinsonD , ThomsonL , et al. Is telephone follow‐up by specialist nurses a cost effective approach?. European Journal of Cancer Supplements2009;7(2‐3):230‐1. BeaverK , Tysver‐RobinsonD , CampbellM , TwomeyM , WilliamsonS , HindleyA , et al. Comparing hospital and telephone follow‐up after treatment for breast cancer: randomised equivalence trial. BMJ2009;338:a3147. [DOI: 10.1136/bmj.a3147] ">Beaver 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nurse‐led telephone vs hospital follow‐up after breast cancer</b> </p> <p> <ul id="CD012425-list-0018"> <li> <p>Resource use included training of nurses in telephone follow‐up, routine follow‐up consultations and diagnostic tests ordered, participant travel, and time of work and unit costs (e.g. salary, qualifications, ongoing training and clinic overhead) </p> </li> <li> <p>Cost was reported as total NHS (UK) cost per participant in GBP (mean/SD) over a mean of 24 months </p> </li> <li> <p>Owing to the cost of nurse training, greater frequency and longer duration of the telephone consultations, and the frequent use of junior medical staff in hospital clinics, the mean costs of follow‐up consultations were higher with telephone follow‐up (MD GBP 55, bias‐corrected 95% CI GBP 29 to GBP 77). </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GBP 179 (118)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GBP 24 (116)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0004" title="BeaverK , WilliamsonS , Martin‐HirschP , KeatingPJ , TomlinsonA , SuttonC , et al. ENDCAT: endometrial cancer telephone follow‐up trial. Psycho‐oncology2013;22:19. BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , AlltonB , et al. Comparing hospital and telephone follow‐up for patients treated for stage‐I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG2017;124:150‐60. [DOI: http://dx.doi.org/10.1111/1471‐0528.14000] BeaverK , WilliamsonS , SuttonC , HollingworthW , GardnerA , TomlinsonA , et al. Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). Psycho‐oncology2016;25:6‐7. DixonP , BeaverK , WilliamsonS , SuttonC , Martin‐HirschP , HollingworthW . Cost‐consequence analysis alongside a randomised controlled trial of hospital versus telephone follow‐up after treatment for endometrial cancer. Applied Health Economics and Health Policy2018;16(3):415‐27. WilliamsonS , BeaverK , GardnerA , Martin‐HirschP . Telephone follow‐up after treatment for endometrial cancer: a qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. European Journal of Oncology Nursing2018;34:61‐7. WilliamsonS , BeaverK , Martin‐HirschP , PatrickK , AnneT , SuttonC . Comparing hospital and telephone follow‐up for women treated for endometrial cancer (ENDCAT trial). European Journal of Cancer2015;51(Suppl 3):S251. ">Beaver 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nurse‐led telephone vs hospital follow‐up after endometrial cancer</b> </p> <p> <ul id="CD012425-list-0019"> <li> <p>Unit cost data were drawn primarily from the unit costs of health and social care and NHS Reference Costs. The cost of a nurse or doctor contact hour included salary (excluding overtime and shift payments), on‐costs (e.g. national insurance contributions), qualifications, the ratio of participant contact to non‐contact time, and overheads. </p> </li> <li> <p>Unit cost data were collected from 2012/13 and inflated from the time of the study using the most recent (2016/17) UK GBP deflator so that costs were expressed in GBP at 2016/17 prices. </p> </li> <li> <p>Reported as total health service mean cost per participant costs at 6 months or 12 months </p> </li> <li> <p>Differences between groups: 6 months, GBP 8 (bias‐corrected 95% GBP −147 to GBP 141); 12 months, GBP −77 (GBP −334 to GBP 154) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months: GBP 434</p> <p>12 months: GBP 746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months: GBP 426</p> <p>12 months: GBP 823</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0007" title="DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . Prospective randomized clinical trial for the evaluation of a stage adjusted reduced follow‐up schedule in cutaneous melanoma patients: results after one year. Annals of Surgical Oncology2016;23(1 Suppl 1):S30. DamudeS , Hoekstra‐WeebersJE , FranckenAB , Ter MeulenS , BastiaannetE , HoekstraHJ . The MELFO‐study: prospective randomized clinical trial for the evaluation of a stage‐adjusted reduced follow‐up schedule in cutaneous melanoma patients ‐ results after 1 year. Annals of Surgical Oncology2016;23(9):2762‐71. [DOI: 10.1245/s10434‐016‐5263‐7] DeckersE , Hoekstra‐WeebersJ , DamudeS , FranckenA , Ter MeulenS , BastiaannetE , et al. The MELFO‐study: a multi‐center prospective randomized clinical trial on the effects of a reduced stage‐adjusted follow‐up schedule on cutaneous melanoma IB‐IIC patients: results after 3‐years. Annals of Surgical Oncology2018;25(1 Suppl 1):S40. NCT01018004 . Comparing follow‐up schedules in patients with newly diagnosed stage IB or stage II melanoma. clinicaltrials.gov/ct2/show/NCT01018004 (first received 20 December 2016). ">Damude 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Less frequent vs conventional follow‐up schedule after melanoma</b> </p> <p> <ul id="CD012425-list-0020"> <li> <p>Study authors calculated total follow‐up costs of the first year for all participants from University Medical Center Groningen, Netherlands (UMCG) based on data from the UMCG financial administration. </p> </li> <li> <p>Cost was reported as total cost per participant (EUR; mean/SD)</p> </li> <li> <p>Study reported a reduction in hospital costs at 1‐year follow‐up of 45% in the intervention group compared to the conventional schedule group. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 417.66 (452.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 761.97 (683.37)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0013" title="GoodwinPJ . Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Commentary on Grunfeld E, Fitzpatrick R, Mant D et al Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial BR J GEN PRACT 1999 Sep;49:705‐10. ACP Journal Club2000;132(3):106. GrunfeldE , FitzpatrickR , MantD , YudkinP , Adewuyi‐DaltonR , StewartJ , et al. Comparison of breast cancer patient satisfaction with follow‐up in primary care versus specialist care: results from a randomized controlled trial. British Journal of General Practice1999;49(446):705‐10. GrunfeldE , GrayA , MantD , YudkinP , Adewuyi‐DaltonR , CoyleD , et al. Follow‐up of breast cancer in primary care vs specialist care: results of an economic evaluation. British Journal of Cancer1999;79(7‐8):1227‐33. GrunfeldE , MantD , VesseyMP , YudkinP . Evaluating primary care follow‐up of breast cancer: methods and preliminary results of three studies. Annals of Oncology1995;6(Suppl 2):47‐52. GrunfeldE , MantD , YudkinP , Adewuyi‐DaltonR , ColeD , StewartJ , et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ1996;313(7058):665‐9. GrunfeldE , YudkinP , Adewuyl‐DaltonR , VesseyMP , MantD . Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ1995;311(6996):54. ">Grunfeld 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GP‐led vs hospital follow‐up after breast cancer</b> </p> <p> <ul id="CD012425-list-0021"> <li> <p>The economic evaluation considered costs to the health service (particularly, the costs of follow‐up visits and diagnostic tests) and costs to the participants (such as lost earnings and out‐of‐pocket expenses) over 18 months. All costs were expressed in 1994 GBP. </p> </li> <li> <p>Cost was reported as average cost per participant in GBP (95% CI)</p> </li> <li> <p>GP participants were seen significantly more frequently and each follow‐up visit lasted longer. GPs ordered more diagnostic tests than did specialists. Although the mean cost per visit in general practice was significantly less, the mean cost of diagnostic tests per visit was similar in the 2 groups. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GBP 64.70 (5.80 to 301.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GBP 195.10 (62 to 737.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0015" title="BoekhoutAH , MaunsellE , PondGR , JulianJA , CoyleD , LevineMN , et al. A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial. Journal of Cancer Survivorship2015;9(4):683‐91. CoyleD , GrunfeldE , CoyleK , JulianJA , PondGR , FolkesA , et al. Cost‐effectiveness of a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):6082. CoyleD , GrunfeldE , CoyleK , PondG , JulianJA , LevineMN . Cost effectiveness of a survivorship care plan for breast cancer survivors. Journal of Oncology Practice2014;10(2):e86‐92. GrunfeldE , JulianJA , PondG , MaunsellE , CoyleD , FolkesA , et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. Journal of Clinical Oncology2011;29(36):4755‐62. GrunfeldE , LevineMN , JulianJA , PondGR , MaunsellE , FolkesA , et al. Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. Journal of Clinical Oncology2011;29(15 Suppl 1):9005. GrunfeldE , PondG , MaunsellE , LevineMN , JulianJA , CoyleD . Impact of survivorship care plans (SCP) on adherence to guidelines, health service measures, and patient‐reported outcomes (PRO): extended results of a multicenter randomized clinical trial (RCT) with breast cancer survivors. European Journal of Cancer2012;48:S147. ">Grunfeld 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SCP vs no SCP after breast cancer</b> </p> <p> <ul id="CD012425-list-0022"> <li> <p>Analysis assessed the healthcare and societal costs (physician visits, diagnostic and laboratory tests, participant travel costs and lost productivity, and additional costs associated with the SCP) and QALYs over the 2‐year follow‐up of the randomised trial. </p> </li> <li> <p>Cost was reported as:</p> <ul id="CD012425-list-0023"> <li> <p>total cost per participant in 2011 CAD</p> </li> <li> <p>QALY</p> </li> </ul> </li> <li> <p>The SCP is not cost‐effective. Total costs per participant were lower for standard care (CAD 698 vs CAD 765), and total QALYs were almost equivalent (1.42 for standard care vs 1.41 for the SCP). The probability that the SCP was cost effective was 0.26 at a threshold value of a QALY of CAD 50,000. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAD 765</p> <p>QALY 1.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAD 698</p> <p>QALY 1.42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0020" title="BloebaumMM , KimmanML , HoubenR , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer: a randomised controlled trial. European Journal of Cancer (Suppl)2009;7(2‐3):319. KimmanML , BloebaumMM , DirksenCD , HoubenRM , LambinP , BoersmaLJ . Patient satisfaction with nurse‐led telephone follow‐up after curative treatment for breast cancer. BMC Cancer2010;10:174. KimmanML , DirksenCD , FalgerP , VoogdA , KesselsA , GijsenB , et al. Results of an RCT investigating the cost‐effectiveness of four follow‐up strategies after breast cancer. European Journal of Cancer (Suppl)2009;7(2‐3):18. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Economic evaluation of four follow‐up strategies after curative treatment for breast cancer: results of an RCT. European Journal of Cancer2011;47(8):1175‐85. KimmanML , DirksenCD , VoogdAC , FalgerP , GijsenBC , ThuringM , et al. Nurse‐led telephone follow‐up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. European Journal of Cancer2011;47(7):1027‐36. KimmanML , DirksenCD , VoogdAC , FalgerP , HupperetsP , KesselsA , et al. Improving the quality and efficiency of breast cancer follow‐up: results from an RCT. European Journal of Cancer (Suppl)2010;8(3):207. KimmanML , VoogdAC , DirksenCD , FalgerP , HupperetsP , KeymeulenK , et al. Improving the quality and efficiency of follow‐up after curative treatment for breast cancer ‐ rationale and study design of the MaCare trial. BMC Cancer2007;7:1‐7. ">Kimman 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nurse‐led telephone vs hospital follow‐up after breast cancer</b> </p> <p> <ul id="CD012425-list-0024"> <li> <p>Analysis included health care (e.g. diagnostic procedures, outpatient clinic visits, telephone interviews) and non‐healthcare‐related costs (e.g. productivity loss, informal care). Cost prices were obtained from the Dutch Governmental manual for healthcare cost analysis. </p> </li> <li> <p>Costs were reported by treatment arm (see note) as:</p> <ul id="CD012425-list-0025"> <li> <p>mean annual costs per participant in 2008 Euros (95% CI) over 12 months</p> </li> <li> <p>QALY (95% CI)</p> </li> </ul> </li> </ul> </p> <p>Note: this study was a 4‐armed 2 x 2 design that also compared the use of an educational group programme (EGP) vs no EGP. We only included the nurse‐led vs hospital follow‐up comparison for this review. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 4672 (3489 to 6033)</p> <p>QALY 0.769 (0.746 to 0.794)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 4419 (3410 to 5501)</p> <p>QALY 0.747 (0.707 to 0.778)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0023" title="KoinbergI , EngholmGB , GenellA , HolmbergL . A health economic evaluation of follow‐up after breast cancer surgery: results of an RCT study. Acta Oncologica2009;48(1):99‐104. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Comparison between nurse‐led check‐ups on demand and follow‐ups by a physician after breast cancer surgery. European Journal of Cancer2003;1:S362. KoinbergIL , FridlundB , EngholmGB , HolmbergL . Nurse‐led follow‐up on demand or by a physician after breast cancer surgery: a randomised study. European Journal of Oncology Nursing2004;8(2):109‐17; discussion 118‐20. ">Koinberg 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nurse‐led on demand vs standard hospital follow‐up after breast cancer</b> </p> <p> <ul id="CD012425-list-0026"> <li> <p>Cost elements included medical examinations (e.g. mammography, pulmonary X‐ray, scintigraphy, CT scans, US, biopsies), visits (nurse, physician, social worker, physiotherapist and breast prosthetic technician visits) and telephone contacts. </p> </li> <li> <p>Costs are reported as mean cost per participant per year of follow‐up by intervention arm in 2006 Euros (95% CI) in Sweden. </p> </li> <li> <p>Specialist nurse intervention with check‐ups on demand was 20% less expensive than routine follow‐up visits to the physician, explained by the numbers of visits to the physician in the respective study arms. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 495 (410 to 797)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 630 (557 to 1055)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0024" title="KokkoR , HakamaM , HolliK . Follow‐up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Research and Treatment2005;93(3):255‐60. KokkoR , HakamaM , HolliK . Role of chest X‐ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Research and Treatment2003;81(1):33‐9. ">Kokko 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Less intensive (CXR only when indicated) vs regular X‐rays after breast cancer</b> </p> <p> <ul id="CD012425-list-0027"> <li> <p>Costs from the hospital perspective (no. of contacts (visits and phone calls) and diagnostic tests) were compared during the first 5 years of follow‐up </p> </li> <li> <p>Mean cost of follow‐up per participant in 2003‐2004 Euros were reported for 4 arms (see note): </p> <ul id="CD012425-list-0028"> <li> <p>A: every 3 months, routine tests (X‐ray every 6 months)</p> </li> <li> <p>B: every 3 months, no routine tests</p> </li> <li> <p>C: every 6 months, routine tests</p> </li> <li> <p>D: every 6 months, no routine tests</p> </li> </ul> </li> <li> <p>Routine examinations in the follow‐up of asymptomatic primary breast cancer participants increase the costs of follow‐up 2.2 times. </p> </li> </ul> </p> <p>Note: the clinical outcomes of this study (survival and recurrence) were reported in a separate paper according to 2 groups: 1 group had regular CXRs every 6 months while the other group had CXR only when clinically needed. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arm B: EUR 1493</p> <p>Arm D: EUR 1050</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arm A: EUR 2269</p> <p>Arm C: EUR 1656</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0029" title="MonteilJ , VergnenègreA , BertinF , DalmayF , GaillardS , BonnaudF , et al. Randomized follow‐up study of resected NSCLC patients: conventional versus 18F‐DG coincidence imaging. Anticancer Research2010;30(9):3811‐6. NCT00199615 . Follow‐up of patients with curative‐intent surgical resection for NSCLC. clinicaltrials.gov/ct2/show/NCT00199615 (first received 20 December 2016). ">Monteil 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>More intensive (CDET) vs CT scans after lung cancer</b> </p> <p> <ul id="CD012425-list-0029"> <li> <p>The analysis included only direct medical costs for each participant (imaging procedure, fixed hospital and patient transportation costs) over 2 years. Reimbursement prices were determined for each procedure by the French Healthcare system using 2002 repayment tariffs. </p> </li> <li> <p>Costs were reported as average cost of follow‐up visits and imaging per participant in Euros (95% CI) </p> </li> <li> <p>CDET imaging was more expensive, provided earlier detection of recurrence, but did not modify survival outcome. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 1104.96</p> <p>(954 to 1240)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 755.47 (640 to 864)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0030" title="MorrisonV , SpencerLH , LeesonS . Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a randomised feasibility trial. Psycho‐oncology2017;26(Suppl 2):3‐4. MorrisonV , SpencerLH , TottonN , PyeK , YeoST , ButterworthC , et al. Trial of optimal personalised care after treatment‐gynaecological cancer (TOPCAT‐G): a randomized feasibility trial. International Journal of Gynecological Cancer2018;28(2):401‐11. PyeK , TottonN , StuartN , WhitakerR , MorrisonV , EdwardsRT , et al. Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT‐G): a study protocol for a randomised feasibility trial. Pilot and Feasibility Studies2016;2:67. [DOI 10.1186/s40814‐016‐0108‐5] ">Morrison 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nurse‐led telephone vs hospital follow‐up after gynaecological cancer</b> </p> <p> <ul id="CD012425-list-0030"> <li> <p>Mean total cost per participant (SD) of all contacts with NHS primary and secondary care services and other cancer services over the 6‐month follow‐up period were calculated. </p> </li> <li> <p>Difference between groups: GBP 26.60 (bootstrapped 95% CI GBP −290.37 to GBP 240.42)</p> </li> <li> <p>Although this difference is not statistically significant, the mean total costs of service use were lower in the intervention group. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GBP 388.84 (320.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GBP 415.44</p> <p>(329.08)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0033" title="OltraA , SantaballaA , MontalarJ , MunárrizB , PastorM , MeseguerA , et al. Cost‐benefit evaluation of a follow‐up program in patients with advanced breast cancer. Randomized study. Revista de Oncología1999;1(Suppl 1):165. OltraA , SantaballaA , MunárrizB , PastorM , MontalarJ . Cost‐benefit analysis of a follow‐up program in patients with breast cancer: a randomized prospective study. Breast Journal2007;13(6):571‐4. ">Oltra 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>More intensive (additional diagnostic tests) vs standard follow‐up after breast cancer</b> </p> <p> <ul id="CD012425-list-0031"> <li> <p>Cost elements were not specified but were calculated over a median of 3 years of follow‐up in a hospital in Spain where participants were recruited from 1997‐1999. </p> </li> <li> <p>Cost reported as:</p> <ul id="CD012425-list-0032"> <li> <p>total cost of follow‐up in Euros</p> </li> <li> <p>mean costs per participant in Euros</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 74,171</p> <p>EUR 1278 per participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 24,567</p> <p>EUR 390 per participant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0034" title="PicardiM , PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , et al. Advanced‐stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission‐‐a randomized trial of routine surveillance imaging procedures. Radiology2014;272(1):262‐74. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: Ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2015;100:7‐8. PuglieseN , CirilloM , ZeppaP , CozzolinoI , CianciaG , PettinatoG , et al. A randomized trial of routine surveillance imaging procedures: ultrasonography plus chest radiograph vs FDG PET/CT for detecting relapse in patients with advanced stage Hodgkin lymphoma. Haematologica2014;99:398‐9. ">Picardi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Less intensive (US/chest radiography) vs standard (PET/CT scans) follow‐up after Hodgkin lymphoma</b> </p> <p> <ul id="CD012425-list-0033"> <li> <p>Cost was calculated from the perspective of the Italian National Healthcare System including costs of imaging procedures and surgical biopsies over median follow‐up of 60 months. </p> </li> <li> <p>Costs were reported as average cost of follow‐up per participant in 2010 Euros</p> </li> <li> <p>Estimated cost per relapse diagnosed with routine PET/CT was 10‐fold higher compared with that diagnosed with routine US/chest radiography (P &lt; 0.0001 for difference between groups). </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 8818</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0037" title="BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial [Efectividad del seguimiento postoperatorio en los pacientes con cáncer colorrectal para la detección de recidivas curables. Análisis preliminar de un estudio multicéntrico, controlado y aleatorizado]. Gastroenterologia y Hepatologia2001;24(2):92, abstract no: 13. BessaX , SalóJ , ArcusaA , ElizaldeJI , BoadasJ , AlentornEB , et al. Preliminary analysis of a multicenter controlled trial to evaluate the effectiveness of postoperative follow‐up to detect curable recurrences in patients with colorectal cancer [Análisis preliminar de un estudio multicéntrico controlado y aleatorizado destinado a evaluar la efectividad del seguimiento postoperatorio en la detección de recidivas curables en los pacientes con cáncer colorrectal]. Gastroenterologia y Hepatologia2001;24(3):150. Rodriguez‐MorantaF , CastellsA , SaloJ , ArcusaA , BoadasJ , BessaV , et al. Efficacy of postoperative surveillance after radical surgery for colorectal cancer (CRC). Analysis of a prospective, multicenter, randomized controlled trial. Journal of Gastroenterology2005;128(4 Suppl 2):Abstract W967. Rodríguez‐MorantaF , SalóJ , AcrusaA , BoadasJ , BessaX , PiñolV , et al. Efficacy of postoperative surveillance in patients with colorectal cancer after radical surgery. A prospective, multicenter, randomized study. Gastroenterologia y Hepatologia2005;28(3):197‐8, abstract no: 126. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , Bessa , X , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>More intensive (CT scan plus colonoscopy) vs simple follow‐up after colorectal cancer</b> </p> <p> <ul id="CD012425-list-0034"> <li> <p>Costs were calculated for all procedures performed during the scheduled follow‐up or as a result of additional work‐up for any suspected recurrence according to Hospital Clinic current billing (participants recruited from 1997‐2001). Indirect costs, such as time lost from work or transportation charges, were not factored into the analysis. </p> </li> <li> <p>Cost were reported as:</p> <ul id="CD012425-list-0035"> <li> <p>cost per participant in Euros for median follow‐up of up to 49 months</p> </li> <li> <p>Cost per resectable tumour recurrence in Euros</p> </li> </ul> </li> <li> <p>Although overall cost of follow‐up was higher in the intensive strategy group (EUR 300,315) than in simple strategy group (EUR 188,630), the intensive surveillance strategy was more efficient when resectability was considered. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 300,315 per participant</p> <p>EUR 16,684 per tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 188,630 per participant</p> <p>EUR 18,863 per tumour</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0046" title="NCT00624260 . Impact of PET Scan on the curative strategy of colo‐rectal cancers : a randomized study. clinicaltrials.gov/ct2/show/NCT00624260 (first received 20 December 2016). SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an openlabel multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology2017;35(15 Suppl 1):no pagination. SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal2017;5(5 Suppl 1):A13. SobhaniI , IttiE , LucianiA , BaumgaertnerI , LayeseR , AndreT , et al. Colorectal cancer (CRC) monitoring by 6‐monthly 18FDG‐PET/CT: an open‐label multicentre randomised trial. Annals of Oncology2018;29(4):931‐7. ">Sobhani 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>More intensive (18FDG‐PET) vs conventional follow‐up after colorectal cancer</b> </p> <p> <ul id="CD012425-list-0036"> <li> <p>Costs were assessed in accordance with the Consolidated Health Economic Evaluation Reporting Standards statement for single‐trial‐based studies. </p> </li> <li> <p>The prospective analysis determined the cost per life‐year gained with 18FDG‐PET/CT vs the standard of care over the 3‐year trial period. Hospital inpatient costs were estimated and average cost for each study group determined with adjustment for the actual length of stay and resources used during the admission including the cost of imaging studies. Discounting was not performed. Total cost (mean/SD) was computed both with and without the cost of 18FDG‐PET/CT in 2016 EUROS. Costs were compared between groups using the Wilcoxon test. </p> </li> <li> <p>Difference between groups P value: without imaging: P = 0.23; with imaging: P = 0.033</p> </li> <li> <p>The probabilistic sensitivity analysis suggested that the intervention strategy increased costs without improving participant outcomes, with a likelihood of 87% for the survival end point </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Without imaging: EUR 14,573 (27,531)</p> <p>With imaging: EUR 18,192 (27,679)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 11,131 (13,254)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012425-bbs2-0048" title="PolinderS , VerschuurEM , SiersemaPD , Kuipers , EJ , SteyerbergEW . Cost comparison study of two different follow‐up protocols after surgery for oesophageal cancer. European Journal of Cancer2009;45(12):2110‐5. VerschuurEM , SteyerbergEW , TilanusHW , PolinderS , Essink‐BotML , TranKT , et al. Nurse‐led follow‐up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. British Journal of Cancer2009;100(1):70‐6. [DOI: 10.1038/sj.bjc.6604811] ">Verschuur 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nurse‐led vs surgeon‐led follow‐up after oesophageal cancer</b> </p> <p> <ul id="CD012425-list-0037"> <li> <p>Cost elements included comprehensive data on hospital costs (inpatient days, health practitioner care, medical treatment), diagnostic interventions and extramural care (GP‐care) for a period of 12 months' follow‐up </p> </li> <li> <p>Costs were reported as total costs per participant, reported in 2006 Euros in the Netherlands </p> </li> <li> <p>The total average costs per participant were not statistically significantly higher for standard follow‐up than nurse‐led follow‐up (EUR 3798 vs EUR 2592; P = 0.11). Costs of nurse‐led follow‐up visits were lower than those of standard follow‐up visits (EUR 234 vs EUR 503; P &lt; 0.001). </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 2592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 3798</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>18FDG:</b> 18F‐fluoro‐2‐deoxy‐D‐glucose; <b>CAD:</b> Canadian Dollar ; <b>CI:</b> confidence interval; <b>CDET:</b> coincidence detection system imaging; <b>CT:</b> computed tomography; EUR: Euro; <b>CXR:</b> chest X‐ray; <b>GBP:</b> Pound Sterling; <b>GP:</b> general practitioner; <b>MD:</b> mean difference; <b>NHS:</b> National Health Service; <b>PET:</b> positron emission tomography; <b>QALY:</b> quality‐adjusted life year; <b>SCP:</b> survivorship care plan; <b>SD:</b> standard deviation; <b>US:</b> ultrasound </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of cost outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/full#CD012425-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012425-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Non‐specialist‐led versus specialist‐led follow‐up</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall Survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.68, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 EORTC‐C30 ‐ Global health status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [‐1.83, 3.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 EORTC‐C30 ‐ Physical functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [‐2.35, 5.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 EORTC‐C30 ‐ Role functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [‐2.75, 7.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 EORTC‐C30 ‐ Emotional functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [‐2.06, 3.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 EORTC‐C30 ‐ Cognitive functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.41 [‐1.52, 10.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 EORTC‐C30 ‐ Social functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.39 [1.60, 9.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 STAI ‐ State anxiety subscale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.55 [‐2.41, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 HADS ‐ Anxiety subscale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.73, 0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 HADS ‐ Depression subscale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.35, 0.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Non‐specialist‐led versus specialist‐led follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/references#CD012425-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012425-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Less intensive versus more intensive follow‐up</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.96, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Time‐to‐detection of recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.79, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Less intensive versus more intensive follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012425.pub2/references#CD012425-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012425.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012425-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012425-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#CD012425-note-0002">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD012425-note-0005">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD012425-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012425-note-0012">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012425\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012425\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012425\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012425\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012425\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012425\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012425\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012425\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012425\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012425\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012425\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012425\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012425\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012425\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012425\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012425\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012425\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012425\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=dLyXbLct&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012425.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012425.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012425.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012425.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012425.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718719458"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012425.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718719461"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012425.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dd72c1ae7f47a',t:'MTc0MDcxODcxOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 